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Introduction to thesis
Since 2005, the Department of Dermatology at the Radboud university medical 
center Nijmegen, established a prospective registry called BioCAPTURE (Continuous 
Assessment of Psoriasis Treatment Use Registry with Biologics). Patient and treatment 
characteristics as well as patient reported outcomes of all consecutive patients with 
psoriasis that are being treated with biologics, i.e. agents derived from living organisms, 
are being registered. From 2010, large regional hospitals have been participating 
in BioCAPTURE. At the moment, nine regional centers contribute to BioCAPTURE. 
The goals of the BioCAPTURE registry are to gather data on the long-term effectiveness, 
drug survival and safety of biologics in patients with psoriasis, as well as collecting 
patient reported outcome measures (PROMs). Over the past eleven years, several 
research questions have been answered using data from BioCAPTURE. This thesis 
contains data from the literature summarized in (systematic) reviews and data from 
the BioCAPTURE registry. The focus of this thesis will be on the long-term effectiveness 
and drug survival of biologics in patients with psoriasis as well as providing 
complementary data for current guidelines. Before disclosing our formulated research 
questions, the reader will first be provided with an overview of psoriasis as a disease 
entity in the first chapter and its treatment options in the second chapter of this thesis. 
In the third chapter, the three main sections of this thesis (i.e., effectiveness, drug survival 
and improvements of effectiveness/efficacy) will be shortly addressed, followed by 
the research questions in chapter 4. Chapters 5-12 include original articles based on 
the formulated research questions. The answers to the research questions will be 
summarized and discussed in chapters 13 (English) and 14 (Dutch).
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1.1  Introduction to psoriasis
Psoriasis is a chronic, immune-mediated, polygenic, inflammatory skin disease.1,2 
Psoriasis is common, with a prevalence of 2-3% in Europe and North America and it 
results in a major economic burden with an annual cost of approximately $ 112 billion 
in the United States in 2013.2-4 Different forms of psoriasis exist, of which chronic 
plaque type psoriasis, i.e. psoriasis vulgaris, represents the most common form of 
psoriasis with approximately 90% of patients with psoriasis affected by it.2 In this 
thesis the term “psoriasis” indicates chronic plaque type psoriasis, unless stated 
otherwise. Psoriasis has an immense impact on the physical, emotional and social 
well-being of patients with this skin disease.5 It impairs quality of life as much as other 
chronic diseases such as cancer, diabetes and heart disease.6 Covered with sharply 
demarcated, erythematous, silvery scaly plaques, patients with psoriasis have been 
stigmatized and even rejected from society.7,8 Recently performed studies show that 
patients with psoriasis are still stigmatized and that sexual difficulties are experienced 
amongst male and female patients.9-11 Extensive research into the pathogenesis of 
psoriasis eventually led to astonishing new therapeutic options for patients with this 
life-altering disease. 
1.2  History of psoriasis
Going back in time, psoriasis probably already existed more than 2000 years ago.12 
Throughout history different words have been suggested and used for psoriasis. The 
Term ‘Zaraath’ in the bible could have been used for the psoriasis that we know 
today.13 However, uncertainty exists since this term could have also been used to 
describe many other skin diseases, e.g. leprosy, eczema and/or scabies.12,14 
Hippocrates (460-377 B.C.), in his Corpus Hippocraticum, used ‘psora’ for the first 
time, which means ‘to itch’ in Greek, but probably used it for another disease entity 
than psoriasis.8,15 The first clinical description of psoriasis stems from Aurelius 
Cornelius Celsus (± 25 B.C. – 45 A.D.), although he used the term ‘impetigo’ to 
describe this skin disease.8 The first physician to use the term psoriasis was Galen 
(± 133-200 A.D.). Robert Willan (1757-1812), of Yorkshire16, was the first to accurately 
describe psoriasis in 1808, but called it ‘lepra’.12,14,17 Austrian physician Ferdinand 
von Hebra was the first to distinguish leprosy from psoriasis in 1841.8 In a congress in 
1946, it was suggested to use “rosa plateada” (silvered rose) instead of psoriasis.14 
Psoriasis, however, remained the world-wide adopted term. 
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1.3  Epidemiology of psoriasis
The prevalence of psoriasis is estimated to be 2-3% in European countries and in 
North America.2,3,18 In non-Caucasian populations, prevalence seems to be lower 
with a prevalence rate of less than 0.5% in certain African countries, China and 
Japan.19-21 Epidemiological research indicates that countries closer to the equator 
have lower prevalence rates compared with countries more distant from it.21 Psoriasis 
is equally distributed between men and women.3 Male patients, however, may have 
more severe psoriasis compared with female patients, which explains the higher 
proportion of men being treated with biologics.22 On the other hand, female patients 
might have psoriasis at an earlier age than male patients.23,24 The age of onset of 
psoriasis shows a bimodal distribution with peaks at 16-22 years and 57-60 years of 
age.25 More than half of patients with psoriasis develop their skin lesions before the 
age of 40 years and approximately 75% of patients before the age of 46.3,26
1.4  Histological features and clinical correlation
In psoriasis, the mitotic activity of basal keratinocytes is increased with keratinocytes 
moving from the basal layer to the cornified layer within one week instead of the 
normal one month period.1 Histopathological changes in the epidermis of the 
psoriasis lesions include acanthosis (thickening of the viable layers), elongation of 
the rede ridges, loss of the granular layer, hyperkeratosis (thickened stratum corneum), 
and parakeratosis (nuclei in the stratum corneum). These features correspond with 
thickening and scaling of the skin of patients with psoriasis.1,2,7 In the dermis, blood 
vessels increase in number and become dilated. These contorted capillaries reach 
into the tips of the dermal papillae and are responsible for the redness of psoriasis 
lesions.2,7 In both the epidermis and dermis, an infiltrate of leukocytes can be seen 
with dendritic cells, T-lymphocytes, macrophages and neutrophils.1,2,7 Neutrophilic 
granulocytes accumulate within the epidermis to form the pustules of Kogoj or 
subcorneal to form Munro’s microabcesses.2 
1.5  The natural course of psoriasis
In untreated individuals that are prone to developing psoriasis, psoriatic lesions may 
erupt due to external or internal triggering factors.7 Once the psoriasis has surfaced, 
lesions may develop locally or more widespread.2 Small pinpoint lesions indicate the 
start of new psoriasis lesions.26 Psoriatic lesions may occur at any site of the body, 
but are usually seen at the extensor sites of arms and legs (i.e., elbows and knees) 
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and on the head and buttocks.26,27 Unfortunately, psoriasis is a skin disease for 
which a complete cure is still absent; once psoriasis surfaces it is a lifelong disease.26 
During the natural course of this disease, the size and/or number of skin lesions may 
increase or decrease or all lesions may disappear completely (complete remission, 
although mostly temporarily).17 In one study, in which 5600 patients with psoriasis 
were followed, 39% achieved complete remission over a long period of time (years).28 
After complete remission, patients may experience recurrence of disease. It is still 
impossible to accurately predict a patient’s clinical course.29,30 Patients with an early 
onset of psoriasis (15-25 years of age) more often have a first degree relative affected 
by psoriasis and usually develop a psoriasis that is more unstable with frequent 
relapses when compared with patients with psoriasis with a late onset of disease 
(60-70 years of age).25 Women who become pregnant usually experience an 
improvement of psoriasis (40-60% of pregnant patients), most of them within the first 
trimester and less within the second.31,32 In about 10-20% of pregnant woman the 
psoriasis deteriorates.31 Breastfeeding has probably no significant effect on 
psoriasis.32
1.6  Factors triggering psoriasis
Genetic susceptibility together with external or internal triggering factors and cells 
from the immune system play a role in the pathogenesis of psoriasis. Factors that 
may trigger psoriasis include smoking, stress, skin trauma (i.e. Koebner phenomenon. 
Also ultraviolet (UV) radiation, i.e. sunburn), infections (e.g. streptococcal throat 
infection), alcohol use and certain drugs such as antimalarials, ß-blockers, angiotensin- 
converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs, lithium and 
imiquimod.33-36 Weight is a factor that seems to have an influence on psoriasis 
severity.33,37 
1.7  Immunopathogenesis of psoriasis
Extensive research has been conducted in elucidating the role of the immune system. 
Current evidence shows a dysregulation of the immune system in patients with 
psoriasis (Figure 1). The immune system can be subdivided into the innate immune 
system which immediately protects the human body from microorganisms and the 
adaptive immune system which forms the second line of protection, is more slowly 
activated and has a memory function.38 The link between the innate and adaptive 
immunity is constituted by the dendritic cell.7 Keratinocytes, macrophages and 
natural killer T-cells belong to the innate immune system.39 Keratinocytes constitute 
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about 95% of cells of the epidermis. They contain the antimicrobial peptide cathelicidin 
(LL-37) in order to prevent microbial infection.40 It is hypothesized that environmental 
factors and genes, in predisposed individuals, may cause keratinocytes to become 
stressed or even damaged. Consequently, these stressed or damaged keratinocytes 
may release LL-37 and self-DNA, which form complexes.2,7,40,41 As a result, nucleases 
will be unable to degrade self-DNA.41 Plasmacytoid dendritic cells will capture these 
newly formed LL-37/self-DNA complexes through endocytoses.40 Then, self-DNA 
will interact with toll-like receptor 9, which lies intracellular within the plasmacytoid 
dendritic cells, and will cause these dendritic cells to produce interferon-α, a cytokine 
of the innate immune system.40,41 In psoriasis, keratinocytes also release their own 
pro-inflammatory cytokines (interleukin (IL)-1, IL-6 and tumor necrosis factor(TNF)- α).7 
Natural killer T-cells and macrophages contribute to the innate immune response by 
releasing TNF-α and interferon-γ. Interferon-α, TNF-α, interferon-γ, IL-1 and IL-6 will 
activate myeloid dendritic cells.2,7 These cells will then travel to nearby lymph nodes 
and produce IL-12 and IL-23 in order to stimulate the formation of T-helper 1 cells and 
T-helper 17 cells, respectively, from naive T cells.7 These helper T-cells of the adaptive 
immune system will produce the cytokines TNF-α, interferon-γ, IL-17 and IL-22 (Figure 1). 
Hereby, they will stimulate the proliferation of keratinocytes and will maintain them in 
a stressful state. As this circle of cytokine release continues, patients will start to 
develop psoriatic lesions.1,2,7 Recent research has shown that neutrophils, by producing 
IL-17, also stimulate keratinocytes into uncontrolled cell division and secretion of 
cytokines.42  
1.8  Genetic susceptibility to psoriasis
Genes have been found to play a role in the development and severity of psoriasis.1 
The risk that an individual might develop psoriasis is 14-30% if one parent is affected 
and 41-75% if both parents are affected by psoriasis.1,3,31,32 In concordant 
monozygotic twins the age of onset, severity, distribution pattern and the course of 
psoriasis appear to be similar when compared with concordant dizygotic twins.43,44 
Many different susceptibility loci for psoriasis have been identified with genome-wide 
linkage studies and genome-wide association studies.43 Susceptibility loci have 
been found related to the adaptive and innate immunity as well as to the skin barrier 
function.30,45 The most important locus and replicated in almost all linkage studies is 
psoriasis susceptibility 1 (PSORS1); a locus in the major-histocompatibility-complex 
region on chromosome 6.3,30 PSORS1 accounts for 35-50% of the heritability of 
psoriasis.3,45 The human leukocyte antigen (HLA)-Cw6 gene is the strongest 
susceptibility allele of the PSORS1 locus to early onset psoriasis and guttate 
psoriasis.30,45,46 In the patients with early onset psoriasis (≤40 years of age) about 
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78% were HLA-Cw6 positive, compared with only ~37% in patients with late onset 
psoriasis (>40 years of age).25 Of the patients that were HLA-Cw6 positive, 
approximately 85% of patients had early onset psoriasis.25 Patients with an early 
onset of disease more often experienced a more severe psoriasis compared with 
patients with a late onset of disease.25 Smoking might play an important role in the 
development of psoriasis as it enhances the expression of genes like HLA-Cw6.34 An 
example of psoriasis associated-genes involved in the innate immunity and skin 
barrier integrity is, respectively, tumor necrosis factor alpha-induced protein 3 
(TNFAIP3) gene and the late cornified envelope (LCE) gene cluster.47     
Figure 1  Schematic overview of the immunopathogenesis of psoriasis
Trigger 
Legend:
NK T cell: Natural killer T cell  |  pDC: plasmacytoid dendritic cell  |  mDC: myeloid dendritic cell
LL-37: cathelicidin  |  IFN: interferon  |  IL: interleukin  |  TNF: tumor necrosis factor  |  Th: T helper cell
Figure is partly based on Figure 2 from Nestle, et al.7
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1.9  Psoriasis and comorbidities
Psoriasis is associated with several comorbidities, including psoriatic arthritis, 
cardiovascular disease, Crohn’s disease, diabetes mellitus (mainly type 2), metabolic 
syndrome (hypertension, obesity, glucose intolerance, dyslipidemia), alexithymia, 
anxiety and depression, cancer (e.g., lymphoma and non-melanoma skin cancer) 
and obstructive sleep apnea.2,3,48-51 Dermatologists should be aware of these 
associations when treating their patients with psoriasis. Although psoriasis is linked 
to these comorbidities, some comorbidities may be the consequence of certain 
treatments (e.g., photochemotherapy resulting in non-melanoma skin cancer) or 
patient behaviour instead of a true relation with the skin disease itself.52,53 
1.10  Psoriasis and quality of life
The quality of life of patients with psoriasis is severely affected by their skin disease.2,54 
The quality of life of patients with psoriasis is usually measured with the Dermatology 
Life Quality Index (DLQI) questionnaire, although at least 20 other questionnaires 
exist.55,56 The DLQI is a validated, 10-item questionnaire and results in a score 
between 0 and 30. A lower score represents a better quality of life (DLQI of 0-1: no 
effect; DLQI of 2-5: a small effect; DLQI 6-10: a moderate effect; DLQI 11-20: a very 
large effect; DLQI 21-30: an extremely large effect on my life).57 Interestingly, not only 
the quality of life of patients with psoriasis is affected, but also the quality of life of 
persons living with these patients.58 
1.11  Measuring severity of psoriasis
The severity of psoriasis can be measured with at least 53 different measures of 
which the Psoriasis Area and Severity Index (PASI), Physician’s Global Assessment 
(PGA) and Body Surface Area (BSA) are widely used in randomized controlled trials 
(RCTs) and daily clinical practice.59-61 Of these, the PASI score is considered the 
most important outcome measure. The PASI score ranges from 0-72, with a higher 
score reflecting a more severe psoriasis.62 The PASI score is calculated as follows: 
0.1(EH + IH + DH)AH + 0.2(EU + IU + DU)AU + 0.3(ET + IT + DT)AT + 0.4(EL + IL + DL)AL, 
with E= erythema (0: absent – 4: very severe),  I= induration (0: absent – 4: very severe), 
D= desquamation (0: absent – 4: very severe), H= head, U= upper extremities, 
T= trunk, L= lower extremities and A= body surface area that is affected by psoriasis 
(0 = no involvement; 1= <10%; 2= 10-29%; 3= 30-49%; 4= 50-69%; 5= 70-89% 
and 6= 90-100% of body surface area affected).62,63 There is no consensus on how 
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to interpret the PASI score, but moderate to severe psoriasis is usually a PASI≥10.64 
The “rule of tens” suggests that moderate to severe psoriasis is an absolute PASI 
score of ≥10 or a BSA score of ≥10 or a DLQI score of ≥10.65 In RCTs, the improvement 
in PASI score compared with baseline PASI score is often used in order to express 
the efficacy of the studied agent.66 A PASI75 indicates a 75% improvement when 
compared with baseline PASI score. A PASI75 of 60% at 16 weeks of treatment means 
that 60% of patients achieved a 75% improvement in PASI score when compared 
with baseline PASI score at 16 weeks of treatment.62 The PGA is scored by the 
dermatologist and might range from 0-5, 0-6 or 0-7 (no psoriasis – very severe 
psoriasis), depending on the PGA used.59 The BSA is the percentage of body surface 
area that is affected by psoriasis (0-100%).   
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2.1  Introduction to the treatment of psoriasis
Psoriasis can be treated with topical treatments, phototherapy, conventional systemic 
agents, biologics and more recently small molecules.67,68 The course of psoriasis is 
different between individuals and therefore psoriasis treatment is patient-centered.69,70 
Many different factors play a role in choosing the appropriate therapy, such as the form, 
location and extent of psoriasis, the patient’s quality of life, comorbidities, (future) 
pregnancy wish, work and hobbies, patient preferences, as well as costs of psoriasis 
treatment.69,71 Patient adherence to therapy is one of the challenges a dermatologist 
faces when treating patients with psoriasis. By explaining the therapeutic options and 
respecting patient preferences, the dermatologist is offered an opportunity to build 
the patient-doctor relationship which is one of the important factors that can increase 
patient adherence to the antipsoriatic therapy. Other factors improving patient adherence 
include treatment satisfaction and satisfaction with the quality of care.72 The limited 
evidence available suggests that patient adherence is highest for biologics, followed 
by oral systemic therapies, phototherapy and lastly topical therapies.72
2.2  Topical therapies
The efficacy of topical therapies for plaque psoriasis has been studied in RCTs.73 
Topical calcineurin inhibitors (tacrolimus and pimecrolimus) are of limited effect for 
psoriasis of the body, but might be used for facial, flexural and genital psoriasis.67 
For psoriasis of the body, very potent corticosteroids (e.g., clobetasol proprionate), 
potent corticosteroids (e.g., bethametasone dipropionate), potent corticosteroids 
combined with vitamin D analogues (e.g., betametasone dipropionate plus calcipotriol), 
monotherapy with vitamin D analogues or vitamin D3 and dithranol are effective.73 
Coal tar and topical retinoids are of limited effect.74 Regarding safety issues, studies 
report that vitamin D causes more skin irritation than corticosteroids.73 Topical 
cortico steroids carry the risk of skin atrophy and adrenal axis suppression.75,76  
2.3  Phototherapy
UV radiation improves psoriasis by inducing apoptosis in different cell types of the 
skin, promoting immunosuppression through the induction of the migration of 
Langerhans cells out of the epidermis and changing the cytokine profile locally (in the 
skin) as well as systemically.77 In the treatment of psoriasis, narrowband UVB therapy 
has replaced broadband UVB therapy due to its higher efficacy and less side-
effects.78 Although oral 8-methoxyPsoralen-UVA (PUVA) is more efficacious than 
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narrowband UVB, narrowband UVB is recommended as first choice phototherapy 
since oral PUVA induces an increased risk of skin cancer and is less easy to use 
compared with narrowband UVB.79-81 It is also possible to use home UVB therapy, 
since this is as effective and safe as narrowband outpatient UVB therapy.82  
2.4  Conventional systemic therapies
The conventional systemic agents that can be used for psoriasis treatment are 
metho trexate, fumarates, acitretin and cyclosporine.67 The long-term use of conventional 
systemic therapies may be hampered by the development of cumulative end-organ 
toxicities (methotrexate and cyclosporine) and drug-drug interactions (methotrexate, 
cyclosporine, acitretin).2,83 
2.4.1 Methotrexate
Methotrexate is a folic acid antagonist and impairs DNA replication by interfering with 
the purine synthesis.67,83 The efficacy of methotrexate is at least similar to that of 
cyclosporine; 60% reached a PASI75 after 16 weeks of treatment.67,81,84 Methotrexate 
can be used for long-term psoriasis treatment.81 Methotrexate carries the risk of 
inducing liver fibrosis and cirrhosis, but the quality of studies analyzing this risk is 
low.67,83,85 Therefore the question remains whether nonalcoholic fatty liver disease in 
patients with psoriasis and obesity, dyslipidaemia and diabetes (i.e., metabolic syndrome) 
is an explanation for the development of methotrexate-induced liver fibrosis.85 
Methotrexate is teratogenic and should not be used by female patients planning their 
pregnancy as well as male patients that wish to father children.67,83 Methotrexate 
should be stopped for at least 3 months before conception in both sexes.81   
2.4.2 Fumarates
Fumarates exert their effect by inhibiting nuclear factor kappa B and by T-cell 
apoptosis.67 Fumarates are well suited for long-term psoriasis therapy. In the Netherlands, 
fumarates are not registered for the treatment of psoriasis. Physicians should regularly 
check for lymphocytopenia because severe and longstanding low lymphocytes may 
lead to the development of progressive multifocal leukoencephalopathy.81,86,87 
Guidelines report a PASI75 of 50-70% at week 16.81,88
2.4.3 Acitretin
Acitretin is a retinoid that exert its effect by binding to nuclear retinoid receptors and 
thereby altering gene transcription. Consequently there is a normalization of the 
keratinocyte proliferation and differentiation.67 In the treatment of psoriasis, acitretin 
monotherapy has a limited efficacy; 23-30% of patients achieve PASI75 after 8-12 
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weeks.81,88 It can, however, be used in combination with phototherapy (e.g., Re-UVB, 
Re-PUVA) or in combination with a biologic. Acitretin monotherapy may be prescribed 
to treat pustular psoriasis and erythrodermic psoriasis.67 Retinoids are teratogenic 
and should only be prescribed with effective contraceptive precautions in women of 
childbearing age.67,83 
2.4.4 Cyclosporine
Cyclosporine is an oral calcineurin inhibitor.67,83 It is an immunosuppressive agent 
that inhibits the calcineurin phosphatase-initiated activation of T-cells.67 Cyclosporine 
has a fast onset of action. Fifty-70% of patients with psoriasis reached a PASI75 after 
12-16 weeks of treatment.81,88 Long-term continuous use of cyclosporine is, however, 
not recommended due to the development of irreversible renal changes (renal toxicity) 
in patients with psoriasis.83 
2.5  Biologics
Biologics are proteins produced in living organisms with the use of recombinant DNA 
technology.89 They interfere with the immunopathogenesis of psoriasis by, for 
example, blocking the function of certain proinflammatory cytokines (Figure 2).90 
Biologics currently approved by the European Medicine Agency (EMA) for the 
treatment of psoriasis are adalimumab, etanercept, infliximab, ustekinumab and 
more recently secukinumab and ixekizumab. Secukinumab, a fully human anti-IL17A 
monoclonal antibody, as well as ixekizumab, a humanized anti-IL17A monoclonal 
antibody, will not be covered in this thesis.91
2.5.1 Adalimumab
Adalimumab (Humira®) was approved for the treatment of psoriasis by the EMA in 
December 2007.81 Adalimumab is a fully human immunoglobulin G1 (IgG1) 
monoclonal tumor necrosis factor-alpha (TNF-α) antibody. It binds to TNF-α and 
blocks its interaction with the TNF receptor and thereby interferes with the immuno-
pathogenesis of psoriasis (Figure 2).92,93 Adalimumab proteins are produced by 
recombinant DNA technology in a mammalian cell expression system.93 Adalimumab is 
injected subcutaneously by the patient in a dose of 80mg at week 0, 40mg at week 1, 
followed by 40mg every other week.81 The efficacy of adalimumab has been assessed 
in RCTs; 53-80% of patients attained PASI75 at week 16.81 Adalimumab is suitable 
for long-term psoriasis treatment.81,94 Short- and long-term adalimumab treatment 
appears to be safe.95-97 The most common adverse events (AEs) reported by patients 
with psoriasis in RCTs on adalimumab treatment are upper respiratory tract infections, 
injection site reactions, headache and in some studies muscle pain.97-102    
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2.5.2. Etanercept
Etanercept (Enbrel®) was approved by the EMA in September 2004.81 Etanercept is 
a fully human dimeric fusion protein.103-105 It consists of the two FC-regions of human 
IgG1 and two receptor regions of the human tumor necrosis factor-receptor II (TNF-
RII).103-108 These two receptors are able to bind soluble and membrane-bound TNF-α 
with an affinity much higher than the naturally occurring monomeric TNF receptors 
in our body.106 By binding the proinflammatory cytokine TNF-α, etanercept inhibits 
the inflammation cascade involved in the development of psoriasis (Figure 2). 
Etanercept proteins are manufactured in a Chinese hamster ovary expression system 
using recombinant DNA technology.103,106 According to label, etanercept is used 
continuously and is being injected subcutaneously by the patient in a dose of 50mg 
biweekly during 12 weeks followed by 50mg once weekly or 25mg biweekly.81 
The efficacy of etanercept from RCTs is that in 49% of patients treated with etanercept 
Figure 2  Biologics interfere with the immunopathogenesis of psoriasis
Legend:
NK T cell: Natural killer T cell  |  pDC: plasmacytoid dendritic cell  |  mDC: myeloid dendritic cell
LL-37: cathelicidin  |  IFN: interferon  |  IL: interleukin  |  TNF: tumor necrosis factor  |  Th: T helper cell
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50mg biweekly, PASI75 is achieved at 12 weeks of treatment.81 This response 
improves until 24 weeks of treatment. Short- and long-term use of etanercept seems 
to be safe, even when used in different dosing regimens.109-111 The most common 
AEs that were mentioned by patients with psoriasis in RCTs on etanercept include 
upper respiratory tract infections, injection site reactions, headache and in some 
studies arthralgia and pruritus.112-120 
2.5.3 Infliximab
Infliximab (Remicade®) was approved by the EMA in September 2005.81 It is a 
chimeric (mouse-human) IgG1 monoclonal antibody that binds directly to TNF-α, 
thereby interfering with the pathogenesis of psoriasis (Figure 2).104 Infliximab proteins 
are manufactured in hybridoma cells of mice using recombinant DNA technology.121,122 
Infliximab is administered intravenously in a dose of 5mg/kg at week 0, week 2, week 
6 and then every 8 weeks.81 RCTs on infliximab treatment in patients with psoriasis 
have shown that PASI75 was reached in approximately 80% of patients at week 10.81 
Infliximab appears to be safe for short- and long-term use, however AEs are common 
during treatment.123-126 In a meta-analysis, there was an 18% increased risk of AEs 
on infliximab treatment compared with placebo treatment across 10-30 weeks of 
treatment.126 In that study, the risk of AEs on etanercept was, however, not statistically 
significantly different compared with placebo for that time period.126 The most 
commonly mentioned AEs in RCTs on infliximab include upper respiratory tract 
infections, headache, increased hepatic enzymes, viral infections and in some 
studies arthralgia.123,127-130 Compared with the other biologics, an infliximab-specific 
AE that might occur is an infusion reaction.126 
2.5.4 Ustekinumab
Approved by the EMA in January 2009, ustekinumab (Stelara®) is a fully human IgG1 
monoclonal antibody that blocks the shared p40 protein subunit of the cytokines 
IL-12 and IL23.88,131 It thereby interferes with the immunopathogenesis of psoriasis 
(Figure 2). Ustekinumab is produced by recombinant DNA technology in transgenic 
mice.132 For the treatment of psoriasis, ustekinumab is prescribed in the following 
doses: 45mg at week 0, week 4 and then every 12 weeks in patients ≤100kg and 
90mg at week 0, week 4 and subsequently every 12 weeks in patients >100kg.88 
In RCTs, ustekinumab reaches a PASI75 in 67%-74% of patients treated with 45mg 
and 68%-71% of patients treated with 90mg at week 12.88 Ustekinumab seems safe 
for short- and long-term use.133-135 Upper respiratory tract infections, headache, 
arthralgia, cough, injection site reactions, back pain, diarrhea and fatigue were common 
AEs reported by patients with psoriasis treated with ustekinumab in RCTs.134-138 
Injection site reactions seem to occur more frequently with etanercept than with 
ustekinumab treatment.118 
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2.6  Small molecules
A more recently approved agent is the small molecule apremilast, an oral phospho-
diesterase 4 inhibitor.139,140 A new and very promising agent is tofacitinib, an oral 
Janus kinase inhibitor.141 Small molecules will not be covered in this thesis.
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This chapter provides background information to the formulated research questions 
in Chapter 4. 
3.1  Effectiveness
Effectiveness is measured in daily practice, while efficacy is measured in RCTs. 
Antipsoriatic agents have been studied in RCTs and the efficacy of these treatments 
are summarized in systematic reviews and guidelines. In RCTs, however, a more 
healthy patient population is included due to strict in- and exclusion criteria. Efficacy 
and safety results are therefore not automatically generalizable to patients in daily 
clinical practice.142,143 To be included in RCTs on biologic agents for psoriasis, 
patients had to have a moderate to severe psoriasis with a PASI at treatment start of 
at least 10 or even 12, had to be biologic naïve (i.e., never used a biologic before) or 
had to be naïve to the (class of) drug investigated. Elderly patients were usually 
ineligible, as were the patients with multiple comorbidities and comedications, mental 
illnesses and patients that were expected to show a low adherence to therapy.97,113, 
130,138,144 Daily practice differs substantially from RCTs in that patient populations 
differ, but also the extent to which the patient is affected by psoriasis (in daily practice 
less severe disease is also treated when a patient has to switch from one biologic 
agent to another biologic), treatment strategies (dose adjustments, combination 
therapies), the time a physician is available per patient as well as physician’s 
experiences and preferences with certain agents. In general, the internal validity of 
RCTs is high and the external validity low, whereas daily practice studies have low 
internal validity and high external validity.145 Daily practice studies with patients with 
psoriasis can therefore be viewed as complementary to RCTs. 
3.2  Drug survival
The duration and the probability that patients will stay on a drug over time can be 
measured with the drug survival. Drug survival is a comprehensive measure of the 
effectiveness and safety of the drug, but also of certain aspects that are not dependent 
on the drug itself such as the number of available treatment options, physician’s and 
patient’s preferences.146 Originally, survival indicates the probability that patients are 
still alive after a certain time period.147 In the drug survival, it is not the probability that 
the patient is still alive, but the probability that the patient will still be on the drug. 
Drug survival is calculated using survival analysis (i.e., Kaplan Meier curves) and it 
can be split by reasons of discontinuation: ineffectiveness, safety, both reasons or 
other reasons or whether the patient discontinued the drug in general (all reasons 
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grouped together). Drug survival can be performed for one drug or for different drugs 
grouped together.148 Of note, drug survival is not the same as effectiveness. In drug 
survival research on psoriasis, for example, when a drug is stopped based on the 
reason that the drug is not effective (any more), this does not mean that the patient 
did not reach a PASI75. It only indicates that the physician decided to discontinue the 
drug because the physician and patient agreed that the drug was not effective 
enough to treat the psoriasis.
3.3  Improvements of efficacy and effectiveness
3.3.1 Guidelines
Guidelines on the treatment of psoriasis are documents created to provide the 
physician guidance in treating the patient with psoriasis. Different nations published 
guidelines on the treatment of psoriasis and these guidelines differ from each other 
in subtle ways.81,149-151 Guidelines may have different levels of evidence (State of the 
art (S)1, S2 or S3). S1-guidelines are based on an informal consensus of an expert 
group, S2k-guidelines on a structured consensus, S2e-guidelines on a systematic 
literature assessment and S3-guidelines on systematic reviews and a structured 
consensus meeting.152 Until recently, the Dutch S3-guidelines on the treatment of 
psoriasis had never been published internationally.153 What the current treatment 
guidelines on psoriasis have in common is that they contain treatment recommendations 
for the physician after systematic reviews of the literature. Guidelines on psoriasis 
provide in this way predominantly evidence on the efficacy and safety of antipsoriatic 
treatments, usually from RCTs. A difference between the Dutch and German 
guidelines is that the latter provide physicians with a flow chart on when to switch or 
adjust treatment in order to improve the effectiveness of agents (treatment goals).151 
As in most guidelines on the treatment of psoriasis data on the commonly used 
combination therapies with systemic antipsoriatic agents (for example, conventional 
systemic agents with biologics) are lacking, we summarized this evidence in this 
thesis.   
3.3.2 Treatment goals
In order to help physicians to improve the effectiveness of systemic antipsoriatic 
treatments and to guide them when to adjust or switch these treatments, PASI50 and 
PASI75 as well as DLQI have been incorporated into the treatment goals.64,154,155 
When a patient reaches PASI75, treatment may be continued. If a patient does not 
reach PASI50, treatment should be adjusted. When a patient reaches PASI50 but not 
PASI75, treatment should be adjusted if DLQI is above 5. With the development of 
new biologic agents (e.g., secukinumab), PASI90 and even PASI100 are more easily 
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reached by patients and it is therefore currently debated whether PASI90 should be 
the new treatment goal instead of PASI75.156 Recently conducted research which 
indicates that a correlation seems to exist between the extent of psoriasis (mean 
percent reduction in PASI) and the quality of life (mean improvement in DLQI) further 
strengthen the concept of PASI90 as a new treatment goal.156,157 In a trial on infliximab 
for psoriasis treatment, patients with a PASI90 had significantly more often a better 
quality of life score (DLQI of 0-1) when compared with patients with a PASI75 but not 
achieving a PASI90.156,158
3.3.3 Combination therapy 
Although combination therapy is common in daily practice psoriasis treatment, 
guidelines lack data and recommendations on this treatment option. Combination of 
treatments might be necessary in order to treat psoriasis and its comorbidity psoriatic 
arthritis, but a second agent could also be started in order to achieve higher efficacy/
effectiveness, or to be able to lower the dose of the first agent, or to attack the 
antibodies the patient has formed during the first agent.159 This thesis will provide the 
reader with evidence from RCTs that have been performed on combination therapy 
with systemic agents in psoriasis treatment.
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4.1 Aims of thesis
The major aims of this thesis are (1) to explore, compare and predict the effectiveness 
of biologics for psoriasis in daily practice and (2) to explore, compare and predict 
treatment success of biologics for psoriasis with drug survival and (3) to explore 
those areas with room for improvement in daily practice psoriasis care. 
4.2  Research questions
4.2.1 Effectiveness
To explore
1:  What is known thus far from literature on the effectiveness of biologics in daily 
practice psoriasis treatment? 
To compare
2:  Which biologic has the highest confounder-corrected effectiveness in daily practice 
psoriasis treatment using data from our prospective BioCAPTURE cohort?
To predict
3:  What are predictors for high clinical effectiveness of biologics for psoriasis in 
daily clinical practice using data from BioCAPTURE?
4.2.2 Drug survival
To explore
4:  What is the long-term overall drug survival of adalimumab, etanercept, and 
ustekinumab in patients with psoriasis?
5:  Is drug survival accompanied with a good skin-specific quality of life in patients 
with psoriasis?
To compare
6: Which biologic has the highest confounder-corrected, long-term, overall drug 
survival in patients with psoriasis?
7:  Which biologic has the highest confounder-corrected, long-term drug survival 
split for reasons of discontinuation, i.e. ineffectiveness and side-effects, in patients 
with psoriasis?  
To predict
8:  What are the predictors of long-term overall drug survival of biologics in patients 
with psoriasis?
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9:  What are the predictors of long-term drug survival split for biologics and split for 
reasons of discontinuation, i.e. ineffectiveness and side-effects, in patients with 
psoriasis?
4.2.3 Improvements of efficacy and effectiveness
To explore
10:  What are the guidelines that dermatologists in the Netherlands should adhere to 
when treating patients with psoriasis in daily practice?
11:  Since information on systemic combination therapy is largely lacking in current 
guidelines on psoriasis treatment, what is the current evidence from RCTs on 
systemic combination treatment in psoriasis?
12:  Do dermatologists already intuitively apply ‘treatment goals’ in patients with 
psoriasis treated with biologics in daily practice?
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Abstract
The efficacy of biologic or conventional systemic therapies for psoriasis has been 
shown in randomized controlled trials. Effectiveness, however, has been studied in 
daily practice cohorts, and no aggregation of effectiveness data is available. This 
systematic review searched PubMed and EMBASE and summarized the real-world 
evidence on effectiveness of biologics (adalimumab, etanercept, infliximab and 
ustekinumab) and conventional systemic therapies (acitretin, cyclosporine, fumarates 
and methotrexate) for the treatment of plaque psoriasis in adults. Thirty-two studies 
were included. Few data were available on infliximab, ustekinumab and conventional 
systemics. Results show that biologics and conventional systemics were effective in 
real-life treatment of psoriasis, with large ranges in the percentage of patients 
reaching 75% improvement in psoriasis area and severity index score compared with 
baseline, especially for etanercept and adalimumab treatment. Combination therapies 
of biologics with conventional systemics, and dose adjustments of biologics were 
frequently applied strategies and may explain the large range in improvements 
between cohorts.
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 57
57
Systematic review effectiveness
5
Introduction
Psoriasis is a common chronic skin disease, with a prevalence of 2–4% (1). Different 
therapeutics have been developed to treat this burdensome disease (2–4). Randomized 
controlled clinical trials (RCTs) have analysed the efficacy of biologic agents (adalimumab, 
etanercept, infliximab and ustekinumab) and conventional systemic therapies 
(acitretin, cyclosporine, fumarates and methotrexate) (5–7). Effectiveness data from 
real-life, observational studies, however, are of added value, since patients and 
treatment strategies in daily practice differ substantially from those in RCTs (8). The 
aim of this study was to systematically search the literature to provide an overview of 
the current evidence on the effectiveness in daily practice of biologic and conventional 
systemic therapies for the treatment of adults with plaque psoriasis. Short-term (week 
12–16), intermediate-term (> 16–≤ 28 weeks) and long-term (≥ 1 year) Psoriasis Area 
and Severity Index (PASI) responses were investigated. The primary objective was to 
show the proportion of patients that reached PASI75 (a 75% reduction in PASI score) 
with biologic and/or conventional systemic agents at week 12–16.
Materials and methods
A systematic literature search was performed on the effectiveness of treatment with 
biologics or conventional systemics in patients with plaque psoriasis in daily practice. 
Inclusion and exclusion criteria are described in Table SI. The decision was arbitrarily 
made to exclude studies in which the number of patients included at baseline was 
< 30, since in these articles the influence of every additional patient reaching PASI75 
has a large influence on the total percentage.
Outcomes
The following outcome measures were chosen (9): (i) PASI (10); (ii) Physician’s Global 
Assessment (PhGA) on a scale of 0–5, 0–6 or 0–7 (11); and (iii) body surface area 
(BSA) (11).
Primary outcome. The primary outcome was the PASI75 score for biologic and 
conventional systemic agents in daily clinical practice at week 12–16.
Secondary outcomes. Secondary outcome measures were PASI75 with intermediate- 
term (17–28 weeks) and long-term (≥ 1 year data) treatment, as well as PASI50, 
PASI90, PASI100 and decrease in mean PASI, PhGA and BSA with short-, intermediate- 
and long-term treatment.
All measures were compared with baseline except if stated otherwise.
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Search strategy
Two electronic databases (Pubmed and EMBASE) were systematically searched, 
and studies from 1990 until May 2014 were included. The term “psoriasis” was 
combined with terms for study design, treatments of interest and outcome measures 
for effectiveness (Table SII).
Data extraction
Two authors (JZ and MEO) independently screened titles and abstracts, and checked 
full articles for inclusion and exclusion criteria as well as references for other eligible 
studies. Data were extracted from text, tables or as numbers in figures and are shown 
in Table SIII. Any differences in decisions about inclusion or extraction were resolved 
by consensus or discussion with a third author (EdJ). The results for PASI75 were 
divided into cohorts using monotherapy and cohorts combining biologic with 
conventional systemic treatments in some or all of the patients during the study 
period, prospective vs. retrospective and short-, intermediate- and long-term results 
of treatment. PASI75 from per protocol analyses are shown. Comparative studies are 
described in a separate section.
Results
A total of 32 articles were included (Fig. 1): 28 on biologics, 3 on conventional 
systemic therapies, and 1 describing both biologic and conventional systemic 
treatment (Table SIII). Seven articles reported results of adalimumab therapy, 20 of 
etanercept, 4 of infliximab, 4 of ustekinumab, 1 of acitretin, 2 of fumarates, 1 of cyclo - 
sporine and 3 of methotrexate. There were 12 prospective and 20 retrospective 
studies. Results from comparative studies and dosing of biologics are described below 
in separate sections. For all effectiveness results the reader is referred to Table SIII.
Biologic therapies
Twenty-eight articles (12–39) reported data on biologic therapies and one article (40) 
compared biologic and conventional systemic treatment. For adalimumab the mean 
baseline PASI scores of patient cohorts ranged from 10.9 to 20.1, for etanercept these 
ranges were 11.3–25.6, for infliximab 14.7–17.7, and for ustekinumab 9.6–22.9.
Adalimumab
Study characteristics. Of the 7 articles studying the effectiveness of adalimumab, 3 
were prospective (13, 17, 18) and 4 retrospective studies (12, 14–16), including a total 
of 461 patients. In the study of Van Lümig et al. (13), only those patients whose 
treatment with etanercept had failed and who had switched to adalimumab were 
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included, and thus they represented a highly selected patient group. The results from 
this study were therefore not included for data aggregation. Dosing regimens varied 
amongst studies, as well as naïvety for biologics, and the number of patients using 
adalimumab in combination with a conventional systemic agent. One retrospective 
study (12) reported the results of adalimumab monotherapy. All 7 studies (12–18) 
reported on long-term therapy results. In all 7 studies (12–18) conventional systemic 
agents were allowed, but no specification was made of the duration and dosages 
used. Combination with a conventional systemic was used in 7–41% (12–18) of 
patients. Methotrexate was used most often. In all studies, the induction dose was per 
license (80 mg at the start and 40 mg at week 1). The maintenance dose was 40 mg 
every other week for most patients. However, in all studies dose adjustments were 
allowed. A dose increase to 40 mg weekly or 40 mg every 10 days was made in 
2–36% (12, 14–16, 18) of patients. In 2 studies, the mean weekly dose of adalimumab 
was 23 mg (13) and 24 mg (17), respectively. In 2 studies (17, 18), a total of 46 patients 
were treated with 40 mg per 3–4 weeks. The mean duration of dose increases/
decreases were not mentioned.
Figure 1  In- and excluded studies
Database searches: 6,289
• Medline: 1,959
• Embase: 4,330   
Included 32 publications 
Included from references
screened: 10 studies  
Included: 304 
Excluded on basis of title
and abstract: 5,995  
Excluded on basis of  full paper: 272
• Not specific citation of
 treatment/dosing: 30
• Combination with UV therapy: 6
• Not outcome measures: 60
• No baseline data: 1
• No daily practice: 34
• No time lines: 25
• Other forms of psoriasis: 14
• Number of patients (< 30): 21
• Language: 21
• Guidelines: 2
• In vitro/lab: 9
• Abstract/poster: 34
• Review: 13
• Rheumatoid arthritis: 2            
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PASI75 outcome for adalimumab. Overall, PASI75 was attained by 27–68% with 
short-term, 31–82% with intermediate-term and 44–89% with long-term (1 and 2 year) 
adalimumab treatment (Table SIII).
Adalimumab monotherapy. In the one retrospective study (12), adalimumab reached 
PASI75 percentages of 38% at week 16, 62% at week 24 and 69% at one year.
Cohorts using adalimumab with conventional systemic treatments. PASI75 results 
from prospective studies were 27–54% (17, 18) at week 12, 31% (17) at week 24, and 
44% (17) at 2 years of adalimumab treatment. In retrospective studies, 56–68% (12, 
14–16) of patients reached PASI75 at week 16 (of which only one study (14) used 
licensed dosing), 50–82% (12, 14–16) at week 24, 48–89% (12, 14–16) at 1 year and 
83% (16) at 2 years.
Etanercept
Study characteristics. Twenty articles studied etanercept therapy in daily clinical 
practice (Table  SIII). Nine studies (13, 18, 20, 22, 24, 26, 32, 33, 35) were prospective 
and 11 retrospective (19, 21, 23, 25, 27–31, 34, 40), including a total of 2,079 patients. 
Five of 20 articles (21, 25, 29, 31, 40) reported results on etanercept monotherapy. In 
7 studies (13, 21, 25, 27, 30, 33, 40) all patients were naïve for biologics, in 12 articles 
a proportion of patients was non-naïve  for biologic therapy. In one article (28) a 
highly selected group of patients was treated with etanercept, since all patients 
switched from efalizumab therapy. Results from this study were not included for data 
aggregation, but can be found in Table SIII. Dosing regimens varied amongst studies. 
It was explored whether PASI75 results differed between cohorts using either 50 mg 
biweekly or 25 mg biweekly as induction dose, but no direct comparisons were 
found.  PASI75 percentage ranges were similar, and thus an aggregation of all PASI75 
percentages is presented here.
Ten studies (13, 18, 23, 25, 29–33, 35) reported long- term results. No prospective 
studies reported solely on etanercept monotherapy. In 15 studies it was reported 
whether a combination therapy with a conventional systemic agent was prescribed 
and the percentages ranged from 0% to 69% (13, 18–20, 22, 24, 27, 28, 30–35, 40).
When combination therapy was allowed, methotrexate was used most often. Eight 
articles studied the licensed dosing of etanercept in (part of) the study and 12 studies 
(13, 18, 19, 22–25, 27, 29, 32, 33, 35) mentioned the ability for physicians to adjust the 
dose, but did not always provide a detailed description. Nine to 26% (18, 23, 27, 29, 
33) of patients had their dose adjusted to 50 mg biweekly during maintenance 
treatment and 3 studies reported a mean weekly dose of etanercept: 64.1 mg (35), 
68.3 mg (32) and 73.4 mg (13). 
PASI75 outcome for etanercept. Overall, PASI75 was attained by 12–66% with 
short-term, 19–85% with intermediate-term, and 49–92.3% with long-term (1- and 
2-year) etanercept treatment.
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Etanercept monotherapy. Retrospective studies reported a PASI75 of 36.1–54.1 (21, 
31) at week 12, 66% (25) at week 16 and 60.5–85% (21, 25, 29, 31) at week 24. At 1 
year PASI75 was 71.4–92.3% (25, 29, 31) and at 2 years 86.9% (31).
Cohorts using etanercept with conventional systemic treatments. In prospective 
studies, etanercept achieved a PASI75 in 12–63% (13, 18, 22, 26, 32, 33) at week 12 
and 19–73.2% (13, 24, 26, 32, 33, 35) at week 24 and 25–69.2% (13, 32, 33, 35) at 1 
year. In retrospective studies 21.4–26% (19, 27, 30, 34) of patients achieved PASI75 at 
week 12, 37–53% (23, 27, 30, 34) at week 24, and 49–54% (23, 30) at one year.
Dosing of etanercept. Of the 8 articles studying the licensed dosing of etanercept in 
(part of) the study, 20–43% and 50–73.2% of patients achieved PASI75 at short- and 
intermediate-term, respectively (Table SIII).
Infliximab
Study characteristics. Four articles were included, 2 prospective (18, 36) and 2 
retrospective studies (40, 41), including a total of 215 patients starting on infliximab. 
Two of 4 articles (36, 40) reported on infliximab monotherapy.  Except for  one  study 
(18),  all  studies prescribed the licensed dose of infliximab. No study mentioned 
long-term results for PASI75. Combination therapy with a conventional systemic was 
prescribed in 5% (18) and  81% (41) of patients. Methotrexate was used most often. In 
2 studies (18, 41) physicians decreased the dose interval (=dose increase) of 
infliximab in 10–23% of patients.
PASI75 outcome for infliximab. Overall, PASI75 was attained by 38–53% at short-term 
and 69% at intermediate-term treatment with infliximab.
Infliximab monotherapy. There were no PASI75 results from studies at week 12, 24 or 
on long-term treatment with infliximab monotherapy. At week 28, PASI75 was 69% 
(36) in one prospective study. 
Cohorts using infliximab with conventional systemic treatments. In the prospective 
study with combination therapy and dose adjustment (18), 38% of the patients who 
previously used biologics and 53% of biologic naïve patients reached PASI75 at week 12.
Ustekinumab
Study characteristics. Four articles described results for ustekinumab; 2 prospective 
(36, 37) and 2 retrospective studies (38, 39), including a total of 315 patients starting 
on ustekinumab. Both prospective studies (36, 37) reported on ustekinumab 
monotherapy. In all but one article (39) a licensed dose of ustekinumab was 
prescribed. One retrospective study (38) showed long-term results. Combination 
therapy with a conventional systemic was prescribed in 9–14% (38, 39) of patients 
and methotrexate was used most often. In one study (39) the dose interval of 
ustekinumab was adjusted (dose increase) in 8% of treated patients due to a partial 
relapse several weeks prior to the next injection.
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PASI75 outcome for ustekinumab. Overall, PASI75 was attained by 63–80% at short- 
term, 58–75.9% at intermediate-term, and 65.5% at long-term (1 year data) with 
ustekinumab treatment.
Ustekinumab monotherapy. Prospectively, PASI75 was attained by 80% (37) of patients 
at week 16 and 58% (36) at week 28 with ustekinumab monotherapy.
Cohorts using ustekinumab with conventional systemic therapy. Two retrospective 
studies, of which one (39) was with dose adjustments, were included and presented 
a PASI75 of 79.3% (39) at week 12 and 63% (38) at week 16, 66.7–75.9% (38, 39) at 
week 24, and 65.5% (39) at 1 year.
Naïve vs. non-naïve patients treated with biologics
Only a minority of included articles tried to assess the difference in biologic response 
between naïve and non- naïve patients, but in most of these articles baseline PASI 
score between both groups was not compared. In only 3 articles (2 adalimumab and 
1 ustekinumab) (16, 17, 39) it was stated that baseline PASI score was comparable 
between groups. For adalimumab, biologic naïve patients seemed to respond better 
compared with non-naïve patients, as measured with PASI75 at certain time-points 
and for ustekinumab the same phenomenon was found for anti-tumour necrosis 
factor alpha (TNF-α) naïve and non-naïve patients.
Conventional systemic therapies
Four articles (40, 42–44) reported on conventional systemic treatment. One article 
was prospective (43) and 3 retrospective (40, 42, 44). No articles were included on 
combination of 2 conventional systemic agents as this was an exclusion criteria in 
order to explore the true effectiveness of conventional systemic agents in daily 
practice. Except for one study on methotrexate (40), all studies reported a mean PASI 
score above 10 at start of treatment (11.6–26.5), which represents patients with 
moderate to severe psoriasis.
Acitretin
Study characteristics. One retrospective study (42) including 62 patients starting on 
acitretin was included. No prospective studies were available.
Monotherapy. In one retrospective study, PASI75 response was attained by 27% (42) 
of patients with a mean dose of 0.38 mg/kg/day at week 12. No prospective or 
retrospective data were available on long-term treatment with acitretin.
Fumarates
Study characteristics. Two articles (43, 44) reported the effectiveness of fumarates in 
daily practice, including a total of 312 patients starting on fumarates. One study was 
prospective and one (44) was retrospective. In one study (43) a maximum daily dose 
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of 360 mg was prescribed at week 6 and in the other study (44) this was 720 mg 
at week 9.
Monotherapy. One retrospective study showed a PASI75 of 47% (44) at week 12, 
63% (44) at week 24, and 76% (44) at 1 year. No long-term results from prospective 
studies were available.
Cyclosporine
Study characteristics. One retrospective article (42) studied the effectiveness of 
cyclosporine in daily practice, including a total of 36 patients starting on cyclosporine. 
In this study, a mean dose of 3.5 mg/kg/day was given.
Monotherapy. In one retrospective study, 46% (42) of patients reached a PASI75 at 
week 12.
Methotrexate
Study characteristics. Three articles (40, 42, 44) studied the effectiveness of methotrexate 
in daily practice, including 189 patients starting on methotrexate. All studies were 
retrospective. In one study (40) the methotrexate dose was 15 mg weekly and was 
given intramuscularly. In another study (44) methotrexate initial dose of 10 mg once 
weekly was increased to a maximum of 20 mg once weekly. Piaserico et al. (42) gave 
methotrexate in a mean weekly dose of 11.7 mg.
Monotherapy. In the retrospective studies, between 40% and 49% (42, 44) of patients 
treated with methotrexate 10–20 mg weekly achieved PASI75 at week 12 and 62% 
(44) at week 24. Eighty-one percent (44) achieved PASI75 at 1 year. No prospective 
data were available.
Comparative studies
Three retrospective studies (40, 42, 44) and 2 prospective studies (18, 36) compared 
anti-psoriatic agents within the study. Piaserico et al. (42) showed that the proportion 
of patients achieving PASI75 with acitretin (27%) was significantly lower than that of 
patients treated with methotrexate (49%, p = 0.01), etanercept (64%, p < 0.0001), 
adalimumab (65%, p < 0.01)  and infliximab (93%, p < 0.001) at week 12. Mean 
baseline PASI score appeared similar between these treatments (methotrexate:  12.7; 
acitretin  14.8;  etanercept  14.9; adalimumab 14.3; infliximab 14.8). Inzinger et al. (44) 
showed that, when prescribed as a primary treatment, the effectiveness of 
methotrexate was similar to that of fumarates; however, the mean PASI at start of 
methotrexate (18.3) was higher than for fumarates (11.6). In this study, no significance 
tests were performed for baseline variables. Gisondi et al. (40) compared mean PASI 
decrease between methotrexate, etanercept and infliximab at week 24. Mean PASI 
decrease was significantly higher for infliximab compared with methotrexate, 
infliximab compared with etanercept, and etanercept compared with methotrexate. 
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Patients treated with etanercept or infliximab, however, had higher baseline PASI 
scores compared with patients receiving methotrexate (p = 0.0001). Between 
etanercept and infliximab treated patients, there was no significant difference in 
baseline PASI score (p = 0.6). The prospective study of Gisondi et al. (36) showed no 
significant differences between ustekinumab and infliximab for mean PASI decrease 
at weeks 4 and 28. Mean baseline PASI scores did not differ between these 2 groups 
(p = 0.1). The prospective study of Menting et al. (18) showed no significant difference 
in mean change in PASI scores between adalimumab, etanercept and infliximab at 
weeks 12 and 24. Baseline PASI did not differ between the 3 groups.
Discussion
To our knowledge, this is the first systematic review on effectiveness in daily practice 
of biologics (etanercept, adalimumab, infliximab and ustekinumab) and conventional 
systemic agents (acitretin, cyclosporine, fumarates and methotrexate). Effectiveness 
data from real-life, observational studies are of added value, since patients and 
treatment strategies in daily practice substantially differ from those in RCTs (8). 
A substantial proportion of patients were achieving PASI75 with short- (week 12–16), 
intermediate- (week 17–28) and long-term (≥ 1 year) treatment with biologics and 
conventional systemic agents, except for acitretin monotherapy.
At short-term, PASI75 was 35–68% for adalimumab, 12–66% for etanercept, 38–53% 
for infliximab, 63–80% for ustekinumab, 27% for acitretin, 47% for fumarates, 46% for 
cyclosporine and 40–49% for methotrexate. At long-term (1- and 2-year data), PASI75 
was 44–89% for adalimumab, 49–92.3% for etanercept, 65.5% for ustekinumab, 76% 
for fumarates and 81% for methotrexate. We encountered a high heterogeneity in 
study design (prospective/retrospective), treatment regimen (e.g. dose adjustments, 
combination with conventional systemic agents) and patient population (e.g. baseline 
PASI scores, naïve/non-naïve) especially in studies on biologic treatments. Possible 
explanatory factors for the large ranges in PASI75 percentages, especially in 
etanercept and adalimumab therapy, were the use of combination strategies with a 
conventional systemic agent and dose adjustments.
In most studies on biologic therapies, concomitant conventional systemic agents 
were allowed and prescribed by physicians (24/29 studies). Methotrexate was mostly 
prescribed as combination therapy. In these studies, data were not analysed 
separately for patients using combination therapy. Therefore, we reported studies on 
combination therapy separately, but found similar PASI75 ranges between mono- 
therapy and combination therapy. There is some evidence from RCTs on combining 
biologics with conventional agents, with most data for etanercept combined with 
methotrexate (45). In daily clinical practice, however, combination strategies are often 
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applied in case of ineffectiveness, and may explain the similar results found in 
patients with and without combination therapies. More studies are needed into 
combination therapy of conventional systemic agents with biologic therapies.
Another explanation for the heterogeneity in study results is that dosing regimens 
differed between studies, especially for  etanercept  and  adalimumab  treatment. In 
adalimumab studies, all articles described dose increases and in studies with 
etanercept in more than half of included studies a dose increase was allowed. 
Aforementioned PASI75 results were therefore achieved with higher doses than 
licensed dose. Dose adjustments were less common in studies on infliximab and 
ustekinumab, although the number of included articles was too small to draw 
definitive conclusions. If this is indeed the case, dose adjustments could lead to 
higher costs for biologic treatment with etanercept and adalimumab compared with 
infliximab and ustekinumab.
Heterogeneity is typical in treating real-life patients and is not studied in RCTs. The 
results from daily practice studies enrich the body of evidence and can be of added 
value to current data from RCTs and guidelines when the quality of data reporting is 
improved. In order to improve this quality, it is strongly advised that authors of future 
studies report the items included in the STROBE statement (46). The following issues 
are of particular importance: study design (prospective, retrospective, wash-out 
period and method of analysis); and patient characteristics (age, sex, body weight, 
baseline PASI score, duration of psoriasis, previous treatments, presence of psoriatic 
arthritis, number of patients with and treatment duration of combinations of systemic 
anti-psoriatic therapies and dosages used). In case of biologic treatment in particular, 
it is important to describe naivety to biologics, previous biologic therapies, and 
dosing regimens.
Comparative studies were scarce and were hampered by differences at treatment 
start. Some RCTs (47–51) compared agents head-to-head. Data from pragmatic 
randomized daily practice studies or comparative effectiveness studies adjusted for 
confounders could be informative and decrease this gap in the evidence in the 
literature.
In conclusion, biologic and conventional systemic agents are effective in daily 
practice. Combination therapies of biologics with conventional systemic treatments 
and dose adjustments of biologics were frequently applied strategies, especially for 
adalimumab and etanercept, and could explain the large ranges in PASI75 results. 
There was a high heterogeneity in study design, treatment regimen and patient 
population between included studies. We made recommendations in order to 
improve the quality of reporting in daily practice studies. Gaps identified were daily 
practice data on infliximab, ustekinumab, conventional systemic therapies, long-term 
treatment, combination therapy and results of direct comparisons on effectiveness 
between anti-psoriatic agents.
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Supplemental material
Table SI  Inclusion and exclusion criteria
Inclusion criteria
Chronic plaque psoriasis Prospective or retrospective Thirty participants or more
Daily practice, database, registries, “real-world”, “real-life”, observational, cohort
Patients aged ≥ 18 years
English, Dutch or German language
Article reports on one of the following effectiveness outcomes: PASI, PhGA on a scale of 
0–5, 0–6 or 0–7 or BSA
Reporting on the effectiveness of following treatments: adalimumab, etanercept, 
infliximab, ustekinumab, acitretin, fumarates, cyclosporine, or
methotrexate
Reporting data analysed with the as-treated approach (per protocol analysis)
Exclusion criteria
Case reports
RCTs or clinical trials Safety studies
In vitro studies and other laboratory studies Pharmacokinetic studies
Cost-effectiveness studies
Open-label studies with a stringent protocol not reflecting daily practice Studies not 
reporting the time point at which effectiveness was measured Studies not reporting the 
dosage of treatment
Studies not reporting data separately per treatment
Studies reporting solely on non-systemic treatments such as phototherapy and topical 
therapies
Studies reporting solely on alefacept or efalizumab since these agents are no longer 
available for psoriasis treatment
Articles reporting on a combination of plaque psoriasis with other subtypes of psoriasis 
when the effectiveness data solely on chronic plaque psoriasis could not be extracted 
from the article
Studies describing only outcomes on psoriatic arthritis
Studies on specific psoriasis patient populations (e.g. psoriasis patients with HIV or 
hepatitis)
Studies in which conventional systemic agents were combined with other conventional 
systemic therapies
In patient cohorts treated with biologics, combination with conventional systemic was 
not excluded but described when appropriate
RCT: randomized controlled trial; PASI: Psoriasis Area and Severity Index; PhGA: Physician’s Global 
Assessment; BSA: body surface area.
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Table SIII  Evidence table
Available online: http://www.medicaljournals.se/acta/content/additional_content/4566SIIITab.pdf
Table SII  Search strategy
Search strategy for PubMed and EMBASE:
Words that indicated daily practice and effectiveness:
“registry”; “database”; “daily practice”; “clinical practice”; “real-world”; “real-life”; 
“treatment outcome”; “observational”; “prospective”; “retrospective”; “PASI”; “PGA”; 
“BSA”
Combined with the treatments of interest:
“drug therapy”; “drug effects”; “therapeutic use”; “dermatologic agents”; “biological 
agents”; “tumour necrosis factor-alpha antagonists”; “anti-TNF”; “TNF- alpha inhibitors”; 
“antibodies monoclonal”; “antibodies monoclonal humanized”; “monoclonal antibody 
CA2”; “TNFR-Fc fusion protein”; “methotrexate”; “cyclosporine”; “acitretin”; “fumaric acid 
esters”; “fumarates”; “etanercept”; “adalimumab”; “infliximab”; “ustekinumab”
TNF: tumour necrosis factor; TNFR-Fc: tumour necrosis factor receptor (p75) Fc fusion protein; PASI: 
Psoriasis Area and Severity Index; PhGA: Physician’s Global Assessment; BSA: body surface area.
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Abstract
Background: The efficacy of etanercept and ustekinumab in psoriasis has been 
compared in one randomized controlled trial. Comparison of the long-term effectiveness 
of biologics in daily practice psoriasis treatment is currently lacking.
Objectives: To compare the effectiveness between the three widely used outpatient 
biologics adalimumab, etanercept and ustekinumab in daily practice psoriasis 
treatment and to correct for confounders.
Methods: Data were extracted from the Continuous Assessment of Psoriasis 
Treatment Use Registry with Biologics (BioCAPTURE). Multilevel linear regression 
analyses (MLRA) and generalized estimating equation (GEE) analyses were 
performed on, respectively, course of mean PASI and PASI75 (75% reduction of PASI 
compared with baseline). Both models were corrected for confounders. Subgroup 
analyses for biologic dose were performed.
Results: We included 356 patients with 513 treatment episodes; 178 adalimumab, 
245 etanercept, 90 ustekinumab. MLRA showed a similar effectiveness between 
adalimumab, etanercept and ustekinumab after one year, but the highest effectiveness 
for ustekinumab during five years of treatment (p=0.047; ustekinumab versus 
etanercept p=0.019). GEE analysis revealed a higher chance of attaining PASI75 with 
adalimumab and ustekinumab compared with etanercept at one year of treatment. 
A higher than label dose was more often used in patients treated with etanercept 
(adalimumab, etanercept and ustekinumab: 31.5%, 55.1% and 16.7% after one year 
[p<0.001]; 39.3%, 71.4% and 24.4% after five years [p<0.001]).
Conclusions: Ustekinumab had the highest effectiveness during five years of 
treatment. Adalimumab and ustekinumab more often reached PASI75 than etanercept 
at one year of treatment. Etanercept was the agent most often prescribed in high 
doses.
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Introduction
Biologics have revolutionized the treatments of psoriasis.1 Randomized controlled 
clinical trials (RCTs) have shown that biologics are effective in treating selected 
patients with psoriasis.2-10 In RCTs, a higher efficacy has been found for ustekinumab 
(USTE) compared with etanercept (ETA).2 RCTs comparing USTE with adalimumab 
(ADA) or ETA with ADA have not been performed. Moreover, patients from RCTs differ 
from patients in daily practice and this might influence effectiveness of biologics in the 
real world.11 Direct comparison of treatments in real-life setting is sparse. A recently 
performed systematic review12 showed that two retrospective studies13,14 and two 
prospective studies15,16 were described that as a secondary objective compared the 
effectiveness of biologics in daily practice, but with short treatment periods (3-7 months), 
with few data on ustekinumab and uncorrected for baseline variables or other confounding 
factors. Long-term comparative real-world effectiveness data on biologic treatment 
for psoriasis, appropriately corrected for confounders, are currently lacking. This 
prospective daily practice study was performed in order to compare the effectiveness 
of the three widely used outpatient biologic treatments ADA, ETA and USTE by 
comparing mean Psoriasis Area and Severity Index (PASI)17,18 decrease during the 
first five years of biologic treatment. Our secondary objective was to compare the 
mean PASI decrease as well as the PASI75 (75% reduction of PASI compared with 
baseline) between these agents, respectively, during the first year and at one year of 
treatment. All effectiveness analyses were corrected for confounders. 
Methods
BioCAPTURE
Data were extracted from the Continuous Assessment of Psoriasis Treatment Use 
Registry with Biologics (BioCAPTURE)19,20 for all patients from inception of the 
registry in 2005. This registry contains prospective daily practice data on all 
consecutive patients with psoriasis treated with biologics from one academic and 
eight non-academic centers.  Patients were treated according to the guidelines21,22 
and recommendations were at the discretion of the attending dermatologist. When 
switching between biologics the newly introduced biologic was usually administered 
at the time point of the next scheduled drug dose of the previous biologic (for ADA 
after 2 weeks, for ETA after 1 week and for USTE after 12 weeks).23 Dose adjustments, 
adjustments of treatment intervals and/or the addition of combination therapies with 
conventional systemic therapies were recorded. The registry was approved by our 
medical ethics committee. Informed consent was obtained from every patient.
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Data collection and extraction
Outcomes
Data from patients were collected at baseline, week 6, week 12, then every three 
months until the first year of biologic treatment and thereafter every 3-6 months. PASI 
scores were extracted for all treatment episodes (TEs); the period in which a patient 
was treated with a certain biologic. In case the patient interrupted the biologic 
treatment for >90 days or if the patient switched to another biologic treatment, a new 
TE commenced. Ninety days is a widely accepted maximum interruption period.20,24,25 
One patient might, thus, have multiple TEs. TEs with at least a baseline PASI and one 
follow-up PASI at week 6 were included for analysis. Baseline PASI score was defined 
as PASI score at start or in case PASI was not recorded at that time point, the closest 
PASI between 90 days before and 7 days after the start of the biologic. The last PASI 
score was the PASI score at the stop date and if it was not recorded at that time point, 
the closest PASI until a maximum of 90 days after the stop date. Baseline patient 
characteristics, biologic treatment duration, the biologic dose and the use of 
concomitant systemic conventional therapy were extracted. Body Mass Index (BMI) 
was calculated from height and weight and expressed as kg/m2.  
Treatments
The cumulative biologic dose was calculated for every TE and subsequently this 
dose was divided by the expected cumulative dose if the patient would have been 
treated according to European Medicines Agency (EMA) label. Then, this ratio was 
expressed as a categorical variable (low-normal or high biologic dose compared 
with label dose, in which high dose represented a ratio >1). The mean biologic dose 
including the induction dose was used to present the dose per biologic group (ADA, 
ETA, USTE). The use of concomitant conventional therapies, such as acitretin, 
cyclosporine, fumarates and methotrexate was categorized into combination therapy 
or bridging therapy. Bridging therapy was defined as the use of a conventional 
systemic agent before the start of a biologic treatment until at least 28 days and for a 
maximum of 90 days after start of the biologic treatment. Combination therapy was 
defined as the start of a conventional systemic agent during biologic treatment with 
the conventional systemic agent being prescribed for at least 28 consecutive days. 
Exposure to a conventional systemic during biologic treatment was defined as 
bridging and/or combination therapy with a conventional systemic during the TE.
Statistical analysis
Analyses were performed using Microsoft Office Excel 2007, SPSS 22.0 (IBM, 
Armonk, NY, USA) and SAS 9.2 software (SAS Institute, Inc., Cary, NC). Variables with 
a normal distribution were presented as mean ± SD, non-normally distributed 
variables as median and inter-quartile range [IQR] and categorical data as N(%). 
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Baseline variables were compared between treatment groups using One-Way 
ANOVA in case of parametric and the Kruskal Wallis test in case of non-parametric 
distribution. Categorical variables were compared using the χ2-test. Analysis on 
baseline characteristics was executed including multiple TEs from the same patient. 
A sensitivity analysis was performed on baseline variables in which only one TE per 
patient per treatment group was included. A P-value of 0.05 was considered 
significant. 
For the primary analysis, multilevel linear regression analysis (MLRA) was performed 
to investigate differences between biologic treatments in mean PASI decrease over 
time during the first year and first five years of biologic treatment. With MLRA it is 
allowed to have repeated, correlated measurements, such as multiple TEs from the 
same patient.26 In addition, a moment in time with very few observations will contribute 
little to the estimate of the treatment effect. Independent variables in this model were 
treatment and time. Firstly, a model was created including the interaction between 
time and biologic treatment to investigate whether a different pattern existed between 
the biologic agents over time. The pattern over time was irregular for all biologic 
agents and therefore a parallel-line model was created without the interaction term. In 
this model, residues were tolerably normally distributed and the requirement of ho-
moscedasticity, i.e. similar variances of residuals at each level of the predictor 
variables, was reasonably met. 
For the secondary analysis, PASI75 scores were calculated with the per protocol 
method27 for Generalized Estimating Equation (GEE) analyses. GEE analysis allows 
to estimate parameters of a generalized linear model when the dependent variable is 
a dichotomous variable.28 A GEE analysis can handle multiple TEs of patients. For 
GEE analysis it was only possible to include the first TE of the same biologic in case 
there were two TEs of the same biologic within the same patient. In addition a 
sensitivity analysis was performed calculating PASI75 using the last-observation-car-
ried-forward (LOCF) method27 in which the last available absolute PASI score was 
carried forward until 1 year of treatment.  
Outcomes of all above mentioned analysis were corrected for confounders. Baseline 
variables that were considered as possible confounders were: age, sex, height, body 
weight, smoking status, alcohol use, family history of psoriasis, psoriatic arthritis, 
duration of psoriasis, baseline PASI score, prior biologic and prior TNF-α use. Those 
that were significantly different between the treatment groups were included in the 
MLRA and GEE as confounders and set as fixed variables.
The biologic dose expressed as low-normal or high compared with label dose and 
exposure to a concomitant conventional systemic therapy during a TE as well as the 
use of combination therapy were also compared between ADA, ETA and USTE 
treatment groups. When significantly different, subgroup analyses were performed. 
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Results
Patients
In total 513 TEs from 356 patients were included; ADA 178 TEs, ETA 245 TEs and 
USTE 90 TEs. For the MLRA all 513 TEs and for GEE analysis 483 TEs were included 
(Figure 1). Baseline patient characteristics, i.e. the characteristics of the patient at 
inclusion in BioCAPTURE, are shown in Table 1. The majority of patients were male 
(62.1%), overweight (BMI 27.4), smokers (74.2%) and had a positive family history of 
psoriasis (65.7%). Median baseline PASI score was 13.1. This is comparable to other 
major psoriasis patient registries.29-31
Baseline TE characteristics
Baseline characteristics of TEs are presented in Table 2; all TEs are included and 
therefore patients can appear more than once. Sensitivity analysis on baseline 
variables with one TE per patient per treatment group resulted in similar p-values as 
the p-values from analyses comparing baseline TE variables with multiple TEs (Table 2 
and Supplement_Table 1). Median baseline PASI score was significantly higher for 
USTE (14.6) and ETA (13.0) compared with ADA (11.1; p=0.001 and p<0.001, 
respectively). Median baseline weight was significantly higher for USTE (92.0 kg) and 
ADA (88.0 kg) compared with ETA (82.8 kg; p=0.001 and 0.003, respectively). Other 
significantly different baseline TE characteristics were biologic naïvity (p<0.001), and 
anti-TNF- α naïvity (p<0.001; Table 2). Patients were significantly less often biologic 
naïve and anti-TNF-α naïve in TEs of USTE compared with ADA (p= 0.003 and 
p=0.009, respectively) and ETA (p<0.001 in both analyses). All significantly different 
baseline characteristics were incorporated into the MLRA and GEE analysis to correct 
for their possible confounding effect.
Treatment characteristics 
Treatment characteristics during the first year and first five years of biologic treatment 
are shown in Table 3. Only the biologic dose expressed as low-normal or high was 
statistically significantly different between biologics after one and five years. Ever 
exposure to a conventional systemic as well as combination therapy were not 
significantly different between the biologics. A description of biologic dose, bridging 
and combination therapy in our cohort can be found in the Supplement and 
Supplement_Table 2.
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Effectiveness
Course of mean PASI
The mean PASI decrease of ADA, ETA and USTE during five years, uncorrected for 
confounders, is visualized in Figure 2A. Mean baseline PASI score differed between 
the agents (ADA 11.6 ± 5.8; ETA 14.7 ± 8.2; USTE 15.1 ± 8.0). It is shown that ADA, 
ETA and USTE treatment resulted in a rapid decrease in mean PASI  during the first 
three months. After one year of treatment mean PASI decrease seemed to stabilize 
for all three biologics (Figure 2A). Uncorrected for confounders, Figure 2A gives the 
impression that ADA and USTE show better responses compared with ETA at one 
year and five years of treatment. This impression remains when only correcting for 
baseline PASI score (Supplement_Figure 1).
Figure 1  Flow chart of included patients into MLRA and GEE analyses
Patients treated with ADA, ETA or USTE from BioCAPTURE (Continuous Assessment of Psoriasis Treatment 
Use Registry with Biologics).
 
TE = treatment episode
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Since a high biologic dose was more often prescribed in ETA treated patients, 
followed by ADA and then USTE, effectiveness was split for low-normal dosed TEs 
and high dosed TEs (Figure 2B; uncorrected for confounders). From this figure, it can 
be seen that all high dosed TEs remained at a higher PASI when compared with low 
dosed TEs. 
Table 1  Baseline patient characteristics
Baseline patient characteristics First ever TE in BioCAPTURE
 N=356
Age at start of  biologic (yrs) 47.6 ± 12.7
Missing: 0
Gender (male) 221 (62.1%)
Missing: 0
Length (cm) 175.5 ± 8.8
Missing: 82
Weight (kg) 84.6 [22.1]
Missing: 78
BMI (kg/m2) 27.4 [6.6]
Missing: 82
Smoking status, present or past (yes) 264 (74.2%)
Missing:6
Alcohol use, present or past (yes) 255 (71.6%)
Missing: 9
Positive family history of psoriasis (yes) 234 (65.7%)
Missing: 12
Psoriatic arthritis, diagnosis by a Rheumatologist (yes) 104 (29.2%)
Missing: 18
Duration of psoriasis until start of biologic (yrs) 19.6 [17.1]
Missing: 2
Baseline PASI score 13.1 [8.0]
Missing: 0
Mean ± SD, Median [IQR], N(%).
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Table 2  Baseline characteristics of included treatment episodes (TEs)
Baseline TE characteristics Adalimumab
N= 178 TEs
Etanercept
N= 245 TEs
Ustekinumab
N= 90 TEs
p
Age at start of  biologic (yrs) 49.0 ± 12.4
Missing: 0
47.1 ± 12.8
Missing: 0
49.3 ± 12.5
Missing: 0
0.208†
Gender (male) 103 (57.9%)
Missing: 0
152 (62.0%)
Missing: 0
58 (64.4%)
Missing: 0
0.523¥
Length (cm) 175.6 ± 8.6
Missing: 16
175.2 ± 8.0
Missing: 76
176.6 ± 8.6
Missing: 8
0.478†
Weight (kg) 88.0 [24.9]
Missing: 16
82.8 [24.3]
Missing: 75
92.0 [21.1]
Missing: 4
0.001‡
BMI (kg/m2) 29.2 [6.5]
Missing: 17
27.1 [6.5]
Missing: 76
28.6 [6.4]
Missing: 8
0.002‡
Smoking status, present  
or past (yes)
135 (75.8%)
Missing: 2
185 (75.5%)
Missing: 4
67 (74.4%)
Missing: 1
0.958¥
Alcohol use, present  
or past (yes)
126 (70.8%)
Missing: 4
172 (70.2%)
Missing: 4
63 (70%)
Missing: 2
0.972¥
Positive family history of 
psoriasis (yes)
121 (68%)
Missing: 5
159 (65.0%)
Missing: 7
59 (65.6%)
Missing: 3
0.796¥
Psoriatic arthritis (yes) 55 (30.9%)
Missing: 7
72 (29.4%)
Missing: 4
23 (25.6%)
Missing: 9
0.330¥
Duration of psoriasis until  
start of biologic (yrs)
20.4 [18.4]
Missing: 2
20.4 [17.7]
Missing: 0
18.43 [13.8]
Missing: 0
0.667‡
Baseline PASI score 11.1 [7.5]
Missing: 0
13.0 [7.9]
Missing: 0
14.6 [12.2]
Missing: 0
<0.001‡
Biologic naïve (yes) 63 (35.4%)
Missing: 0
147 (60.0%)
Missing: 0
16 (17.7%)
Missing: 0
<0.001¥
Anti-TNF-α naïve (yes) 70 (39.3%)
Missing: 0
170 (69.4%)
Missing: 0
21 (23.3%)
Missing: 0
<0.001¥
Mean ± SD, Median [IQR], N(%). N/A = Not applicable
† One-Way ANOVA, ¥ chi-squared test, ‡ Kruskal Wallis test
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Table 3   Treatment characteristics of included treatment episodes (TEs) at one 
and five years of biologic treatment.
Treatment characteristics- 
first year of treatment
Adalimumab
N= 178 TEs
Etanercept
N= 245 TEs
Ustekinumab
N= 90 TEs
p
Cumulative dose of biologic 
(mg)
991 ± 376 3001 ± 1070 268 ± 108 N/A
Time average dose of biologic 
(mg/day)
3.5 ± 0.8 10.4 ± 2.5 0.9 ± 0.3 N/A
Dose higher than EMA label 
during TE (yes)
56 (31.5%)
Missing: 0
135 (55.1%)
Missing: 0
15 (16.7%)
Missing: 0
<0.001¥
Exposure to a conventional 
systemic agent during TE 
(yes)
47 (26.4%)
Missing: 0
58 (23.7%)
Missing: 0
16 (17.8%)
Missing: 0
0.291¥
Combination therapy without 
bridging during TE (yes)
37 (20.8%)
Missing: 0
44 (18.0%)
Missing: 0
14 (15.6%)
Missing: 0
0.554¥
Treatment characteristics- 
first 5 years of treatment
Adalimumab
N= 178 TEs
Etanercept
N= 245 TEs
Ustekinumab
N= 90 TEs
p
Cumulative dose of biologic 
(mg)
2627 ± 2199 9611 ± 8407 604 ± 555 N/A
Average dose of biologic  
(mg/day)
3.4 ± 0.9 9.9 ± 2.6 0.9 ± 0.3 N/A
Dose higher than EMA label 
during TE (yes)
70 (39.3%)
Missing: 0
175 (71.4%)
Missing: 0
22 (24.4%)
Missing: 0
<0.001¥
Exposure to a conventional 
systemic agent during TE 
(yes)
50 (28.1%)
Missing: 0
64 (26.1%)
Missing: 0
18 (20.0%)
Missing: 0
0.353¥
Combination therapy without 
bridging during TE (yes)
40 (22.5%)
Missing: 0
50 (20.4%)
Missing: 0
16 (17.8%)
Missing: 0
0.663¥
Combination or bridging with 
conventional agent
Total: 52 c.s.
Combi: 42 
(81%)
Bridging: 10 
(19%)
Total: 72 c.s.
Combi: 57 
(79%)
Bridging: 15 
(21%)
Total: 20 c.s.
Combi: 18 
(90%)
Bridging: 2 
(10%)
N/A
Concomitant conventional 
systemic drugs (combination 
or bridging; number of agents)
Methotrexate: 
40
Cyclosporine: 
7
Acitretin: 4
Fumarates: 1
Methotrexate: 
42
Cyclosporine: 
11
Acitretin: 14
Fumarates: 3
Tacrolimus: 1
MMF: 1
Methotrexate: 
14
Cyclosporine: 
1
Acitretin: 5
Fumarates: 0
N/A
Mean ± SD, N(%), N/A = Not applicable. C.s. = conventional systemic. MMF: mycophenolate mofetil.  
¥ chi-squared test
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Five year effectiveness - Course of mean PASI
Over 5 years of treatment, MLRA showed a significant difference between medication 
(p=0.047) with overall the most favorable effectiveness results for USTE compared 
with ETA (p=0.019). There were no significant differences between the other biologic 
groups (Supplement_Table 3).
Split for biologic dose, effectiveness of the low-normal dosed TEs of ADA, ETA and 
USTE was comparable as was the effectiveness of high dosed TEs (Supplement_
Table 3). 
One year effectiveness - Course of mean PASI
Overall, MLRA showed no significant differences between ADA, ETA and USTE 
during the first year of treatment (Supplement_Table 3). Also, no significant differences 
were encountered in the low-normal dosed TEs between biologics. Numerically, 
however, ADA and USTE performed better than ETA in both overall effectiveness and 
the effectiveness of low-normal doses. 
One year effectiveness - PASI75 
Per-protocol PASI75 data uncorrected for confounders for the first year of treatment 
are visualized in Supplement_Figure 2. The uncorrected PASI75 percentages were 
ETA 39.1%, ADA 45.9% and USTE 45.3% after one year of treatment. Uncorrected 
PASI75 data for low-normal dosed TEs during the first year of treatment are shown in 
Supplement_Figure 3. This figure represents the percentage of low-normal dosed 
TEs in which a PASI75 was reached, from the total group of low-normal dosed TEs.  
GEE analysis on per-protocol data showed that, overall, ADA and USTE had a higher 
chance in achieving a PASI75 compared with ETA at one year of treatment 
(Supplement_Table 3, overall p=0.028; ADA vs ETA p=0.010; USTE vs ETA p= 0.048). 
Sensitivity analysis on PASI75 LOCF data showed that USTE was better than ADA 
and ETA (Supplement_GEE_LOCF, Supplement_Figures 4&5). 
GEE subanalysis of low-normal dosed TEs showed that ADA had a higher chance 
than ETA, but not USTE in reaching PASI75 (Supplement_Table 3; ADA vs ETA 
p=0.011; ADA vs USTE p=0.546; USTE vs ETA p=0.111). Sensitivity analysis on 
LOCF data showed that USTE was better than ETA, but not better than ADA 
(Supplement_GEE_LOCF, Supplement_Figures 4&5). 
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Figure 2A and B   Mean PASI from baseline until 5 years of biologic treatment  
(as treated analysis), uncorrected for confounders, and split for 
low-normal and high dosed TEs
A
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ADA= adalimumab, ETA= etanercept, USTE= ustekinumab. Low-normal= actual dose was low to normal 
compared with the expected label dose during the treatment episode. High= actual dose was higher than 
the expected label dose during the treatment episode. Notice the difference in mean baseline PASI between 
the different dosing groups.
B
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Discussion
This prospective, multicenter study provides the comparative effectiveness between 
ADA, ETA and USTE in real-life treatment of  patients with psoriasis. USTE had the 
highest overall effectiveness during the first five years of treatment. During the first 
year of treatment USTE and ADA had a higher chance of attaining PASI75 compared 
with ETA. 
No major differences existed between ADA, ETA and USTE in the course of mean 
PASI in low-normal doses during one and five year treatment. Thus, in case low-normal 
doses of biologics were maintained during this study, all biologics had a similar 
effectiveness. Physicians were, however, less often able to maintain a low-normal 
dose in ETA treated patients, followed by ADA and then USTE. Also, all high dosed 
TEs remained at a higher PASI when compared with low dosed TEs. High doses of 
biologics were thus prescribed to a subpopulation of patients with psoriasis with a 
suboptimal response to biologic therapy. Hence, a suboptimal response was more 
often the case in ETA treated patients, followed by ADA and then USTE. Therefore, 
USTE was the drug with the highest overall effectiveness in daily clinical practice 
during five years of treatment. Data from other prospective patient registries are 
needed to verify these observations.
High doses of ADA, ETA and USTE were equally effective over 5 years of treatment. 
High dosed patients, however, remained at a higher mean PASI when compared with 
low dosed patients. Currently, knowledge about the effect of dose adjustments in 
daily practice is scarce.12 Studies on the effect of dose adjustments of the different 
biologics are needed to aid the physician in deciding whether to adjust the biologic 
dose or switch to another biologic agent.
Dose adjustments were most frequently made in ETA, followed by ADA and lastly 
USTE treatment. The observation that in ETA and ADA treatment dose is more 
frequently adjusted when compared with USTE corresponds to a recent systematic 
review.12 Although more TEs of ETA had a higher dosing regimen when compared 
with ADA and USTE, it did not result in a more successful mean PASI course during 
long-term five years treatment. 
That USTE is an effective agent has been shown in RCTs2,6,7,32 with USTE being more 
effective than ETA2. Recent real-world data show that USTE has the highest 
first-course drug survival, which is a comprehensive measure of effectiveness, safety, 
and patients’ and doctors’ preferences24,33. In addition, results from our study 
indicate that USTE might be the preferred agent for long-term psoriasis treatment. 
Differences in effectiveness results between biologics might be explained by the 
difference in mode of action between anti-TNF-α receptor blocker ETA, anti-TNF-α 
antibody ADA and the anti-IL12/IL23 antibody USTE. USTE, by blocking IL-12 and 
IL-23, reduces the survival and proliferation of, respectively, Th1 and Th17 cells. 
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Especially Th17 cells play a key role in the development of psoriasis.34  It can be 
hypothesized that USTE exhibits a higher effectiveness compared with TNFα-inhibitors 
due to the fact that the IL-12 and IL-23 cytokines function more downstream in the 
cascade of cytokines involved in the immunopathogenesis of psoriasis compared 
with the TNF-α cytokine.1,35 It is also known, however, that not every patient reaches 
the same effectiveness results, which in theory could be explained by the activation 
of different sets of genes between patients.36 More research is needed to explain why 
differences in effectiveness are seen between biologic agents and between patients.
A limitation of our study is that patient adherence to biologics was not measured, for 
example with patient questionnaires. The exact dose with which patients are treated 
might therefore vary from the calculated dose. Dose adjustments were, however, 
recorded in our registry and data showed that dose adjustments were indeed given 
to a patient group with suboptimal responses to therapy. Another limitation might be 
that we used PASI75 as an outcome measure for our secondary objective instead of 
PASI 90/100. The number of patients reaching PASI90/100 was, however, insufficient 
for sound analysis in our study. Research with cohorts including larger numbers of 
patients could answer this question. Strengths of our study include the similarity of 
our patients with other major registries, the prospective nature and multicenter 
character of the study, the inclusion of long-term PASI data and biologic doses as 
well as correcting all analyses for confounders. Another strength is the use of MLRA 
that provides us with an estimate of the effect of USTE that is only little influenced by 
the low number of TEs of USTE at the end of five-year treatment. 
This is the first prospective, real-world study in which effectiveness data, i.e. course 
of mean PASI and PASI75, from the first five years of biologic treatment are compared 
between the three most commonly prescribed outpatient biologics ADA, ETA and 
USTE corrected for confounders in patients with psoriasis that were comparable to 
other major psoriasis patient registries. Our data show that, amongst outpatient 
biologics, USTE is the most effective agent in daily practice during five years of 
psoriasis treatment. When the physician was able to keep the patient on a low-normal 
biologic dose the effectiveness between the outpatient biologics was similar. Patients 
on low-normal doses had lower mean PASI scores compared with high dosed 
patients. Keeping a low-normal dose was most often the case in USTE treated 
patients which resulted in USTE being the most effective agent in psoriasis treatment 
in daily practice. When high doses were needed, a similar effectiveness was seen 
between biologics during long-term treatment. These findings warrant replication 
from other prospective daily practice cohorts and further research into dose 
adjustments of biologics in the real-world.   
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Supplemental material
Supplement_Table 1   Baseline and treatment characteristics of included treatment 
episodes (one TE per patient per treatment group)
Baseline TE characteristics Adalimumab
N= 173 TEs
Etanercept
N= 222 TEs
Ustekinumab
N= 88 TEs
p-value
Age at start of  biologic (yrs) 48.8 ± 12.5
Missing: 0
47.0 ± 12.8
Missing: 0
49.5 ± 12.4
Missing: 0
0.184†
Gender (male) 100 (57.8%)
Missing: 0
140 (63.1%)
Missing: 0
56 (63.6%)
Missing: 0
0.500¥
Length (cm) 175.5 ± 8.6
Missing: 16
175.1 ± 8.1
Missing: 67
176.6 ± 8.7
Missing: 8
0.411†
Weight (kg) 87.3 [23.7]
Missing: 16
82.5 [24.8]
Missing: 66
92.0 [21.2]
Missing: 4
0.001‡
BMI (kg/m2) 29.0 [6.5]
Missing: 17
27.1 [6.3]
Missing: 67
28.6 [6.7]
Missing: 8
0.003‡
Smoking status (yes) 132 (76.3%)
Missing: 2
168 (75.7%)
Missing: 3
65 (73.9%)
Missing: 1
0.902¥
Alcohol use (yes) 122 (70.5%)
Missing: 4
158 (71.2%)
Missing: 3
62 (70.5%)
Missing: 2
1.000¥
Positive family history of 
psoriasis (yes)
118 (68.2%)
Missing: 5
142 (64.0%)
Missing: 6
57 (64.8%)
Missing: 3
0.642¥
Psoriatic arthritis (yes) 55 (31.8%)
Missing: 7
68 (30.6%)
Missing: 4
22 (25.0%)
Missing: 9
0.252¥
Duration of psoriasis until  
start of biologic (yrs)
20.3 [18.5]
Missing: 2
20.7 [17.3]
Missing: 0
18.43 [14.0]
Missing: 0
0.691‡
Baseline PASI score 11.2 [7.2]
Missing: 0
13.3 [8.3]
Missing: 0
14.8 [12.2]
Missing: 0
<0.001‡
Biologic naïve (yes) 63 (36.4%)
Missing: 0
147 (66.2%)
Missing: 0
16 (18.2%)
Missing: 0
<0.001¥
Anti-TNF-α naïve (yes) 70 (40.5%)
Missing: 0
170 (76.6%)
Missing: 0
21 (23.9%)
Missing: 0
<0.001¥
Treatment characteristics 
during the first 5 years of 
treatment
Adalimumab
N= 173 TEs
Etanercept
N= 222 TEs
Ustekinumab
N= 88 TEs
p-value
Dose higher than EMA label 
during TE (yes)
68 (39.3%)
Missing: 0
159 (71.6%)
Missing: 0
20 (22.7%)
Missing: 0
<0.001¥
Conventional systemic agent 
ever exposed during TE (yes)
50 (28.9%)
Missing: 0
60 (27.0%)
Missing: 0
18 (20.5%)
Missing: 0
0.334¥
Combination therapy without 
bridging during TE (yes)
40 (23.1%)
Missing: 0
47 (21.2%)
Missing: 0
16 (18.2%)
Missing: 0
0.652¥
Mean ± SD, Median [IQR], N(%). N/A = Not applicable. 
† One-Way ANOVA, ¥ chi-squared test, ‡ Kruskal Wallis test
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Supplement_Biologic dose
After one year of treatment, a higher dose than EMA label was significantly more 
often prescribed in TEs of ETA (n=135; 55.1%) compared with ADA (n=56; 31.5%) 
and USTE (n=15; 16.7%; p<0.001, Table 3). After five years of treatment, TEs of ETA 
had still significantly the highest percentage of TEs with a higher dose than label 
(n=175 TEs; 71.4%), followed by ADA (n=70 TEs; 39.9%) and USTE (n=22 TEs; 24.4%; 
ETA vs ADA p<0.001; ETA vs USTE p<0.001; ADA vs USTE p=0.015). Most 
commonly, high doses were doses adjustments to 75 or 100 mg weekly for ETA, 
40mg weekly for ADA, interval decrease for USTE 45mg and a dose increase of 
USTE to 90mg per 12 weeks. The cumulative dose and the average daily dose of the 
biologics as well as their expected label doses are presented in Table 4. This table 
shows that the mean doses of biologics in daily practice are higher than label dose 
for every biologic, but highest for ETA, followed by ADA and USTE. Dose of USTE 
was lower than expected after the first year of treatment (eTable 2). After 5 years of 
treatment, the mean dose of ETA including the induction dose was 72.1 ± 17.8 mg 
per week (low-normal dosed TEs 61.2 ± 17.4 mg per week; high dosed TEs 76.4 ± 
16.0 mg per week). Mean dose of ADA with induction dose was 49.2 ± 12.0 mg per 
two weeks (low-normal dosed TEs 43.8.± 8.9 mg per two weeks; high dosed TEs 
57.5 ± 11.5 mg per two weeks) and mean dose of USTE with induction dose was 71.5 
± 26.5 mg per 12 weeks (low-normal dosed TEs 45mg and 90mg group, respectively: 
57.3 ± 15.7 mg and 107.0 ± 15.0 mg per 12 weeks; high-dosed TEs 45mg and 90mg 
group, respectively:  79.8 ± 22.6 mg and 125.0 ± 5.4 mg per 12 weeks). 
Supplement_Combination and bridging therapy
After one and five years, ever exposure to a conventional systemic agent (i.e., bridging 
and/or combination therapy) or combination therapy with a conventional systemic 
agent were equally distributed amongst biologic treatment groups (Table 3). After 5 
years, 50 (28.1%), 64 (26.1%) and 18 (20.0%) TEs of ADA, ETA and USTE, respectively, 
were ever exposed to a conventional systemic agent in the form of bridging and/or 
combination therapy. Bridging therapy occurred in 10 (19%), 15 (21%) and 2 (10%) 
TEs of ADA, ETA and USTE. Combination therapy was prescribed in 40 (22.5%), 50 
(20.4%) and 16 (17.8%) TEs of respectively ADA, ETA and USTE. One TE of ETA had 
a bridging as well as one combination therapy. The number of conventional systemic 
agents prescribed as combination therapies and their percentage of the total of 
conventional systemic agents in the biologic treatment group were 42 (81% of 52), 57 
(79% of 72) and 18 (90% of 20) in ADA, ETA and USTE treatment, respectively. In one 
TE of ADA, four TEs of ETA and two TEs of USTE the patients received more than one 
combination treatment during the five year period (ADA: 1TE two times a combination; 
ETA: 2 TEs 2 times a combination, 1 TE 3 times a combination, 1 TE 4 times a 
combination; USTE: 2 TEs 2 times a combination treatment). 
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Supplement_Figure 1   Mean PASI over time according to multilevel linear 
regression analysis only corrected for baseline PASI score
Mean baseline PASI set at 13.0. Ada = Adalimumab; Eta = Etanercept; Uste = Ustekinumab.
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Supplement_GEE_LOCF
Generalized Estemating Equation regression analysis, last-observation-carried-forward 
analysis
Last-observation-carried-forward PASI75 data uncorrected for confounders during 
the first year of treatment is visualized in Supplement_Figure 4. The uncorrected 
PASI75 for ETA was 34.7%, ADA 37.6% and USTE 42.2% at one year of treatment. 
GEE analysis showed a significant difference in favor of USTE compared with ADA 
and ETA in attaining PASI75 after one year of treatment (p=0.014; ADA 0.56; ETA 
0.38; USTE 1.0; USTE vs ETA p=0.004; USTE vs ADA p=0.049; ADA vs ETA p=0.159).
Uncorrected PASI75 data for low-normal dosed TEs are shown in Supplement_Figure 
5. This figure represents the percentage of low-normal dosed TEs in which a PASI75 
was reached, from the total group of low-normal dosed TEs. The uncorrected PASI75 
for low-normal dosed ETA was 36.4%, ADA 47.5% and USTE 50.7% at one year of 
treatment. In the low-dosed TEs, GEE analysis showed that USTE was more effective 
than ETA in achieving PASI75 (p=0.033; ADA 0.65, ETA 0.34, USTE 1.00; USTE vs 
ETA p=0.009; USTE vs ADA p=0.195; ADA vs ETA p=0.069).  
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Abstract
Background:  It is important to assess which patients with psoriasis are more likely 
to achieve high clinical responses on biologics in daily practice.
Objectives: To assess the number of treatment episodes (TEs) that reach PASI100 
(100% reduction in Psoriasis Area and Severity Index), PASI90 or PASI≤5 at week 24 
of biologic treatment, and which baseline patient characteristics predict treatment 
response.
Methods:  Data from patients with psoriasis treated with adalimumab, etanercept, 
infliximab or ustekinumab were extracted from a prospective cohort. Percentages of 
TEs with high clinical responses were described. Univariate and multivariate 
regression analyses were performed with the Generalized Estimating Equation 
method with patient as random effect to elucidate which baseline patient character-
istics were predictors for PASI90 and PASI≤5 at week 24.
Results: In total, 454 TEs were included (159 adalimumab; 193 etanercept; 19 
infliximab; 83 ustekinumab) from 326 patients. At week 24, in 3%, 15% and 59% of 
TEs, respectively, PASI100, PASI90 and PASI≤5 was reached. In TEs without PASI100 
or PASI90 response, PASI≤5 was still achieved in a substantial proportion (58% and 
52% respectively). Baseline PASI≥10 was a strong predictor for reaching PASI90; 
baseline PASI<10 and a lower baseline BMI were significant predictors for PASI≤5 at 
week 24. 
Conclusions: In daily practice, a limited number of patients reached PASI100 or 
PASI90 at 24 weeks of biologic treatment. We showed the importance of including an 
absolute PASI score in the assessment of psoriasis severity. Baseline BMI was an 
important, modifiable predictor for a high response on biologics for psoriasis.
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Introduction
A 90% improvement of the Psoriasis Area and Severity Index (PASI90)  is more and 
more observed with current therapies for psoriasis. PASI90 corresponds better with 
a clear or almost clear psoriasis and with a good quality of life compared with 
PASI75.1-3 Therefore, treatment success in psoriasis is starting to shift from PASI75 to 
PASI90.1 A high clinical response can be defined as reaching a relative PASI measure 
such as PASI90 or PASI100, but can also be described by reaching a low absolute 
PASI score such as PASI≤5. Studies show that a good quality of life is also more often 
achieved in patients with an absolute PASI≤5 compared with PASI>5.1,4,5 The 
difference between relative and absolute PASI might be important in the treatment of 
patients with psoriasis in daily practice, in which patients with high baseline PASI 
scores (PASI≥10) but also with lower baseline PASI scores (PASI<10) are being 
treated with biologics. A lower baseline PASI score might occur in patients that switch 
from one biologic treatment to another. It is more difficult to achieve PASI90 in patients 
with a low PASI score at start of treatment compared with patients with high baseline 
PASI scores. With this study our first research objective was to assess how many 
patients with psoriasis that were treated with biologics in daily practice for 24 weeks, 
reached a high clinical response (PASI90, PASI100, PASI≤5) at week 24. Secondly, 
we wanted to assess how many patients that achieved PASI90 at week 24 also 
reached PASI≤5 at week 24. Thirdly, it was assessed how many patients without 
PASI90 or PASI100 response, still achieved PASI≤5 at week 24. 
Baseline patient characteristics might predict whether a psoriasis patient will reach a 
high clinical response (PASI90, PASI100 or PASI≤5) on biologic treatment. To date, no 
studies have tried to assess which patients with psoriasis are more likely to achieve 
these high clinical responses. Predicting a high clinical response is, however, 
important for personalized treatment and can also increase the awareness of 
physicians for those patients at risk of not achieving a high clinical response. 
Moreover, knowledge on predictors might direct future research, such as randomized 
controlled trials (RCTs) that will try to improve the efficacy of biologics for those 
patients that are not expected to reach a high clinical response based on these 
predictors. Baseline patient characteristics associated with the effectiveness of 
biologics in previous studies were baseline body mass index (BMI), baseline severity 
score, duration of psoriasis and biologic naivity.6-9 Our secondary objective was to 
assess which patients were more likely to achieve a high clinical response by 
analysing which baseline patient characteristics were predictors for high clinical 
response at 24 weeks of treatment with biologics. For our research objectives, we 
used prospective daily practice registry data from BioCAPTURE (Continuous 
Assessment of Psoriasis Treatment Use Registry with Biologics).10
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Methods
BioCAPTURE
BioCAPTURE is a registry containing prospective, multicenter data on biologic 
treatment of patients with plaque psoriasis from daily practice.10 This registry contains 
prospective daily practice data on all consecutive patients with psoriasis treated with 
biologics from one academic and eight non-academic centers. BioCAPTURE was 
approved by the medical ethics committee. Informed consent was obtained from 
every patient. Treatment of patients with psoriasis occurs according to European and 
Dutch guidelines.11,12 Treatment decisions, such as dose adjustments, were made by 
the treating physician.
 
Data extraction 
Data from patients with psoriasis that were treated with biologics (adalimumab [ADA], 
etanercept [ETA], infliximab [IFX] and ustekinumab [USTE]) were extracted from 
BioCAPTURE (2005 – May 2015). Extracted baseline variables were PASI score, age 
at start of biologic, sex, weight, length, BMI, psoriatic arthritis, positive family history 
of psoriasis, duration of psoriasis until start of biologic and biologic naivity. A treatment 
episode (TE) was defined as a period of time in which the patient received a biologic 
without interrupting treatment for >90 days. Ninety days is a widely accepted 
interruption period.13-15 The baseline PASI score of a TE was defined as PASI score at 
start or if it was not recorded at that time point, the closest PASI between 90 days 
prior to and 7 days after the start of the biologic. For each patient, only the first TE per 
biologic was chosen if a patient had received the same biologic twice. One patient 
could have multiple TEs when the patient had switched from one biologic to a different 
biologic agent. The mean average biologic dose during the first 24 weeks was 
calculated. It was also calculated whether the total biologic dose during the first 24 
weeks of treatment was low to normal or higher than European Medicines Agency 
(EMA) label dose. In addition, it was extracted whether during a TE a concomitant 
conventional systemic agent (methotrexate [MTX]; acitretin [NT]; fumaric acid esters 
[FAE]; cyclosporine [CyA]) was prescribed in the first 24 weeks of biologic treatment. 
Bridging and combination therapy were both regarded as the prescription of a 
concomitant conventional agent.
Analyses
Patients that discontinued the biologic treatment due to ineffectiveness before week 
24, were considered non-responders (not achieving PASI90, PASI100 and PASI≤5) at 
week 24. Data from patients who discontinued due to other reasons, such as adverse 
events or  pregnancy whish, were not included in the analyses. To optimize power, all 
biologics were grouped together. The time point to evaluate whether treatment 
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success is being achieved differs between biologics, but an evaluation at 24 weeks 
of treatment seems appropriate for biologics.16,17 Firstly, percentages of TEs in which 
PASI90, PASI100 or PASI≤5 were reached at week 24 were described. Then, the 
percentage of TEs in which PASI90 and PASI≤5 was reached at week 24 as well as 
the percentage of TEs in which PASI90 or PASI100 was not achieved but in which 
PASI≤5 was still achieved at week 24 were calculated. Thereafter, the percentage of 
TEs with a baseline PASI≥10 in which PASI90, PASI100 and PASI≤5 was reached at 
week 24 was described. Lastly, univariate (Supplement_Table 1) and multivariate 
regression analyses were performed to elucidate which baseline patient characteris-
tics were predictors for PASI90 or PASI≤5 at week 24. Baseline PASI score was 
divided into baseline PASI≥10 and <10. Due to low numbers of TEs in which PASI100 
was achieved (15 TEs; 3.3%) at week 24, predictors for this outcome could not be 
assessed. Since one patient could contribute to multiple TEs, the Generalized 
Estimating Equation (GEE) analysis with patient as random effect was chosen in 
order to analyze which baseline patient variables predicted PASI90 and PASI≤5. 
A GEE analysis takes into account the patients that are included more than once in 
the analysis. With GEE analysis, parameters of a generalized linear model are 
estimated when the dependent variable is a dichotomous variable.18 After the 
univariate analyses with GEE, baseline patient variables with a p-value of <0.2 were 
incorporated into the multivariate analyses. Backward selection was manually 
performed by stepwise excluding the baseline patient variable with the highest 
p-value above 0.05. The final predictor model included those baseline patient 
variables that had a p-value of <0.05. For the multivariate analyses, BMI was chosen 
over weight, since these variables highly correlated. Sensitivity analyses with weight 
instead of BMI were performed. Additional sensitivity analyses were performed for (1) 
ADA/ETA as a group (excluding IFX and USTE), (2) TEs with a low to normal label 
biologic dose, (3) TEs without a treatment interruption, (4) TEs without combination 
therapy and (5) PASI≤3 at week 24 because in all TEs with a PASI90 at week 24 an 
absolute PASI score of ≤3 was present. Correction for missing baseline data was 
performed using multiple imputations in SPSS. Predictors were described as (B [95% 
confidence interval]; p-value). Analyses were performed using Microsoft Office Excel 
2007 and SPSS 22.0 (IBM, Armonk, NY, USA).
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Results
Patients
Table 1 shows the characteristics of the 326 included patients from BioCAPTURE. 
Our cohort was comparable to other major daily practice psoriasis registries19,20; 
most patients with psoriasis treated with biologics were male (62.0%), overweight 
(27.6 kg/m2) and had a positive family history of psoriasis (67.5%). Median baseline 
PASI score was 12.8.
Baseline characteristics of treatment episodes
In total, 483 TEs were extracted of which 454 TEs were included; 159 ADA, 193 ETA, 
19 IFX and 83 USTE. Baseline characteristics of TEs are shown per biologic in Table 2. 
Thirty-seven of 454 TEs did not complete 24 weeks due to ineffectiveness, and were 
included into the analyses as non-responders. Since no comparisons between 
biologics were made, no statistical comparisons between baseline characteristics 
Table 1  Baseline patient characteristics of BioCAPTURE
Baseline patient characteristics N=326
Age at start of  biologic (yrs) 47.2 ± 12.6
Missing: 0
Gender (male) 202 (62.0%)
Missing: 0
Length (cm) 175.6 ± 8.7
Missing: 62
Weight (kg) 86.4 [23.0]
Missing: 60
BMI (kg/m2) 27.6 [6.8]
Missing: 62
Positive family history of psoriasis (yes) 214 (67.5%)
Missing: 9
Psoriatic arthritis, diagnosis by a Rheumatologist (yes) 97 (31.1%)
Missing: 14
Duration of psoriasis until start of biologic (yrs) 20.3 [17.2]
Missing: 2
Baseline PASI score 12.8 [8.1]
Missing: 0
Mean ± SD, Median [IQR], N(%).
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were performed. Numerically, median baseline PASI score was highest for patients 
that were treated with IFX (14.5) and lowest for patients on ADA (12.0). Of 454 TEs, 
67.4% (306/454) of TEs had a baseline PASI≥10 and 32.6% (148/454) of TEs had a 
baseline PASI<10. Median baseline weight was highest for patients on IFX (92.0kg), 
followed by USTE (91.3kg), ADA (88.0kg) and lastly ETA (82.5kg). In our cohort, IFX 
was the last resort treatment; all patients that were treated with IFX were biologic 
non-naïve.  
Treatment characteristics of treatment episodes
The treatment characteristics of TEs are shown in Supplement_Table 2. The median 
biologic dose including induction dose was 46 mg per 2 weeks for ADA, 72 mg per 
week for ETA, 7.6 mg/kg/8 weeks for IFX and 62mg per 12 weeks for USTE (USTE 
45mg group: 62 mg per 12 weeks; USTE 90mg group: 123 mg per 12 weeks). In 
17.6%, 45.1% and 10.8% of TEs of, respectively, ADA, ETA and USTE, the biologic 
dose was higher than would be expected by EMA label dose after 24 weeks of 
treatment. Two (12.5%) of 16 TEs that started with 90mg USTE received a starting 
dose higher than label (i.e., in these 2 TEs body weight was ≤100kg) and 9 (13.4%) of 
67 TEs that started with 45mg USTE received a starting dose lower than label (i.e., in 
these 9 TEs body weight was >100kg). All doses of IFX were per EMA label.  Biologics 
were combined with conventional systemic agents in 114 TEs, varying from bridging 
therapy to continuous combination therapy. MTX was the agent most often prescribed. 
Of 454 TEs, in 95 (20.9%) TEs treatment was interrupted with a total of 114 treatment 
interruptions. Time of interruption was usually short (in 97 interruptions ≤4 weeks; in 
17 interruptions >4 weeks). The median time of treatment interruption was 9.5 
[interquartile range (IQR): 14] days.
High clinical response
The number and percentages of TEs in which high clinical responses were achieved, 
are shown in Table 3 and Figure 1.
PASI100 at week 24: In only 3.3% (15/454) of TEs, PASI100 was reached at week 24. 
In all TEs (100%) with PASI100 response at week 24, PASI≤5 was also attained at 
week 24. Of the 439 TEs without PASI100 response, in still 57.6% (253/439) PASI≤5 
was reached at week 24. From 306 TEs with a baseline PASI≥10, in 3.9% (12/306) 
PASI100 was reached at week 24. In 2% (3/148) of TEs with a baseline PASI<10, 
PASI100 was achieved at week 24.   
PASI90 at week 24: In 15% (67/454) of TEs PASI90 was attained at week 24. In all TEs 
(100%) with PASI90 response at week 24, PASI≤5 was also attained at week 24. In all 
TEs (100%) with PASI90 at week 24, PASI≤3 was achieved at week 24. An absolute 
PASI score of 2.7 was the highest absolute PASI score in the PASI90 group. Of the 
387 TEs without PASI90 response, in still 51.9% (201/387) PASI≤5 was reached at 
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week 24. From 306 TEs with a baseline PASI≥10, in 19.0% (58/306) of TEs PASI90 was 
reached at week 24. In only 6.1% (9/148) of TEs with a baseline PASI<10, PASI90 was 
achieved at week 24.
PASI≤5 at week 24: Of 454 TEs, in 268 (59.0%) TEs PASI≤5 was reached at week 24. 
From 306 TEs with a baseline PASI≥10, in 54.6% (167/306) of TEs PASI≤5 was 
achieved at week 24. This was 68.2% (101/148) of TEs with a baseline PASI<10. In 
50.2%, 38.5%, 24.2% and 11.2% of 454 TEs, respectively, PASI≤4, PASI≤3, PASI≤2 
and PASI≤1 was reached at week 24 (Figure 1).
Table 3  Treatment episodes (TEs) reaching PASI100, PASI90 or PASI≤5 at week 24
Outcome Number of TEs 
that reached 
the outcome at 
week 24 
N (% of all TEs 
in study)
Number of 
TEs that did 
not reach the 
outcome at 
week 24
N (% of all TEs 
in study)
Number of TEs 
that reached 
outcome and also 
reached PASI≤5 
at week 24 
N (% of TEs 
that reached 
outcome)
Number of TEs 
that did not reach 
outcome, but still 
reached PASI≤5 
at week 24 
N (% of TEs that 
did not reach 
outcome)
PASI100 15 (3.3%) 439 (96.7%) 15 (100%) 253 (57.6%)
PASI90 67 (14.8%) 387 (85.2%) 67 (100%) 201 (51.9%)
PASI≤5 268 (59.0%) 186 (41.0%) 268 (100%) 0 (0%)
Total number of TEs in study: 454.
Figure 1   Percentage of treatment episodes (TEs) with high effectiveness based on 
absolute PASI scores at week 24
Total number of TEs in study: 454.
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Predictors for high clinical response
After correcting for multiple TEs from the same patients with multivariate GEE 
regression analysis, the most important predictor for reaching a PASI90 response at 
week 24 was baseline PASI≥10 (baseline PASI≥10: 1.284 [0.541-2.027]; p=0.001). 
Predictors for PASI≤5 at week 24, were baseline PASI<10 and a lower baseline BMI 
(baseline PASI<10: 0.555 [0.161-0.949]; p=0.006 and BMI: -0.068 [-0.108- -0.028]; 
p=0.001). 
Sensitivity analyses for PASI≤3 at week 24, revealed the same predictors as the 
analyses for PASI≤5. Sensitivity analyses on ADA/ETA as one group (excluding IFX 
and USTE), also resulted in the same predictors for PASI90, PASI≤5 and PASI≤3. 
Sensitivity analyses with weight instead of BMI showed that baseline PASI remained 
the only predictor for PASI90 at week 24 (baseline PASI≥10: 1.284 [0.541-2.027]; 
p=0.001). For PASI≤5 at week 24,  the significant predictors were baseline PASI<10 
(PASI<10: 0.540 [0.152-0.928], p=0.006) and a lower baseline weight (-0.018 [-0.030- 
-0.007], p=0.001). Sensitivity analyses for PASI≤3 showed the same predictors.
Sensitivity analyses for the TEs with a low to normal label dose during the first 24 
weeks of biologic treatment as well as for the TEs without a treatment interruption, 
resulted in the same predictors for PASI90 and for PASI≤5 as described previously. 
Sensitivity analyses for PASI≤3 in low to normal label dose as well as in the TEs 
without a treatment interruption yielded the same predictors as for PASI≤5. 
Additional sensitivity analyses were performed excluding the TEs that used a 
conventional systemic agent in the first 24 weeks of biologic treatment. These analyses 
resulted in the same predictor for PASI90, i.e. baseline PASI≥10. Predictors for PASI≤5 
were baseline PASI<10, lower baseline BMI (or lower baseline weight) and biologic 
naivity. Biologic naivity, however, highly correlated with baseline PASI score. Biologic 
naive patients were significantly more likely to have a baseline PASI≥10 (0.599 
[0.214-0.983]; p=0.002) compared with patients that had already used a biologic 
previously. Baseline BMI or baseline weight did not correlate with baseline PASI 
score. 
Since USTE is dosed by baseline weight (≤100kg or >100kg), baseline weight was 
divided into these two categories for additional sensitivity analyses. These analyses 
showed that baseline PASI was the only predictor for PASI90 and PASI≤5 and that 
baseline weight was not a predictor for PASI≤5 anymore. 
Discussion
At week 24 in our real-world prospective cohort of patients with psoriasis treated with 
biologics, in only a limited number of TEs PASI100 or PASI90 was reached. In all TEs 
with a PASI100 or PASI90 response, PASI≤5 was also achieved. However, in a 
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substantial proportion of TEs without a PASI100 or PASI90 response, PASI≤5 was still 
achieved (58% and 52% respectively). Of note, from TEs with a baseline PASI≥10, a 
higher proportion achieved PASI≤5 (55%) compared with PASI90 (19%) at week 24. 
Baseline PASI≥10 was a strong predictor for reaching PASI90 at week 24. Baseline 
PASI<10 and a lower baseline BMI were predictors for PASI≤5 at week 24. 
The prescription of concomitant conventional systemic agents and adjusting dosages 
of biologics as well as treatment interruptions were allowed in this daily practice 
cohort to personalize treatment. When analyzing the TEs that were characterized by 
a low to normal biologic dose compared with EMA label dose during the first 24 
weeks of treatment, the same predictors for PASI90 and PASI≤5 were found. This was 
also the case when analyzing TEs without treatment interruptions, as well as in the 
TEs in which no conventional systemic agents were used. Sensitivity analyses for 
weight instead of BMI showed the same predictors for PASI90 and PASI≤5 at week 
24. Since the number of TEs for USTE and IFX were small, sensitivity analyses were 
performed for ADA/ETA as one group. This also resulted in the same predictors for 
PASI90 and PASI≤5. Our results on the predictors of PASI90 and PASI≤5 therefore 
seem to be robust. 
In our study, PASI≤5 was chosen because PASI≤5 is a goal that is widely accepted 
amongst physicians and is associated with a good quality of life.1,4,5 Sensitivity 
analyses were performed for PASI≤3, since in all TEs in which PASI90 was achieved 
at week 24, PASI≤3 was also achieved at week 24. These sensitivity analyses showed 
the same predictors as the analyses for PASI≤5 at week 24, which underscores the 
robustness of our results.
The opinion about treatment success is changing, with PASI90 becoming the new 
treatment goal.1,16 Treatment success, however, can also be defined by reaching 
PASI100 or PASI≤5. With this study we have shown that in daily practice, patients with 
psoriasis treated with biologics (ADA, ETA, IFX, USTE) rarely achieved PASI100 
(3.3%) or PASI90 (15%) and more frequently achieved PASI≤5 (59%) and even lower 
absolute PASI scores, such as PASI≤2 (24.2%) at week 24. In RCTs of these biologics, 
however, PASI90 is often achieved (20-58% of patients) at week 16-28.21-24 This 
might be due to the higher PASI score at start of treatment in RCTs compared with 
daily practice. In our study, high baseline PASI score (PASI≥10) was indeed a predictor 
for reaching PASI90 at week 24. In addition, in daily practice, patients with psoriasis 
that switch from one biologic treatment to another could have a lower baseline PASI 
score than biologic naïve patients. Indeed, we showed that biologic naïve patients 
had significantly more often a baseline PASI score ≥10 compared with biologic 
non-naïve patients. Also, the median baseline PASI score in our cohort was 12.8. The 
mean baseline PASI scores in RCTs were, however, higher and ranged from 18 to 
23.21-24 We also demonstrated that, in daily practice, PASI≤5 was more often achieved 
than PASI90 or PASI100 at week 24, even in patients with a baseline PASI≥10. 
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Therefore, PASI90 might not be the most suitable outcome to assess psoriasis 
severity in patients with psoriasis that are being treated with biologics in daily practice. 
Based on our results, we advise physicians to monitor absolute PASI scores in daily 
practice. We also advise to display absolute PASI scores in publications about 
efficacy/effectiveness from RCTs and cohort studies. 
So far, few studies have tried to assess which baseline patient characteristics were 
associated with the effectiveness of biologics. In literature baseline BMI, baseline 
severity score (PASI and physician global assessment), duration of psoriasis and 
biologic naivity are postulated.6-9 Our study showed that baseline PASI was the most 
important predictor for PASI90 and one of the important predictors for PASI≤5 at 
week 24. A lower baseline BMI was an important predictor of treatment response 
(PASI≤5) at week 24. Both predictors were also found for the more stringent PASI≤3 
at week 24. Recently conducted RCTs have shown that weight loss during biologic 
treatment (ADA, ETA, IFX, USTE) increases the efficacy, also in biologics that are not 
dosed according to weight.25,26 Baseline BMI also predicted biologic discontinuation 
in drug survival studies.27-31 These findings are important because most biologics 
are not dosed based on weight and none of the biologics are currently being dosed 
based on BMI. Patients and physicians might benefit from the finding that baseline 
BMI is a factor that influences the response to biologic therapy, also because BMI 
can be influenced by losing weight. More studies are needed to investigate whether 
weight loss has indeed a positive influence on the short- and long-term efficacy as 
well as on drug survival of biologic therapies before advising all our patients weight 
reduction programs.
Limitations of this study are the low patient numbers that achieve PASI90 or PASI100 
in daily practice and consequently the inability to perform subanalyses for every 
biologic agent separately. Our findings warrant replication in larger daily practice 
studies. A strength of our study is the use of data from the daily practice and 
multicenter BioCAPTURE registry that results in a high external validity. Other 
strengths include the registration of biologic doses and concomitant conventional 
systemic therapies as well as the performed sensitivity analyses.
To conclude, in daily practice where baseline PASI is often lower than in RCTs, a 
limited number of patients reached PASI100 or PASI90 at 24 weeks of biologic 
treatment. Inclusion of an absolute PASI score is important in the assessment of 
psoriasis severity. Our results also underscore the importance of the modifiable 
predictor baseline BMI for reaching a high response on biologic treatment. Future 
research into the influence of weight reduction in patients with psoriasis and the 
influence of BMI on treatment response with newly developed biologics is needed. 
Furthermore, pharmaceutical companies that perform future studies on biologics are 
advised to take into account the patients with high baseline BMI when establishing 
the most appropriate biologic dose.   
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Supplement_Table 1   Variables selected as possible predictors from univariate 
generalized estimating equation regression analyses
Baseline characteristics PASI90 PASI≤5
Age at start of biologic -0.008 [-0.027-0.011] -0.009 [-0.024-0.006]
Gender (female) 0.587 [0.013-1.162] 0.252 [-0.150-0.653]
Weight -0.007 [-0.024-0.010] -0.019 [-0.031- -0.007]
BMI -0.031 [-0.083-0.020] -0.069 [-0.109- -0.030]
Family history of psoriasis (no) 0.543 [-0.090-1.175] 0.150 [-0.266-0.566]
Diagnosis of PSA (no) 0.012 [-0.547-0.571] -0.057 [-0.476-0.362]
Duration of psoriasis -0.002 [-0.023-0.019] -0.003 [-0.019-0.013]
Baseline PASI (PASI<10)§ 1.284 [0.541-2.027] -0.581 [-0.969- -0.194]
Biologic naïve (no) 0.309 [-0.204-0.822] 0.280 [-0.097-0.657]
Numbers are presented as regression coefficient (B) [95% confidence intervals]. Bold regression 
coefficients had a P-value of <0.2 and were incorporated into the multivariate generalized estimating 
equation regression analysis as described in the method section.
§ PASI: psoriasis area and severity index; divided into PASI≥10 and PASI<10
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Abstract
Background: Drug survival is a marker for treatment success. To date, no analyses 
relating dermatological quality-of-life measures to drug survival have been published.
Objectives: (i) To describe 1-year drug survival for adalimumab, etanercept, and 
ustekinumab in a daily practice psoriasis cohort, and (ii) to introduce the concept of 
‘happy’ drug survival, defined as Dermatology Life Quality Index (DLQI) ≤ 5 combined 
with being ‘on-drug’ at a specific time point.  
Methods: Data were extracted from a prospective registry. Drug survival was 
analysed using Kaplan-Meier estimates. ‘Happy’ drug survival was calculated, with 
data split into ‘happy’ (DLQI ≤ 5) vs. ‘unhappy’ (DLQI > 5) at baseline and month 3, 
6, 9, and 12.
Results: 249 treatment episodes were included (101 adalimumab, 82 etanercept, 66 
ustekinumab). The 1-year drug survival rates for ustekinumab, adalimumab, and 
etanercept were 85%, 74%, and 68%, respectively. Ustekinumab showed a better 
confounder-corrected drug survival vs. etanercept (Hazard Ratio (HR) 3.8, p = 0.02) 
and a trend towards better survival vs. adalimumab (HR 2.3, p = 0.1). At baseline, the 
majority (n=115, 73%) was considered ‘unhappy’ and a minority ‘happy’ (n=42, 27%) 
(ratio ‘happy’:‘unhappy’ was 1 : 2.7). The percentage of treatment episodes with 
‘happy’ on-drug patients increased to 79% after 1 year. 
Conclusions: Ustekinumab showed a better overall drug survival than etanercept, 
and a trend towards a better overall drug survival than adalimumab. After 1 year, 
patients reported to be ‘happy’ in 79% of episodes and ‘unhappy’ in 21%. We 
introduced the new concept of ‘happy’ drug survival because the proportion of 
on-drug patients with good quality of life is an important indicator for treatment 
success.
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Introduction
In daily practice, adalimumab (ADA), etanercept (ETA) and ustekinumab (USTE) are 
frequently used biologics for the treatment of moderate-to-severe psoriasis when 
patients do not respond, or have a contraindication to, classic antipsoriatic treatments. 
In January 2009, USTE was registered; from that time point on, all three agents were 
equally available. ETA and ADA share their target, as both agents inhibit tumour 
necrosis factor (TNF)-α.1 In contrast, USTE inhibits interleukins 12 and 23 by binding 
to the shared p40 unit.2 All three agents have shown their efficacy and safety in 
multiple (randomized) controlled trials.3-18 Real-world drug survival studies 
comprising survival rates and associated predictors of ADA and ETA have been 
published, but vary in study design and outcome.19-23 Studies regarding drug survival 
of USTE are scarce.24,25 Clemmensen et al. found that only 4.5% of patients 
discontinued USTE after 321 days. Lack of response to previous anti-TNF-α treatment 
did not impair the response to USTE.24 In a retrospective Japanese psoriasis cohort, 
the 1-year drug survival of USTE was 97%.25 
In addition to the above-mentioned drug survival studies, quality-of-life (QoL) 
measures are also important in the process of evaluating psoriasis treatments. For 
this purpose, we introduced a new concept named ‘happy’ drug survival, combining 
drug survival rates with QoL. We used the  Dermatology Life Quality Index (DLQI), a 
frequently used QoL measure in dermatological research.26,27 A DLQI < 5 is 
considered to reflect no or mild influence on QoL.28 In this study, we explored the 
proportion of ‘on-drug’ patients who also achieved a good dermatological QoL, as 
defined by DQLI ≤ 5. 
The objectives of this study were (i) to describe the 1-year drug survival for ADA, ETA 
and USTE in a daily practice psoriasis cohort during a period when all agents were 
equally available; and (ii) to analyse the proportion of treatment episodes in which 
patients showed a ‘happy’ drug survival in the first year of treatment (DLQI ≤ 5 and 
being ‘on-drug’).
Methods
BioCAPTURE registry
Dermatology Life Quality Index measures and data on drug survival were extracted 
from a prospective registry containing daily practice data from all patients with 
psoriasis treated with biologics (BioCAPTURE, Continuous Assessment of Psoriasis 
Treatment Use REgistry with biologics). This registry was founded at the department 
of Dermatology of the Radboud University Medical Center Nijmegen in 2005 and is 
based there. Eight regional nonacademic centres have participated in the registry 
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since 2011. The BioCAPTURE registry was approved by the medical ethics committee 
of the Radboud University Medical Center. According to Dutch law, informed consent 
from patients was not mandatory in this noninterventional study, but it is currently 
obtained from every newly included patient.
Protocol and data collection
Preferably, patients were treated according to the regimens recommended by the 
European Medicines Agency label and the European and Dutch national guidelines 
for treatment with biologics.29,30 Patients started one of the following treatments: (i) 
ADA induction dose of 80 mg at start and 40 mg at week 1, followed by a maintenance 
dose of 40 mg every other week; (ii) ETA 50 mg twice weekly for the first 12 weeks, 
followed by 50 mg weekly; or (iii) USTE 45 mg (body weight < 100kg) or 90 mg (body 
weight ≥ 100kg) at baseline, then after 4 weeks and every 12 weeks thereafter. 
Dosage adjustments, interval changes and/or combination therapy with topical or 
conventional antipsoriatic systemic therapies were allowed as this study reflects daily 
practice. When the biologic was considered ineffective by the treating physician and/
or was considered to be related to severe or disturbing side effects, it was withdrawn.
Patients were seen approximately once every 3 months at our outpatient department 
and data were collected at every visit. Collected data included patient and treatment 
characteristics, effectiveness [including Psoriasis Area and Severity Index (PASI)], 
side effects and medication adjustments. Every 3 months, patients received 
questionnaires (including DLQI) by mail. All data were entered into a Microsoft Access 
database and checked for completeness by the data manager. For further statistical 
analyses, data were analysed with SPSS Statistics 20.0 (IBM, Armonk, NY, U.S.A.).  
Drug survival analysis
ADA, ETA and USTE treatment episodes starting from January 2010 were analysed 
in this study. Infliximab was  left out of the analysis due to a low number of patients. If 
patients received more than one treatment episode of the same agent (e.g. two 
episodes of ETA) in our registry, only the first treatment episode was analysed. If 
patients received different agents in our registry, all treatment episodes were 
analysed. The follow-up period was ≥ 6 months. When a treatment episode was 
interrupted for < 90 days, it was considered as one continuous episode. Patients 
often discontinue their treatment for short intervals due to holidays, infections or 
(elective) surgery. In recently published drug survival studies, 90 days was an 
accepted maximum interruption period.20,31  
We analysed drug survival rates using Kaplan-Meier estimates. Every discontinuation 
was considered as an event in the survival analysis. Patients were censored when 
lost to follow-up, or if still using the biologic at the moment of data lock. Drug survival 
rates were read from the Kaplan-Meier survival curves. Differences in drug survival 
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between groups were analysed using a log-rank (Mantel-Cox) test, or described 
when survival curves crossed. 
A sensitivity analysis for USTE drug survival was carried out to take account of the 
different discontinuation dates that can be chosen when analyzing this agent. In this 
manuscript, we present the last date of injection plus 8, 10 or 12 weeks (depending 
on the original scheme of the patient) in our primary analyses (most positive 
approach). In contrast with this approach, the last date of injection can be chosen as 
the USTE discontinuation date (most conservative approach). This sensitivity analysis 
is presented separately. 
For all biologics taken together, the difference between overall drug survival curves 
was compared for biologic naive versus non-naive episodes.
Confounder correction of drug survival analysis
Patient and treatment characteristics were compared for ADA, ETA, and USTE 
treatment episodes, and for biologic naive and non-naive episodes. Pearson’s 
chi-squared test was used for characteristics with categorical outcomes. For the 
comparison of characteristics between the three different agents, a one-way ANOVA 
for continuous outcomes with a parametric distribution, and a Kruskal-Wallis test for 
continuous outcomes with a nonparametric distribution was used. For the comparison 
based on biologic naive versus non-naive episodes, characteristics with continuous 
outcomes with a parametric distribution were analysed using an independent t-test 
or, in case of a nonparametric distribution, using a Mann-Whitney U test. When char-
acteristics were significantly different between groups they were corrected for using 
multivariate Cox regression analysis. If closely related variables were both candidates 
for confounder correction (e.g. weight and body mass index), a selection based on 
biological mechanisms was made to choose only one confounder. Sex and age were 
included as fixed variables in all models independent of their significance value. 
Subsequently, possible confounders were added as covariates to this model. Hazard 
ratios with P-values resulting from this multivariate Cox regression analysis are 
described.  
‘Happy’ drug survival
‘Happy’ drug survival was defined as  DLQI ≤ 5 and being ‘on-drug’ at a specific time 
point. A DLQI > 5 while being ‘on-drug’ was considered as an ‘unhappy’ treatment 
episode. All patients who returned at least one DLQI questionnaire in the first year of 
treatment were included in this analysis. Ratios and percentages for ‘happy’ vs. 
‘unhappy’ episodes were calculated at 0, 3, 6, 9, and 12 months using a per protocol 
approach. Missing data were found to be at random time points and were handled as 
such. To synchronize the drug survival curve with the DLQI measurement points, an 
actuarial drug survival analysis was carried out. The actuarial survival curve and the 
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frequencies of DLQI ≤ 5 (‘happy’) and DLQI > 5 (‘unhappy’) were visualized in one 
graph. Not all patients returned questionnaires; therefore this subanalysis consisted 
of a smaller group than the original cohort in this paper. A head-to-head comparison 
of ‘happy’ drug survival curves between the different treatments was considered 
inappropriate due to lack of power. 
Results
Patient and treatment characteristics
In total of 249 treatment episodes in 213 unique patients were included in this drug 
survival analysis, comprising 101 ADA episodes, 82 ETA episodes and 66 USTE 
episodes. Patient and treatment characteristics for each drug are presented in Tables 1 
and 2. For all agents taken together, 59 episodes (24%) were discontinued in the 
first year. The most frequent reason for discontinuation was ineffectiveness of therapy 
(n=33, 13%), followed by side effects (n=16, 6%), and a combination of ineffectiveness 
and side effects (n=7, 3%). Three treatments were stopped due to other reasons 
(wish for pregnancy, ineffectiveness of biologic on arthritis symptoms, and 
work-related issues). The median dosage of ADA was 40mg every 2 weeks, and the 
Table 1  Patient characteristics 
ADA
N=101
ETA
N= 82
USTE
N= 66
P-value
Sex (male)
Age (years)a
Age at onset of psoriasis (years)
Disease duration (years)
59 (58.4)
46.4 ± 12.2
22.2 [0-57.8]
20.8 [0.9-53.6]
47 (57.3)
46.1 ± 14.2
19.8 [0-58.1]
19.3 [0.5-63.9]
40 (60.6)
48.9 ± 12.5
25.8 [2.3-66.5]
17.1 [2.9-57.2]
0.91g
0.35h
0.07f
0.55f
Psoriatic arthritis (yes) 29 (35.4)c 18 (27.3)d 16 (31.4)e 0.48g
Weight (kg)
BMI (kg m-2)
89.8 ± 18.8
28.8 ± 5.6
82.5 ± 17.8
26.8 [17.7-55.1]
93.0 ± 17.3
29.4 [21.9-59.0]
0.01h
0.02f
Baseline PASIb 11.3 [2.6-38.4] 11.8 [0.6-42.1] 15.4 ± 7.8 0.03f
Treated at  
an academic center
Treated at  
a nonacademic center
73 (72.3)
28 (27.7)
59 (72.0)
23 (28.0)
39 (59.1)
27 (40.9)
0.15g
mean±SD, median [range], n (%)
ADA: adalimumab; ETA: etanercept; USTE: ustekinumab; PASI: Psoriasis Area and Severity Index.  a Age at 
time of inclusion in this study, b90 days before, or 7 days after starting the study biologic. Psoriatic arthritis 
status for c82, d66, e51 patients available. fKruskal-Wallis test, gPearson’s chi-squared test, hOne way ANOVA
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median dosage of ETA was 75mg per week. For USTE, the median dosage was 
45mg per 12 weeks in patients weighing 
< 100kg and 68mg per 12 weeks in patients weighing ≥ 100kg. Thus the median ETA 
dose was higher, and the median USTE dose in patients weighing ≥ 100kg was lower 
than the recommended label dose. Other median dosages corresponded with the 
recommended dose. All characteristics were compared for differences between 
drugs. Characteristics that were statistically different between drugs were incorporated 
in the confounder-corrected subanalysis as described later.
Drug survival rates
In the uncorrected survival curves, the highest absolute 1-year survival rates were 
seen for USTE followed by ADA and ETA, with percentages of 85%, 74% and 68%, 
respectively (Fig. 1). The drug survival of USTE was significantly higher than that of 
ETA (log-rank test, p= 0.032), and USTE showed a trend towards a better survival 
than ADA (log-rank test, p= 0.066). The curves for ADA and ETA drug survival 
crossed over frequently, therefore no statistical analysis was carried out to compare 
these two biologics. Sensitivity analysis of overall drug survival, with conservative 
Table 2  Treatment characteristics  
ADA
N=101
ETA
N=82
USTE
N=66
P-value
Naive for biologics
Naive for TNF-α 
antagonists
49 (48.5)
51 (50.5)
53 (64.6)
54 (65.9)
21 (31.8)
25 (37.9)
< 0.001f
< 0.001f
Median dose
Median dose (pt <100kg)
Median dose (pt ≥100kg)
40.0 [26.7-93.3]a
NA
NA
75.3 [50.0-100.0]b
NA
NA
45.0 [35.8-135.0]c
45.0 [35.8-113.5]d
68.3 [45.0-108.0]e
NA
Concomitant methotrexate
Concomitant acitretin
27 (26.7)
1 (1.0)
16 (19.5)
4 (4.9)
10 (15.2)
2 (3.0)
0.18f
NAg
Reason for discontinuation:
   Ineffectiveness
   Side effects
    Ineffectiveness and  
side effects
   Other reasons
   Lost to follow up
15 (14.9)
5 (5.0)
5 (5.0)
1 (1.0)
1 (1.0)
14 (17.1)
8 (9.8)
2 (2.4)
0 (0.0)
2 (2.4)
4 (6.1)
3 (4.5)
0 (0.0)
2 (3.0)
2 (3.0)
NA
mean±SD, median [range], n (%)
ADA, adalimumab; ETA, etanercept; USTE, ustekinumab; TNF, tumour necrosis factor; NA, not applicable. 
Data from a101, b75, c63, d34, e16 available. fPearson’s chi-squared test, gPearson’s chi-squared test not 
possible due to insufficient cases with acitretin.
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handling of USTE discontinuation dates (date of discontinuation was date of last 
injection), also revealed a better of drug survival of USTE vs. ETA, and a trend towards 
a better survival vs. ADA (log-rank test, p= 0.039 and p= 0.085, respectively).
Drug survival rates with confounder correction
The baseline variables weight, PASI and prior biologics were significantly different 
when compared between the three agents (Tables 1 and 2). These variables were 
therefore included for confounder correction, together with the fixed variables age 
and sex. For confounder-corrected overall drug survival, USTE drug survival was 
higher than that of ETA (Hazard Ratio (HR) 3.822; 95% confidence interval (95% CI) 
1.203-12.139; p= 0.023), and showed a trend towards a better survival than that of 
ADA (HR 2.330; 95% CI 0.837-6.489; p= 0.1). ETA and ADA showed similar drug 
survival curves (HR 1.132, 95% CI 0.565-2.269, p= 0.727). 
Figure 1   Overall 1-year drug survival of adalimumab, etanercept and ustekinumab 
for patients with psoriasis
N=249, event=discontinuation in general. In all groups, no median drug survival could be calculated as 
> 50% of patients were still on-drug at the end of the study. In the first 3 months of treatment, survival curves for 
the different agents cross; after 3 months, a trend towards a better drug survival for ustekinumab was seen. 
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As for the confounder-corrected sensitivity analysis with conservative handling of 
USTE discontinuation dates, USTE drug survival was still significantly higher than that 
of ETA (HR 3.604, 95% CI 1.135-11.443, p= 0.03), and showed a trend towards a 
better survival than that of ADA (HR 2.147, 95% CI 0.769-5.991, p= 0.14).
Drug survival rates for biologic naive vs. non-naive episodes
For ADA, ETA and USTE taken together, Kaplan-Meier curves did not show different 
trends for biologic naive vs. non-naive treatment episodes (log-rank test, p= 0.803) 
(Fig. 2). About half (49%, n=123) of the treatment episodes considered biologic naive 
treatments and 51% (n=126) biologic non-naive. The absolute 1-year drug survival 
percentages were 76% in biologic naive and 75% in non-naive treatments. Survival 
curves were corrected for the following possible confounders: treatment setting, 
drug, disease duration and baseline PASI, together with age and sex as fixed 
variables. No statistically significant difference between biologic naive and non-naive 
treatment episodes was seen after confounder correction (HR 0.99, 95% CI 
0.536-1.814, p 0.965).
Figure 2   Overall 1-year drug survival of biologic naive vs. non-naive patients  
with psoriasis
N=249, event=discontinuation in general. In both groups, no median drug survival time could be calculated as 
> 50% of patients were still on-drug at the end of study. After 1 year, no trends towards a difference between the 
overall drug survival for naive vs. non-naive patients is seen. 
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Figure 3 shows the ‘happy’ drug survival curve. This subcohort consisted of 74 ADA 
(40%), 62 ETA (33%), and 50 USTE (27%) episodes in which at least one DLQI 
questionnaire was returned in the first year of treatment. The subcohort accounted for 
75% of the original cohort. At baseline, the majority of patients who returned the 
questionnaire at start of the study (157 of 186) were considered ‘unhappy’ (n=115, 
73%), with a DLQI score > 5. A minority were considered ‘happy’ (n=42, 27%). The 
ratio of  ‘happy’ to ‘unhappy’ was 1 : 2.7 at that time. Of all returned questionnaires, 
the relative percentage considered ‘happy’ increased over time. In 64%, 69%, 72%, 
79% of the episodes a DQLI ≤ 5 was scored after 3, 6, 9 and 12 months, respectively. 
This led to reversed ‘happy’ : ‘unhappy’ ratios compared with the baseline ratio. 
Ratios of 1.8 : 1,  2.2 : 1, 2.6 : 1, and 3.7 : 1 were seen after 3, 6, 9 and 12 months, 
respectively. 
Figure 3   ‘Happy’ drug survival of patients with psoriasis on adalimumab, 
etanercept or ustekinumab
‘Happy’ drug survival combines the actuarial drug survival of biologics (black line) with the percentage of 
patients with Dermatology Life Quality Index (DLQI) ≤ 5 (‘happy’) vs. DLQI > 5 (‘unhappy’). This cohort 
consisted of 186 treatment episodes: 74 with adalimumab, 62 with etanercept and 50 with ustekinumab. 
Data were available for only 157 patients at baseline.
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Analysis comparing the group that returned DLQI questionnaires revealed no 
differences in baseline characteristics compared with the group in which no 
questionnaires were returned, except for the fact that the responder group was larger 
in nonacademic hospitals (Pearson’s chi-squared test, p= 0.02). At baseline and 
months 3, 6, 9, and 12, questionnaires were not returned in 16%, 34%, 40%, 42%, and 
40% of cases, respectively.
Discussion
The 1-year drug survival rates of  USTE, ADA and ETA were 85%, 74% and 68% 
respectively. Multivariate Cox regression analysis of drug survival corrected for 
confounders showed that USTE had a significantly better 1-year drug survival rate 
than ETA, and had a trend towards a better drug survival than ADA. Biologic naive 
and non-naive treatment episodes had comparable 1-year drug survival rates. The 
proportion of on-drug patients with a good QoL is an important indication of treatment 
success. For this purpose, we introduced the ‘happy’ drug survival analysis. At the 
moment of initiating a biologic in the majority of episodes patients reported to be 
‘unhappy’ (DLQI > 5), with a ratio of 1.0 : 2.7 for ‘happy’ vs. ‘unhappy’. In time, this 
ratio reversed, leading to a majority of ‘happy’ (DLQI ≤ 5) on-drug episodes, with a 
ratio of 3.7 : 1.0 after 12 months.
Clemmensen et al. have shown a better USTE drug survival than ADA and ETA 
together.24 We found a 1-year drug survival rate of 85% for USTE, which was slightly 
lower than survival rates in the Danish cohort24 and in a retrospective Japanese 
cohort.25  In these studies, USTE 1-year survival rates of 
> 90% were found. We found no differences in drug survival rates for biologic naive 
vs. non-naive patients. These results correspond with many previous studies on drug 
survival and efficacy 23,32-39, but contradict Danish studies on drug survival.21,24 
Dosages of biologics could influence drug survival. In the present cohort, the median 
doses of ADA, and USTE patients < 100kg, corresponded with the dose recommended 
by the label. However, USTE patients ≥ 100kg used a slightly lower dose than the 
recommended dose, and patients on ETA used a higher dose. From this study 
design, we cannot evaluate whether lower ETA dosages would lead to different 
survival curves. The influence of underdosing in USTE is thought to be of limited 
influence, as doctors were free to increase the dose in case of nonresponse. Another 
hypothesis regarding influencing factors of drug survival is that the low frequency of 
USTE injections could lead to better compliance and therefore better drug survival. 
We were however not able to test this in the present study.
The new concept of ‘happy’ drug survival was used to investigate whether drug 
survival corresponds with a good dermatological QoL. This concept provides a 
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broader measurement of treatment success, combining drug survival with patient-re-
ported outcomes. As DLQI is a frequently used Qol tool in daily practice and in clinical 
studies, the present concept is thought to be easily adaptable to various settings. 
Eventually, this broad measurement could be used in large groups to compare 
different biologics. In the present cohort, we found a pronounced increase in the 
proportion of treatment episodes with ‘happy’ patients using biologics after 3 months, 
followed by a gradual rise until 12 months. After 1 year, most episodes with on-drug 
patients showed a good disease-related QoL. Still, one-fifth of this treated group 
reported a DLQI > 5. It is important to identify the needs that are not fulfilled for this 
subgroup.
It must be taken into account that this drug survival study is based on a daily practice, 
whereby  different factors could be of influence. Important factors are the behaviour 
of physicians and patients and the availability of other treatment options. To minimize 
the influence of these factors, both academic and peripheral patients and doctors 
were represented, and data were collected in a time frame in which ADA, ETA and 
USTE were equally available. As the groups (ADA, ETA, USTE) were heterogeneous 
for specific characteristics, we corrected for possible confounders using a multivariate 
Cox regression model. For instance, we corrected for biologic naivety because more 
biologic non-naive patients were present in the USTE group. This could hypothetically 
lead to a longer persistence due to a limited number of alternatives. The corrected 
survival curves still show the same results as the uncorrected version, and we 
therefore think that the influence of non-naivety is limited. Moreover, in the vast 
majority of cases infliximab was still available, and in many cases one of the other 
anti-TNF-α agents as well. 
Patients were not randomized to treatments and this could have led to selection bias. 
However, this bias is inherent in a noninterventional daily practice study. As this study 
is based on daily practice research, dose adjustments and use of antipsoriatic 
comedication was allowed. Methotrexate use was substantial, but we found no 
difference in the amount of users between drugs. Therefore, it was not considered to 
be a confounder. To evaluate whether drug survival of a specific biologic could be 
improved by addition of methotrexate, a randomized study would be preferred. 
The ‘happy’ drug survival analysis is based partly on questionnaires, wherein 
responder bias could have played a role. Missing questionnaires were at random 
time points, therefore no selection bias for questionnaires at specific time points was 
expected in this study. The DLQI is designed to measure disease-related QoL, hence 
the term ‘happy’ in the ‘happy’ drug survival concept refers to cutaneous disease-re-
lated QoL. However, it is plausible that major life events or non-disease related issues 
could have influenced the ‘happy’ drug survival.
This study shows that ADA, ETA and USTE have high real-world drug survival rates in 
the first year of therapy. USTE showed a better overall drug survival than ETA and a 
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trend towards a better drug survival than ADA. Treatment episodes with and without 
prior biologics showed no differences in drug survival rates, which is reassuring 
within the context of switching to other therapies. 
We introduced the ‘happy’ drug survival analysis as a new concept combining QoL 
measures with drug survival. The proportion of episodes with ‘happy’ on-drug 
patients increased from 27% at baseline to 79% after 12 months. It is important to 
identify the needs that are not fulfilled for the subgroup of ‘unhappy’ patients. 
Measuring whether actively treated patients have a good disease-related QoL is an 
indicator for treatment success. The concept of ‘happy’ drug survival could be a 
meaningful tool to bring patient care to a next level. 
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Abstract
Background: Predictors  for successful treatment are important for personalized 
medicine. Predictors for drug survival of biologics in psoriasis have been assessed 
but not split for different biologics nor for the reason of discontinuation.
Objectives: To compare long-term drug survival between the outpatient biologics 
adalimumab, etanercept and ustekinumab in patients with psoriasis and to elucidate 
predictors for overall survival, drug discontinuation due to ineffectiveness and due to 
side-effects for every biologic separately. 
Methods: Ten years of data were extracted from the prospective, multicenter, 
long-term  BioCAPTURE registry. Kaplan Meyer survival analyses and confound-
er-corrected Multivariate Cox Regression analysis for Drug Survival (MCR-DS) were 
performed to compare drug survival between biologics. To elucidate the predictors 
for different reasons of discontinuation for every biologic, univariate Cox regression 
analyses and Multivariate Cox Regression analyses for Predictors (MCR-P) with 
backward selection were performed.
Results: In total, 526 treatment episodes - 186 adalimumab, 238 etanercept and 102 
ustekinumab - were included covering 1333 treatment years. MCR-DS showed a 
significantly higher overall survival for ustekinumab compared with adalimumab and 
etanercept. MCR-P showed that higher body mass index (BMI) was a predictor for 
discontinuation due to ineffectiveness for etanercept and ustekinumab and that 
female sex was a predictor for discontinuation due to side-effects for adalimumab, 
etanercept and ustekinumab.
Conclusions: Ustekinumab has the highest confounder-corrected long-term drug 
survival in psoriasis treatment compared with adalimumab and etanercept. Higher 
BMI is a predictor for discontinuation due to ineffectiveness in etanercept and 
ustekinumab, and female sex is a consistent predictor for discontinuation due to 
side-effects in all three outpatient biologics. 
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Introduction
Adalimumab (ADA), etanercept (ETA) and ustekinumab (USTE) have enriched the 
therapeutic armamentarium of dermatologists by increasing the number of drugs 
available for outpatient psoriasis treatment.1 In order to optimize psoriasis treatment 
strategies in clinical practice, several real-world studies have assessed drug survival 
of individual biologics2-8, compared drug survival between biologics9-18 or searched 
for clinical characteristics that might predict the discontinuation of biologic agents2-
7,9,11,12. Drug survival is a comprehensive measure of the effectiveness, safety as well 
as the preferences of both the patient and physician and reflects the probability a patient 
will stay on the drug over time.19 
Although drug survival is becoming an increasingly popular outcome measure in 
biologic treatment of psoriasis, still only a limited number of daily practice studies are 
available that use prospective data from multiple centres to compare biologic 
agents.9-12 Also, several different clinical characteristics have been stated to predict 
treatment discontinuation in prospective and retrospective studies, but were usually 
only analysed for treatment discontinuation in general (i.e., overall drug survival) and 
for all included biologics instead of performing analyses for every biologic separately. 
This has the potential of missing important predictors, as predictors for discontinuation 
might differ between different reasons of discontinuation and between biologics. 
Among predictors for drug discontinuation in general, female sex is mentioned most 
often, especially in prospective studies.2,3,9,11,12,15 Female sex has also been found 
to predict overall survival of biologic treatment in other inflammatory diseases.20 
Thus far, research into predictors for discontinuation split for ineffectiveness and 
side-effects has only gained little attention. Moreover, the few studies that have 
addressed this issue have not been conducted with the same variables at start, 
leading to a heterogeneity in the selection of candidate predictors.2,3 
With this study, drug survival of the three biologics was assessed with the aim to 
elucidate predictors for the drug survival of ADA, ETA and USTE as a group as well 
as separately per biologic for overall drug survival, drug failure due to ineffectiveness 
and due to side-effects. The study set out to elucidate the predictors for these most 
commonly prescribed outpatient biologics in a uniform way, i.e. by selecting the 
candidate predictors from a set of baseline variables that were similar for each 
biologic treatment, and to elucidate predictors for different reasons of discontinuation 
for every biologic separately. This approach might aid physicians in their treatment 
strategies and increase awareness for those patients at risk of discontinuing that 
specific biologic treatment. 
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Methods
BioCAPTURE
BioCAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry with 
Biologics) is a registry with prospective clinical practice data on biologic treatment of 
plaque psoriasis.10,21 Data from all real-world consecutive patients starting biologic 
treatment from one academic and eight non-academic centres were included. 
Patients participating in clinical trials were excluded. BioCAPTURE was approved by 
the medical ethics committee and, although not mandatory, informed consent was 
obtained from every patient. Patients with psoriasis were treated according to 
European and Dutch Guidelines22,23 and treatment recommendations were made by 
the treating physician.
 
Data extraction 
Patient characteristics and reason for treatment discontinuation, i.e. ineffectiveness, 
side-effects or other, were extracted from BioCAPTURE for all patients from inception 
of the registry (2005) until May 2015. Baseline variables that were extracted were: age 
at start of biologic, sex, weight, body mass index (BMI) divided into six categories9 
(underweight <18.5; normal weight 18.5-24.99; overweight 25.0-29.99; obese I 
30.0-34.99; obese II 35.0-39.99; obese III >40 kg/m2), positive family history of 
psoriasis, psoriatic arthritis, duration of psoriasis until start of biologic, baseline PASI 
score, biologic naivity, antitumour necrosis factor (anti-TNF)-naivity and the presence 
of at least one comorbidity in medical history (hepatitis B or C, chronic kidney or liver 
disease, HIV or cancer, except for non-melanoma skin cancer)2,24 that would have 
excluded the patient from participating in trials of biologics. When a patient had 
received different biologics over time, the first treatment episode (TE) of every 
biologic was used for analysis. In case the patient interrupted the biologic treatment 
for ≤90 days, the TE was considered to be continuous. Ninety days is a widely 
accepted maximum interruption period.9,10,15 All available long-term data were used 
for drug survival and predictor analyses.
Long-term drug survival analysis
Drug survival was analysed using Kaplan-Meier estimates. An event in the overall 
survival analysis was defined as every discontinuation of biologic treatment. 
Additional analyses for the events ‘side-effects’ and ‘ineffectiveness’ were also 
carried out. Censoring was performed for patients still on biologic treatment at the 
moment of data lock or patients that were lost to follow-up, or for other reasons than 
the reason of interest. 
For USTE the last date plus 8, 10 or 12 weeks, depending on the dosing regimen of 
the patient was chosen for the primary analyses. Since USTE has a low frequency of 
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administration and discontinuation date can influence drug survival, a sensitivity 
analysis was performed with the last date of injection of USTE as the discontinuation 
date. This conservative approach is presented in the Supplementary file.
Confounder correction for long-term drug survival
Baseline variables were compared between treatment groups using One-Way 
ANOVA in case of parametric and the Kruskal-Wallis test in case of non-parametric 
distribution. Categorical variables were compared using the χ2-test. Significantly 
different characteristics between ADA, ETA and USTE were corrected for with 
Multivariate Cox Regression analysis for Drug Survival (MCR-DS) in order to adjust 
for their possible confounding effect when comparing drug survival between different 
biologics. Some variables highly correlated and therefore only one variable was 
chosen for the confounder correction based on p-value; weight was chosen over BMI 
and biologic-naivity was chosen over anti-TNF-α-naivity. Sex and age at start of the 
biologic were set as fixed variables. Possible confounders, i.e. the variables that were 
significantly different between treatment groups, were added as covariates to the 
MCR-DS. Hazard ratios were extracted from the models and are described.
Predictors for drug survival
To elucidate the predictors for drug survival of ADA, ETA and USTE as a group and 
separately per biologic for overall drug survival, drug failure due to ineffectiveness 
and side-effects, firstly all baseline variables were tested with univariate Cox-regression 
analysis with the p-value set at <0.2. Possible predictor variables were then 
incorporated in the Multivariate Cox Regression analysis for Predictors (MCR-P; to 
distinguish this multivariate analysis from the previously mentioned MCR-DS). On the 
basis of the univariate analysis, BMI was chosen over weight for the multivariate 
analyses with MCR-P. For the MCR-P backward selection was performed to elucidate 
the final predictors.
All analyses were performed with IBM SPSS Statistics version 20.0 (IBM, Armonk, NY, 
USA). A p-value of <0.05 was considered significant.  Variables with a Gaussian 
distribution were presented as mean ± SD, non-parametrically distributed variables 
as median [IQR] and categorical data as N(%).
Results
Patients
In total, 526 TEs were included - 186 ADA, 238 ETA and 102 USTE - with a total of 
1333 years of treatment. The characteristics of the patient at inclusion in BioCAPTURE 
are shown in Table 1. The majority of patients were male (60.9%, n=226), overweight 
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(median BMI 27.8) and had a positive family history of psoriasis (66.0%). Psoriatic 
arthritis was present in 28.6% of patients. The median PASI score at baseline was 
13.2.
Baseline patient characteristics
The baseline patient characteristics per biologic are presented in Table 2. The median 
baseline weight was significantly higher for USTE (92.0 kg) and ADA (88.0 kg) than for 
ETA (84.0 kg; p=0.002 and 0.025, respectively). The median baseline BMI was 
significantly higher for ADA (29.0 kg/m2) and USTE (28.2 kg/m2) compared with ETA 
(27.7 kg/m2; p= 0.033 and p=0.029, respectively), but not for ADA compared with 
USTE (p= 0.094). The median baseline PASI score was significantly higher for USTE 
(13.4) and ETA (13.2) than for ADA (11.1; p=0.007 and p<0.001, respectively). Patients 
were significantly less often biologic naïve and anti-TNF-α naïve in TEs of USTE 
compared with ADA (p= 0.004 and p=0.012, respectively) and ETA (p<0.001 in both 
analyses). 
Table 1  Baseline patient characteristics 
Baseline patient characteristics First ever treatment episode  
in BioCAPTURE
N=371
Age at start of  biologic (yrs) 47.5 ± 12.8 
Missing: 0
Sex (male) 226 (60.9%)
Missing: 0
Length (cm) 175.4 ± 8.9
Missing: 79
Weight (kg) 86.0 [22.0]
Missing: 75
BMI (kg/m2) 27.8 [6.6]
Missing: 79
Positive family history of psoriasis (yes) 245 (66.0%)
Missing: 13
Psoriatic arthritis, diagnosis by a Rheumatologist (yes) 106 (28.6%)
Missing: 18
Duration of psoriasis until start of biologic (yrs) 19.9 [17.6]
Missing: 2
Baseline PASI score 13.2 [7.7]
Missing: 11
Mean ± SD, Median [IQR], N(%),yrs: years; PASI: Psoriasis Area and Severity Index.
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Long-term drug survival analysis
All available data on long-term drug survival for ADA, ETA and USTE are shown in 
Figure 1. During five years of treatment, overall drug survival was in favour of USTE 
(One year: 84.0% USTE, 75.8% ETA, 74.6% ADA; Five year: 61% USTE, 41% ADA and 
34% ETA). Percentages decreased for ADA to 35% at six years and for ETA to 20% at 
ten years of treatment. Survival rates of drug survival split for ineffectiveness were 
again in favour of USTE with percentages of 79% for USTE, 54% for ADA and 45% for 
ETA at five years of treatment. These percentages decreased further for ADA to 50% 
at six years and for ETA to 31% at ten years. Five-year survival percentages for dis-
Table 2  Baseline patient characteristics per biologic
Baseline patient 
characteristics
Adalimumab
N= 186 
patients
Etanercept
N= 238 
patients
Ustekinumab
N= 102 
patients
p-value
Age at start of  biologic (yrs) 48.7 ± 12.8
Missing: 0
46.9 ± 12.7
Missing: 0
50.1 ± 12.5
Missing: 0
0.072†
Gender (male) 106 (57%)
Missing: 0
146 (61.3%)
Missing: 0
66 (64.7%)
Missing: 0
0.410¥
Length (cm) 175.5 ± 8.5
Missing: 16
174.8 ± 8.5
Missing: 66
176.7 ± 8.9
Missing: 8
0.223†
Weight (kg) 88.0 [24.0]
Missing: 16
84.0 [24.3]
Missing: 65
92.0 [21.2]
Missing: 4
0.005‡
BMI (kg/m2) 29.0 [6.5]
Missing: 17
27.7 [3.5]
Missing: 66
28.2 [6.7]
Missing: 8
0.038‡
Positive family history of 
psoriasis (yes)
127 (68.3%)
Missing: 6
154 (64.7%)
Missing: 6
69 (67.6%)
Missing: 3
0.637¥
Psoriatic arthritis (yes) 61 (32.8%)
Missing: 7
71 (29.8%)
Missing: 5
28 (27.5%)
Missing: 9
0.329¥
Duration of psoriasis until 
start of biologic (years)
20.5 [18.4]
Missing: 2
20.4 [10.5]
Missing: 0
19.6 [9.6]
Missing: 0
0.849‡
Baseline PASI score 11.1 [7.2]
Missing: 7
13.2 [8.2]
Missing: 7
13.4 [11.5]
Missing: 4
<0.001‡
Biologic naïve (yes) 65 (34.9%)
Missing: 0
152 (63.9%)
Missing: 0
19 (18.6%)
Missing: 0
<0.001¥
Anti-TNF-α naïve (yes) 73 (39.2%)
Missing: 0
174 (73.1%)
Missing: 0
25 (24.5%)
Missing: 0
<0.001¥
Mean ± SD, Median [IQR], N(%). BMI: Body Mass Index; PASI: Psoriasis Area and Severity Index; TNF: 
tumour necrosis factor
† One-Way ANOVA, ¥ chi-squared test, ‡ Kruskal Wallis test
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continuation due to side-effects were 83% for USTE, 80% for ETA and 76% for ADA. 
These percentages were 70% for ADA at six years and 70% for ETA at ten years of 
treatment. Sensitivity analyses yielded similar percentages (see Supplemental 
material).
Comparing long-term drug survival corrected for confounders 
Confounder correction was performed on drug survival analysis by incorporating the 
significantly different baseline patient characteristics into the Multivariate Cox 
Regression analysis for Drug Survival (MCR-DS) (Table 2). Age and sex were set as 
fixed variables. Using all long-term data (see Figure 1), overall drug survival corrected 
for confounders showed a significantly higher drug survival for USTE when compared 
with ADA [hazard ratio (HR) 1.743, 95% confidence interval (CI) 1.085 – 2.799] and for 
USTE compared with ETA [HR 2.155, 95%CI 1.306 – 3.555]. For ADA and ETA, overall 
survival was similar [HR 0.774, 95%CI 0.560-1.069]. 
Confounder-corrected drug survival of discontinuation due to ineffectiveness showed 
a significantly higher survival for USTE when compared with ADA [HR 2.739, 95%CI 
1.420 – 5.282] and for USTE compared with ETA [HR 2.908, 95%CI 1.463 – 5.778]. 
Survival of ADA versus ETA showed no differences [HR 0.798, 95%CI 0.542-1.174]. 
Confounder-corrected drug survival of discontinuation due to side-effects showed a 
significantly higher survival for USTE compared with ADA [HR 2.346, 95%CI 1.024 – 
5.371] and USTE compared with ETA [HR 2.582, 95%CI 1.022 – 6.522]. Drug survival 
of ADA compared with ETA was not statistically different [HR 0.927, 95%CI 0.517 – 
1.660]. One- and 5-year confounder-corrected drug survival data are presented in 
the supplement.
Predictors for long-term drug survival
Variables from the univariate analyses that were incorporated in the Multivariate Cox 
Regression analysis for Predictors (MCR-P) for the different biologics are shown in 
Supplement_Table 1. 
Predictors for ADA, ETA and USTE as one group of biologics. MCR-P for overall 
survival showed that female sex (hazard ratio (HR) 1.453; 95% confidence interval 
(95% CI) 1.104-1.916) and higher BMI (HR 1.179; 95% CI 1.041-1.335) were predictors 
of discontinuation. MCR-P showed that higher BMI (HR 1.252; 95% CI 1.075-1.457) 
and biologic naivity (HR 1.392; 95% CI 1.003-1.933] were predictors of discontinuation 
due to ineffectiveness and that female sex (HR 2.825; 95% CI 1.792-4.717) was a 
predictor of discontinuation due to side-effects. 
Predictors for ADA. MCR-P for overall survival as well as for survival due to ineffec-
tiveness yielded no significant predictors. BMI was the last variable in both analyses, 
but was not significant. MCR-P for side-effects showed that female sex (HR 2.907; 
95% CI 1.348-6.289) was a predictor of discontinuation.
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Predictors for ETA. Female sex (HR 1.767; 95% CI 1.183-2.639), higher BMI (HR 
1.252; 95% CI 1.039-1.509) and the presence of specific comorbidities (HR 1.894; 
95% CI 1.036-3.460) were predictors of overall discontinuation. MCR-P showed that 
higher BMI (HR 1.339; 95% CI 1.066-1.682) was a predictor for discontinuation due to 
ineffectiveness. Female sex (HR 2.326; 95% CI 1.012-5.348), higher BMI (HR 1.466; 
95% CI 1.007-2.077) and age at start of ETA treatment (HR 1.422; 95% CI 1.055-1.917) 
were predictors for discontinuation due to side-effects.
Predictors for USTE. MCR-P showed that higher BMI (HR 1.429; 95% CI 1.008-2.028) 
was a predictor for overall survival. Higher BMI (HR 1.977; 95% CI 1.218-3.210) was a 
predictor for discontinuation due to ineffectiveness and female sex (HR 4.016; 95% CI 
1.003-16.129) was a predictor of discontinuation due to side-effects. In the group of 
patients with bodyweight >100kg who failed USTE due to ineffectiveness, five (83%) 
of six patients were treated with 90mg and were thus treated  according to the 
guidelines.22,23   
Side-effects resulting in discontinuation of the biologic agent  
in female and male patients
In total 79 patients discontinued their biologic treatment due to side-effects; 30 (38%) 
for ADA, 40 (51%) for ETA and 9 (11%) for USTE. Side-effects per biologic are 
presented in Supplement_Table 2. Forty-five (57%) of 79 patients were female. 
Number (percentage) of female/male patients with side-effects leading to treatment 
discontinuation was 20 (25%)/ 10 (9.4%) for ADA, 19 (20.7%)/ 21 (14.4%) for ETA and 
6 (16.7%)/ 3 (4.5%) for USTE. There was a heterogeneity in experienced side-effects 
and no pattern in type of side-effect was found between female and male patients. 
Infections, mainly of the respiratory tract, were a common reason for discontinuing 
ADA and ETA, but not USTE treatment. There were also no patterns found for 
infections between female and male patients, nor between ADA and ETA. The only 
side-effects that could be characterized as typical for female patients were a cystitis 
in one female patient during ADA treatment, breast cancer in one female patient on 
ETA treatment and cervical cancer in one female patient on ETA treatment. One 
female patient on ADA treatment and one male patient on ETA treatment stopped 
their treatment due to feelings of depression.  
Biologic dose
The mean±SD cumulative dose of the biologics was 2783±2353mg for ADA, 
9720±8746mg for ETA and 632±587mg for USTE (ADA: 50±18mg per 2 weeks; ETA: 
76±18 mg per week, USTE≤100kg: 69±32mg per 12 weeks; USTE>100kg: 97mg± 
38mg per 12 weeks). In our cohort, patients treated with ADA and ETA more often had 
a dose increase (i.e., a higher dose than the recommended label dose) compared 
with patients treated with USTE (ADA 40%; ETA 69%; USTE 27% of patients). 
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Figure 1   Ten-year drug survival for adalimumab, etanercept and ustekinumab
  Figure 1A  Ten-year overall drug survival for adalimumab, etanercept and ustekinumab. 
  Figure 1B  Ten-year drug with discontinuation due to ineffectiveness split per biologic. 
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Discussion
This prospective, comparative, multicenter, long-term drug survival study showed 
that a higher BMI was a predictor for drug discontinuation due to ineffectiveness for 
ETA and USTE and that female sex was a consistent predictor for discontinuation due 
to side-effects for ADA, ETA as well as USTE. USTE had the highest confounder-cor-
rected long-term drug survival in psoriasis treatment, compared with ADA and ETA.
Consistently with our study, a higher BMI was previously found to predict overall 
biologic discontinuation in psoriasis treatment.25-27 BMI was also a predictor of 
overall biologic survival in patients with rheumatoid arthritis.28 However, overall 
biologic survival is a result of drug discontinuation due to ineffectiveness, side-effects 
and other reasons.19 Of these, ineffectiveness is the main reason for discontinuation 
of biologics in psoriasis treatment.9,11 Highlighting the predictors for ineffectiveness 
is therefore of interest. Our study elucidated that a higher BMI is a predictor of biologic 
discontinuation due to ineffectiveness for ETA as well as USTE, but was not a 
significant predictor for drug survival of ADA. Given the current results from different 
  Figure 1C  Ten-year drug with discontinuation due to side-effects split per biologic. 
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studies, one might consider that patients with psoriasis with a higher BMI should be 
encouraged to lose weight before and during their biologic treatment. Indeed, a 
recently performed randomized controlled trial showed a positive effect of a 
diet-exercise combination over an information-only strategy on psoriasis severity in 
patients with who were being treated with systemic agents such as biologics.29 In 
another randomized trial, psoriasis severity was significantly lower in the diet group 
than in the control group at 24 weeks of biologic treatment.30
Previous studies on overall drug survival of biologics as a group have stated that 
female sex was a predictor for biologic discontinuation in psoriasis treatment.2,3,9,11,12,15 
Also, in rheumatoid arthritis and in axial spondyloathritis, female sex predicted overall 
drug discontinuation of anti-TNF-α therapies grouped together.20,31  So far, only one 
study on predictors highlighted ADA treatment for psoriasis by using data from a 
smaller BioCAPTURE cohort and found that female sex was a predictor for ADA 
 discontinuation due to side-effects.2 Our present study with extended data from 
BioCAPTURE shows that female sex is a predictor for drug discontinuation due to 
side-effects for ADA, ETA as well as USTE in psoriasis treatment. The exact reason 
behind this is unclear. No different pattern in type or severity of side-effects was 
found between female and male patients in our study. The fact that female sex is a 
predictor in all three biologics suggests that there is no class-effect and that other 
reasons should be considered. For example, although scarce, publications on this 
topic have demonstrated gender differences in the presentation of symptoms, 
prognosis of diseases and treatment outcomes as well as in communication.32 In a 
study regarding hospital in-patients it was shown that severe adverse drug reactions 
were seen more often in women than men.33 Regardless of the underlying reason, 
our results can increase the awareness of physicians that female patients have a 
higher chance of discontinuing biologic therapy for psoriasis due to side-effects 
compared with male patients.
There are several studies that have assessed biomarkers in order to predict treatment 
success for the individual patient, such as genetic, blood or tissue biomarkers.34 
Patient characteristics, however, can also serve as predictors for treatment success. 
Our analyses contribute to the first steps of developing a predictor model for biologic 
treatment in psoriasis. Other large prospective studies are needed to confirm our 
results. 
So far, only a small number of daily practice studies have used prospective data from 
multiple centres to compare biologic agents.9-12 Similar to findings in these studies, 
our study with long-term data showed that USTE had the highest confounder-corrected 
overall drug survival compared with both ADA and ETA. Unique in our study is the 
confounder-corrected drug survival split for discontinuation due to ineffectiveness 
and side-effects. Again, USTE had the highest drug survival in both analyses 
compared with ADA and ETA. Moreover, infliximab and not USTE was the last resort 
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biologic for psoriasis treatment in this study. Also, doses were more often higher than 
label dose for ETA>ADA>USTE. We did not expect that the missing data on weight 
had a major influence on our presented confounder-corrected drug survival outcomes, 
since ETA had more cases in total compared with USTE. Indeed, our results were 
similar when missing data on weight were imputed by the median weight of patients 
for that biologic. Our data, together with data from previous studies, might aid 
physicians in their choice of long-term biologic treatment for patients with psoriasis.
A limitation of our study is the lower number of patients when compared with 
nation-wide registries from larger countries.9 Strengths of our study are the detailed 
documentation of patient characteristics in our registry, the multicenter and 
prospective setting as well as the performed drug survival analyses split for every 
biologic and split for reasons of discontinuation. Furthermore, candidate predictors 
were chosen from baseline variables that were similar for every biologic, increasing 
the homogeneity in analysis.
In conclusion, this prospective, comparative, multicenter, long-term drug survival 
study shows that higher BMI is a predictor for drug discontinuation due to ineffective-
ness for ETA and USTE and that female sex is a consistent predictor for discontinua-
tion due to side-effects for ADA, ETA as well as USTE. Furthermore, USTE has the 
highest confounder-corrected long-term drug survival. Comparative results from the 
long-term drug survival aid the physician in choosing the most-suited long-term 
treatment for their individual patients with psoriasis.  Our data also help to increase 
the awareness among physicians that higher BMI influences drug survival in ETA and 
USTE, and that female patients are prone to discontinuation of ADA, ETA as well as 
USTE because of side-effects.
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Sensitivity analysis for drug survival uncorrected for confounders
Sensitivity analysis with USTE last date of injection (Supplement_Figure 1 to 3). 
Overall drug survival percentages after five years were USTE 63%, ADA 41% and ETA 
34%. Percentages were 35% for ADA after six years, and 20% for ETA after ten years. 
Five-year survival rates of discontinuation due to ineffectiveness were 80%, 54% and 
45% for USTE, ADA and ETA, respectively. These were 50% for ADA after six years 
and 31% for ETA after ten years. Five-year survival percentages for discontinuation 
due to side-effects were 84% for USTE, 80% for ETA and 76% for ADA. These 
percentages were 70% for ADA after six years and 70% for ETA after ten years.
Sensitivity analysis for drug survival corrected for confounders
Sensitivity analysis with USTE last date of injection. All available long-term data were 
used for drug survival analyses. Overall drug survival showed a higher drug survival 
for USTE when compared with ADA [hazard ratio (HR) 1.689, 95% confidence interval 
(CI) 1.051 – 2.713] and for USTE compared with ETA [HR 2.079, 95%CI 1.261 – 3.428]. 
For ADA and ETA, overall survival was similar [HR 0.774, 95%CI 0.560-1.069]. 
Confounder- corrected drug survival of discontinuation due to ineffectiveness showed 
a higher survival for USTE when compared with ADA [HR 2.634, 95%CI 1.365 – 5.083] 
and for USTE compared with ETA [HR 2.792, 95%CI 1.406 – 5.541]. Survival of ADA 
versus ETA showed no differences [HR 0.798, 95%CI 0.542-1.174]. Confounder-cor-
rected drug survival of discontinuation due to side-effects showed a higher survival 
of USTE when compared with ADA [HR 2.295, 95%CI 1.002 – 5.260] and USTE 
compared with ETA [HR 2.470, 95%CI 0.980 – 6,224]. Drug survival of ADA compared 
with ETA was not statistically different [HR 0.927, 95%CI 0.517 – 1.660].
Confounder corrected drug survival analysis at one year and  
five years of biologic treatment
Overall drug survival corrected for confounders showed a trend towards a higher 
drug survival for USTE when compared with ADA at one year [hazard ratio (HR) 
1.766, 95% confidence interval (CI) 0.924 – 3.378] and a significantly higher drug 
survival for USTE when compared with ADA at five years [HR 1.731, 95%CI 1.077 – 
2.784]. Overall drug survival corrected for confounders showed a higher drug survival 
for USTE compared with ETA at one and five years [one year: HR 3.132, 95%CI 1.533 
– 6.401; five years: HR 2.214, 95%CI 1.337 – 3.667]. Survival of ADA versus ETA 
showed no differences [one year: HR 0.881, 95%CI 0.551 – 1.407; five years: HR 
0.769, 95%CI 0.553 – 1.069]. 
Confounder-corrected drug survival of discontinuation due to ineffectiveness showed 
a significantly higher survival for USTE when compared with ADA [one year: HR 
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2.773, 95%CI 1.184 – 6.493; five years: HR 2.716, 95%CI 1.407 – 5.242] and for USTE 
compared with ETA [one year: HR 3.524, 95%CI 1.354 – 9.172; five years: HR 3.033, 
95%CI 1.525-6.032]. Survival of ADA versus ETA showed no differences [one year: 
HR 1.028, 95%CI 0.595 – 1.776; five years: HR 0.787, 95%CI 0.533 – 1.163]. 
Confounder-corrected drug survival of discontinuation due to side-effects showed a 
similar drug survival of USTE compared with ADA at one year (HR 2.344; 0.718-7.652], 
a significantly higher survival of USTE when compared with ADA at five years [HR 
2.345, 95%CI 1.019 – 5.395] and a higher survival for USTE compared with ETA at 
both one and five years of treatment [one year: HR 4.748, 95%CI 1.325 – 17.022; five 
years: HR 2.645, 95%CI 1.017 – 6.877]. Drug survival of ADA compared with ETA was 
not statistically different at both one and five years of treatment [one year: HR 0.777, 
95%CI 0.346 – 1.742; five years: HR 0.965, 95%CI 0.525 – 1.774].
Supplement_Figure 1   Ten-year overall drug survival with USTE last date of injection
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Supplement_Figure 2   Ten-year drug survival with discontinuation due to ineffectiveness 
– sensitivity analysis with USTE last date of injection
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Supplement_Figure 3   Ten-year drug survival with discontinuation due to side-effects 
– sensitivity analysis with USTE last date of injection
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Supplement_Table 1   Variables selected as possible predictors from  
univariate Cox-regression analyses 
ADA,ETA and 
USTE together
Overall drug 
survival
ADA, ETA and 
USTE together
Drug survival with 
discontinuation 
due to 
ineffectiveness
ADA, ETA and 
USTE together
Drug survival with 
discontinuation 
due to side-effects
ADA
Overall drug 
survival
ADA
Drug survival with 
discontinuation 
due to 
ineffectiveness
ADA
Drug survival with 
discontinuation 
due to side-effects
ETA
Overall drug 
survival
ETA
Drug survival with 
discontinuation 
due to 
ineffectiveness
ETA
Drug survival with 
discontinuation 
due to side-effects
Age at start of biologicŦ 0.994 
[0.901-1.010]
0.994 
[0.881-1.121]
1.129
[0.945-1.350]
1.035
[0.878-1.221]
1.062
[0.872-1.294]
1.056
[0.795-1.404]
1.012
[0.883-1.160]
0.871
[1.014-0.859-1.197]
1.141
[0.885-1.470]
Sex (Female) 1.531 [1.198-1.956] 1.359 
[1.004-1.839]
2.369
[1.516-3.703]
1.430
[0.943-2.169]
1.410
[0.856-2.322]
3.143
[1.468-6.728]
1.517
[1.089-2.114]
1.285
[0.854-1.934]
1.748
[0.937-3.259]
Trial eligible† (No) 1.234 
[0.843-1.806]
1.533 
[0.995-2.360]
1.533
[0.995-2.360]
1.097
[0.550-2.187]
1.675
[0.826-3.398]
1.675
[0.826-3.398]
1.467
[0.894-2.405]
1.432
[0.782-2.623]
1.432
[0.782-2.623]
Weight‡ 1.009 [1.002-1.017] 1.010 
[1.001-1.019]
1.013
[1.000-1.026]
1.007
[0.996-1.018]
1.005
[0.992-1.019]
1.007
[0.989 – 1.026]
1.014
[1.003-1.026]
1.017
[1.004-1.031]
1.023
[1.002-1.045]
BMI¥ 1.219 [1.074-1.383] 1.258 
[1.082-1.463]
1.311
[1.044-1.646]
1.191
[0.978-1.450]
1.199
[0.949-1.516]
1.297
[0.944-1.783]
1.285
[1.058-1.560]
1.339
[1.066-1.682]
1.528
[1.068-2.188]
Family history of 
psoriasis (No)
0.945 
[0.722-1.236]
1.084 
[0.786-1.496]
0.803
[0.485-1.327]
0.778
[0.483-1.252]
0.860
[0.491-1.505]
0.433
[0.166-1.133]
1.077
[0.756-1.536]
1.276
[0.839-1.939]
1.065
[0.547-2.074]
Diagnosis of PSA (No) 0.995 
[0.764-1.296]
0.903 
[0.656-1.243]
1.195
[0.728-1.962]
1.085
[0.696-1.691]
1.043
[0.612-1.778]
0.962
[0.454-2.037]
1.057
[0.739-1.513]
0.883
[0.579-1.346]
1.809
[0.831-3.935]
Duration of psoriasis$ 0.905 [0.881-1.009] 0.942 
[0.825-1.075]
0.891
[0.732-1.085]
1.011
[0.856-1.194]
1.060
[0.872-1.289]
0.997
[0.748-1.330]
0.771
[0.655-0.908]
0.792
[0.649-0.966]
0.792
[0.586-1.071]
Baseline PASI§ 0.996 
[0.980-1.013]
1.004 
[0.984-1.024]
0.994
[0.965-1.025]
0.979
[0.941-1.018]
0.999
[0.995-1.046]
0.970
[0.907-1.038]
1.004
[0.983-1.024]
1.008
[0.984-1.033]
0.999
[0.961-1.038]
Biologic naïvefl (No) 0.908 
[0.711-1.160]
0.779 
[0.577-1.050]
1.240
[0.789-1.948]
1.386
[0.860-2.233]
1.394
[0.787-2.466]
1.598
[0.682-3.742]
0.903
[0.640-1.274]
0.716
[0.464-1.105]
1.285
[0.685-2.410]
Anti-TNF-α naïve (No) 0.890 
[0.697-1.136]
0.785 
[0.581-1.063]
1.039
[0.668-1.615]
1.371
[0.867-2.170]
1.392
[0.803-2.414]
1.327
[0.605-2.910]
0.785
[0.532-1.157]
0.645
[0.393-1.059]
0.881
[0.430-1.806]
Numbers are presented as hazard ratio [95% confidence intervals]. Bold hazard ratios had a P-value of <0.2.
Ŧ  Age in 10 year intervals
†  Trial eligible: patients were trial eligible if they did not have a prior history of hepatitis B or C, chronic 
kidney or liver disease, HIV or cancer, except for non-melanoma skin cancer.
‡  For the multivariate model, BMI was chosen instead of weight.
¥  Body Mass Index is divided into underweight (<18.5 kg/m2); normal weight (18.5-24.99 kg/m2), 
overweight 25-29.99 kg/m2), obese I (30-34.99 kg/m2), obese II (35-39.99 kg/m2) and obese III (>40 kg/m2).
$  Duration of psoriasis until start of biologic in 10 year intervals
§  PASI: psoriasis area and severity index
fl  For the multivariate model, biologic naïve was chosen instead of anti-TNF-α naïve
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Supplement_Table 1   Variables selected as possible predictors from  
univariate Cox-regression analyses 
ADA,ETA and 
USTE together
Overall drug 
survival
ADA, ETA and 
USTE together
Drug survival with 
discontinuation 
due to 
ineffectiveness
ADA, ETA and 
USTE together
Drug survival with 
discontinuation 
due to side-effects
ADA
Overall drug 
survival
ADA
Drug survival with 
discontinuation 
due to 
ineffectiveness
ADA
Drug survival with 
discontinuation 
due to side-effects
ETA
Overall drug 
survival
ETA
Drug survival with 
discontinuation 
due to 
ineffectiveness
ETA
Drug survival with 
discontinuation 
due to side-effects
Age at start of biologicŦ 0.994 
[0.901-1.010]
0.994 
[0.881-1.121]
1.129
[0.945-1.350]
1.035
[0.878-1.221]
1.062
[0.872-1.294]
1.056
[0.795-1.404]
1.012
[0.883-1.160]
0.871
[1.014-0.859-1.197]
1.141
[0.885-1.470]
Sex (Female) 1.531 [1.198-1.956] 1.359 
[1.004-1.839]
2.369
[1.516-3.703]
1.430
[0.943-2.169]
1.410
[0.856-2.322]
3.143
[1.468-6.728]
1.517
[1.089-2.114]
1.285
[0.854-1.934]
1.748
[0.937-3.259]
Trial eligible† (No) 1.234 
[0.843-1.806]
1.533 
[0.995-2.360]
1.533
[0.995-2.360]
1.097
[0.550-2.187]
1.675
[0.826-3.398]
1.675
[0.826-3.398]
1.467
[0.894-2.405]
1.432
[0.782-2.623]
1.432
[0.782-2.623]
Weight‡ 1.009 [1.002-1.017] 1.010 
[1.001-1.019]
1.013
[1.000-1.026]
1.007
[0.996-1.018]
1.005
[0.992-1.019]
1.007
[0.989 – 1.026]
1.014
[1.003-1.026]
1.017
[1.004-1.031]
1.023
[1.002-1.045]
BMI¥ 1.219 [1.074-1.383] 1.258 
[1.082-1.463]
1.311
[1.044-1.646]
1.191
[0.978-1.450]
1.199
[0.949-1.516]
1.297
[0.944-1.783]
1.285
[1.058-1.560]
1.339
[1.066-1.682]
1.528
[1.068-2.188]
Family history of 
psoriasis (No)
0.945 
[0.722-1.236]
1.084 
[0.786-1.496]
0.803
[0.485-1.327]
0.778
[0.483-1.252]
0.860
[0.491-1.505]
0.433
[0.166-1.133]
1.077
[0.756-1.536]
1.276
[0.839-1.939]
1.065
[0.547-2.074]
Diagnosis of PSA (No) 0.995 
[0.764-1.296]
0.903 
[0.656-1.243]
1.195
[0.728-1.962]
1.085
[0.696-1.691]
1.043
[0.612-1.778]
0.962
[0.454-2.037]
1.057
[0.739-1.513]
0.883
[0.579-1.346]
1.809
[0.831-3.935]
Duration of psoriasis$ 0.905 [0.881-1.009] 0.942 
[0.825-1.075]
0.891
[0.732-1.085]
1.011
[0.856-1.194]
1.060
[0.872-1.289]
0.997
[0.748-1.330]
0.771
[0.655-0.908]
0.792
[0.649-0.966]
0.792
[0.586-1.071]
Baseline PASI§ 0.996 
[0.980-1.013]
1.004 
[0.984-1.024]
0.994
[0.965-1.025]
0.979
[0.941-1.018]
0.999
[0.995-1.046]
0.970
[0.907-1.038]
1.004
[0.983-1.024]
1.008
[0.984-1.033]
0.999
[0.961-1.038]
Biologic naïvefl (No) 0.908 
[0.711-1.160]
0.779 
[0.577-1.050]
1.240
[0.789-1.948]
1.386
[0.860-2.233]
1.394
[0.787-2.466]
1.598
[0.682-3.742]
0.903
[0.640-1.274]
0.716
[0.464-1.105]
1.285
[0.685-2.410]
Anti-TNF-α naïve (No) 0.890 
[0.697-1.136]
0.785 
[0.581-1.063]
1.039
[0.668-1.615]
1.371
[0.867-2.170]
1.392
[0.803-2.414]
1.327
[0.605-2.910]
0.785
[0.532-1.157]
0.645
[0.393-1.059]
0.881
[0.430-1.806]
Numbers are presented as hazard ratio [95% confidence intervals]. Bold hazard ratios had a P-value of <0.2.
Ŧ  Age in 10 year intervals
†  Trial eligible: patients were trial eligible if they did not have a prior history of hepatitis B or C, chronic 
kidney or liver disease, HIV or cancer, except for non-melanoma skin cancer.
‡  For the multivariate model, BMI was chosen instead of weight.
¥  Body Mass Index is divided into underweight (<18.5 kg/m2); normal weight (18.5-24.99 kg/m2), 
overweight 25-29.99 kg/m2), obese I (30-34.99 kg/m2), obese II (35-39.99 kg/m2) and obese III (>40 kg/m2).
$  Duration of psoriasis until start of biologic in 10 year intervals
§  PASI: psoriasis area and severity index
fl  For the multivariate model, biologic naïve was chosen instead of anti-TNF-α naïve
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Supplement_Table 1   Continued 
USTE
Overall drug 
survival
USTE
Drug survival with 
discontinuation 
due to 
ineffectiveness
USTE
Drug survival with 
discontinuation 
due to side-effects
Age at start of biologicŦ 0.926
[0.676-1.268]
0.804
[0.511-1.265]
1.618
[0.891-2.939]
Sex (Female) 2.128
[0.999-4.530]
1.668
[0.560-4.968]
4.024
[1.005-16.108]
Trial eligible† (No) 1.042
[0.312-3.481]
2.553
[0.698-9.339]
2.553
[0.698-9.339]
Weight‡ 1.020
[0.996-1.045]
1.036
[1.001-1.071]
0.991
[0.948-1.036]
BMI¥ 1.429
[1.008-2.028]
1.977
[1.218-3.210]
0.728
[0.342-1.553]
Family history of psoriasis 
(No)
0.951
[0.410-2.207]
1.148
[0.334-3.938]
1.213
[0.289-5.088]
Diagnosis of PSA (No) 0.598
[0.259-1.383]
0.668
[0.195-2.284]
0.650
[0.155-2.725]
Duration of psoriasis$ 1.024
[0.748-1.402]
1.038
[0.665-1.619]
0.881
[0.486-1.594]
Baseline PASI§ 0.997
[0.949-1.047]
1.013
[0.948-1.083]
1.038
[0.959-1.124]
Biologic naïvefl (No) 0.927
[0.348-2.469]
0.701
[0.191-2.577]
1.659
[0.204-13.495]
Anti-TNF-α naïve (No) 1.428
[0.539-3.785]
1.081
[0.296-3.945]
2.548
[0.316-20.551]
Numbers are presented as hazard ratio [95% confidence intervals]. Bold hazard ratios had a P-value of <0.2.
Ŧ  Age in 10 year intervals
†  Trial eligible: patients were trial eligible if they did not have a prior history of hepatitis B or C, chronic 
kidney or liver disease, HIV or cancer, except for non-melanoma skin cancer.
‡  For the multivariate model, BMI was chosen instead of weight.
¥  Body Mass Index is divided into underweight (<18.5 kg/m2); normal weight (18.5-24.99 kg/m2), 
overweight 25-29.99 kg/m2), obese I (30-34.99 kg/m2), obese II (35-39.99 kg/m2) and obese III (>40 kg/m2).
$  Duration of psoriasis until start of biologic in 10 year intervals
§  PASI: psoriasis area and severity index
fl  For the multivariate model, biologic naïve was chosen instead of anti-TNF-α naïve
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Supplement_Table 2   Side-effects leading to discontinuation of biologic 
reported per agent 
Side-effect leading to 
treatment discontinuation
Adalimumab
N= 186 patients
Etanercept
N=238
Ustekinumab
N=102
80 106 92 146 36 66 
Infectiona 7 (3.8%) 5 (4.7%) 5 (5.4%) 4 (2.7%) 0 0
Inflammation 1 (1.3%) 0 1 (1.1%) 3 (2.1%) 0 0
Auto-immune disorder 0 0 0 1b (0.7%) 0 0
Laboratory abnormalities 0 1c (0.9%) 0 1d (0.7%) 1e (2.8%) 0
Psychological / mood disorder 1 (1.3%) 0 0 1 (0.7%) 0 0
Neoplasm, malign 2f (2.5%) 0 4g (4.3%) 3h 0 2i (3.0%)
Drug reaction 3 (3.8%) 0 1 (1.1%) 0 0 1 (1.5%)
Change of type of psoriasis 2 (2.5%) 0 0 0 0 0
Ophthalmology 1j (1.3%) 0 0 0 0 0
Otology 1k (1.3%) 0 0 0 0 0
DermatologyL 1 (1.3%) 0 1 (1.1%) 1 (0.7%) 2 (5.6%) 0
Musculoskeletalm 1 (1.3%) 1 (0.9%) 0 0 0 0
Cardiovascular 0 1n (0.9%) 0 3o (2.1%) 2p (5.6%) 0
Pulmonaryq 0 1 (0.9%) 2 (2.2%) 0 0 0
Gastro-intestinalr 0 0 2 (2.2%) 1 (0.7%) 0 0
Renal 0 0 1s (1.1%) 0 0 0
Malaise 0 1 (0.9%) 1 (1.1%) 2 (1.4%) 1 (2.8%) 0
Injection-site reaction 0 0 1 (1.1%) 1 (0.7%) 0 0
a  e.g., upper respiratory tract infection, flu, pneumonia, cystitis, tuberculosis
b  Stage II sarcoïdosis
c  p-ANCA positivity
d  leucopenia, neutropenia, trombopenia
e  increase of ALAT and yGT
f  basal cell carcinoma (2 patients)
g  Cervical carcinoma (one patient), squameus cell carcinoma and basal cell carcinoma (one patient), 
breast cancer (one patient), lung cancer (one patient)
h  Esophageal cancer (one patient), superficial spreading melanoma (one patient), multiple myeloma 
(one patient)
i  Renal cell carcinoma (one patient), bladder cancer (one patient)
j  Dry eyes
k  Progressive hear loss 
L  e.g., worsening of pre-existing hidradenitis suppurativa, Grover’s disease, itch
m  e.g., muscle pain
n  Hypertension
o  myocardial infarction (one patient), heart failure (one patient), heart rhythm disorder (one patient)
p  hypertension (one patient), cerebrovascular accident (one patient)
q e.g. dyspnea, persistent coughing without signs of an infection
r e.g., nausea, diarrhea
s nephrotic syndrome
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Abstract
This document provides a summary of the Dutch S3-guidelines on the treatment of 
psoriasis. These guidelines were finalized in December 2011 and contain unique 
chapters on the treatment of psoriasis of the face and flexures, childhood psoriasis 
as well as the patient’s perspective on treatment. They also cover the topical treatment 
of psoriasis, photo(chemo)therapy, conventional systemic therapy and biological 
therapy.
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Introduction to the guidelines
J. Zweegers, E.M.G.J. de Jong, Ph.I. Spuls
1.1 Short introduction to psoriasis
Psoriasis is a chronic, inflammatory skin disease with a prevalence of 2-3% in the 
Western population [1, 2]. The most common clinical form of psoriasis is the chronic 
plaque type (90%). Abnormalities of the nails are seen in 50-80% of patients with 
psoriasis and 20-30% also suffer from psoriatic arthritis. Other subtypes are inverse/
genital, facial, scalp, guttate, erythrodermic, pustular, and palmoplantar psoriasis. 
Patients with psoriasis have strongly reduced quality of life scores with a quality of life 
similar to patients with diabetes mellitus, cardiovascular diseases, breast cancer, and 
depression [3]. Psoriasis is a disease that reaches further than the skin and may have 
systemic symptoms, such as metabolic syndrome. It may be associated with other 
chronic inflammatory diseases such as Crohn’s disease, rheumatoid arthritis, and 
diabetes mellitus [4]. In psoriasis an abnormal local immune reaction can be seen, 
with a significantly elevated number of activated T-cells and dendritic cells and an 
enhanced production of cytokines. Cytokines that appear in large numbers in 
psoriatic lesions are TNF-alpha, type 1 and type 2 interferons, IL-12, IL-22, IL-23, and 
IL-17A [1, 5]. 
Therapies for psoriasis available in the Netherlands include topical treatments (corti-
costeroids, calcineurin inhibitors, Vitamin D3 analogues, coal tar, dithranol, 
combination preparations), photo(chemo)therapy (UVB, PUVA), and systemic 
therapies. The conventional systemic therapies include methotrexate, cyclosporine, 
acitretin, and fumaric acid esters. In targeting specific elements of the immune 
system, biologics have been added to the therapeutic armamentarium relatively 
recently. These expensive drugs are indicated for patients with moderate to severe 
psoriasis after ineffective phototherapy, methotrexate, or cyclosporine therapy or 
when these more common therapies are contraindicated or not being tolerated. Of 
the biologics, infliximab and adalimumab are antibodies against TNF-alpha and 
etanercept is a soluble TNF-alpha receptor fusion protein. Ustekinumab is a 
monoclonal antibody against the IL-12/IL-23 p40 protein.
1.2  Update of the Dutch S3-guidelines on the treatment of psoriasis
In 2003, the Dutch Society of Dermatology and Venereology introduced the first 
evidence-based guidelines on the treatment of psoriasis [6]. In 2006-2007, Germany 
published their first guidelines based on the Dutch guidelines of 2003 [7]. In 2009, 
the European S3-guidelines from the European Dermatology Forum appeared in the 
literature and were based on the Dutch, British, and German S3-guidelines [8]. 
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In 2005, the Dutch Society of Dermatology and Venereology updated the practice 
guidelines from 2003 by updating the literature and including biologics to the 
guidelines. In 2009, these guidelines were revised slightly, specifically to improve the 
safety around prescribing methotrexate.
In 2011, the Dutch Society of Dermatology and Venereology finalized a complete 
update of the S3-guidelines on the treatment of psoriasis in Dutch, which is available 
online (Dutch S3-Guidelines on the Treatment of Psoriasis 2011; http://www.huidarts.
info/documents/uploaded_file.aspx?id=579). Besides an update of the chapters on 
topical therapy, phototherapy, conventional systemic therapy, and biologic therapy 
for chronic plaque type psoriasis, these guidelines contain new chapters on the 
treatment of psoriasis of the face and flexures, childhood psoriasis, and the patient’s 
perspective on treatment. The European S3-guidelines on the systemic treatment of 
psoriasis vulgaris by Pathirana, et al. (2009) were used as a basis for the Dutch 
S3-guidelines on the treatment of psoriasis 2011. We will summarize these Dutch 
S3-guidelines in this article.
Also in 2011, the Dutch Society for Rheumatology initiated additional, multidisciplinary 
guidelines (Dutch society of Rheumatology, Dermatology and Venereology, Gastro-
enterology and Hepatology, Physicians for Pulmonology and Tuberculosis and 
Internal Medicine as well as the Dutch Arthritis Association) on the use of biologics 
in daily practice [9] (http://www.reumabond.nl/downloads/algemeen/Mijn%20leven/
Medicijnen/Biologicals/Richtlijn_biologicals_geautoriseerd.pdf). These multidisciplinary 
guidelines answer questions on commonly encountered issues relating to treatment 
with biologics. Topics include pregnancy, surgical procedures, travelling abroad, and 
vaccination. We will not discuss these guidelines here.
1.3  Goals of the guidelines
The Dutch S3-guidelines on treatment of psoriasis 2011 contain recommendations in 
order to aid decision-making on treatment of psoriasis in daily practice. The guidelines 
are based on systematic reviews, primary research, and expert opinions. The guidelines 
are intended for dermatologists, but other personnel involved in treating psoriasis, 
such as general practitioners, could also benefit from it.
1.4  Composition of the working group
Dermatologists as well as patient representatives participated in the working group. 
Academic and peripheral centers had to be equally represented. These guidelines 
were developed independently of pharmaceutical companies. Conflicts of interest of 
working group members are mentioned within these guidelines.  
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 167
167
Summary of Dutch S3-guidelines
10
1.5  Methods
The working group worked for two consecutive years (8 meetings) on a draft of the 
Dutch S3-guidelines. The working group formulated several key questions, which in 
combination with the chapters of the European S3-guidelines (Pathirana et al. 2009), 
served as the framework for these guidelines. Existing chapters of the European 
S3-guidelines were translated and updated. Chapters on the treatment of psoriasis of 
the face and flexures and on the treatment of childhood psoriasis were based on 
additional, separate systematic reviews (10-12). The search strategies executed to 
develop these guidelines are stated in appendix 1 of the Dutch S3-guidelines 
(appendix 1 of the Dutch S3-guidelines, available online: http://www.huidarts.info/
documents/uploaded_file.aspx?id=579). 
An assessment and literature evaluation form were used to select the relevant 
literature (appendix 2 of the Dutch S3-guidelines, available at http://www.huidarts.
info/documents/uploaded_file.aspx?id=579). A full text version of the relevant studies 
was requested. Subsequently, these studies were selected according to inclusion 
and exclusion criteria and methodological quality (Table 1). Grades of evidence (GE) 
were assessed for selected articles (Table 2). Then, the members of the working 
group formulated conclusions and treatment recommendations based on included 
studies and provided these conclusions with an evidence level (Table 2). The final 
chapters were discussed and the concept guidelines were published online. 
Dermatologists were able to provide additional comments. These comments were 
implemented in the final version of the guidelines and approved by the Dutch Society 
of Dermatology and Venereology in December 2011. 
1.6   Structure of the Dutch S3-Guidelines on the Treatment  
of Psoriasis 2011
The Dutch S3-guidelines are divided into different chapters, related to the different 
treatments of chronic plaque psoriasis, psoriasis of the face and flexures, and childhood 
psoriasis. A separate chapter provides an overview of the patient’s perspective on 
treatment of psoriasis. 
Every chapter starts with the key questions. Subsequently, for each treatment a short 
introduction is provided, followed by the mechanism of action, dosing regimen, efficacy, 
adverse effects/safety, contraindications, monitoring, conclusions, considerations, 
and treatment recommendations. Conclusions are based on current best evidence 
(Table 1 and 2). The working group members decided to provide conclusions on 
biologics solely based on grade of evidence A2. Translation of these conclusions into 
treatment recommendations for daily practice was established by the working group 
by considering different aspects, such as efficacy, safety, use, availability, and costs 
of treatment as well as patients’ and physicians’ preferences. In doing so, the Dutch 
Society of Dermatology and Venereology hopes to increase transparency of the 
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Dutch S3-guidelines. A summary of the considerations of these different aspects is 
given in this article and can be found within the summary tables for each treatment 
(see below).
Table 1  In- and exclusion criteria for the performed literature search* 
Inclusion criteria Exclusion criteria
Prospective studies (except for psoriasis in 
children)
Case reports (except for psoriasis in 
children) and abstracts
Meta-analysis and studies on induction of 
remission (treatment duration ≤ 16 weeks)
Studies with intralesional or topical 
administration of systemic treatment 
(instead of oral administration)
Monotherapy (except for the combination 
therapies retinoids/phototherapy and 
topical vitamin D/steroids)
Old-fashioned equipment
Dutch, English, French and German studies Studies prescribing drugs that are not 
being used in the Netherlands
Studies with the following parameters:  
the percentage of patients with nearly 
complete remission (≥ 90%), the 
percentage of patients with partial 
remission (≥ 75%) (and/or duration 
of remission and/or percentage of 
improvement of psoriasis measured by 
PASI, PGA, global severity, body surface 
area, clearance)
Studies on phototherapy of only parts  
of the body
Dosing regimen and route of administration 
have to be stated in studies
Methotrexate dosage > 25 mg/week
Studies with separate data on psoriasis in 
adults and in children
Acitretin < 0.5 mg/kg/day
Studies with well-described separate data 
on several clinical subtypes of psoriasis or 
in case 75% of studied patients have one 
clinical subtype of psoriasis
Cyclosporine > 5 mg/kg/day
Studies with well-described separate 
data on levels of severity in patients with 
psoriasis or in case 75% of studied patients 
have moderate to severe psoriasis (PASI  
≥ 8, topical therapy not sufficient)
*Note: In case of uncertainty whether a study was performed prospectively the study was excluded. To avoid 
inaccuracy, data on the percentage of patients with ≥ 90% remission were not extrapolated to the 
percentage of ≥ 75% remission.
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 169
169
Summary of Dutch S3-guidelines
10
1.7  Legal consequences of the guidelines
Guidelines are composed in order to guide physicians in providing current, best 
medical care. The insights on treatment of chronic plaque psoriasis as stated in these 
guidelines are broadly agreed upon in the Netherlands. However, physicians are not 
legally required to follow these recommendations. In individual cases it may be 
desired or may even be necessary to deviate from the recommendations in these 
guidelines. In doing so, the Dutch physician must argue and document his/her different 
proceedings and if possible involve the patient in the decision-making.
1.8  Authorization
The full version of the Dutch S3-guidelines on treatment of psoriasis has been 
authorized by the Dutch Society of Dermatology and Venereology in December 2011. 
The present summary document has been agreed upon by all members of the working 
group who wrote chapters for the Dutch version of the S3-guidelines. The working 
group members approved this summary document.
1.9  Revision of the guidelines
The strength of guidelines lies in their continuous revision. Current medical studies as 
well as daily practice data and comments by users of these guidelines need to be 
implemented in future chapters. New chapters will be added to the Dutch S3-guidelines 
after updating searches on new developments in psoriasis treatment.
Table 2  Grades of Evidence and Evidence Levels 
Grades of Evidence (GE)
A1  Meta-analysis that includes at least one randomized clinical trial with a grade of 
evidence of A1; the results of the different studies included in the meta-analysis must 
be consistent
A2  Randomized, double-blind clinical study of high quality (e.g. sample-size calculation, 
flow chart of patient inclusion, ITT analysis, sufficient size)
B  Randomized clinical study of lesser quality, or other comparative study (e.g. non-
randomized cohort or case-control study)
C  Non-comparative study
D  Expert opinion
Evidence Levels (EL)
1  One study of level A1 or at least two independently performed studies of level A2
2  At least two independently performed studies of level B
3  One study of level A2 or B or studies of level C
4  Little or no systematic empirical evidence; expert opinions
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2. Treatment of psoriasis
2.1 Choice of treatment
Deciding which treatment to choose involves the ranking of different criteria. For the 
topical therapies, phototherapies and systemic monotherapies, the working group 
ranked the different drugs by different criteria, such as the degree of efficacy, safety, 
adverse effects, quality of life/treatment satisfaction, costs of therapy, and follow-up. 
Efficacy is divided into ≥90%, indicating almost complete remission, and ≥ 75%, 
indicating partial remission. Safety is divided into damage to vital organs, dysfunctions, 
teratogenicity, carcinogenicity after long-term use, toxicity in overdose, and drug 
interactions. In table 3, ranking is displayed from +, indicating less common or less 
serious, to +++, indicating most frequent or most serious. All criteria have been 
ranked separately for the different psoriatic treatments and cannot be calculated into 
a total score.
The working group did not value some of the criteria as more important as others. 
However, patients were able to value criteria in the evaluation of the patient’s 
perspective (Table 3 and chapter 5). The working group holds the opinion that in 
choosing treatment, the decision has to be made in agreement with the patient and 
can deviate on individual basis from the norm outlined in these guidelines.
2.2  Topical therapies
P.C.M. van de Kerkhof, R.J. Borgonjen
Table 4  Calcineurin inhibitors 
Recommended initial 
dosage
Tacrolimus (Protopic®) 0.03% ointment, followed by 0.1% 
ointment 1-2x daily
Pimecrolimus (Elidel®) 1% ointment 1-2x daily
Recommended 
maintenance dosage
Apply until clearance of psoriatic lesions is reached.  
Then continue regular skin care (i.e., basic treatment, non-
medicated ointments)
Important adverse effects
(See SmPC)
Burning sensation
Folliculitis, viral skin infections.
Prevention/treatment of 
adverse effects
Stop treatment in case of adverse effects or intolerable 
burning sensation. Applying topical corticosteroids or 
disinfectants will rapidly improve symptoms.
Absolute contraindications
(See SmPC)
Hypersensitivity to calcineurin inhibitor or 
any other component of the preparation
Primary or secondary immune deficiencies
Malignant or premalignant skin lesions
Pregnancy and breast feeding
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EL: 2
Calcineurin inhibitors improve psoriasis compared with placebo if 1) the 
calcineurin inhibitor is being used under occlusion, 2) the calcineurin inhibitor 
is combined with a drug that enhances skin penetration (e.g. salicylic acid 
gel) or 3) the concentration of the calcineurin inhibitor is at least 3 times the 
registered concentration for atopic dermatitis in the Netherlands. It must be 
noted that included studies used small patient samples and suffered from 
substantial drop-outs (18-46%). In a larger study no difference was found 
between tactrolimus gel, tacrolimus cream and calcipotriol ointment.
A2 Ortonne et al., 2006 (13)
B Carrol et al., 2005 (14)
Treatment recommendation
Tacrolimus and pimecrolimus may be used 1-2x daily for chronic plaque type psoriasis 
in the face, flexures, and anogenital region (see chapter: Treatment of psoriasis of the 
face and flexures) as an additive (interval treatment) or as a replacement of cortico-
steroids. Use on other localizations is not recommended.
Be alert to adverse effects, such as burning sensation or irritation of the skin.
Calcineurin inhibitors should not be applied under occlusion or used in combination 
with UV-therapy.
Table 4  Continued 
Relative contraindications
(See SmPC)
Skin infections (e.g., herpes simplex, folliculitis)
UV-light exposure
Liver disorder
Age <2 years
Live vaccines
Important drug 
interactions
No known drug interactions
Costs 30 g Protopic 0.03% ointment or Elidel cream = €25.79
Protopic 0.1% ointment = €29.04
Special notes Because of FDA warning: careful when using calcineurin 
inhibitors combined with phototherapy
Due to lack of evidence, do not prescribe calcineurin 
inhibitors during pregnancy and breast feeding
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Dithranol
Table 5  Dithranol 
Recommended initial 
dosage
Conventional therapy (hospitalized patients): 
Initial dosage 0.1% cream or ointment 1x daily, applied on 
the psoriatic lesions. Do not rinse the preparation. Double 
concentration, guided by skin irritation, every 3 days until a 
concentration of 1-3% is reached. In case of extreme skin 
irritation, consider lowering dosage. Treatment duration: 4-6 
weeks; after 2-3 weeks improvement should be noticed. No 
rebound-effect has been noted when treatment is terminated 
prematurely.
Short-contact therapy (non-hospitalized patients): Initial 
dosage 0.1% cream or ointment applied on the psoriatic 
lesions, during 10-30 minutes. Rinse the preparation with 
lukewarm water. Increase the concentration to 1, 2 or 3% 
based on the amount of skin irritation. Apply during 10-30 
minutes. In patients suffering from an irritative response on 
0.1%, a concentration of 
0.05% should be considered.
Recommended 
maintenance dosage
Not recommended for long-term therapy
Important adverse effects
(See SmPC)
Erythema and burning sensation
Discoloration of skin, hair, nails and clothing Blisters and 
necrosis
Prevention/treatment of 
adverse effects
When plaques are sharply demarcated the surrounding skin 
can be protected with zinc paste. Erythema and burning 
sensation can be treated with topical corticosteroids during 
1-2 days. In case dithranol comes in contact with the eyes, 
this could cause strong irritation or iritis. Rinse the eyes 
thoroughly with water or prescribe an isotonic saline solution, 
followed by treatment with topical corticosteroids. 
Absolute contraindications
(See SmPC)
Erytrodermic psoriasis
Pustular psoriasis
Psoriatic plaques nearby the eyes or mucosa
Relative contraindications
(See SmPC)
Pregnancy (never treat >30% of the skin
surface)
Children
Infants
Important drug 
interactions
Topical preparations with salicylic acid or urea can enhance 
the effect of dithranol. 
Administration of photosensitizing agents in combination with 
dithranol can enhance the photosensitizing effects.
Costs €1.83 – €3.92. Additional costs include hospitalization or 
outpatient treatment.
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EL: 1
The results of the evaluated studies indicate a complete remission (PASI 
reduction of 100%) in 30-70% of patients and a partial remission (PASI 
reduction of 75%) in 26-100% of patients after treatment for 5-8 weeks. 
The differences in efficacy are probably due to the lack of a standardized 
dithranol treatment strategy and to the differences in clinical settings: home 
treatment versus outpatient treatment versus hospitalized treatment.
Skin irritation, burning sensation, erythema and intermittent brown 
discolorations are frequently reported adverse effects. Systemic adverse 
effects have never been reported.
A2 Monastirli et al., 2002 (15); Saraswat et al., 2007 (16)
B Gerritsen et al., 1998 (17); Prins et al., 2001 (18); Thune et al., 1992 (19); 
de Mare et al., 1988 (20); Prins et al., 2000 (21); Hutchinson et al., 2000 (22); 
Mahrle et al., 1990 (23); Swinkels et al., 2002 (24); Van de Kerkhof et al., 2002 
(25); Agrup et al., 1985 (26); de Korte et al., 2008 (27); Swinkels et al., 2004 
(28); Van de Kerkhof et al., 2006 (29)
C Agarwal et al., 2002 (30)
Treatment recommendation
Dithranol monotherapy is recommended in patients with moderate to severe psoriasis 
for induction therapy during hospitalization or outpatient treatment.
Dithranol short-contact therapy may be an alternative treatment to phototherapy or 
systemic therapy in patients with moderate to severe psoriasis.
In patients who are unresponsive or have a contraindication to calcipotriol, corticos-
teroids, photo(chemo)therapy, systemic therapy, and biologics, dithranol is a last 
resort.
Dithranol therapy should be applied during a maximum of 4-8 weeks. Maintenance 
or long-term therapy is impractical and has no advantages. 
In treating severe chronic plaque type psoriasis, it is recommended to add 
phototherapy or topical preparations (Vitamin D3 analogues, corticosteroids) to 
dithranol treatment because of higher efficacy.
Table 5  Continued 
Special notes A mild burning sensation indicates effective treatment 
concentration.
Do not apply dithranol on the breasts in breastfeeding 
women.
Patients not experienced with dithranol therapy should 
receive outpatient or hospitalized treatment.
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Corticosteroids
Table 6  Corticosteroids 
Recommended initial 
dosage
1x daily
Recommended 
maintenance dosage
Taper when psoriasis improves, for example beta methasone 
dipropionate 1x daily for 3 weeks, then 1x / 2 days for 1 
week, followed by 1x / 3 days for 1 week and then ceasing 
medication
Important adverse effects
(See SmPC)
Skin atrophy, teleangiectasias, secondary infection, rosacea, 
perioral dermatitis, corticosteroid-induced acne
Prevention/treatment of 
adverse effects
Adverse effects occurring after long-term treatment include 
skin atrophy and teleangiectasias. These adverse effects are 
hard to treat. Try to avoid these adverse effects by taking into 
consideration therapeutic class of drug, location of drug use 
and treatment duration. A higher therapeutic class means 
a higher risk of adverse effects. Long-term treatment with a 
high potent corticosteroid increases the risk of skin atrophy. 
The face, genitals, neck and flexures are especially prone 
to skin atrophy. In the flexures a secondary infection could 
occur. The face is prone to rosacea, perioral dermatitis and 
corticosteroid-induced acne. The scalp and the soles of 
hands and feet can be treated with potent corticosteroids for 
months or sometimes years before skin atrophy appears. 
Absolute contraindications None
Relative contraindications
(See SmPC)
Rosacea, perioral dermatitis
Skin infections with bacteria (tuberculosis, lues), fungi, 
viruses (herpes simplex, herpes zoster, chicken-pox)
Adverse effects of vaccines
Important drug 
interactions
None
Costs €2.44 daily for topical corticosteroids (10 most prescribed 
preparations were taken into account) 
€57.24 per month for mometasone furoate (based on  
100g / week)
Special notes Most patients are afraid to use corticosteroids. Consequently, 
a detailed advice on benefits and disadvantages needs to be 
given to patients.
During pregnancy, potent corticosteroids may induce 
intrauterine growth restriction when used on large surfaces 
for a long time period.
During breastfeeding, do not apply corticosteroids on 
the breasts in order to avoid hospitalization of the infant. 
The mother must stop breastfeeding in case of long-term 
treatment with potent corticosteroids.  
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EL: 1
After applying high potent corticosteroids (beta methasone dipropionate 2x 
daily) a substantial improvement or complete remission of skin lesions is 
seen in 46-56% of patients with psoriasis
A1 Mason et al., 2009 (12)
A2 Papp et al., 2003 (31); Douglas et al., 2002 (32); Kaufmann et al., 2002 
(33)
B Weston et al., 1988 (34); Bagatell, 1988 (35)
EL: 1
Therapy with corticosteroids of very high potency (clobetasol-17-propionate 
2x daily) has a similar efficacy in 68-89% of patients with psoriasis
A2 Gottlieb et al., 2003 (36); Lowe et al., 2005 (37)
B Decroix et al., 2004 (38); Lebwohl et al., 2002 (39); Weston et al., 1988 (34); 
Lee et al., 2009 (40)
C Mazzotta et al., 2007 (41)
EL: 2
Due to the small number of available studies and varying study-outcome it 
is unclear whether clobetasol-17-propionate is more effective as a cream, 
lotion, spray or foam.
A2 Lowe et al., 2005 (37)
B Lebwohl et al., 2002 (39); Lee et al., 2009 (40)
C Mazotta et al., 2007 (41)
EL: 2
Owing to the small number of available studies it is unclear whether 1x 
daily application of topical corticosteroids is more effective than 2x daily 
application.
A2 Kaufmann et al., 2002 (33)
Treatment recommendation
Topical corticosteroids are recommended for the treatment of mild to severe chronic 
plaque psoriasis. Combination therapy with calcipotriol, phototherapy, or systemic 
therapy may be prescribed, thereby reducing the total dosage of corticosteroids 
significantly.
The class of corticosteroids prescribed depends upon the areas of skin affected.
It is important to be aware of the occurrence of skin atrophy or teleangiectasia, 
especially when corticosteroids are used as long-term therapy and are being applied 
in areas prone to these adverse effects.
Owing to lack of evidence for 2x daily application of corticosteroids over 1x daily 
application, it is recommended to start with 1x daily.
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Conclusions of the Dutch guidelines
EL: 3
Coal tar monotherapy (10% LCD) seems to improve psoriatic lesions when 
compared with placebo, but is less effective than betamethasone valerate.
B Thawornchaisit et al., 2007 (42)
EL: 2
Coal tar (5%) is being used in clinical studies combined with phototherapy. 
When combined with UV-light a reduction of 75% in PASI score (PASI 
75) was reached in 45-80% of participants after 15-20 applications. The 
evidence on the additive effect of coal tar when combined with phototherapy 
is insufficient. The addition of coal tar might result in a faster and longer 
remission.
B Bagel, 2009 (43); Belsito et al., 1982 (44)
C Frost et al., 1979 (45)
Table 7  Coal tar 
Recommended initial 
dosage
No recommended initial dosage; the dosage of coal tar  
may vary
Recommended 
maintenance dosage
It is not recommended to use coal tar for maintenance or 
long-term therapy
Important adverse effects
(See SmPC)
Coal tar odor, staining,phototoxicity
Prevention/treatment of 
adverse effects
The brown-black stains in clothing and the penetrating 
odor are unavoidable. Patients should exercise caution with 
exposure to sunlight in order to avoid UV-erythema.
Absolute contraindications
(See SmPC)
Pregnancy and breastfeeding
Xeroderma pigmentosum, dysplastic nevus syndrome, basal 
cell nevus syndrome
Relative contraindications
(See SmPC)
Intense exposure to sunlight or UV-light during treatment
Prior history of skin cancer
Important drug 
interactions
There are no drug interactions reported for topical use of 
coal tar products
Costs €3.51 daily
Special notes The Goeckerman-method consists of application of coal tar 
during 1-2 hours followed by UVB therapy. Optimal dosage 
of UVB is reached when the treated skin does not become 
erythematous. In outpatient care, pix lithantracis is often used 
and in combination with UV-therapy shows a higher efficacy 
when compared with liquor carbonis detergens (LCD)/UV-light 
combination therapy.  
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Treatment recommendation
Coal tar is not the first-choice of treatment for chronic plaque psoriasis.
Coal tar as a monotherapy is outdated. Nowadays, treatment options exist that are 
less hazardous and more practical.
Only when therapeutically necessary, coal tar or pix lithanthracis may be used in 
combination with UVB or PUVA to treat recalcitrant chronic plaque psoriasis.
Tazarotene
Tazarotene is not available in the Netherlands and therefore not included in these 
guidelines.
Vitamin D3 analogues
Table 8  Vitamin D3 analogues
Recommended initial 
dosage
Calcipotriol: 2x daily on affected areas of the skin
Calcitriol: 2x daily on affected areas
Calcipotriol/betamethasone: 1x daily on affected areas 
Recommended 
maintenance dosage
Calcipotriol: ≤15g cream or ointment daily and ≤100g weekly
Calcitriol: ≤30g ointment daily and ≤35% of body surface area
Calcipotriol/betamethasone: continuous use during 4 weeks. 
Owing to lack of evidence on long-term continuous therapy, 
intermittent use of this drug is recommended
Important adverse effects
(See SmPC)
Burning sensation, redness
Overdosing: hypercalcemia, bone resorption, possibly uric 
acid kidney stones, or even kidney failure 
Prevention/treatment of 
adverse effects
Do not treat unaffected skin areas. In case of skin irritation, 
adjust frequency of therapy or stop briefly. Topical 
corticosteroids may reduce irritation. 
Absolute contraindications None
Relative contraindications
(See SmPC)
Pustular psoriasis
Diseases involving disorders of calcium metabolism
Treatment with medication that can cause hypercalcemia
Serious kidney or liver disease
Due to lack of experience, treatment during pregnancy and 
breastfeeding should be avoided
Important drug 
interactions
Topical salicylic acid (inactivation), avoid other topical 
irritating preparations
Oral calcium supplementation, oral vitamin D3, thiazide 
diuretics: check serum calcium levels 
Costs 120g calcipotriol cream: €37.26
100g calcitriol ointment: €23.70
100g Dovobet (calcipotriol/betamethasone): €68,-
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EL: 1
After topical application of vitamin D3 analogues 30-50% of patients with 
mild to moderate chronic plaque psoriasis improved substantially or even 
achieved almost complete remission within several weeks
A2 Camarasa et al., 2003 (46); Kragballe et al., 2004 (47); Zhu et al., 2007 
(48); Guenther et al., 2000 (49)
EL: 1
Efficacy and tolerance of vitamin D3 analogues are enhanced by combining 
therapy with topical corticosteroids during the first phase of treatment. 
Usage of calcipotriol/betamethasone dipropionate ointment or gel is 
preferred because of a higher patient compliance with 1x daily application
A2 Papp et al., 2003 (31); Douglas et al., 2002 (32); Kaufmann et al., 2002 
(33); Tabolli et al., 2009 (50); Guenther et al., 2002 (51); Kragballe et al., 2004 
(47); Ortonne et al., 2004 (52); Kragballe et al., 2006 (53); Peeters et al., 2005 
(54); Saraceno et al., 2007 (55)
Treatment recommendation
Vitamin D3 analogues are recommended as topical therapy for chronic plaque psoriasis.
Efficacy and tolerance is higher for the combination of vitamin D analogues with cor-
ticosteroids when compared with both monotherapies. The combination preparation 
is preferred because of its 1x daily application.
For treatment of moderate to severe chronic plaque psoriasis the use of topical 
vitamin D3 analogues combined with UV-therapy or systemic therapy is recommended.
Table 8  Continued
Special notes Do not apply calcipotriol before treatment with UV-light.  
It can diminish the effect of UV-therapy. Calcipotriol may be 
administered after phototherapy.
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2.3  Phototherapy
E.P. Prens, W.J.A. de Kort, M.B.G. Koek
Table 9  Phototherapy
Registration for psoriasis More than 50 years of experience with the oldest modality 
(Goeckerman)
Recommended control 
parameters before starting 
treatment
Regular inspection of skin every 8 to 10 treatments. Ask for 
UV-erythema.
Recommended initial 
dosage
Individual dosage depends on skin type; follow one 
treatment regimen until erythema occurs, then:
UVB: 70% of the minimal erythema dosage (MED)
Oral PUVA: 75% of the minimal phototoxic dosage (MPD)
Bath/cream PUVA: 30-50% of MPD
Recommended 
maintenance dosage
Increase dosage (10-30%) based on erythema 
Onset of effect After 2-3 weeks
Response rate UVB: 75% of patients a PASI 75 after 4-6 weeks (EL: 2)
PUVA: complete clearance of skin lesions in 75-90% of 
patients (EL: 2)
Absolute contraindications Photodermatoses/photosensitivity, skin malignancies, 
treatment with cyclosporine (immunosuppressant) and 
expected treatment with cyclosporine in future.
PUVA: pregnancy or lactation. This is a relative 
contraindication for bath PUVA.  
Relative contraindications Epilepsy, pregnancy or lactation (for bath PUVA), 
unavoidable therapy with photosensitizing agents, skin type I, 
dysplastic melanocytic nevi, prior history of skin cancer, poor 
compliance, physical or emotional inability to sustain therapy 
(heart failure NYHA class III-IV, claustrophobia), presence of 
actinic skin damage, children < 18 years, high cumulative 
number of treatments or dosage (for UVB: 400 treatments, 
this equals approximately 600-800 J/cm2 for narrow band 
UVB and 120-180 J/cm2 for broadband UVB therapy).
For oral PUVA: High cumulative number of treatments (1000 
J/cm2 or 150-200 treatments), prior arsenic treatment or 
ionizing radiation, significant liver damage.   
Most common adverse 
effects
≥1/10: Erythema, itch, hyperpigmentation. Only for PUVA: 
nausea. Only for excimer laser: blistering.
Important drug 
interactions
Note: medication capable of inducing phototoxicity or 
photoallergy.
Special notes Combination with topical preparations may work 
synergistically. PUVA should not be combined with 
cyclosporine. Eyes must be protected during phototherapy, 
as well as the penis and scrotum.
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Table 10  Important adverse effects of UVB and PUVA therapy
Most frequently Erythema, itch, hyperpigmentation
Only PUVA: nausea
Only excimer laser: blistering
Frequently -
Sometimes Blistering
Rarely Oral PUVA: squamous cell carcinoma, 
basal cell carcinoma
Very rarely -
Table 11  List of medication capable of inducing phototoxicity and photoallergy
 Drugs inducing phototoxicity Drugs inducing photoallergy
Tetracyclines Tiaprofenic acid
Phenothiazine Promethazine
Griseofulvin Chlorpromazine
Nalidixine acid Hydrochlorothiazide
Furosemide Quinine
Amiodarone Para-aminobenzoic acid (PABA) ointments
Piroxicam Desinfectants (hexachlorophene, others)
Tiaprofenic acid
Table 12  Starting dosage UVB therapy (56)
Skin type UVB broadband (mJ/cm2) Narrow band UVB (mJ/cm2)
I 20 200
II 30 300
III 50 500
IV 60 600
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Table 13  Treatment regimen UVB phototherapy (56)
Step 1
Assessment of MED
Assess after 24 hours
Step 2
Start of therapy
Starting dosage According to skin type or 
70% of MED
Step 3
Treatment 2-3 times  
per week
No erythema Increase by 30%
Minimal erythema Increase by 20%
Persisting asymptomatic 
erythema
Do not increase dosage
Painful erythema Interrupt treatment until 
symptoms disappear
Step 4
Resume treatment
After disappearance of 
symptoms
Lower last dosage by 50%
Increase further by 10%
Table 14   Treatment regimen localized UVB phototherapy (excimer laser or lamp) (57)
Step 1
Assessment of MED
Assess after 24 hours
Step 2
Start of therapy
Starting dosage 2x-4x of MED
Step 3
Treatment 2 times per week
Persisting asymptomatic 
erythema
Increase with 1x-2x MED
Painful erythema Interrupt treatment until 
symptoms disappear
Step 4
Resume treatment
After disappearance of 
symptoms
Repeat last dosage
Table 15   PUVA: most commonly used photosensitizing agents and their dosage 
(56, 58)
Modality Photosensitizing agent Dosage or concentration
Oral PUVA 8-methoxypsoralen (8-MOP)
5-methoxypsoralen (5-MOP)
0.6 mg/kg
1.2 mg/kg
Bath PUVA 8-MOP 0.5-5.0 mg/L
localized PUVA (emulsion or gel) 8-MOP 1%-0.005%
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UVB (broadband) 
EL: 2
About 75% of all patients treated with broadband UVB 2-3 times per week 
achieved at least PASI 75 response after 4-12 weeks (depending on UV 
schedule) and clearance was reached in most cases.
A2 Dover et al., 1989 (59)
B Coven et al., 1997 (60); Orfanos et al., 1979 (61); Petrozzi, 1983 (62); 
Ramsay et al., 2000 (63)
Table 16  PUVA starting dosages (57)
Skin type Oral PUVA Bath PUVA
8-MOP 
(J/cm2)
5-MOP 
(J/cm2)
1.0 mg/L 8-MOP
(J/cm2)
I 0.3 0.4 0.2
II 0.5 1.0 0.3
III 0.8 1.5 0.4
IV 1.0 2.0 0.6
Table 17  PUVA treatment regimen (57)
Step 1
Assessment of minimal 
phototoxic dosage
Oral PUVA: assess after 72-96 h
Bath PUVA: assess after 72-96 h
Step 2
Start of therapy
Starting dosage Oral PUVA: According to 
skin type or 75% of MPD
Bath PUVA: According to 
skin type or 30-50% of MPD
Step 3
Treatment 2x per week
No erythema, good 
response
Increase by 30% (max. 2 
times per week)
Minimal erythema Do not increase
Persisting asymptomatic 
erythema
Do not increase
Painful erythema Interrupt treatment until 
symptoms disappear
Step 4
Resume treatment
After disappearance of 
symptoms
Lower last dosage by 50%; 
increase further by 10%
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UVB (narrow band)
EL: 2
63% - >75% of all patients treated with narrow band UVB 2-3 times per week 
reached at least PASI 90 response within 20 weeks of treatment. Presumably 
higher response percentages are achieved for PASI 75. Exact data are not 
available since performed studies date before the “PASI-era”.
B Arnold et al., 2001 (64); Gordon et al., 1999 (65); Markham et al, 2003 (66); 
Youssef et al., 2008 (67)
EL: 2
It is unclear whether phototherapy > 3 times per week results in a higher 
efficacy and faster response.
B Coven et al., 1997 (60); Grundmann-Kollmann et al., 2004 (68); 
Leenutaphong et al., 2000 (69) 
EL: 2
The percentage of patients achieving PASI 75, PASI 90 or complete 
clearance is equally high for home UVB phototherapy as for outpatient 
phototherapy.
A2 Koek et al., 2009 (70)
B Cameron, 2002 (71)  
EL: 2
No significant difference exists between home and outpatient phototherapy 
for total cumulative dosage of UVB at the end of treatment.
There is also no difference between both therapies for percentage of 
adverse effects as for the number of adverse effects experienced at least 
once by patients with psoriasis.    
A2 Koek et al., 2009 (70)
B Cameron, 2002 (71)  
UVB 308 nm
EL: 2
Individual plaques disappear completely (in 33-37%) or almost completely 
(about 70%) after treatment with the excimer laser for 8-16 weeks.
 B Hacker et al., 1992 (72); Taibjee et al., 2005 (73); Trehan et al., 2002 (74); 
Goldinger et al., 2006 (75)
C Feldman et al., 2002 (76); Han, 2008 (77)
EL: 3
There is evidence the results of the excimer lamp equal the excimer laser.
B Kollner et al., 2005 (78)
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Oral PUVA
EL: 2
After 12-16 weeks, 75-90% of patients achieve near complete clearance of 
skin lesions when treated with oral PUVA 2-4 times per week
A2 Yones et al., 2006 (79)
B Caca-Biljanovska et al., 2002 (80); Barth et al., 1978 (81); Berg et al., 1994 
(82); Buckley et al., 1995 (83); Calzavara-Pinton et al., 1992 (84); Collins et 
al., 1992 (85); Cooper et al., 2000 (86); Diette et al., 1984 (87); Hanke et al., 
1979 (88); Khurshid et al., 2000 (89); Kirby et al., 1999 (90); Park et al., 1988 
(91); Parker et al., 1984 (92); Parrish et al., 1974 (93); Rogers et al., 1979 (94); 
Vella Briffa et al., 1978 (95); El-Mofty et al., 2008 (96)
C Henseler et al., 1981 (97) 
Bath PUVA
EL: 2
The results of bath PUVA equal oral PUVA when treatment frequencies are 
similar.
B Caca-Biljanovska et al., 2002 (80); Barth et al., 1978 (81); Berg et al., 1994 
(82); Buckley et al., 1995 (83); Calzavara-Pinton et al., 1992 (84); Collins et 
al., 1992 (85); Cooper et al., 2000 (86); Diette et al., 1984 (87); Hanke et al., 
1979 (88); Khurshid et al., 2000 (89); Kirby et al., 1999 (90); Park et al., 1988 
(91); Parker et al., 1984 (92); Parrish et al., 1974 (93); Rogers et al., 1979 (94); 
Vella Briffa et al., 1978 (95); El-Mofty et al., 2008 (96)
Retonoid plus PUVA / UVB
EL: 2
There is evidence that combination therapy with PUVA / acitretin or narrow 
band UVB / acitretin achieves higher efficacy and is dose-sparing in regard 
to cumulative UV dosage.
B Saurat et al., 1988 (98); Carlin et al., 2003 (99); Lauharanta et al., 1989 
(100)
Instructions for phototherapy
Prior to treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Medical history and physical examination need to be directed at prior exposure, 
melanocytic nevi (in particular dysplastic type) and skin cancer
· Additional UV exposure due to recreational activities should be taken into account
· Prescription of UVA protecting sunglasses is obligatory before commencing oral PUVA 
therapy
· 
During treatment
· Physical examination
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· UV dosages should be documented with precise cumulative units (J/cm2 or mJ/cm2) 
and number of treatments
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· Ask for the occurrence of erythema on a regular basis in order to accurately determine 
treatment dosage
· Physicians should report adverse effects, therapeutic response and concomitant 
treatments within the medical record
· Eyes should always be protected during phototherapy with sunglasses with UV-
protection as well as at least 8 hours after oral-PUVA treatment
· Cover the genital area when skin lesions are absent. If desired, healthy skin of the face 
and other unaffected areas may be covered (possibly with adequate sunscreens). The 
area of covered skin needs to be the same during every treatment since a shift of 1 cm 
may cause burns due to unequal sensitivity of this area to UV light
· It is essential for the patient to avoid additional sun exposure and/or to use sunscreens
After treatment
· After a treatment course, cumulative UV-dosage and number of treatments should be 
registered
· Especially patients with high number of treatment episodes (200-250x PUVA) need to be 
screened routinely for skin cancer during their entire life
Treatment recommendation
Phototherapy is recommended for induction therapy of moderate to severe chronic 
plaque psoriasis. Narrow band UVB is recommended as first choice; PUVA is advised 
in case UVB is ineffective.
8-MOP or methoxsalen is preferred for PUVA therapy. This preparation, however, is 
being withdrawn from the market. The manufacturer states Oxsoralen (methoxsalen 
10 mg capsules) can be imported by the pharmacist with a delivery time of  a week.
Oxsoralen is not registered in the Netherlands and will not be reimbursed. The 
dermatologist should contact the health insurance of the patient to arrange a 
reimbursement for a non-registered drug.
The use of excimer lasers should be limited to treatment directed at single, therapy 
resistant psoriatic plaques.
UV maintenance therapy is not recommended owing to decreased efficacy after 
repetitive UV-exposure and increased chance of UV skin damage. The number of 
treatment courses should be limited to a maximum of 2 per year.
UV-therapy after or during immunosuppressant drugs, especially cyclosporine, demands 
special attention.
Both home and outpatient UVB phototherapy are available for the treatment of psoriasis. 
The dermatologist should, in consultation with the patient, decide which treatment 
setting is preferred. 
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2.4  Conventional systemic therapies
Methotrexate
E.M.G.J. de Jong
Table 18  Methotrexate 
Registration for psoriasis 1958
Recommended control parameters before 
starting treatment
Hb, leucocytes and differential, 
thrombocytes, liver enzymes, serum 
creatinine, urine sediment, pregnancy 
test, HBV/HCV, serum albumin, PIIINP if 
available, X-thorax in case of suspected 
tuberculosis on anamnesis.
Recommended initial dosage 5-10 mg weekly
Recommended maintenance dosage 5-22.5 mg weekly (oral, subcutaneous or 
intramuscular)
Onset of effect After 4-12 weeks
Response rate PASI 75 in 35-73% of patients after 16 weeks
Absolute contraindications
(See SmPC)
Severe infections, serious kidney and 
liver diseases, bone marrow diseases, 
substantial hematologic abnormalities, 
men and women planning to have children, 
pregnancy, breastfeeding, pulmonary 
fibrosis or poor lung function, alcohol 
abuse, immune deficiencies, acute peptic 
ulcer, drug abuse.
Relative contraindications
(See SmPC)
High age, less serious kidney and liver 
diseases, ulcerative colitis, history of 
HBV or HCV, poor compliance, gastritis, 
diabetes, history of malignancies, heart 
failure, drug interactions
Most common adverse effects
(See SmPC)
≥1/10: stomatitis, dyspepsia, nausea, 
loose of appetite. Increase of serum 
transaminases.
≥1/100 - ≤1/10: oral ulcers, diarrhea. 
Exanthema, erythema, itch. Headache, 
fatigue, sleepiness. Interstitial alveolitis 
or pneumonitis: symptoms of potentially 
severe damage are dry, unproductive 
cough, dyspnoe and fever. Leukopenia, 
anemia, trombopenia.
Important drug interactions Trimethoprim, probenecide, retinoids, 
NSAIDs 
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Conclusions of the Dutch guidelines
EL: 1
Methotrexate is effective for the treatment of plaque psoriasis in adults. After 
16 weeks, in 35-73% of patients with psoriasis a PASI 75 response was 
reached on 15-22.5mg methotrexate weekly.
A2 Flystrom et al., 2008 (101); Ranjan et al., 2007 (102); Saurat et al., 2008 
(103); Heydendael et al., 2003 (104); Akhyani et al., 2010 (105)
Table 18  Continued 
Special notes Dosing once a week; overdose may 
lead to leukocytopenia or pancytopenia 
which may be life-threatening. Continue 
oral contraceptives until 3 months after 
cessation of MTX.
Alcohol consumption, obesity, hepatitis and 
diabetes increase the risk of hepatotoxicity. 
In geriatric patients a lower dose of MTX 
is usually prescribed and kidney function 
should be monitored on a regular basis.
Table 19  Important adverse effects of MTX 
Most frequently Stomatitis, dyspepsia, nausea, loose of 
appetite. Increase of serum transaminases. 
Hair loss.
Frequently Oral ulcers, diarrhea. Leukopenia, anemia, 
trombopenia.
Sometimes Fever, shivers, depression, infections
Rarely Nephrotoxicity, liver fibrosis / cirrhosis
Very rarely MTX alveolitis or pneumonitis.
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Instructions for MTX use
Prior to treatment
· Medical history and physical examination
· Assessing disease severity, preferably with PASI or PGA
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Laboratory controls (Table 21)
· Start contraceptives in fertile women (start after menstruation), contraceptive measures 
in men
· In case liver function screening shows abnormalities, refer to specialist for further 
evaluation
· Influenza vaccination is recommended
· X-thorax in case of suspected tuberculosis on anamnesis.
During treatment
· Objective assessment of disease severity using PASI or PGA
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Medical history
· Physical examination
· Laboratory controls (Table 21)
· Contraceptive measures in fertile women and men
· Administer folic acid once weekly at least 24 hours after MTX*
· Intake of MTX with milk reduces the absorption of MTX
After treatment
· Women should not become pregnant and men should not conceive children during 
MTX treatment and 3 months thereafter.
* Folic acid dosage varies in the literature between 1 to 5mg daily and 1 to 2.5-10mg weekly (Prey, 2009).
The working group of these guidelines holds the opinion that dosage of folic acid should be flexible with 
1mg daily (except for the day of MTX intake) to 5-10mg once weekly administered at least 24 hours after 
MTX intake. The guidelines of the Dutch Society of Rheumatology advice to prescribe at least 5mg of folic 
acid weekly, at least 24 hours after MTX intake. It is recommended to double this dosage in case MTX 
dosage becomes ≥15mg weekly.
Table 20  List of medication and drug interactions 
Medicine Type of drug interaction
Colchicin, cyclosporine, NSAIDs, penicillin, 
probenecide, salicylic acids, sulfonamides
Reduced renal clearance of MTX
Chloramphenicol, co-trimoxazol, 
cytostatics, ethanol, NSAIDs, sulfonamides
Increased risk of bone marrow and 
gastrointestinal toxicity
Barbiturates, co-trimoxazol, phenytoin, 
probenecide, NSAIDs, sulfonamides
Interaction with plasma protein binding
Ethanol, leflunomide, retinoids, 
tetracyclines
Increased risk of hepatotoxicity
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Table 22   PIIINP (amino-terminal propeptide of type III pro-collagen) cut-off levels 
and clinical guidance 
PIIINP (amino-terminal propeptide of type III pro-collagen) for psoriasis
Reference range: 1.7 – 4.2 mcg/L.
First serum sample before starting MTX, thereafter 1x every 3 months.
Confounding factors: arthritis, age <18 years, scleroderma, myeloproliferative disorders, 
malignancies (breast carcinoma, hepatocellular carcinoma, ovarian carcinoma), recent 
myocardial infarction.
A gastroenterologist should be consulted (after exclusion of confounding factors) when:
PIIINP value is >8.0 mcg/L prior to starting MTX
PIIINP value is >4.2 mcg/L in at least 3 samples during a 12 month time period
PIIINP value is >8.0 mcg/L in at least 2 consecutive samples
PIIINP value is >10 mcg/L in 1 sample. In this case, provisionally stop MTX.
Table 21  Laboratory controls 
Parameter* Prior to treatment After the first week 
of treatment
During the first  
two months  
1x every 2 weeks, 
thereafter every  
2-3 months.
Hb, leucocytes 
and differential, 
thrombocytes, 
erythrocytes
X X X
Liver enzymes 
(ALAT, AP, yGT)
X X X
Serum creatinine X X X
Urine sediment X X X
Pregnancy test X
HBV/HCV X
Serum albumin** X X X
PIIINP if available X Every 3 months***
Further testing may be required based on patient’s status, risk and exposures.
*   Decrease MTX dosage or stop MTX in case leukocytes are <3.0, neutrophils <1.0, thrombocytes<100 
or liver enzymes >2x the upper limit normal range
**   In certain patients (e.g. suspicion of hypoalbuminemia or patients using other medication with strong 
serum albumin binding properties)
***  Liver biopsy should be considered in selected patients, e.g. patients with a continuous elevated PIIINP 
level (>4.2 mcg/l in at least 3 samples during a 12 month time period)
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Treatment recommendation
Treatment with methotrexate (15-22.5 mg/week) is effective for plaque psoriasis and 
induces a reduction of PASI score of at least 75% (PASI75) in 35-73% of patients after 
16 weeks of treatment. Owing to its slow onset of effect, methotrexate is less suitable 
for short induction treatment than for long-term therapy. 
It is recommended to supply folic acid to reduce the risk of hepatic adverse effects. 
The dosage may vary from 1mg daily (except for the first day of MTX intake) to 5-10mg 
once weekly, with a time interval between MTX intake and start of folic acid of at least 
24 hours. 
Before starting MTX therapy and every 3 months thereafter, it is recommended to 
monitor for liver damage by measuring liver enzymes and PIIINP.
PIIINP measurement should be available for all Dutch dermatologists. Values should 
be given preferably with interpretation of the results and advice. Several hospitals 
Table 23   Liver biopsy: Roenigk classification of liver damage and its  
therapeutic consequences 
Histological classification:
Grade I: Normal
Grade II: Changes, no fibrosis
Grade IIIA: Mild fibrosis
Grade IIIB: Moderate to severe fibrosis
Grade IV: Cirrhosis
Therapeutic consequences:
Grade I and II: MTX may be continued
Grade IIIA: MTX may be continued, but liver biopsy needs to be repeated after 6 months
Grade IIIB and IV: stop MTX
Table 24   Folic acid dosage in case of MTX overdose 
Serum MTX (M) Parenteral administration of folic acid 
once every 6 hours (dosage in mg)
5 x 10-7 20
1 x 10-6 100
2 x 10-6 200
>2 x 10-6 Increase dosage proportionally 
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should offer the possibility of PIIINP measurement. Currently, PIIINP measurement is 
available in the University Medical Centre Nijmegen and VU Medical Centre 
Amsterdam.
Because of the occurrence of overdosing of MTX (e.g. prescribed once daily instead 
of once weekly) with sometimes lethal consequences it is recommended to prescribe 
the recipe for MTX carefully. It must be clearly stated that dosage is once weekly. It is 
strongly advised by The Dutch health inspection that physicians should state the 
indication of MTX on the recipe. Patients should be informed about the once weekly 
treatment regimen.
Owing to the possible mutagenic effects of MTX fertile men and woman should be 
strongly advised to use reliable contraceptives.
Cyclosporine
Ph.I. Spuls, M. de Groot
Table 25   Cyclosporine 
Registration for psoriasis 1993
Recommended control 
parameters before starting 
treatment
Hb, leucocytes and differential, thrombocytes, serum 
creatinine, urea, uric acid, liver enzymes (ASAT, ALAT), 
bilirubin, alkaline phosphatase, yGT, LDH, albumin, sodium, 
potassium, magnesium only in case of muscle cramps, urine 
sediment, cholesterol / triglycerides, pregnancy test, blood 
pressure.
Recommended initial 
dosage
2.5-3 (max. 5) mg/kg per day for 4-6 weeks. When skin does 
not improves, increase to 5 mg/kg/day
Recommended 
maintenance dosage
Lower dosage every two weeks until a maintenance dosage 
of 0.5-3 mg/kg/day is reached, divided into 2 doses. 
Increase dosage in case of recurrence of psoriasis. Maximal 
total duration of therapy: 2 years. (EDF guidelines, 2009)
Onset of effect After 4 weeks
Response rate The response is dose-dependent. After 8-16 weeks 
of treatment with 3 mg/kg/day, PASI 75 is reached in 
approximately 50% of patients after 8 weeks.
Absolute contraindications
(See SmPC)
History of serious adverse effects on or hypersensitivity to 
cyclosporine, poor kidney function, severe liver disease, 
severe hypertension, serious infections, malignancy (current 
or past, especially hematologic or cutaneous malignancies 
except for basal cell carcinoma), concurrent PUVA treatment, 
contra-indicated concomitant medication, vaccination with 
live vaccines, gout. 
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Table 25   Continued 
Relative contraindications
(See SmPC)
Prior potential carcinogenic treatment (arsenic, PUVA > 
1000 J/cm2 or 150-200 applications), prior long-term MTX 
use, psoriasis induced by serious infection or medication 
(beta blocker, lithium, antimalarial medication), liver 
function disorders, hyperuricemia, hyperkalemia, epilepsy/
convulsions, inadequate efficacy in the past, simultaneous 
treatment with nephrotoxic drugs, polypharmacy (e.g., 
HIV patients), simultaneous use of other systemic 
immunosuppressive drugs, concurrent phototherapy, 
simultaneous use of systemic retinoids or retinoid therapy 
4 weeks prior to commencing cyclosporine treatment, drug 
or alcohol related diseases or substance abuse or alcohol 
abuses, pregnancy/breastfeeding, current treatment with 
ricinus oil preparations.
Most common adverse 
effects
(See SmPC)
≥1/100 - <1/10: kidney insufficiency (dose-dependent), 
irreversible kidney damage (long-term therapy), 
hypertension, gingival hyperplasia, reversible gastrointestinal 
complaints (dose-dependent), tremor, fatigue, headache, 
burning sensation of hands and feet, reversible 
hyperlipidemia (especially in combination with systemic 
corticosteroids), hypertrichosis, abnormal liver function tests.
Important drug 
interactions
Many different drug interactions: see SmPC text and Dutch 
guidelines (http://www.huidarts.info/documents/uploaded_
file.aspx?id=579)
Special notes Increased risk of lymphoproliferative diseases in transplant 
patients. Increased risk of squamous cell carcinoma in 
patients with psoriasis after photo(chemo)therapy (106).
Special warnings:
- The capsules contain a small amount of alcohol (intake of 
100 mg capsules equals 0.1 g alcohol)
- There is a potential risk of drug interactions, especially with 
statins (increased risk of myopathy).
- When idiopathic intracranial hypertension is diagnosed, 
cyclosporine should be stopped in order to avoid permanent 
decline in vision.
- Yearly assessment of GFR is the most accurate method in 
order to assess kidney tolerance to cyclosporine in long-term 
therapy.
-  Supplementation with magnesium seems to protect 
against loss of kidney function as well as chronic 
cyclosporine nephrotoxicity by adapting the activity of 
nitrogen monoxide synthase (107).
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Conclusions of the Dutch guidelines
EL: 1
Cyclosporine is effective for the treatment of moderate to severe chronic 
plaque psoriasis in adults. PASI 75 was reached in 20-71% of patients with 
psoriasis on 2.5-5 mg/kg/day cyclosporine at week 8-16 and PASI 90 was 
reached in 33% of patients on 3-5 mg/kg/day at week 16. Most included 
studies showed a clinical relevant response 4-6 weeks after commencing 
therapy.
A2 Heydendael et al., 2003 (104); Gisondi et al., 2008 (108); Koo, 1998 (109); 
Ellis et al., 1991 (110)
Table 25   Continued 
Special notes Special attention to switching therapies:
- Switching from cyclosporine to other cyclosporine (other 
manufacturer): be aware of differences in biological 
availability and if necessary adjust dosage.
- Cyclosporine may be used after systemic retinoid therapy, 
that is 4 weeks after cessation of retinoid treatment.
- Fumaric acid esters and cyclosporine are usually not 
combined.
- In case of insufficient response to cyclosporine a 
switch to a biological agent may be considered. A period 
of simultaneous usage of both biological agent and 
cyclosporine may be considered in spite of synergistic 
toxicity (infections, hepatotoxicity). 
Table 26   Important adverse effects of cyclosporine 
Frequently Kidney insufficiency (dose-dependent), irreversible kidney 
damage (long-term therapy), hypertension, gingival 
hyperplasia, reversible gastrointestinal complaints (dose-
dependent), tremor, fatigue, headache, burning sensation 
of hands and feet, reversible hyperlipidemia (especially in 
combination with systemic corticosteroids), hypertrichosis, 
abnormal liver function tests.
Sometimes Convulsion, gastrointestinal ulcers, weight gain, 
hyperglycemia, hyperuricemia, hyperkalemia, 
hypomagnesemia, acne, anemia. 
Rarely Ischemic heart disease, pancreatitis, polyneuropathy 
(motoric), decreased eyesight, decreased hearing, 
central ataxia, myopathy, erythema, itch, leucopenia, 
thrombocytopenia.
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 196
196
Chapter 10
Instructions for cyclosporine use
Prior to treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Medical history and physical examination need to be directed at prior diseases and 
current comorbidity (e.g., serious infections, (skin) malignancies, kidney and liver 
diseases). Also, possible drug-interactions involving current concomitant medication 
and contraindications should be ruled out
· Measure blood pressure at two separate consultations if first measurement was elevated
· Laboratory controls (Table 27)
· Reliable contraceptive (note: contraceptives with progesterone become less effective)
· Gynecological screenings should be performed on a regular basis according to the 
Dutch national guidelines on cervix carcinoma
· Inform patients about vaccination (especially live attenuated vaccines), patient’s 
susceptibility to infections (take infections serious, apply adequate medical assistance), 
drug interactions (inform other treating physicians on therapy), avoidance of excessive 
sun exposure, advice the use of sunscreens
During treatment
· Objective assessment of disease severity (such as PASI / BSA / PGA; arthritis)
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Physical examination should include examination of skin and mucous membranes for 
formation of skin malignancies (also inspect for increase of hair growth on the body, 
gingival changes), signs of infections, gastrointestinal or neurological symptoms
· Repeat the advice on avoidance of excessive sun exposure and using sunscreens
· Check concomitant medication
· Measure blood pressure
· Laboratory controls (Table 27)
· If creatinine levels are increased or if patient is treated > 1 year, assess the creatinine 
clearance (or 51 Cr-labeled EDTA clearance if available)
· Routine assessment of cyclosporine serum levels is not recommended (see Dutch S3-
guidelines for details: http://www.huidarts.info/documents/uploaded_file.aspx?id=579)
· Reliable contraceptive
After treatment
· After cessation of cyclosporine, the dermatologist needs to inspect the patient for the 
formation of skin malignancies, especially in cases in which extensive UV-therapy or UV-
exposure preceded cyclosporine treatment.
Table 26   Important adverse effects of cyclosporine 
Very rarely Microangiopathic hemolytic anemia, hemolytic uremic 
syndrome, colitis (isolated cases), papillary oedema (isolated 
cases), idiopathic intracranial hypertension (isolated cases).
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Treatment recommendation
3-5 mg/kg/day Cyclosporine is recommended for induction therapy in patients with 
moderate to severe plaque psoriasis. Because of its fast onset of action, cyclosporine 
is appropriate for short-term induction therapy or crisis intervention. 
Cyclosporine may be used to induce remission in adults with moderate to severe chronic 
plaque psoriasis who are undertreated with topical preparations or phototherapy.
Cyclosporine may be used for long-term treatment (up to 2 years) in individual cases, 
but patients must be screened intensively for signs of toxicity, especially for decrease 
in kidney function and the development of hypertension.
Table 27   Laboratory controls 
Parameter Prior to 
treatment
Treatment period (in weeks)
2 4 8 12 16
Blood count* X X X X X X
Liver values** X X X X X X
Electrolytes*** X X X X X X
Serum creatinine X X X X X X
Urine sediment X X X
Urea and uric acid X X X X X
Pregnancy test 
(urine)
X
Cholesterol, 
triglycerides
X**** X X
Magnesium***** X X X
* Leucocytes, thrombocytes, erythrocytes
** Transaminase, AP, yGT, bilirubin, LDH, albumin
*** Sodium, potassium
**** Recommended 2 weeks prior to treatment and on the first day of treatment (fasting).
***** Only if indicated (e.g., muscle cramps). Also consider CPK.
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Retinoids
M. te Booij, P.C.M. van de Kerkhof, M.C. Pasch
Conclusions of the Dutch guidelines
EL: 2
Acitretin is effective in the treatment of adult patients with moderate to severe 
plaque psoriasis. 11% (A2) – 50% (B) of patients with psoriasis treated with 
0.5 mg/kg/day acitretin reached PASI 90 response at week 8-12 and 25-41% of 
patients reached PASI 75 at week 8-12 when treated with 10-75 mg/day acitretin.
A2 Kragballe et al., 1989 (112)
B Gupta et al., 1998 (113); van de Kerkhof et al., 1998 (114)
Table 28  Retinoids 
Registration for psoriasis 1992 (Germany)
Recommended control 
parameters before starting 
treatment
Hb, Hct, leukocytes, trombocytes, liver enzymes (ASAT, 
ALAT), AP, yGT, serum creatinine, pregnancy test, blood glucose 
(fasting), triglycerides/cholesterol/HDL, perform X-ray 
examination of bones when symptoms exist (Ormerod, 2010)
Recommended initial 
dosage
0.3-0.5 mg/kg/day during 4 weeks, followed by 0.5-0.8 mg/
kg/day
Recommended 
maintenance dosage
Individual dosage depends on response and tolerance
Onset of effect After 4-8 weeks
Response rate Varies strongly and is dose-dependent, unambiguous 
conclusions cannot be stated, 25-75% reach partial 
remission (PASI 75) (30-40 mg/day) (Level of evidence: 3)
Absolute contraindications
(See SmPC)
Kidney and liver damage, fertile women planning to have 
children, concomitant medication interacting with retinoids, 
hepatotoxic concomitant medication, pregnancy, breast-
feeding, alcohol abuse, blood donation.
Relative contraindications
(See SmPC)
Alcohol use (111), diabetes mellitus, use of contact lenses, 
children, history of pancreatitis, hyperlipidemia (especially 
hypertrygliceridemia) and hyperlipidemia treated with 
medication, atheroclerosis.  
Most common adverse 
effects
(See SmPC)
≥ 1/10: vitamin A toxicity (cheilitis, xerosis, epistaxis, 
alopecia, increased skin fragility)
≥ 1/100 to < 1/10: conjunctivitis (be aware of contact 
lenses), hair loss, photosensitivity, hyperlipidemia.
Important drug 
interactions
Phenytoin, tetracycline, methotrexate, alcohol, minipill, lipid 
lowering drugs (see also table 30).
Special notes Continue contraceptive use at least 2 years after cessation of 
medication in fertile women
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Table 29  Important adverse effects of retinoids 
Most frequently Vitamin A toxicity (xerosis, cheilitis)
Frequently Conjunctivitis (be aware of contact lenses), hair loss, 
photosensitivity, hyperlipidemia.
Sometimes Muscular, joint and bone pain, retinoid-induced dermatitis
Rarely Gastrointestinal complaints, hepatitis, jaundice. Bone 
changes with long-term use.
Very rarely Idiopathic intracranial hypertension, decreased color vision, 
nyctalopia 
Table 30  List of medication and drug interactions 
Medicine Type of drug interaction
Tetracycline Induction of idiopathic intracranial hypertension 
Phenytoin Shift of plasma proteins
Vitamin A Increasing the effect of retinoids
Methotrexate Hepatotoxicity
Low dosage of pill with progesterone Insufficient contraceptive effect
Lipid lowering drugs Increased risk of myotoxicity
Antifungal imidazoles Hepatotoxicity
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Instructions for retinoid use
Prior to treatment
· Medical history and physical examination should be directed at muscle and skeletal 
problems. When patients experience symptoms supplementary imaging studies may be 
performed
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Exclude the possibility of pregnancy/lactation: patients have to be extensively informed 
about the teratogenic risk of the drug, the necessity of long-term effective contraceptives 
up to 2 years after cessation of acitretin therapy and the possible consequences of 
pregnancy during retinoid use: this must be well documented by the physician
· Patients should be informed about the specific risks of excessive alcohol consumption. 
Inform female patients about the increased conversion of acitretin into etretinate
· Direct the patient that blood donation is not allowed during and until 1 year after 
treatment
· Laboratory controls (Table 31)
· 
Instructions for retinoid use
Prior to treatment
· Medical history and physical examination should be directed at muscle and skeletal 
problems. When patients experience symptoms supplementary imaging studies may be 
performed
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Exclude the possibility of pregnancy/lactation: patients have to be extensively informed 
about the teratogenic risk of the drug, the necessity of long-term effective contraceptives 
up to 2 years after cessation of acitretin therapy and the possible consequences of 
pregnancy during retinoid use: this must be well documented by the physician
· Patients should be informed about the specific risks of excessive alcohol consumption. 
Inform female patients about the increased conversion of acitretin into etretinate
· Direct the patient that blood donation is not allowed during and until 1 year after 
treatment
· Laboratory controls (Table 31)
During treatment
· Capsules should be taken during a meal or with milk
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· It is required to avoid pregnancy. Treatment is started at the second or third day of 
the menstruation cycle after adequate contraceptive use for at least 1 month prior to 
treatment. It is recommended to use 2 contraceptives simultaneously (e.g., condom 
+ pill; IUD/NuvaRing + pill; note: avoid the use of preparations with low dose 
progesterone / mini-pill) during treatment and up to 2 years after cessation of treatment
· Avoid excessive usage of alcohol
· Ask patient about symptoms of the back and joints. When patients experience 
symptoms supplementary imaging studies may be performed
· Laboratory controls (Table 31)
After treatment
· Reliable contraceptives in fertile women up to 2 years after cessation of treatment
· It is recommended to use 2 contraceptives simultaneously, as stated above
· Patients are not allowed to be blood donors for 1 year after cessation of treatment
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Treatment recommendation
0.5mg/kg/day acitretin is recommended for induction therapy of moderate to severe 
psoriasis.
When induction therapy is considered to be effective after 10 – 16 weeks, maintenance 
therapy may be considered using the lowest effective dosage.
When conventional systemic therapies are indicated, acitretin is not recommended 
as first-choice monotherapy.  
Fertile women planning to have children should not be treated with acitretin owing to 
its teratogenic properties.
Table 31   Laboratory controls 
Parameter Prior to 
treatment
Treatment period (in weeks)
1 2 4 8 12 16
Blood count* X X X
Liver values** X X X X X
Serum creatinine X
Pregnancy test 
(urine)
X Monthly during treatment
Blood glucose 
(fasting)
X
Tryglicerides, 
cholesterol, HDL
X X X
Further testing may be required based on clinical symptoms, risk and exposures
* Hb, Hct, leukocytes, thrombocytes
** ASAT, ALAT, AP, yGT
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Fumaric acid esters
H.B. Thio, E.P. Prens
Conclusions of the Dutch guidelines
EL: 2
Fumaric acid esters result in almost complete remission in 24% (weighted 
average, 18-46%) of patients after 16 weeks of treatment. Partial remission 
(PASI 75) is seen in 50-70% of patients after 16 weeks of treatment. Good 
efficacy was reached in both short-term and long-term (maintenance) 
therapy.
A2 Altmeyer et al., 1994 (115); Gollnick et al., 2002 (116)
B Nugteren-Huying et al., 1990 (117); Kolbach et al., 1992 (118); Nieboer et 
al., 1990 (119)
C Altmeyer et al., 1996 (120); Bayard et al., 1987 (121); Litjens et al., 2003 
(122); Carboni et al., 2004 (123); Mrowietz et al., 1999 (124)
Table 32  Fumaric acid esters 
Registration for psoriasis 1994 (Germany), not registered in the Netherlands
Recommended control 
parameters before starting 
treatment
Complete blood count, liver enzymes serum creatinine, urine 
sediment, pregnancy test.
Recommended initial 
dosage
See dosing scheme (Table 33)
Recommended 
maintenance dosage
Determine individually
Onset of effect After 6 weeks
Response rate 18-46% PASI 90 after 16 weeks of treatment
50-70% PASI 75 after 16 weeks of treatment
Absolute contraindications
(See SmPC)
Severe liver and/or kidney diseases, gastrointestinal 
diseases, hematological malignancies, pregnancy or 
breastfeeding
Relative contraindications
(See SmPC)
Hematological diseases (deviation in blood count), 
simultaneous usage of drugs that have the potential to 
induce nephrotoxicity
Most common adverse 
effects
(See SmPC)
≥ 1/10: diarrhea, flushing
≥ 1/100 to < 1/10: cramps, flatulence, lymphocytopenia, 
eosinophilia
Important drug 
interactions
No known drug interactions
Special notes Especially applicable for long-term therapy 
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Instructions for use of fumaric acid esters
Prior to treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Medical history and physical examination
· Laboratory controls (Table 35)
During treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Physical examination
· Laboratory controls (Table 35)
After treatment
· None
Table 33  Dosing scheme for dimethyl fumarate 
Time Dimethyl fumarate 30 mg
Number of tablets / day
Dimethyl fumarate 120 mg
Number of tablets / day
Week 1 0-0-1 -
Week 2 1-0-1 -
Week 3 1-1-1 -
Week 4 - 0-0-1
Week 5 - 1-0-1
Week 6 - 1-1-1
Week 7 - 1-1-2
Evaluate clinical response:
In case PASI response ≥ 50%
In case PASI response ≤ 50%
Maintain 1-1-2
Proceed to 2-1-2 (week 8)
Week 8 - 2-1-2
Week 9 - 2-2-2
Table 34  Important adverse effects of fumarates 
Most frequently Diarrhea, flushing
Frequently Cramps, flatulence, lymphocytopenia, eosinophilia
Sometimes Nausea, dizziness, headache, fatigue, proteinuria, increase 
of creatinine levels, increase of liver enzymes levels
Rarely Isolated increase of ALAT or bilirubin
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Treatment recommendation
Fumaric acid esters are recommended according to dosing scheme for induction 
therapy of patients with moderate to severe chronic plaque psoriasis.
When induction therapy is considered to be effective after 10 – 16 weeks, maintenance 
therapy may be considered using the lowest effective dosage.
Fumaric acid esters may be considered as first-choice systemic monotherapy.
2.5  Biologics
Biologics in general
T.E.C. Nijsten
Therapeutic response
The primary outcome in the evaluation for therapeutic response of psoriatic drugs 
remains the improvement of clinical disease severity (PASI 75 or PGA mild to absent), 
but patient-reported outcome measures (e.g. patient preference, treatment 
satisfaction and/or improvement in quality of life) are increasingly important [125]. 
The momentum of treatment evaluation is preferentially 24 weeks (initiation period), 
Table 35  Laboratory controls 
Parameter Prior to 
treatment
Treatment 
period (months)
3rd month, thereafter  
once every 3 months,  
followed by once every 6 months 
after 1 year of treatment
1 2
Total blood count 
(leucocytes, 
differential)
X X X X
Liver enzymes 
(yGT, ALAT, ASAT)
X X X X
Serum creatinine X X X X
Urea X X X X
Cholesterol X X X X
Urine sediment X X X X
Urine protein X X X X
Pregnancy test 
(urine)
X
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but for some treatments this may be at 16 weeks (e.g. adalimumab and infliximab).
When therapeutic response is considered suboptimal (PASI 75%-50% and PASI 
50%) or insufficient by the patient several alternatives are possible: increase dosage 
or dosage frequency, combination therapy (for example adding topical therapies, 
UV-therapy and/or methotrexate or acitretin) or switch to another (biologic) therapy. 
Transition
Clinical experience shows that switching between biologics of the same or different 
class may be effective in patients not responding to an anti-TNF alpha agent. 
Insufficient therapeutic response to a TNF-alpha antagonist does not imply ineffec-
tiveness of the other biologics inhibiting TNF alpha. Of course patients can be 
switched to ustekinumab, a biologic with a completely different mode of action. The 
same applies vice versa. The evidence of the effectiveness of switching between 
biologics is derived from small observational studies and (retrospective) case series 
[126, 127].
Hepatitis / HIV
Owing to the immunosuppressive properties of biologics it is advised to exclude 
chronic and active infections with HBV, HCV, and HIV in patients with psoriasis before 
commencing biologic therapy. The following recommendations are based upon 
small case-series since solid clinical studies are lacking.
In chronic carriers of hepatitis B (HBsAg positive), there is a risk of reactivation of the 
virus (with the complication of acute liver failure). Therefore, these patients should not 
be treated with biologics, except when simultaneously treated with nucleoside 
analogues and guided by a gastrointestinal (GI) specialist.
In HCV infected patients with psoriasis, biologic therapy may be started with adequate 
monitoring and in consultation with a GI specialist. HCV, in contrast to HBV, lacks the 
possibility of integrating into the DNA of hepatocytes and thus the risk of HCV flares 
is absent. 
In HIV infected patients with psoriasis, anti-TNF alpha therapy may be prescribed 
when the infection is controlled by HAART therapy. Additional controls are required 
given the possibility of drug interactions. Naturally, the patient should be treated in 
close consultation with the treating physician. Such experiences are lacking for 
ustekinumab therapy. 
Malignancies
The risk of the occurrence of malignancies (especially lymphomas and cutaneous 
squamous cell carcinomas) related to immunosuppressive agents such as biologics 
remains an issue of concern. Patients with psoriasis may already have an increased 
risk of developing skin cancer because of prior UV-phototherapy (especially PUVA), 
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which is further increased after initiation of immunosuppressive drugs (e.g., 
cyclosporine and biologics) in patients with a history of high levels of UV exposure 
[128, 129, 130, 131]. Therefore, all patients and especially those with a prior history of 
intensive immunosuppressive therapy or PUVA therapy should be examined for 
melanoma and non-melanoma skin cancer prior to and during anti-TNF alpha 
treatment.
Spontaneous reporting registries have identified an increased risk of hepatosplenic 
T-cell carcinoma, which is often lethal, in patients using infliximab and adalimumab.
Long-term effects of ustekinumab are likely to be comparable to other biologics but 
relatively little is known because relatively few patients have used these drugs for a 
long period compared with the TNF antagonists. In clinical trials, some patients 
developed a basal cell carcinoma during ustekinumab treatment. Hence, screening 
for malignancies by physical examination (mainly the skin) and a complete blood 
sample is being advised before commencing therapy with ustekinumab.
In order to optimally assess the long-term safety and stimulating effects on the 
carcinogenesis of biologics well-designed and independent post-marketing studies 
(phase IV) are needed. Until now, few studies on the long-term safety are published 
[132, 133]. Large (inter)national prospective registers (e.g. PsoNet) of patients on 
biologic therapy may be helpful in detecting and estimating the risks associated with 
the use of biologics. Physicians are therefore encouraged to participate in patient 
registers (if available).
Demyelinating diseases
TNF-alpha antagonists are associated with the development or worsening of 
demyelinating diseases and multiple sclerosis.
Cardiovascular diseases
TNF-alpha antagonists are able to worsen (pre-existing) heart failure and should not 
be prescribed to patients with psoriasis with severe congestive heart failure (NYHA 
class III or IV). Patients with a mild form of heart failure being administered an anti-TNF 
alpha agent for psoriasis should be carefully monitored and also guided by a 
cardiologist.
Data from a meta-analysis seem to implicate a short-term increased risk for 
myocardial infarction, cerebrovascular accident, and cardiovascular mortality for 
ustekinumab (and briakinumab) [134]. Further studies are required, but this seems to 
be a specific complication of this class of biologics.   
Infections
TNF-alpha antagonists increase the risk of infection including tuberculosis (TB). 
Reactivation of (latent) TB seems to occur more often with infliximab and adalimumab 
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therapy compared with etanercept. It is mandatory to screen for latent TB before 
commencing therapy with a biologic (see chapter: screening for tuberculosis). Other 
infections include upper and lower respiratory tract infections, urinary tract infections 
and skin infections [135].
Pregnancy
The experience with biologics just before and during pregnancy is too limited to claim 
safety of its (continuous) use.
Fertility
It is uncertain whether biologics reduce spermatogenesis [136, 137, 138]. No data 
has been published about the influence of TNF-alpha blockade on female fertility. 
Transplacental passage
Biologics (adalimumab, infliximab and etanercept) may pass the placental barrier 
during the first, second, and especially third trimester [139].
Lactation
Mothers wishing to breastfeed their child have to be informed about the uncertainty 
of the influence of biologics on children and need to be advised about alternatives for 
lactation.
Biologics and antibody formation
L.L.A. Lecluse
As with other foreign proteins, treatment with biologics may cause antibody formation. 
Neutralizing antibodies have been shown against adalimumab, infliximab, and 
ustekinumab, but not against etanercept [132, 140, 141]. For adalimumab and 
infliximab routine screening can be done. Antibodies against ustekinumab are tested 
in an experimental setting at this moment. 
When to check for antibodies
Assessment of antibody titer may be indicated in patients treated with adalimumab or 
infliximab when:
I There is a significant decrease in effectiveness of the agent involved 
II The psoriasis is recalcitrant to improvement since commencing therapy
III An infusion reaction occurs (only with infliximab) 
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How to interpret and act on antibody titers
Situation I
The effectiveness of the biologic declines, the antibody titer is low, and serum 
concentration value of the biologic is decreased.
The biologic may be continued, but dosing frequency or dosage of this drug may be 
increased to reduce antibody formation. Costs of treatment will rise.
Situation II
There is no clinical sign of effectiveness of the biological agent, the antibody titer 
shows high levels of antibodies, and the biologic serum concentration is undetectable.
The biologic should not be continued because the antibodies are neutralizing the 
biological agent. Consider switching to a biologic of a similar or different therapeutic 
class.
Situation III
There is no clinical sign of effectiveness of the biological agent, the antibody titer 
shows no antibodies, and the biologic serum concentration is within normal range.
The patient does not respond to therapy. Consider switching to a biologic of a different 
therapeutic class.
Screening for tuberculosis
A.C.Q. de Vries, H. van Deutekom, T.E.C. Nijsten, Ph.I. Spuls
Table 36  Plan of action for tuberculosis screening
Diagnostic approach to TB, regardless of BCG vaccination status, prior to and during follow-
ups of treatment with biologic agents. Physicians should be alert to the occurrence of TB 
during treatment and 6 months thereafter [142]. During treatment yearly screening is advised 
for latent TB. Medical history, Mantoux and IGRA are recommended. To limit the influence of 
immunosuppressive drugs on Mantoux and IGRA a treatment-free interval may be introduced 
a week before screening.
Medical history: 
· Symptoms indicating possible TB
· Prior history of TB, possibly treated sufficiently
· Exposition to TB
· Originating from or recent long stay in an epidemic area
· Risk patient
· BCG vaccination status
Physical examination, consider:
· Auscultation of lungs when symptomatic (non-specific for TB diagnosis)
· Scar (left) upper arm (possible BCG vaccination)
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Chest X-ray
· Signs of active or past TB?
 Consult pulmonologist in case of abnormalities
Mantoux
· ≥ 5mm induration à positive à consider latent TB infection (LTBI) or active TB infection 
(TBI) à consult pulmonologist
·  < 5mm induration: 
- age < 65 years: draw blood for IGRA test 
 - age ≥ 65 years: repeat Mantoux after 2 weeks
 • ≥ 5mm induration à positive à consult pulmonologist
 • < 5mm induration à draw blood for IGRA test
IGRA (Altena, 2010)
Mantoux IGRA Diagnosis Management
< 5mm Negative Depending on 
medical history
- Start a biologic agent when 
medical history (symptoms, prior 
history, exposition, origin, recent 
stay, risk patient) reveals no signs 
of or risk to TB
- In case medical history reveals 
signs of or risk to TB, consult 
a pulmonologist for further 
diagnostics and treatment
- HIV-infected patients with a low 
CD-4 count could still have a TB 
infection
≥ 5mm < 10mm Negative Strongly 
 consider LTBI  
and active TB
Consult pulmonologist for further 
diagnostics and treatment
> 10 mm Negative LTBI Consult pulmonologist for further 
diagnostics and treatment
Every value QFT-G
0.2-0.35 U/ml
Strongly  
consider LTBI
Consult pulmonologist for 
treatment
Every value Positive
(QFT-G  
> 0.35 U/ml)
LTBI Consult pulmonologist for 
treatment
Treatment:
A
Active TB or (considered) LTBI à consult pulmonologist for treatment, in some cases for 9 
months (143).
During treatment of LTBI a biologic agent may be started after 1-3 months. There is no 
consensus about this issue, thus, it is recommended to start treatment in consultation with a 
pulmonologist (142, 143).
B
Preference of biologic agent: (see also table 37) Studies suggest that reactivation of latent 
TB is less common in etanercept compared with adalimumab or infliximab (143, 144). This 
could be related to the different mode of action and binding to TNF-alpha. For ustekinumab, 
at present, there is no available data.
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Adalimumab
H.B. Thio
Table 37  Biologic agents classified by TB risk 
High risk
(143, 144)
Infliximab
Adalimumab
Prednisone ≥ 15mg/day
Cytostatic agents
Average risk
(143, 144)
Etanercept
Low risk Methotrexate (one case reported at Lareb)
Cyclosporine (one case reported at Lareb)
Too little evidence Ustekinumab
Table 38  Adalimumab 
Registration for psoriasis December 2007 (EMA)
Recommended control 
parameters before starting 
treatment
Complete blood count, liver enzymes, erythrocyte 
sedimentation (ESR) / CRP, serum creatinine, urine sediment, 
pregnancy test, HBV / HCV, HIV (prior to treatment). 
TB screening summarized: medical history, physical 
examination, chest X-ray, Mantoux test, Quantiferon test. 
Recommended initial 
dosage
Loading dosage: 80 mg subcutaneous
Recommended 
maintenance dosage
40 mg subcutaneous 1x every 2 weeks
Onset of effect After 4 weeks
Response rate 53-80% PASI 75
24-52% PASI 90
Absolute contraindications
(See SmPC)
Hypersensitivity to adalimumab, severe active infections, 
chronic HBV, active TB, heart failure (NYHA III/IV), pregnancy 
or lactation, malignancy or lymphoproliferative disorder in 
recent history (< 5 years and excluded are BCC, KIN III, CIN 
III), demyelinating disorders, vaccination with live vaccines.
Relative contraindications
(See SmPC)
Heart failure (NYHA I/II), hepatic and biliary disorders, HCV, 
PUVA >1000J/cm2 or 150-200 treatments (especially when 
cyclosporine has been prescribed afterterwards), HIV or 
AIDS, Wegener’s granulomatosis.
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Conclusions of the Dutch guidelines
EL: 1
Adalimumab is effective for the treatment of moderate to severe chronic 
plaque psoriasis in adult patients. After 16 weeks of treatment (Gorden et 
al., at week 12), PASI 75 was reached in 53-80% and PASI 90 in 24-52% of 
patients with psoriasis treated with adalimumab.
A2 Gordon et al., 2006 (145); Menter et al., 2008 (146); Saurat et al., 2008 
(103)
Table 38  Continued 
Most common  
adverse effects
(See SmPC)
≥ 1/10: respiratory tract infections (including lower and upper 
respiratory tract infections, pneumonia, sinusitis, pharyngitis, 
nasopharyngitis, and viral herpes pneumonia), leucopenia 
(including neutropenia, agranulocytosis), anemia, increased 
lipid levels, headache, abdominal pains, nausea and vomiting, 
increased liver enzymes, rash (including scaly rash), myalgia, 
injection site reactions (including injection site erythema).
≥ 1/100 to < 1/10: systemic infections (including sepsis, 
candidiasis and influenza), intestinal infections (including 
viral gastroenteritis), skin and subcutaneous infections 
(including paronychia, cellulitis, impetigo, necrotizing fasciitis 
and herpes zoster), etc. (see SMPC or http://www.huidarts.
info/documents/uploaded_file.aspx?id=579)
Important drug 
interactions
Abatacept, Anakinra
Special notes Vaccination with live vaccines should not be administered 
during treatment with a biologic. Depending on the drug’s 
half-life, the biologic must be stopped 4-8 weeks prior to 
immunization and may be restarted 2-3 weeks after vaccination.
Table 39  Important adverse effects of adalimumab 
Most frequently Injection site reactions, respiratory tract infections, headache, 
abdominal pains, nausea and vomiting, rash, myalgia, bone 
marrow depression
Frequently (Severe) infections, benign tumors, skin cancer, mood 
swings (inter alia depression), anxiety, fatigue, sensory 
disturbances, migraine, dizziness, itch, pyrosis
Sometimes Tuberculosis, lymphoma
Rarely -
Very rarely Drug-induced lupus, sudden cardiac death, multiple 
sclerosis
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Instructions for adalimumab use
Prior to treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Consider assessing HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Medical history and physical examination should be directed at therapeutic history, 
malignancies, infections, congestive heart failure and neurological symptoms
· Recommended actions are:
- Check for skin cancer
- Check for lymphadenopathy
- Laboratory controls (Table 41)
- Chest X-ray, Mantoux test and QuantiFERON-TB Gold test
- Pregnancy test
· Contraception
During treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Perform a TB screening annually (medical history, mantoux and IGRA)
· Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Physical examination should be directed at malignancies, risk factors for serious 
infections, congestive heart failure and neurological symptoms
· Recommended actions are:
- Check for skin cancer
- Check for lymphadenopathy
- Laboratory controls (Table 41)
- Urine sediment
· Contraception
After treatment
· After treatment with adalimumab physicians are advised to perform regular follow-ups 
with medical history and physical examination
· Reliable contraceptives until 5 months after treatment, if indicated
· Physicians are encouraged to document their patients’ parameters into registers  
(if available) to evaluate long-term efficacy and safety of biologics
Table 40  List of medication and drug interactions 
Medicine Type of drug interaction
Anakinra Increased risk on serious infection
Immunosuppressive mediation 
(cyclosporine, other biologics)
Increased immunosuppression
PUVA Risk of skin cancer
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Treatment recommendation
Adalimumab is recommended for induction therapy (80 mg at week 0, followed by 40 
mg every 2 weeks) in patients with moderate to severe chronic plaque psoriasis, 
when photo(chemo)therapy and conventional systemic treatments are ineffective, 
contraindicated, or not being tolerated.
Table 41   Laboratory controls 
Parameter Prior to 
treatment
Treatment period 
(weeks)
Thereafter  
once every 3 months
4 12
Total blood count X X X X
Liver enzymes X X X X
Serum creatinine X X X X
Urine sediment X X X X
Erytrocyte 
sedimentation (ESR), 
CRP
X X X X
Pregnancy test 
(urine)
X X X X
HBV / HCV X
HIV X
Further testing may be required based on clinical symptoms, risk and exposures
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Etanercept
T.E.C. Nijsten
Conclusions of the Dutch guidelines
EL: 1
Etanercept is effective for the treatment of moderate to severe plaque 
psoriasis in adult patients. At week 12, PASI 75 was reached in 30-34% and 
PASI 90 in 11% of patients when etanercept was prescribed in a dosage of  
2 x 25 mg per week. When 2 x 50 mg etanercept is administered, PASI 75 and 
PASI 90 are reached in 47-49% and 21% of patients, respectively, at week 12. 
These percentages increase with 10% at week 24.
A2 Gottlieb et al., 2003 (147); Leonardi et al., 2003 (148); Tyring et al., 2006 
(149); Papp et al., 2005 (150)
Table 42  Fumaric acid esters 
Registration for psoriasis September 2004 (EMA)
Recommended control 
parameters before starting 
treatment
Complete blood count, liver enzymes, ESR / CRP, serum 
creatinine, urine sediment, pregnancy test, HBV / HCV, 
HIV. TB screening summarized: medical history, physical 
examination, chest X-ray, Mantoux test, Quantiferon test. 
Recommended initial 
dosage
2x25 mg/week, 1x50 mg/week or 2x50 mg/week (week 0-12)
Recommended 
maintenance dosage
2x25 mg/week, 1x50 mg/week or 2x50 mg/week
Onset of effect After 6-8 weeks
Response rate PASI 75 in 33 or 49% after 12 weeks (2x25 or 2x50 mg/week)
Absolute contraindications
(See SmPC)
Hypersensitivity to etanercept, severe active infections, 
chronic HBV, active TB, heart failure (NYHA III/IV), pregnancy 
or lactation, malignancy or lymphoproliferative disorder in 
recent history (< 5 years and excluded are BCC, KIN III, CIN 
III), demyelinating disorders, vaccination with live vaccines.
Relative contraindications
(See SmPC)
Heart failure (NYHA I/II), hepatic and biliary disorders, HCV, 
PUVA >1000J/cm2 or 150-200 treatments (especially when 
cyclosporine has been prescribed afterterwards), HIV or 
AIDS, Wegener’s granulomatosis.
Most common adverse 
effects
(See SmPC)
≥ 1/10: infections (including lower and upper respiratory 
tract infections, pneumonia, bronchitis, cystitis and skin 
infections), injection site reactions (including bleeding, 
bruising, erythema, itch, pain, swelling).
≥ 1/100 to < 1/10: allergic reactions, auto-antibody 
formation, pruritus, fever.
Important drug 
interactions
Anakinra, Abatacept, immunosuppressives (cyclosporine, 
other biologics), PUVA.
Special notes Weight gain
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 215
215
Summary of Dutch S3-guidelines
10
Instructions for etanercept use
Prior to treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Medical history and physical examination should be directed at therapeutic history, 
malignancies, infections, congestive heart failure and neurological symptoms
· Recommended actions are:
- Check for skin cancer
- Check for lymphadenopathy
- Laboratory controls (Table 45)
- Chest X-ray, Mantoux test and QuantiFERON-TB Gold test
- Pregnancy test
· Contraception
Instructions for etanercept use
Prior to treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
Table 43   Important adverse effects of etanercept
Most frequently Infusion reactions, infections (upper respiratory tract, 
bronchitis, skin infections)
Frequently Pruritus, antibody formation, allergy
Sometimes Thrombocytopenia, urticaria, angioedema, severe infections 
(for example: pneumonia, cellulitis and sepsis), uveitis, Non-
melanoma skin cancer, interstitial lung disease, rash
Rarely Anemia, leucopenia, neutropenia, pancytopenia, vasculitis, 
subacute and discoid LE, demyelinating disease, TB 
reactivation, convulsions, heart failure, severe allergy, liver 
function abnormalities
Very rarely Aplastic anemia
Table 44   List of medication and drug interactions
Medicine Type of drug interaction
Anakinra Neutropenia and severe infections
Immunosuppressive mediation 
(cyclosporine, other biologics)
Increased immunosuppression
PUVA Risk of skin cancer (especially squamous 
cell carcinoma)
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· Medical history and physical examination should be directed at therapeutic history, 
malignancies, infections, congestive heart failure and neurological symptoms
· Recommended actions are:
- Check for skin cancer
- Check for lymphadenopathy
- Laboratory controls (Table 45)
- Chest X-ray, Mantoux test and QuantiFERON-TB Gold test
- Pregnancy test
· Contraception
During treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Perform a TB screening annually (medical history, mantoux and IGRA)
· Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Physical examination should be directed at malignancies, risk factors for serious 
infections, congestive heart failure and neurological symptoms
· Recommended actions are:
- Check for skin cancer
- Check for lymphadenopathy
- Laboratory controls (Table 45)
- Urine sediment
· Contraception
After treatment
· After treatment with etanercept physicians are advised to perform regular follow-ups  
with medical history and physical examination
· Physicians are encouraged to document their patients’ parameters into registers  
(if available) to evaluate long-term efficacy and safety of biologics
Table 45   Laboratory controls 
Parameter Prior to 
treatment
Treatment period 
(weeks)
Thereafter  
once every 3 months
4 6
Total blood count X X X X
Liver enzymes X X X X
Serum creatinine X X X X
Urine sediment X X X X
Erytrocyte 
sedimentation (ESR), 
CRP
X X X X
Pregnancy test X X X X
HBV / HCV X
HIV X
Further testing may be required based on clinical symptoms, risk and exposures
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Treatment recommendation
Etanercept is recommended for induction therapy (2 x 25 mg, 1 x 50 mg or 2 x 50 mg 
per week) (maximum of 24 weeks) in patients with moderate to severe chronic plaque 
psoriasis, when photo(chemo)therapy and conventional systemic treatments are 
ineffective, contraindicated, or not being tolerated.
When induction therapy with etanercept is effective after 10-16 weeks, low dose 
etanercept (2 x 25 mg per week or 1 x 50 mg per week) should be prescribed as 
maintenance therapy.
Infliximab
M. de Groot
Table 46   Infliximab 
Registration for psoriasis September 2005 (EMA)
Recommended control 
parameters before starting 
treatment
Complete blood count, liver enzymes, ESR / CRP, serum 
creatinine, urine sediment, pregnancy test, HBV / HCV, 
HIV. TB screening summarized: medical history, physical 
examination, chest X-ray, Mantoux test, Quantiferon test. 
Recommended initial 
dosage
5 mg/kg body weight
Recommended 
maintenance dosage
5 mg/kg body weight week 2, 6, and thereafter every 8 weeks
Onset of effect After 2-5 weeks
Response rate PASI 75 in 80% of patients after 10 weeks
Absolute contraindications
(See SmPC)
Hypersensitivity to infliximab, severe active infections, 
chronic HBV, active TB, heart failure (NYHA III/IV), pregnancy 
or lactation, malignancy or lymphoproliferative disorder in 
recent history (< 5 years and excluded are BCC, KIN III 
and CIN III), demyelinating disorders, vaccination with live 
vaccines.
Relative contraindications
(See SmPC)
Heart failure (NYHA I/II), hepatic and biliary disorders, HCV, 
PUVA >1000J/cm2 or 150-200 treatments (especially when 
cyclosporine has been prescribed afterterwards), HIV or 
AIDS, Wegener’s granulomatosis.
Most common  
adverse effects
(See SmPC)
≥ 1/10: none
≥ 1/100 to < 1/10: viral infections (e.g., flu, viral herpes 
infection), serum sickness-like symptoms, headache, 
vertigo, dizziness, flush, lower respiratory tract infection (e.g., 
bronchitis, pneumonia), upper respiratory tract infections, 
sinusitis, dyspnoea, abdominal pains, diarrhea, nausea, 
dyspepsia, elevated transaminases, urticaria, rash, pruritus, 
hyperhidrosis, dry skin, infusion related reactions, chest pain, 
fatigue, fever
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Conclusions of the Dutch guidelines
EL: 1
Infliximab is effective for the treatment of moderate to severe chronic plaque 
psoriasis in adult patients. About 64% - 88% of patients treated with 5mg/kg 
infliximab reached PASI 75 at week 10. About 41% - 57% of patients treated 
with infliximab (5mg/kg) reached PASI 90 at week 10.
A2 Antoni et al., 2005 (151); Menter et al., 2007 (152); Reich et al., 2005 
(153); Gottlieb et al., 2004 (154)
Instructions for infliximab use
Prior to treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Medical history and physical examination should be directed at therapeutic history, 
malignancies, infections, congestive heart failure and neurological symptoms
· Recommended actions are:
Table 46   Continued 
Important drug 
interactions
Abatacept, Anakinra
Special notes Reliable contraceptives in fertile women until 6 months after 
infliximab treatment
Table 47  Important adverse effects of infliximab 
Most frequently Infusion reactions, infections, nausea, diarrhea, difficulty 
breathing, dizziness, fatigue
Frequently Headache, flushing, pruritus, urticaria, fever, elevated 
transaminases
Sometimes Serum sickness-like disease, cutaneous lupus 
erythematosus, severe infections, anaphylactic reaction, 
circulation problems, depression 
Rarely Opportunistic infections, tuberculosis, pancytopenia, 
vasculitis, demyelinating diseases
Very rarely Myelitis transversa, psoriasis (including pustular psoriasis), 
hepatocellular damage. In patients with Crohn’s disease 
and ulcerative colitis hepatosplenic T-cell lymphoma may be 
induced. 
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- Check for skin cancer
- Check for lymphadenopathy
- Laboratory controls (Table 48)
- Urine sediment
- Chest X-ray, Mantoux test and QuantiFERON-TB Gold test
- Pregnancy test
· Contraception
During treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Perform a TB screening annually (medical history, mantoux and IGRA)
· Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Physical examination should be directed at malignancies, risk factors for serious 
infections, congestive heart failure and neurological symptoms
· Recommended actions are:
- Check for skin cancer
- Check for lymphadenopathy
- Laboratory controls (Table 48)
- Urine sediment
· Contraception
After treatment
· After treatment with infliximab physicians are advised to perform regular follow-ups with 
medical history and physical examination
· Reliable contraceptives until 6 months after cessation of treatment, if indicated
· Physicians are encouraged to document their patients’ parameters into registers (if 
available) to evaluate long-term efficacy and safety of biologics
Table 48   Laboratory controls 
Parameter Prior to 
treatment
Treatment period 
(weeks)
Thereafter,  
prior to every infusion
4 6
Total blood count X X X X
Liver enzymes X X X X
Serum creatinine X X X X
Urine sediment X X X X
Erytrocyte 
sedimentation (ESR), 
CRP
X X X X
Pregnancy test X X X X
HBV / HCV X
HIV X
Further testing may be required based on clinical symptoms, risk and exposures
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Treatment recommendation
Infliximab is recommended for induction therapy when photo(chemo)therapy and 
conventional systemic treatments are ineffective, contraindicated, or not being tolerated.
It is advised to prescribe infliximab 5mg/kg in patients with moderate to severe 
chronic plaque psoriasis at week 0, 2, 6, and every 8 weeks thereafter.
When induction therapy with infliximab is effective after 10-16 weeks, maintenance 
therapy with infliximab is recommended for every 8 weeks.
It is advised to combine infliximab therapy with 7.5 mg methotrexate per week in order 
to prevent antibody formation and to lower the risk of infusion reactions.
Ustekinumab
Ph.I. Spuls, P.A. Poblete-Gutiérrez, J. de Bes
Table 49  Ustekinumab 
Registration for psoriasis 20th November 2008 (EMA)
Recommended control 
parameters before starting 
treatment
Complete blood count, liver enzymes, ESR / CRP, serum 
creatinine, urine sediment, pregnancy test, HBV / HCV, 
HIV. TB screening summarized: medical history, physical 
examination, chest X-ray, Mantoux test, Quantiferon test. 
Recommended initial 
dosage
45 mg, patients > 100 kg 90 mg at week 0, 4 and 16
Recommended 
maintenance dosage
45 mg/12 weeks, patients > 100 kg 90 mg/12 weeks
Onset of effect After 2 weeks
Response rate PASI 75 in 66-76% of patients
Absolute contraindications
(See SmPC)
Hypersensitivity to ustekinumab, severe active infections, 
chronic HBV, active TB, heart failure (NYHA III/IV), pregnancy 
or lactation, malignancy or lymphoproliferative disorder in 
recent history (< 5 years and excluded are BCC, KIN III 
and CIN III), demyelinating disorders, vaccination with live 
vaccines.
Relative contraindications
(See SmPC)
Heart failure (NYHA I/II) and a prior history of or increased 
risk for cardiovascular accident or acute myocardial 
infarction. Hepatic and biliary disorders, HCV, PUVA >1000J/
cm2 or 150-200 treatments (especially when cyclosporine 
has been prescribed afterterwards), HIV or AIDS, Wegener’s 
granulomatosis.
Most common adverse 
effects
(See SmPC)
≥ 1/10: nasopharyngitis and upper respiratory tract infections
≥ 1/100 to < 1/10: inflammation of subcutaneous connective 
tissue (cellulitis), viral infection of the upper respiratory tract, 
hypersensitivity reactions (including rash and urticaria), 
depression, dizziness, headache, sore throat, stuffy nose, 
diarrhea, pruritus, back pain, myalgia, fatigue, erythema on 
injection site
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Conclusions of the Dutch guidelines
EL: 1
Ustekinumab is effective for the treatment of moderate to severe chronic 
plaque psoriasis in adult patients. PASI 75 was reached in 67% of patients 
treated with ustekinumab (45 mg at week 0, 4 and 16) at week 12. PASI 75 
was reached in 66-76% of patients treated with ustekinumab 90 mg (week 0, 
4 and 16). A maximum effect was observed in more than three-quarters of 
the research population (PASI 75) after 24 weeks.
A2 Leonardi et al., 2008 (155); Papp et al., 2008 (132)
Instructions for ustekinumab use
Prior to treatment
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Medical history and physical examination should be directed at therapeutic history, 
malignancies, infections, TB, heart and kidney diseases and neurological symptoms
· Recommended actions are:
- Check for skin cancer
- Check for lymphadenopathy
- Laboratory controls (Table 51)
- Urine sediment
- Chest X-ray, Mantoux test and QuantiFERON-TB Gold test
- Vaccinations in concordance with the National Immunization Program
Table 49  Continued 
Important drug 
interactions
Unknown
Special notes Reliable contraceptives are mandatory in fertile women until 
15 weeks after ustekinumab treatment
Table 50  Important adverse effects of ustekinumab 
Most frequently Nasopharyngitis, upper respiratory tract infections, 
headache, arthralgia
Frequently Cellulitis, viral infections of upper respiratory tract, 
depression, dizziness, headache, sore throat, stuffy nose, 
diarrhea, pruritus, back pain, myalgia, fatigue, erythema on 
injection site, urticaria
Very rarely Severe infections or allergy
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- Pregnancy test
· Reliable contraceptives in fertile women during treatment and until 15 weeks after 
cessation of treatment
During treatment (every 3 months)
· Objective assessment of psoriasis (such as PASI / BSA / PGA; arthritis)
· Perform a TB screening annually (medical history, mantoux and IGRA)
· Consider the assessment of HRQoL (e.g. DLQI, Skindex-29 or Skindex-17 or VAS)
· Recommended actions are:
- Check for skin cancer
- Laboratory controls (Table 51)
- Urine sediment
After treatment
· Follow-up visits for assessing symptoms of psoriasis
· Reliable contraceptives until 15 weeks after cessation of treatment, if indicated
· Physicians are encouraged to document their patients’ parameters into registers (if 
available) to evaluate long-term efficacy and safety of biologics
Table 51   Laboratory controls 
Parameter Prior to 
treatment
After 4 weeks Thereafter  
once every 12 weeks
Total blood count X X X
Liver enzymes X X X
Serum creatinine X X X
Urine sediment X X X
Erytrocyte 
sedimentation (ESR), 
CRP
X X X
Pregnancy test X X X
HBV / HCV X
HIV X
Further testing may be required based on clinical symptoms, risk and exposures
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Considerations when prescribing biologics
T.E.C. Nijsten
The following table highlights the considerations per biologic.
Table 52   Considerations when prescribing biologics 
Etanercept (E) Adalimumab (A) Infliximab (I) Ustekinumab (U)
Less efficacy 
compared with A, 
I and U. However, 
maximum efficacy 
may be reached 
after 24 weeks
Higher efficacy 
compared with E 
(after 12 and 24 
weeks)
Higher efficacy 
compared with E 
(after 12 and 24 
weeks)
Higher efficacy 
compared with E 
(after 12 and 24 
weeks)
Fast initial response
Less effective than 
U
No head-to-head 
trials with this 
biologic
No head-to-head 
trials with this 
biologic
More effective than E
Drug survival rate 
below I (daily 
practice data)
Drug survival rate 
below I (daily 
practice data)
Highest drug 
survival rate 
compared with A 
and E (daily practice 
data)
Drug survival rate is 
high during 1 year 
(daily practice data)
Injection site 
reaction
Injection site 
reaction
Infusion reaction Injection site reaction
Thrombocytopenia, 
leucopenia and 
pancytopenia
Thrombocytopenia, 
leucopenia and 
pancytopenia
Thrombocytopenia, 
leucopenia and 
pancytopenia
Thrombocytopenia, 
leucopenia and 
pancytopenia
Less TB reactivation 
compared with A 
and I
More TB reactivation 
compared with E
More TB reactivation 
compared with E
Little long-term 
experience
Non-neutralizing 
antibody formation
Neutralizing 
antibody formation, 
possibly clinically 
relevant
Neutralizing 
antibody formation, 
clinically relevant
High dosage (2x50 
mg/week) leads to 
high costs
Loading dosage at 
start increases cost 
at start.
In extreme obese 
patients (> 100kg) 
costs will rise. 
Loading dosage at 
start increases cost 
at start.
In extreme obese 
patients (> 100kg) 
costs will rise. 
Loading dosage at 
start increases cost 
at start.
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 224
224
Chapter 10
Conclusions
Adalimumab or low-dose etanercept (1x50 mg/week) are the preferred first-choice 
treatments in otherwise healthy, biologic-naïve patients with psoriasis. Adalimumab 
seems to be more effective than etanercept in the short-term, but may be related to 
clinically relevant antibody formation. Infliximab is preferred in acute situations (e.g., 
severe exacerbation of plaque psoriasis, off-label for psoriatic erythroderma or 
generalized pustular psoriasis) because of high efficacy and fast clinical response, 
followed by a maintenance dosage of this agent. Also, infliximab is important in 
patients not responding to other TNF-alpha agents. Although ustekinumab is highly 
effective, the working group holds the opinion that until long-term efficacy and safety 
are elucidated this agent should be reserved for patients responding insufficiently to 
TNF-alpha antagonists.
Table 52   Continued 
Etanercept (E) Adalimumab (A) Infliximab (I) Ustekinumab (U)
Long treatment 
interval (3 months). 
(Higher user 
friendliness)
Daily practice data indicate biologics to be less effective when compared with data from 
randomized controlled trials. Hence, the dosage of biologics is higher in daily practice.
This table is a summary of the paragraph “considerations when prescribing biologics” within the Dutch 
guidelines on the treatment of psoriasis 2011 (http://www.huidarts.info/documents/uploaded_file.
aspx?id=579). The content of this table is based upon the following references: [125-127, 134, 156-160].
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3. Treatment of psoriasis of the face and flexures
P.C.M. van de Kerkhof, C.L.M. van Hees
Epidemiology
Conclusions of the Dutch guidelines
EL: 3
Psoriasis of the face is present in 17-46% and psoriasis of the flexures in  
6.8-36% of patients with psoriasis. Hence, psoriasis cannot be regarded as  
a rare manifestation in these areas.
C Fauéré et al., 2005 (161); Dubertret et al., 2006 (162); van de Kerkhof et al., 
2000 (163); Farber et al., 1968 (164); Farber et al., 1974 (165); Wang et al., 
2005 (166); Nanda et al., 1990 (167); Puissant, 1970 (168); Nyfors et al., 1975 
(169)
D van de Kerkhof et al., 2007 (10)
Recommendation 
It is recommended to further study the efficacy and safety of treatments (preferably 
by randomized, double blind, controlled trials), given the frequency of psoriasis of the 
face and flexures.
Clinical signs
Conclusions of the Dutch guidelines
EL: 4
Psoriasis of the face is a prognostic marker for a severe form of psoriasis. 
Psoriasis of the flexures is not a prognostic marker.
C Park et al., 2004 (170)
D van de Kerkhof et al., 2007 (10)
EL: 4
Psoriasis of the face and psoriasis of the flexures should not be considered 
two different disease entities, but as a variation of localization of the same 
disease.
D van de Kerkhof et al., 2007 (10)
EL: 3
Clinical signs of facial psoriasis suggest there are three forms: hairline 
psoriasis, sebo-psoriasis and true facial psoriasis.
C Woo et al., 2008 (171)
D van de Kerkhof et al., 2007 (10)
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EL: 4
Otitis externa and ocular manifestations may drastically decrease quality of 
life and should therefore not be neglected.
D van de Kerkhof et al., 2007 (10)
Pathogenetic aspects
Conclusions of the Dutch guidelines
EL: 3
Evidence is small to absent on the role of microbiological factors in the 
pathogenesis of psoriasis of the face and flexures.
C Rosenberg et al., 1989 (172)
D van de Kerkhof et al., 2007 (10)
EL: 3
The reaction to UV radiation differs between patients with facial psoriasis. At 
least 5% of patients with psoriasis has photosensitive psoriasis.
C Farber et al., 1968 (164); Farber et al., 1974 (165); Lane et al., 1937 (173); 
Lomholt et al., 1963 (174); Braun-Falco et al., 1972 (175)
D van de Kerkhof et al., 2007 (10)
Recommendation
It is recommended to exclude photosensitive diseases such as lupus erythematosus 
and polymorphic light eruption in patients with photosensitive psoriasis.
Antimicrobial treatment
Conclusions of the Dutch guidelines
EL: 3
There is no evidence that antimicrobial treatment is effective for psoriasis of 
the flexures.
C Leigheb et al., 2000 (176)
EL: 3
There is evidence antifungal treatment may be effective for sebo-psoriasis of 
the face.
C Doering., 1985 (177); Faergemann, 1985 (178)
Considerations
The efficacy of antiseptic, antibacterial, and antifungal treatments has sparsely been 
investigated in comparing studies. Randomized and double blind trials are lacking.
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Treatment recommendation
Antimicrobial treatment is not indicated for the treatment of psoriasis of the face and 
flexures.
Dithranol and coal tar
Conclusions of the Dutch guidelines
EL: 3
The efficacy of dithranol combined with coal tar is similar as for fluocinolone 
acetonide cream.
B Heller, 1989 (179)
Considerations
The evidence of the efficacy of dithranol is also being supported by decades of 
clinical experience.
Skin irritation and stains in textile limit the use of these treatments.
Treatment recommendation
Discoloration and skin irritation limit the use of dithranol and coal tar. Dithranol and 
coal tar are not indicated for first-line therapy, except in cases in which first-line 
therapies fail.
Topical corticosteroids
Conclusions of the Dutch guidelines
EL: 3
Evidence about the efficacy and safety of topical corticosteroids comes 
from a non-comparative study (topical corticosteroids until 12 weeks) and 
a double blind, randomized vehicle-controlled study (topical corticosteroids 
during 4 weeks).
B Kreuter et al., 2006 (180)
C Lebwohl et al., 2001 (181)
Considerations
Textbooks state that low-potent (class 1-2) topical corticosteroids are effective and 
safe, whereas mid-potent (class 2-3) topical corticosteroids induce perioral dermatitis 
and striae, especially during long-term use.
Treatment recommendation
Topical corticosteroids class 1-2 (low-potency) are first-choice treatments for 
psoriasis of the face and flexures during a limited treatment period. Subsequently, 
topical non-steroidal agents should be prescribed.
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Vitamin D3 analogues
Conclusions of the Dutch guidelines
EL: 2
Vitamin D analogues are effective for the treatment of psoriasis of the face 
and flexures.
A2 Liao et al., 2007 (182)
B Ortonne et al., 2003 (183)
C Duweb et al., 2003 (184); Kienbaum et al., 1996 (185); Langer et al., 1996 
(186)
EL: 3
Calcitriol is superior over calcipotriol regarding safety profile.
B Ortonne et al., 2003 (183)
Treatment recommendations
Vitamin D3 analogues are first-choice treatments for psoriasis of the face and flexures. 
Calcitriol induces less adverse effects, such as erythema and irritation, than 
calcipotriol.
Calcineurin inhibitors
Conclusions of the Dutch guidelines
EL: 1
The efficacy of calcineurin inhibitors for the treatment of psoriasis of the face 
and flexures has been assessed in 4 independent A2-studies (2 placebo-
controlled studies, 1 comparative study with clobetasone butyrate and 1 
comparative study with calcitriol).
A2 Lebwohl et al., 2004 (187); Gribetz et al., 2004 (188); Kleyn et al., 2005 
(189); Liao et al., 2007 (182)  
Considerations
Calcineurin inhibitors are not registered for this treatment indication.
Treatment recommendations
Low-potent (class 1-2) topical corticosteroids during 2-4 weeks are the first-choice 
treatment of psoriasis of the face and flexures. Calcineurin inhibitors or Vitamin D3 
analogues may also be prescribed. Calcineurin inhibitors may be used for long-term 
treatment.
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Photo(chemo)therapy
Conclusions of the Dutch guidelines
EL: 4
No studies have been conducted measuring the efficacy and safety of 
photo(chemo)therapy. However, clinical experience shows these treatments 
improve psoriasis of the face and flexures.
D van de Kerkhof et al., 2007 (10)
Treatment recommendations
When topical therapies provide insufficient disease control, phototherapy is an option 
for the treatment of psoriasis of the face and flexures.
Systemic therapies
Conclusions of the Dutch guidelines
EL: 4
No studies have been conducted measuring the efficacy and safety of 
methotrexate, cyclosporine, acitretin, fumaric acid esters and biologics 
for the treatment of psoriasis of the face and flexures. However, clinical 
experience shows these treatments improve psoriasis in these locations.
D van de Kerkhof et al., 2007 (10)
EL: 3
There is evidence available indicating botulinum toxin is effective for the 
treatment of psoriasis of the flexures.
C Zanchi et al., 2008 (190)
Considerations
Botulinum toxin is not registered for the treatment of psoriasis. The costs of this 
treatment are substantial.
Treatment recommendations
When topical therapies provide insufficient disease control, systemic therapies are 
an option.
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4. Treatment of childhood psoriasis 
M.M.B. Seyger
Introduction
All drugs mentioned in these guidelines have not been registered for the treatment of 
childhood psoriasis. Thus, usage of these drugs is off-label, with the exception of 
etanercept, which is registered for plaque psoriasis in children aged eight years or 
older. Off-label use of drugs is not uncommon, according to the Medicine Evaluation 
Board (MEB; Netherlands: CBG) and Inspection for Health Care (IGZ), if justified. The 
treating physician is obligated to inform the patient about the advantages and 
disadvantages of off-label drug use.
Topical corticosteroids
Conclusions of the Dutch guidelines
EL: 3
Halobetasol cream 0.05% and clobetasol proprionate emulsion 0.05% twice 
daily may be effective treatments for childhood psoriasis. Reported adverse 
effects during treatment were relatively mild.
C Herz et al., 1991 (191); Kimbal et al., 2008 (192)
D Feicht, 1982 (193)
Considerations
Published literature on the use of topical corticosteroids in childhood psoriasis is 
scarce. The number of treated patients is low and the treatment period short. Also, 
different vehicles were being used. Nonetheless, topical corticosteroids are important 
in the physician’s treatment arsenal for treating childhood psoriasis.
Treatment recommendations
The use of topical corticosteroids is rewarding in childhood psoriasis. It is recommended 
to use topical corticosteroids of class 2-3 (mild-potency).
Vitamin D3 analogues
Conclusions of the Dutch guidelines
EL: 3
Calcipotriol is an effective and mostly well tolerated treatment option for 
plaque type childhood psoriasis. Adverse effects are mild.
A2 Oranje et al., 1997 (194)
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EL: 3
Calcitriol seems to be an effective treatment for childhood psoriasis with mild 
adverse effects.
B Perez et al., 1995 (195)
Considerations
Both calcipotriol and calcitriol are not registered for use in children. Calcipotriol is no 
longer available as monotherapy in the Netherlands.
Treatment recommendations
Given the efficacy and mild adverse effect profile of Vitamin D3 and analogues 
(calcipotriol), these agents are recommended as first-choice therapy for childhood 
psoriasis. A combination with topical corticosteroids class 2-3 (mild potency) is 
recommended.
Calcineurin inhibitors
Conclusions of the Dutch guidelines
EL: 3
Tacrolimus 0.1% seems to be effective and safe for short-term treatment 
of childhood psoriasis of the face and flexures. Long-term efficacy has not 
been described in studies.
C Brune et al., 2007 (196); Steele et al., 2005 (197)
EL: 3
Due to small numbers of treated patients, no conclusions can be drawn on 
the use of pimecrolimus for childhood psoriasis.
C Amichai, 2004 (198); Mansouri et al., 2006 (199)
Considerations
Studies covered by these guidelines only describe the efficacy of 0.1% tacrolimus in 
children with psoriasis of the face and flexures. Calcineurin inhibitors are not registered 
for this treatment indication. In children (≤ 16 years) with eczema, tacrolimus 0.03% is 
registered.
Treatment recommendations
It is recommended to consider treatment with tacrolimus 0.03% or 0.1% in children 
with therapy resistant psoriasis of the face and flexures.
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Dithranol
Conclusions of the Dutch guidelines
EL: 3
Dithranol is effective and safe for treatment of childhood psoriasis.
C Zvulunov et al., 1994 (200); Guerrier et al., 1983 (201)
D Schubert et al., 2007 (202)
Considerations
To reduce the risk of adverse effects (discolorations and skin irritation) dithranol should 
be used in a daycare unit setting. This also increases compliance and guarantees a 
more effective treatment regimen. 
Treatment recommendations
It is strongly recommended to prescribe dithranol treatment for children with psoriasis 
if treatment with topical corticosteroids and vitamin D3 analogues failed. This should 
preferably take place in a daycare unit.
Phototherapy
Conclusions of the Dutch guidelines
EL: 3
Narrowband UVB treatment for children with plaque psoriasis or guttate 
psoriasis has positive results and a relatively mild adverse effect profile 
during a mean treatment period of 12 weeks.
C Al-Fouzan et al., 1995 (203); Jain et al., 2007 (204); Jury et al., 2006 (205); 
Pasic et al., 2003 (206); Tay et al., 1996 (207)
No conclusion 
possible
Evidence on the efficacy of PUVA treatment for childhood psoriasis is too 
limited.
D Kim et al., 1998 (208); Thappa et al., 2006 (209)
Considerations
Uncertainty persists on the long-term safety of UVB phototherapy. UVB therapy 
results in actinic damage and premature skin aging. UVB is carcinogenic. Oral PUVA 
has a carcinogenic effect.
Treatment recommendations
It is recommended to limit the use of UVB phototherapy in children with psoriasis. 
Especially in children less than 12 years of age and a fair skin type, UVB should be 
considered with great care. PUVA therapy is contraindicated in children with psoriasis 
given its carcinogenic effect.
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Antibiotics
Conclusions of the Dutch guidelines
EL: 3
The efficacy of oral antibiotics and its use in children with guttate psoriasis 
remains controversial.
C Patrizi et al., 1994 (210)
D Pacifico, 1993 (211)
Considerations
If, on anamnesis, the psoriatic plaques erupted after a severe throat infection or the 
psoriasis deteriorated after a throat infection, it is recommended to perform a throat culture.
Treatment recommendations
When, on anamnesis, a throat infection may have induced or worsened the psoriasis 
and the performed throat culture is positive, it is recommended to consider the use 
of oral antibiotics.
Retinoids
Conclusions of the Dutch guidelines
EL: 3
Etretinate is effective in treating pustular or erytrodermic psoriasis. However, 
adverse effects are frequently encountered.
C Rosinska et al., 1988 (212); van de Kerkhof, 1985 (213); Pavicic et al., 1986 
(214); Kim et al., 1991 (215); van der Rhee et al., 1980 (216)
No conclusion 
possible
The use of acitretin in childhood psoriasis has not been thoroughly studied. 
Therefore, no conclusions can be stated in these guidelines. However, 
given the positive experiences with etretinate, it is likely that acitretin is also 
effective in pustular and erythrodermic childhood psoriasis. 
Considerations
Etretinate is no longer available. Acitretin is a metabolite of etretinate, therefore, the 
efficacy of acitretin is probably similar to etretinate. Considerations about general 
safety are described in the chapter of retinoids in the full Dutch S3-guidelines: http://
www.huidarts.info/documents/uploaded_file.aspx?id=579. Special attention should 
be given to the occurrence of skeletal toxicities in children on long-term retinoid 
therapy [217].
Treatment recommendations
It is recommended to consider the use of acitretin in children with pustular or 
erytrodermic psoriasis. It is firmly recommended not to treat adolescent women, 
given the potential teratogenic effects.
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Treatment with acitretin may be considered in other types of childhood psoriasis.
Cyclosporine
Conclusions of the Dutch guidelines
EL: 3
The described efficacy of cyclosporine treatment in childhood psoriasis is 
ambiguous. Safety aspects were sparsely described.
C Mahe et al., 2001 (218); Kilic et al., 2001 (219); Alli et al., 1998 (220); 
Torchia et al., 2006 (221) 
 
Considerations
Adverse effects of cyclosporine in children with psoriasis were sparsely described in 
studies. In children with atopic dermatitis, this agent was well tolerated for a period of 
one year [222]. Given the potential cumulative toxicity, especially children should be 
treated with caution [223].
Treatment recommendations
Given the previous considerations and the contradictive evidence on cyclosporine for 
childhood psoriasis, it is recommended to use this agent only in exceptional cases.
Methotrexate
Conclusions of the Dutch guidelines
EL: 3
Methotrexate is effective for the treatment of moderate to severe childhood 
psoriasis. Most evidence is on plaque psoriasis. Short-term adverse effects 
are relatively mild and can easily be treated.
C Collin et al., 2006 (224); Kaur et al., 2008 (225); Kumar et al., 1994 (226); 
Kalla et al., 1996 (227); Dogra et al., 2004 (228); Dogra et al., 2005 (229); 
Ivker et al., 1993 (230)  
 
Considerations
Long-term safety of methotrexate for childhood psoriasis has not been studied. 
However, this drug has been used for decades for the treatment of juvenile idiopathic 
arthritis without severe adverse effects. Therefore, this treatment is considered safe 
[231].
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 235
235
Summary of Dutch S3-guidelines
10
Treatment recommendations
Methotrexate is recommended as first-choice systemic treatment in children with 
moderate to severe plaque psoriasis. Dosage is between 0.2-0.4 mg/kg/week. Folic 
acid 5mg should be administered 24 hours after methotrexate intake. Methotrexate 
should not be administered with milk products as this negatively affects its efficacy.
Biologics
Conclusions of the Dutch guidelines
EL: 3
Etanercept is effective for the treatment of plaque psoriasis in children. 
Dosage was 0.8 mg/kg/week. Short-term adverse effects are usually 
infections.
A2 Paller et al., 2008 (232)
No conclusion 
possible
Infliximab seems effective for induction of remission. However, firm 
conclusions cannot be made on the results of 4 patients.
D Pereira et al., 2006 (233); Farnsworth et al., 2005 (234); Menter et al., 2004 
(235); Weishaupt et al., 2007 (236)
Considerations
Knowledge on long-term adverse effects of biologics is insufficient. It is unknown 
whether biologics increase the risk of lymphoma and skin cancer in patients with 
psoriasis. The safety and effectiveness of etanercept was registered for children with 
juvenile idiopathic arthritis during 8 consecutive years. In these 8 years, the authors 
found no increase of severe adverse effects [231].
Treatment recommendations
Given the uncertainty concerning long-term safety of biologics, care should be taken 
in prescribing these agents in children with moderate to severe psoriasis. Etanercept 
is recommended when topical therapies, e.g. dithranol, as well as UVB (in older 
children) and methotrexate are ineffective, contraindicated, or not being tolerated.
The working group holds the opinion that children treated with etanercept should be 
registered in a national database to evaluate long-term safety.
Other topical and systemic therapies
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 236
236
Chapter 10
Conclusions of the Dutch guidelines
No conclusion 
possible
No conclusions can be drawn on the efficacy and safety of Chinese 
drugs, excimer laser, tazarotene, wratizolin, fumaric acid esters, dapsone, 
prednisone, tonsillectomy and colchicine. 
C Lin et al., 2006 (237); Pahlajani et al., 2005 (238); Diluvio et al., 2007 (239); 
Michalowski et al., 1983 (240); Gunther et al., 2004 (241); Yu et al., 2001 
(242); Fernandes-EI et al., 2000 (243); Tsuge et al., 1995 (244); McMillin et al., 
1999 (245); Hone et al., 1996 (246); Wahba et al., 1980 (247); Zachariae et 
al., 1982 (248)
Considerations
None
Treatment recommendations
No conclusions can be drawn from the literature on the efficacy and safety of other 
therapies. These therapies are not recommended.
5. The patient’s perspective
J. de Korte, O.D. van Cranenburgh
The experiences and opinions of patients with chronic skin diseases are becoming 
increasingly important for the assessment of their general and skin-related health 
status, and for the treatment of their skin disease. These patients’ perspectives are 
generally captured with so-called Patient Reported Outcomes (PROs). PROs are 
reports or assessments of any aspect of a patient’s health status and/or treatment 
impact that are directly expressed by the patient, i.e. without the interpretation of 
others [249]. Examples of PROs are: disease severity, health-related quality of life, 
cost-benefit, safety, compliance, treatment preference, and satisfaction with treatment. 
Health-related quality of life (HRQoL) of patients with psoriasis, i.e. the physical, 
emotional and social functioning and well being of patients, has been referred to 
throughout the Dutch S3-guidelines on the treatment of psoriasis 2011. The practice 
guidelines ‘Photo(chemo)therapy and systemic therapy in severe chronic plaque- 
psoriasis’ 2003 (updated 2005 and 2009) also addressed that, in exceptional cases, 
patients with less severe psoriasis may be prescribed a biological agent when there 
is a considerable loss of quality of life (Skindex-29 ≥ 35, combined with a PASI ≥ 8) (6).
In order to gain insight into psoriasis patients’ satisfaction with treatment, we 
conducted a cross-sectional, national, web-based, survey. Aims of this survey were 
to assess the degree of patients’ satisfaction with prior and current dermatological 
treatments and to study how patients value 1) effectiveness, 2) safety, 3) convenience 
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and 4) organization of treatment, 5) information about treatment, and 6) the doctor- 
patient relationship.
Our study comprised 2070 patients (response rate: 43%), aged ≥ 18 years, with a 
self-reported diagnosis of psoriasis and treated or being treated with topicals, 
phototherapy, and/or systemic therapies. The questionnaire survey was preceded by 
literature search, results from a focus group session (N=9), and results from a 
previous survey (conducted for the first Dutch evidence-based psoriasis guidelines, 
2005). The literature search revealed the importance of specifying domains of 
treatment satisfaction [250, 251]. 
The questionnaire survey was comprised of 27, mainly multiple-choice questions on 
patient characteristics, disease duration and severity, prior and current treatments, as 
well as generic and specific treatment satisfaction. Questions about treatment 
satisfaction were answered on a 5-point scale: 1 = very dissatisfied and 5 = very 
satisfied. The group of “Satisfied patients” was defined as the group of patients with 
scores of 4 and 5 and the group of “Dissatisfied patients” as the group of patients 
with a score of 1. Patients with scores 2 and 3 were excluded from analysis.
For an extensive report on methodology, patient characteristics, data analysis, and 
results we refer to the complete Dutch S3-guidelines on the treatment of psoriasis 
2011: http://www.huidarts.info/documents/uploaded_file.aspx?id=579. An international 
peer-reviewed publication is in preparation [252].
Conclusions 
Following conclusions and recommendations are based on the research report.
EL: 3
1. About 1 out of 3 patients with psoriasis (32.4%) was satisfied with prior 
treatments. About 1 out of 14 patients (7.0%) was dissatisfied with prior 
treatments.
2a. About half of patients with psoriasis (53.8%) was satisfied with their 
current treatment. Patients with topical therapies were least satisfied, 
patients with systemic therapies were most satisfied.
2b. Patients receiving a topical therapy were least satisfied with effectiveness 
and convenience of treatment. Patients receiving phototherapy were 
least satisfied with effectiveness of treatment. Patients with systemic 
treatment were least satisfied with safety of treatment.
3. Patients value the effectiveness of treatment as the most important 
domain of satisfaction. The doctor-patient relationship was valued as 
important as treatment safety, and more important than convenience.
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Recommendations on quality of life and treatment satisfaction
1. In dermatological practice, it is recommended to explicitly address the influence 
of psoriasis on quality of life by:
 a)  Asking patients directly about their quality of life or by means of standardized 
questionnaires such as the DLQI or Skindex, if applicable and relevant.
 b)  Modifying treatment and care, if necessary, based on current evidence.
2. In dermatological practice, it is recommended to explicitly address treatment 
satisfaction by:
 a)  Asking patients directly about their treatment satisfaction (general as well as 
specific) regarding: 1) effectiveness, 2) safety, 3) convenience, 4) organization 
of treatment, 5) information about treatment, and 6) the doctor-patient 
relationship).
 b)  Modifying treatment and care, if necessary, based on current evidence.
3. Additionally, it is recommended to professionals to determine norms or cut-off 
points for the interpretation of scores of satisfaction and dissatisfaction with 
treatment, based on evidence, suitability, and feasibility.
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Abstract
Importance: Combined use of systemic agents may be necessary to achieve 
disease control in therapy-resistant patients. However, to our knowledge, an overview 
of evidence, including quality assessments, is not yet available, and no guidance on 
monitoring, contraindications, and interactions exists. 
Objective: To summarize and critically appraise the evidence on efficacy and safety 
of combination therapy with systemic agents in plaque-type psoriasis.
Evidence review: Through March 2013, an electronic search limited to randomized 
clinical trials was performed in MEDLINE, EMBASE, The Cochrane Library and 
ongoing trial registers. The quality of evidence was evaluated using the Grading of 
Recommendations Assessment, Development and Evaluation approach.
Findings: The initial search retrieved 2583 records, of which 17 met the inclusion 
criteria. Most studies favored combination therapy, albeit with low significance and 
low quality of evidence. Etanercept plus methotrexate was the only combination 
therapy investigated with an adequate sample size (n = 478). In the short term, this 
combination had superior efficacy with a moderate quality of evidence compared 
with etanercept monotherapy (Psoriasis Area and Severity Index 75; relative risk, 1.28: 
95% CI, 1.14-1.45). Although this finding coincided with an increase in adverse events 
(relative risk, 1.25; 95% CI, 1.10-1.42), the overall safety profile remained acceptable. 
Conclusions and Relevance: This systematic review provides a comprehensive 
overview on the validity of different systemic combination therapies. For most 
combinations, insufficient evidence is available. Initial results indicate that combined 
therapy with etanercept plus methotrexate may  be beneficial in patients that are 
therapy resistant under intensive follow-up. Dose reductions should be taken into 
account to minimize adverse events.
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 255
255
Systematic review combined use of systemic agents
11
Introduction
Combination therapy with systemic agents is used in clinical practice because it may 
enhance efficacy, accelerate the onset of remission, and reduce adverse events 
(AEs) by permitting dose reductions. However, it may also induce more, unknown, 
and other AEs, and no guidance is available on monitoring, contraindications, and 
interactions. Although several systematic reviews1-3 provide a summary of studies 
that report on combination therapy with systemic agents, no risk of bias assessments 
of the individual studies were provided. The National Clinical Guideline Centre performed 
quality assessments on combination therapy with retinoids and phototherapy, but no 
other combination therapies with systemic agents were analyzed.4 Recommendations 
in clinical guidelines on combination therapy, if any, are frequently based on few 
randomized clinical trials (RCTs) or observational studies, case reports, and expert 
opinion.5-8 We conducted a systematic review of RCTs on the efficacy and safety of 
combination therapy with systemic agents for plaque-type psoriasis. The quality of 
evidence was assessed using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach.9
Methods
Search method
A medical librarian (J.L.) performed a literature search to identify RCTs of combination 
therapy with systemic agents in plaque-type psoriasis. Through March 2013, 
MEDLINE (OVID, from 1948), EMBASE (OVID, from 1980), Cochrane Central Register 
of Controlled Trials (CENTRAL, from inception), PubMed (the publisher subset 
fraction, which contains publications ahead of print that are not yet included in OVID 
MEDLINE) and ongoing trial registers (http://clinicaltrials.gov/) were searched with no 
language restrictions. The latest update was March 2013. Animal studies were safely 
excluded by using double negation. The search strategies consisted of searching for 
the keywords psoriasis and combination therapy in Medical Subject Headings and 
titles and abstracts. In MEDLINE and EMBASE, the topic search was combined with 
a methodological filter adapted from the Cochrane Central Register of Controlled 
Trials to identify RCTs and clinical controlled trials (eFigure 1 in the Supplement 
details the entire MEDLINE search).10-11 The search included an iterative process for 
each database to refine the search strategy through incorporation of new search 
terms as new relevant citations were identified (i.e., by checking reference lists and 
citing articles using ISI Web of Science [Thomson Reuters]). Reference Manager 
software, version 12.0 (Thomson Reuters) was used to deduplicate, store, and analyze 
the search results. 
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Selection criteria
The RCTs (N >10) that reported on the efficacy and safety of combination therapy 
with systemic agents compared with systemic monotherapy or another systemic 
combination therapy in plaque-type psoriasis were included. Studies that reported 
on other types of psoriasis, sequential or rotational therapies, and unclear (i.e., 
Chinese herbal) combination therapies were excluded and studies that reported on 
alefacept and efalizumab were excluded because these treatment modalities are no 
longer available. Furthermore, studies that reported on phototherapy plus acitretin 
were excluded because, for this type of combination therapy, an overview of RCT 
evidence according to the GRADE approach already exists4 (Figure 1).
Figure 1  Search strategy and retrieved articles
3256 Records identified by literature
search        
           646 Medline (OVID) 
         1983 Embase (OVID) 
           564 Central 
             63 PubMed (publisher subset)  
17 Trials reporting on combination
therapy with  systemic agents in
psoriasis met inclusion criteria     
19  Excluded because of psoriatic arthritis,
nonrandomized trials, Chinese herbal therapies,
< 10 study participants, or full text unavailable     
2583 Records after duplicates removed  
2547 Ineligible entries because of reporting on topical
combination therapy, psoriasis other than
chronic plaque type, combination therapy with
alefacept or efalizumab, additional PUVA or
UV-B, sequential or rotational therapy, or
outcomes not related to efficacy or safety           
           
36 Potentially relevant trials assessed
in full text   
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Study selection 
Titles and abstracts from the electronic searches were screened, and full manuscripts 
of all citations that met the predefined selection criteria were obtained. Subsequently, 
full articles were examined for inclusion or exclusion. The selection was independently 
performed by two reviewers (C.B. and J.Z.). Any disagreements were resolved by 
consensus or arbitration of a third reviewer (P.I.S.). 
Data extraction
Information on study reference, year of publication, study design, number of patients, 
baseline disease severity, treatment regimen, duration of combination therapy, and 
follow-up were extracted. Critical and important outcomes were selected to assess 
the quality of evidence. Critical outcomes were defined as the proportion of patients 
who attained Psoriasis Area and Severity Index (PASI) 75, PASI 90, and a Physician 
Global Assessment (PGA) of clear or almost clear; withdrawals because of AEs; 
proportion of patients who experienced serious adverse events (SAEs); and mean 
change in Dermatology Life Quality Index (DLQI). Important outcomes were defined 
as number of withdrawals because of lack of efficacy, proportion of patients with AEs, 
mean change in PASI (0-72, 0-16 and 0-18), mean time to clearance, and mean time 
to relapse. Only results from intention-to-treat (ITT) analysis were used if both ITT and 
per-protocol data were available. Efficacy outcomes were divided into 2 groups 
based on duration of combination therapy: ≤ 12 weeks or >12 weeks. The number of 
events and total number of participants in each group were used for extracting 
dichotomous variables. Means and standard deviations (SDs) were used for extracting 
continuous variables. 
Assessment and Evaluation of the Quality of Evidence
The risk of bias in the individual studies was assessed in duplicate (C.B. and J.Z.) 
using the Cochrane Risk of Bias tool.10 Accordingly, we graded sequence generation, 
allocation concealment, blinding of caregivers and outcome assessors, incomplete 
outcome data, selective outcome reporting, and other sources of bias as low, unclear 
or high risk of bias. Subsequently, an overall assessment for each RCT was conducted 
using the same three criteria. The quality of evidence for each outcome (body of 
evidence) was assessed according to the GRADE approach9 by using the GRADE 
profiler software, version 3.2.2.12
Statistics
The threshold for statistical significance was set at P<0.05 for effect sizes. Mean 
difference (MD) with 95% confidence interval (95% CI) was calculated for continuous 
variables. An imputed correlation coefficient of 0.70 was used to calculate the 
change-from-baseline SDs. The value of the correlation coefficient could not be 
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imputed from another study and was therefore hypothesized.10 Relative risk or risk 
ratio (RR) with a 95% CI was used to calculate the effects for dichotomous outcomes. 
The Optimal Information Size (OIS) was calculated using a relative risk ratio (RRR) of 
25% and assuming an α of 0.05 and a  of 0.2 if consideration of 95% CIs alone 
suggested a robust effect, but the total sample size and the number of events were 
small.13 Meta-analysis to calculate a weighted treatment effect across trials and a 
funnel plot to detect publication and other reporting biases by plotting could not be 
performed because of a lack of more than one trial of the same comparison or 
absence of similar treatment regimens.
Results
Trial Characteristics
The search identified 2583 references to RCTs that investigated combination therapy 
with systemic agents for psoriasis. Thirty-six references were selected for full-text 
examination, and 17 RCTs with a total of 1071 participants (median, 71 participants; 
range, 10-478 participants) were included (Figure 1). The characteristics of included 
studies and outcome measures used for analysis are listed in Table 1. 
Quality of evidence of the included studies 
Assessment of the risk of bias of the individual studies resulted in low risk for 3 trials 14-16 
intermediate risk for 5 trials17-21 and high risk for 9 trials22-30.Methodological limitations 
were unclear allocation concealment (14/14 trials), inadequate or partial blinding 
(14/14), unclear baseline comparability (8/14), unclear random sequence generation 
(5/14) and per-protocol analysis (5/14). The overall quality of evidence at outcome 
level ranged from moderate to very low because of risk of bias, insufficient sample 
size, small number of events, and wide 95% CI (eTables 1-16 in the Supplement).
Effects of interventions 
Duration of systemic combination therapy ≤ 12 weeks 
PASI 75 
Nine trials15,16,18-21,25,26,30 assessed the proportion of patients who attained a PASI 
75. Two of these trials16,18 found statistically significant differences in favor of 
etanercept plus methotrexate (MTX) with moderate quality of evidence (eTable 6 in 
the Supplement). Zachariae et al18 found that 54.8% of patients in the etanercept plus 
MTX group attained PASI 75 compared with 25.0% in the etanercept plus MTX 
tapering group (MTX discontinued at week 4) (RR 2.19; 95% CI 1.07-4.49). Gottlieb et 
al16 demonstrated that 77.4% of patients in the etanercept plus MTX group attained 
PASI 75 compared with 60.3% in the etanercept plus placebo group (RR 1.28; 95% CI 
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1.14-1.45). A trial by Wolf et al26 found statistically significant differences in favor of 
ustekinumab plus UVB with very low quality of evidence. In patients treated with 
ustekinumab, 77.8% attained PASI 75 on UVB irradiated body halves compared with 
11.1% on unirradiated body halves (RR 7.0; 95% CI 1.07-45.9) (eTable 5 in the 
Supplement).
PASI 90
Four trials15,16,18,25 assessed the proportion of patients attaining PASI 90 or higher. 
The trial by Gottlieb et al16 found a statistically significant difference, with 52.3% of 
patients in the etanercept plus MTX group attaining PASI 90 compared with 33.1% of 
patients in the etanercept plus placebo group (RR 1.58; 95% CI 1.27-1.97) (eTable 6 
in the Supplement). Quality of evidence was moderate. 
PGA of clear or almost clear
Five trials15,16,18,20,25 assessed the proportion of patients who attained a PGA of clear 
or almost clear. Two trials16,18 found a statistically significant difference between 
treatment groups with moderate quality of evidence in favor of etanercept plus MTX 
(eTable 6 in the Supplement). Gottlieb et al.16 found that 72.0% in the etanercept plus 
MTX group attained a PGA of clear or almost clear compared with 54.4% in the 
etanercept plus placebo  group (RR 1.32; 95% CI 1.15-1.52), and Zachariae et al.18 
found that 71.0% of patients in the etanercept plus MTX group attained a PGA of clear 
or almost clear compared with 39.3% in the etanercept plus MTX tapering  group (RR 
1.81; 95% CI 1.08-3.02). 
Mean change in PASI
Nine trials18,20,21,23-27,29 assessed the mean change in PASI from baseline. Three 
trials26,27,29 demonstrated a statistically significant difference between treatment 
groups with very low quality of evidence. Wolf et al26  found a mean change in PASI 
of 4.1 in favor of UVB irradiated body halves compared with UVB unirradiated body 
halves in patients treated with ustekinumab (eTable 5 in the Supplement), and 
Ezquerra et al29 found a mean change in PASI of 4.6 in favor of acitretin plus calcitriol 
compared with acitretin monotherapy (eTable 13 in the Supplement). El-Mofty et al27 
found a mean change in PASI of 9.04 in favor of MTX monotherapy compared with 
sulfasalazine plus pentoxifylline (eTable 11 in the Supplement). 
Mean and median time to clearance
Two trials24,30 assessed the mean time to clearance. Danno et al30  found a statistically 
significant difference of 2.5 weeks in favor of etretinate plus eicosapentaenoic acid 
(fish oil) compared with etretinate monotherapy (eTable 15 in the Supplement). Quality 
of evidence was very low. 
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Table 1   Characteristics of included studies 
Study reference Year Study design No. of 
patients
Baseline 
disease 
severity 
 Intervention Control group Study 
length 
(wk)
Follow 
up
(wk)
Efficacy outcome 
measures used in 
study analysis
Safety outcome 
measures used in 
study analysis 
Other outcome 
measures used in 
study analysis 
Phototherapy in combination with traditional systemic agentsa
Mahajan et al.17 2007 RCT, 
single-blinded,
ITT analysis
N = 40 >10% of 
body surface 
involvement
UVB thrice weekly  
+ MTX 0.5 mg/kg
Placebo + UVB thrice 
weekly 
24 12 PASI 75
Withdrawal due to 
lack of efficacy 
% patients with AEs Mean time to 
clearance/ relapse
Asawanonda et al.14 2006 RCT, double blind,
ITT analysis
N = 24 >20% of 
body surface 
involvement
UVB thrice weekly  
+ MTX 15mg/wk
Placebo + UVB thrice 
weekly 
24 24 PASI 90
Mean change in 
PASI 
% patients with AEs
Withdrawal due to 
AEs
Median time to 
clearance/relapse
Mean change in 
DLQI 
Shehzad et al.22 2004 RCT, 
open-label
per protocol 
analysis
N = 60 PASI > 10 PUVA 4 treatments/wk 
+ MTX 10mg/wk
1. PUVA 4 treatments/wk
2. MTX 10mg/wk
32 - Mean change in 
PASI 
- Mean time to 
clearance
Prystowsky et al.23 1996 RCT, 
Patient-blinded,
per-protocol 
analysis 
N = 19 >20% of 
body surface 
involvement
UVB 4 treatments weekly 
+ calcitriol  
0.5-2.0 µg/day
UVB 4 treatments weekly 
+ placebo
5 - Mean change in 
PASI (scale 0-16)
- -
Gupta et al.24 1989 RCT, 
Double-blind,
Per-protocol 
analysis 
N = 20 10 – 50%  of 
body surface 
involvement
UVB twice/wk  
+ 10 capsules eicosa-
pentaenoic acid daily
UVB twice/wk +10 
capsules olive oil daily 
8 - Mean change in 
PASI (scale 0-18)
-
Phototherapy in combination with biologics
Lynde et al.15 2012 RCT,
investigator-blinded,
ITT-analysis
N = 75 PASI > 10 UVB thrice weekly  
+ Etanercept 50mg/wk 
Etanercept  50mg/wk 12 - PASI 75/ PASI 90
PGA of clear/ 
almost clear 
Withdrawal due to 
lack of efficacy 
% patients with 
SAEs
Mean change in 
DLQI 
Park et al.25 2012 RCT,
Open-label,
ITT-analysis 
N = 30 PASI > 10 
and 
>10% of 
body surface 
involvement
UVB thrice weekly  + 
Etanercept 50mg/wk
Etanercept 50mg/wk 12 - PASI 75/ PASI 90
PGA clear or 
almost clear
Mean change in 
PASI 
- -
Wolf et al.26 2011 RCT, 
left-right, 
open-label,
per-protocol 
analysis 
N = 10 PASI > 10 UVB thrice weekly  + 
Ustekinumab 
45 or 90mg at week 0 
and 4
Ustekinumab 
45 or 90mg once every 
three weeks
6 - PASI 75
Mean change in 
PASI 
% patients with 
AEs/ Withdrawal 
due to AEs  
-
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Table 1   Characteristics of included studies 
Study reference Year Study design No. of 
patients
Baseline 
disease 
severity 
 Intervention Control group Study 
length 
(wk)
Follow 
up
(wk)
Efficacy outcome 
measures used in 
study analysis
Safety outcome 
measures used in 
study analysis 
Other outcome 
measures used in 
study analysis 
Phototherapy in combination with traditional systemic agentsa
Mahajan et al.17 2007 RCT, 
single-blinded,
ITT analysis
N = 40 >10% of 
body surface 
involvement
UVB thrice weekly  
+ MTX 0.5 mg/kg
Placebo + UVB thrice 
weekly 
24 12 PASI 75
Withdrawal due to 
lack of efficacy 
% patients with AEs Mean time to 
clearance/ relapse
Asawanonda et al.14 2006 RCT, double blind,
ITT analysis
N = 24 >20% of 
body surface 
involvement
UVB thrice weekly  
+ MTX 15mg/wk
Placebo + UVB thrice 
weekly 
24 24 PASI 90
Mean change in 
PASI 
% patients with AEs
Withdrawal due to 
AEs
Median time to 
clearance/relapse
Mean change in 
DLQI 
Shehzad et al.22 2004 RCT, 
open-label
per protocol 
analysis
N = 60 PASI > 10 PUVA 4 treatments/wk 
+ MTX 10mg/wk
1. PUVA 4 treatments/wk
2. MTX 10mg/wk
32 - Mean change in 
PASI 
- Mean time to 
clearance
Prystowsky et al.23 1996 RCT, 
Patient-blinded,
per-protocol 
analysis 
N = 19 >20% of 
body surface 
involvement
UVB 4 treatments weekly 
+ calcitriol  
0.5-2.0 µg/day
UVB 4 treatments weekly 
+ placebo
5 - Mean change in 
PASI (scale 0-16)
- -
Gupta et al.24 1989 RCT, 
Double-blind,
Per-protocol 
analysis 
N = 20 10 – 50%  of 
body surface 
involvement
UVB twice/wk  
+ 10 capsules eicosa-
pentaenoic acid daily
UVB twice/wk +10 
capsules olive oil daily 
8 - Mean change in 
PASI (scale 0-18)
-
Phototherapy in combination with biologics
Lynde et al.15 2012 RCT,
investigator-blinded,
ITT-analysis
N = 75 PASI > 10 UVB thrice weekly  
+ Etanercept 50mg/wk 
Etanercept  50mg/wk 12 - PASI 75/ PASI 90
PGA of clear/ 
almost clear 
Withdrawal due to 
lack of efficacy 
% patients with 
SAEs
Mean change in 
DLQI 
Park et al.25 2012 RCT,
Open-label,
ITT-analysis 
N = 30 PASI > 10 
and 
>10% of 
body surface 
involvement
UVB thrice weekly  + 
Etanercept 50mg/wk
Etanercept 50mg/wk 12 - PASI 75/ PASI 90
PGA clear or 
almost clear
Mean change in 
PASI 
- -
Wolf et al.26 2011 RCT, 
left-right, 
open-label,
per-protocol 
analysis 
N = 10 PASI > 10 UVB thrice weekly  + 
Ustekinumab 
45 or 90mg at week 0 
and 4
Ustekinumab 
45 or 90mg once every 
three weeks
6 - PASI 75
Mean change in 
PASI 
% patients with 
AEs/ Withdrawal 
due to AEs  
-
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Table 1   Continued 
Study reference Year Study design No. of 
patients
Baseline 
disease 
severity 
 Intervention Control group Study 
length 
(wk)
Follow 
up
(wk)
Efficacy outcome 
measures used in 
study analysis
Safety outcome 
measures used in 
study analysis 
Other outcome 
measures used in 
study analysis 
Biologics in combination with traditional systemic agents
Gottlieb et al.16 2012 RCT,
double-blind,
ITT-analysis 
N = 478 PASI > 10/ 
>10% of 
body surface 
involvement
Etanercept 50mg/wk + 
MTX 7.5-15.0 mg/wk
Etanercept 50mg/wk + 
Placebo 
12 - PASI 75/PASI 90 
PGA clear or 
almost clear 
Withdrawal due to 
lack of efficacy 
% patients with 
AEs and SAEs/ 
Withdrawal due 
to AEs 
-
Zachariae et al.18 2008 RCT, 
open-label, ITT-
analysis 
N = 60 PASI > 8/
>10% of 
body surface 
involvement
Etanercept         50mg 
twice weekly for 12 
weeks then 50mg/wk + 
MTX > 7.5mg/wk
Etanercept 50mg twice 
weekly for 12 weeks 
then 50mg/wk + MTX 
discontinued at wk4
24 - PASI 75/PASI 90
PGA clear or 
almost clear 
Mean change in 
PASI 
Withdrawal due to 
lack of efficacy 
% patients with 
AEs and SAEs/
Withdrawal due 
to AEs 
Mean change in 
DLQI
Gisondi et al.19 2008 RCT, 
investigator-
blinded,
ITT-analysis 
N = 60 Clinically 
stable 
moderate to 
severe plaque 
type psoriasis
Etanercept 50mg/wk + 
acitretin 0.4mg/kg/day
1. Etanercept 50mg/wk
2. Acitretin 0.4mg/kg/
day
24 - PASI 75 
Withdrawal due to 
lack of efficacy
% patients with 
AEs
-
Combination of traditional systemic agents
Study reference Year Study design No. of 
patients
Baseline 
disease 
severity 
Intervention Control group Study 
length 
(wk)
Follow 
up
(wk)
Efficacy outcome 
measures used in 
study analysis
Safety outcome 
measures used in 
study analysis
Other outcome 
measures used in 
study analysis
El-Mofty et al.27,b 2011 RCT, 
unclear blinding, 
ITT-analysis 
N = 16 >25% of 
body surface 
involvement
Sulfasalazine 2g/day + 
pentoxifylline 1200mg/
day
MTX 25mg/wk 8 - Mean change in 
PASI 
Withdrawal due to 
lack of efficacy 
% patients with 
AEs
-
Mittal et al.20 2009 RCT, double-blind, 
ITT-analysis 
N = 41 >20% of 
body surface 
involvement
Acitretin 25mg/day + 
pioglitazone
hydrochloride 15mg/
day 
Acitretin 25mg/day + 
placebo
12 - PASI 75
PGA clear or 
almost clear 
Mean change in 
PASI 
Withdrawal due to 
lack of efficacy
% patients with 
AEs and SAEs/
Withdrawal due 
to AEs
-
Gupta et al.28,c 2007 RCT, 
open-label,
per-protocol 
analysis 
N = 24 PASI > 10/
>10% of 
body surface 
involvement
MTX 15mg/wk + 
betamethasone 3mg/wk
MTX 15mg/wk ? ? - - Mean time to 
clearance
Mean time to 
relapse
Ezquerra et al.29 2007 RCT, unblinded, 
per-protocol 
analysis 
N = 40 PASI > 15 
and < 40 
Acitretin  25mg/d + 
calcitriol 0.25 µg/d
Acitretin 25mg/d 12 - Mean change in 
PASI 
% patients with 
AEs
-
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Table 1   Continued 
Study reference Year Study design No. of 
patients
Baseline 
disease 
severity 
 Intervention Control group Study 
length 
(wk)
Follow 
up
(wk)
Efficacy outcome 
measures used in 
study analysis
Safety outcome 
measures used in 
study analysis 
Other outcome 
measures used in 
study analysis 
Biologics in combination with traditional systemic agents
Gottlieb et al.16 2012 RCT,
double-blind,
ITT-analysis 
N = 478 PASI > 10/ 
>10% of 
body surface 
involvement
Etanercept 50mg/wk + 
MTX 7.5-15.0 mg/wk
Etanercept 50mg/wk + 
Placebo 
12 - PASI 75/PASI 90 
PGA clear or 
almost clear 
Withdrawal due to 
lack of efficacy 
% patients with 
AEs and SAEs/ 
Withdrawal due 
to AEs 
-
Zachariae et al.18 2008 RCT, 
open-label, ITT-
analysis 
N = 60 PASI > 8/
>10% of 
body surface 
involvement
Etanercept         50mg 
twice weekly for 12 
weeks then 50mg/wk + 
MTX > 7.5mg/wk
Etanercept 50mg twice 
weekly for 12 weeks 
then 50mg/wk + MTX 
discontinued at wk4
24 - PASI 75/PASI 90
PGA clear or 
almost clear 
Mean change in 
PASI 
Withdrawal due to 
lack of efficacy 
% patients with 
AEs and SAEs/
Withdrawal due 
to AEs 
Mean change in 
DLQI
Gisondi et al.19 2008 RCT, 
investigator-
blinded,
ITT-analysis 
N = 60 Clinically 
stable 
moderate to 
severe plaque 
type psoriasis
Etanercept 50mg/wk + 
acitretin 0.4mg/kg/day
1. Etanercept 50mg/wk
2. Acitretin 0.4mg/kg/
day
24 - PASI 75 
Withdrawal due to 
lack of efficacy
% patients with 
AEs
-
Combination of traditional systemic agents
Study reference Year Study design No. of 
patients
Baseline 
disease 
severity 
Intervention Control group Study 
length 
(wk)
Follow 
up
(wk)
Efficacy outcome 
measures used in 
study analysis
Safety outcome 
measures used in 
study analysis
Other outcome 
measures used in 
study analysis
El-Mofty et al.27,b 2011 RCT, 
unclear blinding, 
ITT-analysis 
N = 16 >25% of 
body surface 
involvement
Sulfasalazine 2g/day + 
pentoxifylline 1200mg/
day
MTX 25mg/wk 8 - Mean change in 
PASI 
Withdrawal due to 
lack of efficacy 
% patients with 
AEs
-
Mittal et al.20 2009 RCT, double-blind, 
ITT-analysis 
N = 41 >20% of 
body surface 
involvement
Acitretin 25mg/day + 
pioglitazone
hydrochloride 15mg/
day 
Acitretin 25mg/day + 
placebo
12 - PASI 75
PGA clear or 
almost clear 
Mean change in 
PASI 
Withdrawal due to 
lack of efficacy
% patients with 
AEs and SAEs/
Withdrawal due 
to AEs
-
Gupta et al.28,c 2007 RCT, 
open-label,
per-protocol 
analysis 
N = 24 PASI > 10/
>10% of 
body surface 
involvement
MTX 15mg/wk + 
betamethasone 3mg/wk
MTX 15mg/wk ? ? - - Mean time to 
clearance
Mean time to 
relapse
Ezquerra et al.29 2007 RCT, unblinded, 
per-protocol 
analysis 
N = 40 PASI > 15 
and < 40 
Acitretin  25mg/d + 
calcitriol 0.25 µg/d
Acitretin 25mg/d 12 - Mean change in 
PASI 
% patients with 
AEs
-
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Withdrawal because of lack of efficacy 
Four trials15,16,20,27 assessed the proportion of patients who were withdrawn because 
of  lack of efficacy. No statistically significant differences among treatment groups 
could be found, and quality of evidence was very low. 
Mean change in DLQI 
A trial by Lynde et al15 assessed the mean change in DLQI from baseline. No statistically 
significant differences between treatment groups were found, and quality of evidence 
was very low. 
Duration of systemic combination therapy > 12 weeks
PASI 75
Three trials17-19 assessed the proportion of patients who attained PASI 75. Two trials 
found a statistically significant difference between treatment groups. 
Mahajan et al17 found that 95% in the UVB plus MTX group attained PASI 75 compared 
with 70% in the UVB plus placebo group (RR 1.36; 95% CI 1.0-1.84), with very low 
quality of evidence (eTable 1 in the Supplement). Zachariae et al18  found that 71.0% 
of patients in the etanercept plus MTX group attained PASI 75 compared with 35.7% 
in the etanercept plus MTX tapering group (RR 1.99; 95% CI 1.15-3.43) with moderate 
quality of evidence (eTable 6 in the Supplement).
Table 1   Continued 
Study reference Year Study design No. of 
patients
Baseline 
disease 
severity 
 Intervention Control group Study 
length 
(wk)
Follow 
up
(wk)
Efficacy outcome 
measures used in 
study analysis
Safety outcome 
measures used in 
study analysis 
Other outcome 
measures used in 
study analysis 
Combination of traditional systemic agents
Reitamo et al.21,b 2001 RCT, double-blind,
ITT-analysis 
N = 33 PASI > 12 Sirolimus 3.0mg/m/d  
+ cyclosporine 1.25mg/
kg/d
Cyclosporine 5mg/kg/d 8 4 PASI 75
Mean change in 
PASI 
Withdrawal due to 
adverse events
-
Danno et al.30 1998 RCT, unblinded, 
ITT-analysis
N = 40 Moderately 
involved, 
chronic plaque 
type psoriasis 
Etretinate 20mg/d+ 
eicosapentaenoic acid 
1800mg/d
Etretinate 20mg/d 12 - PASI 75 
(scale 0 to 12)
% patients with 
AEs
Mean time to 
clearance 
a   Concomitant treatment with phototherapy and acitretin was excluded, because for this type of 
combination therapy, an overview of RCT evidence according to the GRADE approach already exists.
b   Only the most clinically relevant comparisons are reported (sulfasalazine plus pentoxifylline vs. MTX 
monotherapy and sirolimus 3.0 mg/m/d + cyclosporine 1.25 mg/kg/d vs. sirolimus 5 mg/kg/d) )
c   Efficacy in terms of PASI outcomes were based on non-randomized patients
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PASI 90 
Two trials14,18 assessed the proportion of patients who attained PASI 90. A trial by 
Asawanonda et al14 found a statistically significant difference between treatment 
groups, with 90.9% of patients in the UVB plus MTX group attaining PASI 90 compared 
with 38.5% in the UVB plus placebo group (RR 2.36; 95% CI 1.16-4.82) (eTable 1 in the 
Supplement). Quality of evidence was very low. 
PGA of clear or almost clear
A trial by Zachariae et al18 assessed the proportion of patients who attained a PGA of 
clear or almost clear and had a statistically significant difference, with 67.7% of 
patients in the etanercept plus MTX group compared with 35.7% in the etanercept 
plus MTX tapering group attaining a PGA of clear or almost clear (RR 1.90; 95% CI 
1.09-3.30) (eTable 6 in the Supplement). Quality of evidence was very low. 
Mean change in PASI
Three trials14,17,18 assessed the mean change in PASI from baseline. Two trials found 
a statistically significant difference with very low quality of evidence. Zachariae et al18 
found a mean change in PASI of 5.1 in favor of MTX plus etanercept compared with 
etanercept plus MTX tapering (eTable 6 in the Supplement), and Asawanonda et al14 
found a mean change in PASI of 7.75 in favor of UVB plus MTX compared with UVB 
plus placebo (eTable 1 in the Supplement). 
Table 1   Continued 
Study reference Year Study design No. of 
patients
Baseline 
disease 
severity 
 Intervention Control group Study 
length 
(wk)
Follow 
up
(wk)
Efficacy outcome 
measures used in 
study analysis
Safety outcome 
measures used in 
study analysis 
Other outcome 
measures used in 
study analysis 
Combination of traditional systemic agents
Reitamo et al.21,b 2001 RCT, double-blind,
ITT-analysis 
N = 33 PASI > 12 Sirolimus 3.0mg/m/d  
+ cyclosporine 1.25mg/
kg/d
Cyclosporine 5mg/kg/d 8 4 PASI 75
Mean change in 
PASI 
Withdrawal due to 
adverse events
-
Danno et al.30 1998 RCT, unblinded, 
ITT-analysis
N = 40 Moderately 
involved, 
chronic plaque 
type psoriasis 
Etretinate 20mg/d+ 
eicosapentaenoic acid 
1800mg/d
Etretinate 20mg/d 12 - PASI 75 
(scale 0 to 12)
% patients with 
AEs
Mean time to 
clearance 
a   Concomitant treatment with phototherapy and acitretin was excluded, because for this type of 
combination therapy, an overview of RCT evidence according to the GRADE approach already exists.
b   Only the most clinically relevant comparisons are reported (sulfasalazine plus pentoxifylline vs. MTX 
monotherapy and sirolimus 3.0 mg/m/d + cyclosporine 1.25 mg/kg/d vs. sirolimus 5 mg/kg/d) )
c   Efficacy in terms of PASI outcomes were based on non-randomized patients
Abbreviations: AE, adverse effect; DLQI, Dermatology Life Quality Index; GRADE, Grading of 
Recommendations Assessment, Development and Evaluation; ITT, intention to treat; PASI, Psoriasis Area 
and Severity Index; PGA, Physician Global Assessment; PUVA, psoralen-UV-A; RCT, randomized clinical 
trial; SAE, severe adverse event
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Mean and median time to clearance
Four trials14,17,22,28 assessed the mean or median time to clearance and found 
statistically significant differences between treatment groups, with very low quality of 
evidence. Gupta et al28  found a difference in time to clearance of 9.3 days in favor of 
MTX plus bethametasone compared with MTX monotherapy (eTable 12 in the 
Supplement). Shehzad et al22 found a difference in time to clearance in favor of 
Psoralen-UV-A (PUVA) plus MTX of 3 weeks compared with PUVA monotherapy and 
of 5.5 weeks compared with MTX monotherapy (eTables 2 and 3 in the Supplement). 
Asawanonda et al14  found a time to clearance of 4 weeks for UVB plus MTX compared 
with >24 weeks for UVB plus placebo, and Mahajan et al17 found a difference in mean 
time of clearance of 6 weeks in favor of UVB plus MTX compared with UVB plus 
placebo (eTable 1 in the Supplement). 
Time to relapse 
Three trials14,17,28 assessed the mean or median time to relapse. Gupta et al28 
demonstrated a statistically significant difference of 53.24 days in favor of MTX plus 
bethametasone compared with MTX monotherapy with very low quality of evidence 
(eTable 12 in the Supplement). 
Withdrawal because of lack of efficacy 
Three trials17-19 assessed the proportion of patients who were withdrawn because of 
lack of efficacy. No statistically significant differences between treatment groups 
were found, and quality of evidence was very low. 
Mean change in DLQI 
Two trials14,18 assessed the mean change in DLQI from baseline. No statistically 
significant differences between treatment groups were found, and quality of evidence 
was very low. 
Overall summary across studies
Phototherapy in combination with traditional systemic agents
Small statistically significant differences in favor of UVB plus MTX14,17 and PUVA plus 
MTX22 were found. For UVB plus fish oil24 and UVB plus calcitriol23, no significant 
superiority was found. No major differences in safety profiles between treatment 
groups were found, and no SAEs were reported. Quality of evidence was very low for 
all outcomes in this section.
Phototherapy in combination with biologics
Small statistically significant differences in favor of UVB plus ustekinumab were 
found.26 For UVB plus etanercept, no significant superiority was found.15,25 No major 
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differences in safety profiles between treatment groups were found. No SAEs were 
reported in the combination therapy groups compared with 3 SAEs in the monotherapy 
groups; all were considered to be unrelated to study treatment. Quality of evidence 
was very low for all outcomes in this section.
Biologics in combination with traditional systemic agents
Statistically significant differences in terms of efficacy in favor of etanercept plus MTX 
were found, with moderate quality of evidence.16,18 However, this effect coincided 
with a statistically significant increase in AEs. In the etanercept plus MTX group, 
74.9% of patients experienced AEs compared with 59.8% of patients in the etanercept 
plus placebo group (RR 1.25; 95% CI 1.10-1.42). For infectious AEs, a statistically 
significant higher incidence was found in the combination therapy group compared 
with the group treated with etanercept plus placebo (34.7% vs. 25.9%; RR 1.34; 95% 
CI 1.02-1.76)16.  
Most AEs were considered mild to moderate. Five SAEs were reported in the 
etanercept plus MTX groups compared with 8 SAEs in the control groups (etanercept 
plus placebo and etanercept plus MTX tapering). 
Seven SAEs were considered to be related to study medication: 2 in the combination 
therapy groups (infection and vomiting) and 5 in the control groups (infections, 
pustular psoriasis, heart insufficiency, and atrial fibrillation). Quality of evidence for 
safety outcomes ranged from moderate (AEs) to very low (SAEs) (eTable 6 in the 
Supplement).
For etanercept plus acitretin compared with etanercept monotherapy, dose reductions 
without loss of efficacy were found with very low quality of evidence.19 No major 
differences in safety profiles between these treatment groups were found, and no 
SAEs were reported.
Combination of traditional systemic agents
Small statistically significant differences in favor of acitretin plus calcitriol29, etretinate 
plus eicosapentaenoic acid30,  and betamethasone plus MTX28 were found. For acitretin 
plus pioglitazone hydrochloride20 and sirolimus plus cyclosporine21, no significant 
superiority was found, although dose reductions were possible for sirolimus plus 
cyclosporine. Equal efficacy for sirolimus plus low-dose cyclosporine (1.25mg/kg) 
compared with cyclosporine monotherapy (5.0mg/kg) was found.21 Statistically 
significant lower efficacy was demonstrated for sulfasalazine plus pentoxifylline 
compared with MTX monotherapy.27
No major differences in safety profiles between treatment groups were found. One SAE 
was reported in the monotherapy groups20 compared with no SAEs in the combination 
therapy groups. Quality of evidence was very low for all outcomes in this section.
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Discussion
Several RCTs have been conducted in the field of combination therapy with systemic 
agents, but only one large-scale, methodologically well-designed clinical trial 
exists.16 All combination therapies evaluated in this study had either superior or 
similar efficacy compared with control groups except for one study which showed 
lower efficacy for sulfasalazine plus pentoxifylline compared with MTX monotherapy27. 
The RCT conducted by Gottlieb et al16 (moderate quality of evidence) contributes to 
the evidence of the superior efficacy of etanercept plus MTX over etanercept 
monotherapy in the short term, although this increased efficacy was accompanied by 
a higher incidence of AEs and, specifically, significantly more infectious AEs. The AEs 
were mild to moderate, and the incidence of SAEs was low and comparable in both 
treatment groups. For 6 other combination therapies with systemic agents, statistically 
significant superiority for some outcomes was found (very low quality of evidence 
mainly because of insufficient sample sizes). Some of these combination therapies 
could be valuable in high need patients, but more high-quality research is needed 
before recommendations for clinical practice can be made. 
When comparing baseline characteristics of patients enrolled in RCTs of combination 
therapies17-30 with baseline characteristics of patients enrolled in large-scale RCTs of 
single agents31-37, no to minor differences in disease severity, disease duration, or 
prior systemic therapies were found for most comparisons. However, in 5 combination 
therapy trials (PUVA plus MTX22, UVB plus fish oil24, sulfasalazine plus pentoxifylline27, 
acitretin plus calcitriol29 and sirolimus plus cyclosporine21), patients with more severe 
and relatively more difficult-to-treat psoriasis were included compared with patients 
included in large-scale, systemic single-agent RCTs.31-37 
Overall safety profiles for combination therapy with systemic agents seem tolerable in 
the short term, and the incidence of SAEs was very low. Long-term data are missing. 
Real-life data from observational registries may additionally inform us in the future 
and will be needed to monitor the long-term safety profile of combination therapy with 
systemic agents. 
Potential biases and limitations in this study are as follows. There was significant 
heterogeneity in clinical outcome measures and treatment duration between trials 
included in this study, which may influence the precision of overall effect sizes and 
make it impossible to combine results in a meta-analysis. To obtain a complete 
overview on efficacy and safety of systemic combination therapy, it would be of 
interest to add data from high quality observational studies. Small controlled studies 
might not provide substantial greater evidence compared with open observational 
trials.
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Conclusions 
Implications for practice 
The available clinical evidence on the efficacy and safety of combination therapy with 
systemic agents reveals that most evidence currently exists for the superior efficacy 
of etanercept plus MTX in the short term. This combination therapy may be beneficial 
in the treatment of therapy-resistant patients. However, treatment should be well-
monitored, and dose reductions of either agent should be taken into consideration to 
minimize AEs. Unfortunately, all other combination therapies included had very low 
quality of evidence for all outcomes selected for this review. The lack of good data for 
these combination therapies does not mean that these combinations are not valuable, 
but only that they did not have enough power to provide evidence-based recommen-
dations. In severe therapy-resistant patients, the introduction of these systemic 
combination therapies with well-monitored follow-up could be considered.
Implications for research
Long-term, methodologically well-designed studies with adequate sample size 
achieved by performing a priori power and sample size calculations that compare the 
different combination therapies with monotherapy and other combination therapies 
are needed. To improve the comparability of data, clinical homogeneity should be 
reached by clear descriptions of the populations (e.g., isolated plaque-type psoriasis 
or involvement of joints [arthritis psoriatica], disease severity, durations of treatment, 
outcome measurements, and time points of assessments). Future studies should 
include assessments of quality of life. Furthermore, future trials must be performed 
with sufficient duration to report the efficacy of the intervention (preferably > 24 
weeks), and follow-up must be long enough to be able to detect AEs and relapse 
rates after treatment discontinuation.
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Supplemental material
The following supplemental material is available online: http://archderm.jamanetwork.
com/article.aspx?articleid=1899249
• eTable 1 ‘Evidence profile UVB plus MTX vs. UVB monotherapy’  
• eTable 2 ‘Evidence profile PUVA plus MTX vs. PUVA monotherapy’
• eTable 3 ‘Evidence profile PUVA plus MTX vs. MTX monotherapy’
• eTable 4 ‘Evidence profile etanercept plus UVB vs. etanercept monotherapy’
• eTable 5 ‘Evidence profile ustekinumab plus UVB vs. ustekinumab monotherapy’
• eTable 6 ‘Evidence profile etanercept plus MTX vs. etanercept monotherapy’
• eTable 7 ‘Evidence profile etanercept plus acitretin vs. etanercept monotherapy’
• eTable 8 ‘Evidence profile etanercept plus acitretin vs. acitretin monotherapy’
•  eTable 9 ‘Evidence profile Acitretin + Pioglitazonehydrochloride vs. acitretin plus 
placebo’
•  eTable 10 ‘Evidence profile sirolimus 3.0mg plus cyclosporine 1.25mg vs. 
cyclosporine 5mg monotherapy’
• eTable 11 ‘Evidence profile sulfasalazine plus pentoxifylline vs. MTX monotherapy’
• eTable 12 ‘Evidence profile MTX + oral betamethasone vs. MTX monotherapy’
• eTable 13 ‘Evidence profile acitretin plus calcitriol vs. acitretin monotherapy’
• eTable 14 ‘Evidence profile UVB plus Calcitriol vs. UVB plus Placebo’
•  eTable 15 ‘Evidence profile etretinate plus eicosapentaenoic acid vs. etretinate 
monotherapy’
• eTable 16 ‘Evidence profile UVB plus fish oil vs. UVB monotherapy’
• eFigure 1: Search in MEDLINE
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Abstract
Background: Treatment goals have been developed to optimize daily clinical practice 
psoriasis care, but have not yet been studied in real life.
Objectives: To investigate to what extent treatment decisions made by dermatologists 
in daily clinical practice for patients with psoriasis on biologics are already in 
accordance with treatment goals without the active application of the treatment goals 
algorithm.
Methods: Data were extracted from a prospective daily practice cohort of patients 
with psoriasis on biologics. Analysis was done on effectiveness (Psoriasis Area and 
Severity Index score) and quality of life (Dermatology Life Quality Index questionnaire). 
Treatment decisions such as dosage adjustments, combination treatments, or 
switching therapy were compared with the treatment goals algorithm.
Results: In 64% (253 of 395) of visits, physicians followed the treatment goals 
algorithm. There were 162 (41%) visits in which there should have been a treatment 
modification according to treatment goals (group Modify) and a modification was 
indeed made in 59 of these 162 visits (36%). In 233 (59%) visits no treatment 
modification was necessary (group Continue) and therapy was indeed not modified 
in 194 of 233 visits (83%).
Conclusions: Physicians acted in accordance with treatment goals in the majority of 
patient visits. In the patient group not achieving these goals, physicians should have 
modified therapy according to treatment goals but continued the same therapeutic 
regimen in the majority of visits. Optimizing therapy and defining barriers in the latter 
group might increase treatment results in daily practice psoriasis care.
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Introduction
Psoriasis is a chronic skin disease with great impact on the quality of life (QoL) of 
patients.1,2 Moderate-to-severe psoriasis is usually treated with systemic and biologic 
therapies, although undertreatment does occur.3-5 In order to guide physicians with 
treatment decisions in daily practice, a European consensus on treatment goals was 
published in 2011.3,6 These treatment goals advise to continue treatment when 
baseline Psoriasis Area and Severity Index (PASI) score has improved by at least 75% 
(PASI≥75; treatment success) or when a Dermatology Life Quality Index (DLQI) score 
of ≤ 5 is reached in patients with a PASI score improvement of between 50% and 75% 
(PASI50-75; intermediate response). In contrast, treatment should be adjusted when 
PASI50 is not reached (treatment failure) or when treatment response is intermediate 
with a DLQI score of >5.3 Modification strategies include increasing dosage of 
current therapy or reducing treatment intervals, adding topical or systemic therapy, or 
changing the drug.6 Treatment goals are shown in Figure 1. Recently, treatment goals 
have been evaluated for adalimumab therapy using data from three randomized 
clinical trials (CHAMPION, REVEAL and BELIEVE).7  However, treatment goals have 
been formulated for use in daily clinical practice and it is known that the daily practice 
patient differs substantially from the clinical trial patient.8 In addition, daily practice 
patients are being treated according to the opinion of their physician and therefore 
treatment decisions may vary considerably. 
The main objective of this study was to investigate to what extent treatment decisions 
made in clinical practice are already in accordance with the treatment goals without 
the active application of the treatment goals algorithm. This may allow us to identify 
the gap between daily practice and the future situation after optimal implementation 
of treatment goals.
Methods
BioCAPTURE registry
For this study, data were used from the prospective registry BioCAPTURE that 
contains data from all patients with psoriasis treated with biologics from 2005 until 
now who gave informed consent. One academic and eight nonacademic centres 
participate in data collection. The BioCAPTURE registry was approved by the medical 
ethics committee of the Radboud University Medical Center.
Patients
Patients treated between 1 March 2010 and 31 December 2012 were included in the 
present analysis. Patient characteristics were collected including sex, family history of 
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psoriasis, psoriatic arthritis, mean baseline PASI score at the start of therapy, body 
mass index, age at onset of disease and age at start of the biologic. Patients were 
treated with biologics (etanercept, adalimumab, infliximab and ustekinumab) 
according to European and Dutch guidelines on psoriasis treatment. Patients were 
allowed to have multiple treatment episodes (TEs) that were defined as continuous 
treatment periods with one of the aforementioned biologics. A treatment interruption 
of 90 days during treatment with the same drug was allowed. During treatment, 
patient visits were scheduled every 3 months.
Assessments
To measure psoriasis severity, PASI scores were calculated at every visit and 
registered in the database.9 Physicians were trained by an experienced research 
nurse to assess PASI scores. Scores were regularly double-checked by this nurse. 
From March 2010, DLQI measures were conducted every 3 months during the first 
year and every year thereafter in patients starting on biologics or switching to new 
biologics. The DLQI is a validated questionnaire measuring QoL in patients with 
dermatological conditions and has been translated into different languages.10,11 
Lower DLQI scores indicate better QoL. Data on biologic treatment, conventional 
systemic and intensive topical (i.e., dithranol) treatment during study period were 
recorded, as well as dosages of antipsoriatic medication. PASI scores, DLQI data 
and information on treatment decisions were extracted from the database for patient 
visits at baseline (i.e., start of medication) and at months 3, 6, 9 and 12. During patient 
Figure 1   Treatment goals in psoriasis. Adapted from Mrowietz, et al.3
PASI <50 PASI ≥50 - <75 
 PASI ≥75  
DLQI >5 DLQI ≤5
Modify
treatment
regimen 
 
 
 
Continue
treatment
regimen
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visits, PASI scores were visible for treating physicians whereas PASI percentages 
compared with baseline and  DLQI scores were not. Therefore, patients were treated 
without the knowledge of whether patients reached treatment goals criteria for 
treatment modification or continuation of treatment without modification (Fig. 1).
Data analysis
PASI scores were compared with baseline (month 0) in order to calculate PASI 
percentages for included visits. Hereafter, patient visits were grouped into three PASI 
percentage groups according to treatment goals in order to calculate the number of 
visits with treatment success (i.e., PASI≥75): (1) PASI<50, (2) PASI50-75 and (3) 
PASI≥75. In accordance with the treatment goals, the DLQI was calculated for patient 
visits in the intermediate response group (PASI50-75) to discriminate between high 
QoL (DLQI ≤ 5) and low QoL (DLQI > 5). If no DLQI score was available for a visit in 
the intermediate group, this visit was excluded from further analyses. Subsequently, 
information on treatment decisions for all included visits were extracted from the 
database at months 3, 6, 9 and 12 with a range of 2 weeks prior to and 2 weeks after 
the defined month. After that, patient visits were grouped into (a) group Modify, in 
which treatment modification is being recommended according to treatment goals 
and (b) group Continue, in which the treatment regimen may be continued and no 
treatment modifications are necessary according to treatment goals. In these two 
groups, it was recorded how often modifications were indeed carried out, and how 
often treatment was not changed. 
Treatment modifications made by physicians were described and grouped as follows: 
(1) increasing dose (or reducing dose intervals) of the biologic, (2) increasing dose of 
the conventional systemic drug, (3) increasing dose of both biologic and conventional 
systemic drug, (4) decreasing dose of biologic, (5) decreasing dose of conventional 
systemic drug, (6) decreasing dose of both biologic and conventional systemic drug, 
(7) adding conventional systemic therapy to a biologic, (8) adding intensive topical 
therapy (i.e., dithranol), (9) switching of therapy, and (10) other modifications. 
As baseline PASI scores might influence the ability to reach PASI 75, the median 
baseline PASI scores were calculated in the groups Modify and Continue, and 
compared. To assess the difference in QoL between the groups Modify and Continue, 
median DLQI scores were calculated and compared. For the group Modify, a 
subanalysis of DLQI was performed  for patient visits in which a modification in 
treatment was indeed made compared with those visits in which the same therapeutic 
regimen was continued.
Statistics
Descriptive statistics were used and expressed as percentages, means ± standard 
deviations (SD) or median (range). In the case of repeated measures within patients 
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only descriptive statistics were used. Mann-Whitney U-test was used to compare 
baseline PASI scores between groups Modify and Continue. P-value was set at 0.05. 
IBM SPSS Statistics 20 (IBM, Armonk, NY, U.S.A.) was used for analyses.
Results
Patients
A total of 161 patients were identified from our cohort with 192 TEs (Fig. 2). TEs with 
only one PASI score at baseline or without a baseline PASI score were excluded 
(n=28). This resulted in 164 TEs from 139 patients and 454 visits for which a PASI 
percentage could be calculated. Patient characteristics are shown in Table 1. Of the 
164 TEs, in 72 (44%) TEs adalimumab therapy was prescribed, 54 (33%) TEs 
etanercept, in 33 (20%) TEs ustekinumab and in 5 (3%) TEs infliximab therapy was 
prescribed.
Assessments
There was a PASI50 in 30% (134 of 454), a PASI50-75 in 30% (138 of 454) and a 
PASI≥75 response (treatment success) in 40% (182 of 454) of visits (Fig. 2). After 
excluding 59 visits due to missing DLQIs, 395 visits were left for analyses. In 41% 
percent of visits (162 of 395) treatment should have been modified (group Modify) 
and in 59% (233 of 395) therapy did not have to be modified (group Continue) 
according to treatment goals. The median baseline PASI score was significantly 
lower in the group Modify (10.5 [0.6-38.4]) than in the group Continue (12.2 [3.8-42.1], 
P= 0.004)). 
Table 1  Patient characteristics
Patient characteristics N = 139
Male gender, n (%); N= 139 88 (63.3)
Positive family history of psoriasis, n (%); N= 133 85 (61.2)
Psoriatic arthritis, n (%); N= 123 44 (31.7)
BMI, median [range]; N= 101 28.0 [17.7-53.2] 
Baseline PASI score, median [range]; N= 139 11.2 [2.0-42.1]
Age at onset of psoriasis (years), mean ± SD; N= 136 24.8 ± 13.0
Age at start of biologic therapy (years), mean ± SD; N= 139 47.4 ± 13.0
BMI: Body Mass Index; PASI: Psoriasis Area and Severity Index
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DLQI scores for included visits were grouped based on PASI percentage achieved 
(Fig. 3). In the group PASI<50 and PASI50-75 with a DLQI score, 41% and 35% of 
visits, respectively, showed a DLQI score of > 5, representing low QoL according to 
treatment goals. However, when PASI≥75 was reached, 19% of visits showed a DLQI 
> 5. In visits with a PASI≥75, 50% of DLQI scores were 0, indicating optimal QoL 
compared with 7% in visits with a PASI<50.
Median DLQI at visits for those in the group Modify was compared with median DLQI 
of patients on visits in the group Continue. Scores were 6.00 [0-30] and 1.00 [0-16] 
respectively, indicating a higher QoL in the group Continue.
Within the group Modify, two subgroups were present: one with treatment modification 
and one without modification (Fig. 2). Median DLQI at visits was compared between 
these subgroups: 7.00 [0-16] versus 6.00 [0-30] for modified and not modified, 
respectively.
Treatment decisions
The treatment goals algorithm was followed by physicians in 64% (253 of 395) of 
visits (Fig. 2); in the group Modify, therapy was indeed modified in 59 of 162 visits, 
and in the group Continue therapy was continued without modification in 194 of 233 
visits. Table 2 shows numbers of treatment decisions for the groups Modify and 
Continue. In both groups, there were no treatment modifications due to a serious 
adverse event.
Modification necessary according to treatment goals (group Modify)
In the group Modify, in 36% (59 of 162) of visits therapy was indeed modified and in 
64% (103 of 162) of visits therapy was not modified. There were 61 modifications 
(Table 2). Most often (46%; 28 of 61) a dose increase of biologic, conventional 
systemic or both was carried out. Of these, a dose increase of the biologic was the 
most frequently applied strategy.  In 18% (11 of 61) of modifications  there was a 
switch to another biologic. In 13% (8 of 61) of modifications there was an interruption 
or restart of biologic or conventional systemic therapy.  In 11% of modifications (7 of 
61) it was decided to decrease the dose of biologic or conventional systemic therapy, 
despite of a PASI<50 or a PASI50-75 with a DLQI>5. One dose decrease included 
etanercept from 2x50 mg per week to 1x50mg per week according to label at month 
3. Conventional systemic therapy was stopped twice; methotrexate was stopped due 
to desire for pregnancy and cyclosporine was stopped because it was prescribed 
only as bridging therapy. By month 3, 41% (25 of 61) of modifications had already 
been made. At this time point, a switch to another biologic was the most frequently 
chosen treatment strategy, followed by a dose increase of biologic therapy. 
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Figure 2   Flow chart of PASI responses, DLQI scores and treatment modification in 
the prospective daily practice cohort BioCAPTURE
The treatment goals flow chart using daily practice data from patients with psoriasis on biologics in the 
BioCAPTURE cohort. TEs: treatment episodes; PASI: Psoriasis Area and Severity Index; DLQI: Dermatology 
Life Quality index
161 patients  
192 TEs  
139 patients  
164 TEs  
28 TEs excluded; only one 
PASI measurement available
454 visits for PASI 
percentage calculation  
 
Treatment 
failure  
PASI <50 
N= 134 (30%) 
Intermediate response  
PASI ≥50 - <75 
N= 138 (30%) 
Treatment 
success  
PASI ≥75 
N= 182 (40%) 
N= 79 DLQIs 
DLQI >5 
N= 28 (35%) 
DLQI ≤5 
N= 51 (65%) 
Treatment modification necessary 
(group Modify)  
N= 162 (41%) 
No modification: 103 (64%)  
Modification:  59 (36%)  
No treatment modification necessary 
(group Continue)  
N= 233 (59%) 
No modification: 194 (83%) 
Modification: 39 (17%)  
N= 59 excluded;
no DLQI available 
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 283
283
Treatment goals
12
No modification necessary according to treatment goals 
(group Continue)
In the group Continue, in 83% (194 of 233) of visits the same therapeutic regimen was 
indeed continued. In 30 of 194 (15%) visits, the biologic dose could have been 
decreased by physicians because treatment goals were reached but a high dose 
was continued. 
In 17% (39 of 233) of visits there were 40 modifications (Table 2). Most often (65%; 
26 of 40) dose of biologic or conventional systemic was decreased. Of these, dose 
decrease of biologic was the most frequent. Twelve modifications included the 
decrease of etanercept dose from 2x50mg per week to 1x50 or 2x25mg per week 
according to label at month 3. In two modifications (5%), low-dose methotrexate 
was added as combination therapy. The dose of biologic was increased in 18% of 
modifications (7 of 40). As shown in Table 2, there was no switch of therapy in the 
group Continue. Forty-three percent of modifications (17 of 40) were made in month 3. 
The most frequently applied modification in this subgroup was a dose decrease of 
the biologic. 
Figure 3   DLQI scores for different PASI percentage groups
DLQI scores from patients with psoriasis in the BioCapture cohort. DLQI: Dermatology Life Quality Index; 
PASI: Psoriasis Area and Severity Index.
454 PASI
percentages  
PASI <50 
N= 134 (30%) 
PASI ≥50 - <75  
N= 138 (30%) 
PASI ≥75  
N= 182 (40%) 
N= 71 DLQIs  
- 29 DLQI >5 (41%)  
- 42 DLQI ≤5 (60%)  
N= 98 DLQIs 
- 19 DLQI >5 (19%) 
- 79 DLQI ≤5 (81%)  
N= 79 DLQIs 
- 28 DLQI >5 (35%) 
- 51 DLQI ≤5 (65%)  
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Table 2   Treatment modifications during patient visits in the daily practice  
cohort Biocapture
Treatment groups Group Modify
PASI < 50 and
PASI ≥50-<75 + DLQI >5
N=162 (41%)
Group Continue
PASI ≥50-<75 + DLQI ≤5 
and PASI ≥75
N = 233 (59%)
No modification 103 (64%) visits 194 (83%) visits
Modification
1. Dose increase of 
- biologic
- conventional systemic
- both
2. Dose decrease of
- biologic
- conventional systemic
-  both
3. Stop of 
- biologic
- conventional systemic
4. Addition of 
-conventional systemic
- intensive topical therapy
- both
5. Switching therapy to
- biologic therapy
- conventional systemic
- intensive topical therapy
6. Other
 59 (36%) visits;  
61 modifications
24
3
1
3 (1 according to label)
4
0
0
2b,c
3
1e
0
11
1
0
8f
39 (17%) visits;  
40 modifications
7
0
0
20 (12 according to label)
6a
0
1b
1d
2
0
0
0
0
0
3f
Data are stated as N (%).
a   One patient also restarted biologic therapy after an upper respiratory tract infection
b   Due to desire for pregnancy 
c   One patient had a dose decrease of biologic and stopped conventional systemic therapy
d   Due to adverse effects (somnolence)
e   This patient also had a treatment interruption of biologic therapy due to liver function abnormalities
f   Interruption or restart of biologic or systemic combination therapy due to, e.g., flu, urinary tract infection, 
other infections, liver function abnormalities
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Discussion
In this prospective daily practice cohort of patients with psoriasis treated with biologics, 
in the majority (64%) of visits physicians followed the treatment goals algorithm 
intuitively. In 59% of visits, treatment goals were reached. In a large percentage of 
visits (64%) in which patients needed adjustment of therapy according to the treatment 
goals, no treatment modifications were made by physicians. 
One study recently assessed adalimumab efficacy in three phase III clinical trials 
using the psoriasis treatment goals as evaluation method.7 This study showed that in 
the CHAMPION, REVEAL and BELIEVE study at week 16, treatment success was 
achieved by 79.3%, 72.1% and 68.2% respectively. Moreover, treatment goals for 
continuing therapy without modification were reached by > 70% of patients. In our 
study, percentages were lower: 40% of visits achieving treatment success and 59% 
of visits reaching treatment goals. However, in the present analysis we used data 
from all biologics available instead of only adalimumab, and in a daily practice setting 
in contrast to a randomized controlled trial. In real life, treatments are known to show 
lower success rates.12-14 To the best of our knowledge, this is the first daily practice 
study analysing to what extent advice resulting from following the treatment goal 
algorithm is followed in daily practice.
In the present study, physicians were unaware of the components of treatment goals 
(DLQI and PASI percentage) and therefore unaware of treatment failure or treatment 
success according to these goals. Although physicians were not using treatment 
goals, in the majority of visits physicians followed treatment goals algorithm intuitively. 
This can be explained by the high effectiveness of biologics in most visits, so 
physicians did not have to make changes to treatment strategies according to 
treatment goals. If patients did not reach treatment goals, it was shown that, in the 
majority of visits, physicians preferred to continue treatment without modification, so 
that is where there might be ‘room for improvement’. 
Achieving treatment success seems important for patients with psoriasis in order 
to reach a sufficient QoL. Using data from randomized clinical trials, Mattei et al.15 
have recently showed that patients treated with biological therapies have better 
QoL scores in the PASI≥75 group. The same results were seen in the daily practice 
situation in the present study. Patients with a PASI≥75 had better QoL scores 
more frequently, compared with patients in the remaining groups. Nineteen per cent 
of visits with a DLQI score showed low QoL (DLQI>5) in the PASI≥75 group 
compared with about 35-40% in the other two groups. Fifty per cent of DLQI scores 
were 0 in the PASI≥75 group, indicating optimal QoL, compared with only 7% in the 
PASI<50 group. These results strengthen the definition of treatment success in 
the treatment goals, i.e. achieving a PASI≥75 response compared with baseline. 
It must be noted that 19% of available DLQI scores in the group achieving PASI ≥75 
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indicated low QoL. It might be of interest to establish what needs are not fulfilled for 
these patients. 
We analysed whether baseline PASI scores influenced the possibility for patients 
to achieve treatment goals. Patients with high baseline PASI scores might achieve 
treatment success, and therefore treatment goals, more easily compared with patients 
with low baseline PASI scores, as these are expressed with a relative measure. This is 
especially important in the comparison between patients naive or nonnaive (switchers) 
for biologics, as the latter group often starts with a lower baseline PASI. Median 
baseline PASI score at start was compared between the groups Modify and Continue 
and was significantly lower for the group Modify (p=0.004), although scores only 
differed with 1.7. This difference is small and  will probably not explain why patients 
end up in the group Modify or Continue. In the current treatment goals there is no 
differentiation between naive and nonnaive patients. 
Our cohort showed that in the group Modify, median DLQI was similar between 
patient visits with a treatment modification compared with visits without a treatment 
modification. Hence, in daily practice in which treatment goals were not being 
implemented, the decision to modify therapy seems not to be influenced by the 
patient’s perceived QoL. It might therefore be worthwhile to conduct DLQI 
questionnaires prior to the clinical visit in order to identify those patients with a low 
QoL to optimize their care.  
As shown, there is considerable ‘room for improvement’ in the care of patients with 
psoriasis. Optimized treatment might be achieved by the consequent application of 
treatment goals. In this respect, lessons can be learned from previous studies in 
rheumatoid arthritis, hypertension, and diabetes.16-19 The TICORA study for tight 
control in rheumatoid arthritis showed that a strategy of intensive outpatient 
management compared with routine daily practice improved disease activity and 
QoL at no additional costs.  However, mixed results are seen in diabetes care.20 
Furthermore, implementation research in the field of rheumatology has shown that 
there are many reasons not to modify treatment while treatment goals advised to do 
so.21 These findings may also apply to the field of dermatology. Possible factors 
include the presence of comorbidities, comedication, safety issues, number of 
available treatments left, not being aware of PASI percentages and DLQI scores, and 
reticence in physicians and patients.
The current treatment goals flowchart does not incorporate dose decreases in 
patients who meet criteria for continued treatment without modification. Evidence for 
dose decrease of biologics beyond the label is scarce in the field of psoriasis. It 
should be worthwhile to focus on this issue in future studies in order to decrease 
costs and improve safety. 
Other barriers to implementing treatment goals might include the requirement that 
physicians should assess PASI scores and conduct DLQI measurements during 
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patient visits. This requires optimal logistics and a time effort from physicians. 
Therefore it seems important to analyse further the impact of implementation of 
treatment goals on the care of patients with psoriasis.
A limitation of the present study is that topical treatments in combination with biologics 
were used as well, but not analysed in this study because data on nonintensive 
topicals were not completely recorded in the database. Another limitation is that there 
were missing data from DLQI questionnaires, which could lead to responder bias. 
However, the percentage of missing data was similar between groups. The strengths 
of this study are the inclusion of different clinical centers and doctors (both academic 
and nonacademic), the daily practice environment itself, and the ‘blindedness’ of 
doctors for DLQI scores and PASI percentages.  
This study addresses European treatment goals in daily clinical practice. Results 
show that in daily practice in which treatment goals were not yet implemented, 
physicians usually followed treatment goals intuitively in visits in which treatment 
goals were achieved. On the other hand, in patients with suboptimal response to 
therapy, frequently the same therapeutic regimen was continued. This shows an 
urgent need for identification of barriers to using treatment goals and the need for 
implementation studies as this might increase the rate of treatment success and the 
number of patients with psoriasis with optimal QoL on systemic therapies including 
biologics in daily clinical practice.
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Summary and discussion
In the Netherlands, approximately 500.000 persons suffer from psoriasis, of which ± ⅓ 
has moderate-severe to severe psoriasis. As stated in the introduction of this thesis, 
psoriasis is a skin disease with a major impact on the quality of life. Improving health 
care and optimizing treatment for patients with psoriasis is a continuous process in 
which scientific research is essential.
The goals of this thesis were to explore, compare and predict the effectiveness of 
biologics for psoriasis in daily practice with different measures for effectiveness (i.e., 
absolute and relative PASI scores), to explore drug survival (a composite measure for 
treatment success, i.e. effectiveness, safety, and patients’ and physicians’ behaviour) 
and to explore treatment success by combining drug survival with a skin-specific 
quality-of-life-questionnaire (i.e., the Dermatology Life Quality Index [DLQI]), to compare 
and predict long-term drug survival, as well as to explore the areas with room for 
improvement in daily practice psoriasis care. These studies are important for choosing 
the right therapy for the right patient and to improve the care of patients with psoriasis.
The studies included in this thesis are based on data from the literature and from 
BioCAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry with 
Biologics). BioCAPTURE is a prospective, multicenter cohort of patients with moderate to 
severe psoriasis, treated with biologics. Data on effectiveness, safety, patient reported 
outcome measures and cost-effectiveness are being collected. BioCAPTURE is 
established at the Department of Dermatology in the Radboudumc Nijmegen since 
2005. From 2010, large regional centers have participated and at the moment, nine 
regional centers contribute to the BioCAPTURE registry. BioCAPTURE therefore 
represents data from both academic and non-academic centers.
Data from daily practice cohorts are important and relevant, because the real-world 
patient with psoriasis that is being treated in daily practice differs from the patients in 
RCTs.1 Randomized controlled trials are essential in the development of new drugs, 
but have to be complemented with practice based evidence. Randomized controlled 
trials have a high internal validity but often a low external validity, whereas daily 
practice studies are intended to have a high external validity but often at the price of 
a low internal validity. Other differences between daily practice studies and RCTs are: 
(1) daily practice studies may include large numbers of patients and patients with 
different patient characteristics (i.e., higher age, more comorbidities, use of 
concomitant medication)1, (2) daily practice studies may comprise a long period of 
follow-up2,  (3) treatment strategies in daily practice studies are different from RCTs 
(combination treatment, dose adjustments)3, (4) daily practice studies are important 
when evaluating drug safety4 as large numbers of patients with a longer period of 
follow-up can be evaluated, and (5) in daily practice studies, the behaviour of 
physicians and patients can be assessed5. 
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In this chapter, the research questions from Chapter 4 are answered and the results 
from studies described in Chapter 5 – 12 are integrated and discussed. In addition, 
possibilities for future research are formulated.
Effectiveness 
To explore
Research question 1: What is known thus far from literature on the effectiveness 
of biologics in daily practice psoriasis treatment?
The systematic review described in Chapter 5 was performed to aggregate the 
available evidence on the effectiveness of biologics and conventional systemic agents 
in daily practice psoriasis treatment. Until then, no systematic review of effectiveness 
data of biologics and conventional systemic agents for psoriasis was available in the 
literature. The primary objective was to show the proportion of patients that reached 
PASI75 (a 75% reduction in baseline PASI score) with biologic treatments and/or 
conventional systemic agents at week 12-16 (short-term) in daily clinical practice. 
Other time points for evaluation of effectiveness were weeks 17-28 (intermediate-term) 
and ≥1 year (long-term). 
Eventually, 32 studies were included. We showed that biologics and conventional 
systemic agents were effective in the treatment of psoriasis in daily practice. A substantial 
proportion of patients with psoriasis were achieving PASI75 with short-, intermediate- 
and long-term treatment, except for acitretin monotherapy.  
The results of the effectiveness of biologics and conventional systemic agents in daily 
practice as showed in our systematic review are visualized in Table 1.
Ranges of PASI75 were large, especially for etanercept and adalimumab (Table 1). 
In this systematic review, we encountered differences in study design (prospective / 
retrospective), differences regarding treatment regimens (e.g., dose adjustments, 
combination with conventional systemic agents), and patient characteristics (e.g. 
baseline PASI score, naïve/non-naïve).
A high heterogeneity in reporting cohort data from daily practice was encountered. 
Studies did not always specify important baseline characteristics such as baseline 
PASI score, or naivity to biologics. The use of concomitant antipsoriatic medication 
and the dose of biologics (dose increase, interval decrease or increase) was not 
mentioned in all studies. Hence, we made recommendations to improve the quality 
of reporting of daily practice studies.
Since the effect of dose adjustments and combination therapy with a conventional 
systemic agent was often not described in studies, it is possible that these treatment 
adjustments resulted in the large PASI75 ranges. In most studies on biologic 
therapies, concomitant conventional systemic agents were allowed and prescribed 
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by physicians. Mostly methotrexate was used for combination therapy. Another 
explanation was the use of dose adjustments. Especially in studies on adalimumab 
and etanercept, dose adjustments were allowed and prescribed by physicians. 
Although results from RCTs and daily practice cannot be directly compared, PASI75 
ranges achieved with antipsoriatic treatments in daily practice were in line with ranges 
stated in guidelines on psoriasis treatment.6-8 We did not expect this, since earlier 
studies from our BioCAPTURE cohort and from other cohorts showed lower PASI75 
percentages in daily practice than in RCTs.9-11 Possible explanations for the similarity 
of achieved PASI75 percentages in daily practice and RCTs are the prescribed 
combination therapies and adjusted doses of biologics in daily clinical practice.
Evidence gaps identified by this systematic review were daily practice data on the 
effectiveness of infliximab, ustekinumab, conventional systemic agents, combination 
therapy of biologics with conventional systemic agents, long-term treatment and 
direct comparisons of effectiveness between anti-psoriatic agents. 
With our systematic review we found only a small number of comparative studies in 
which biologics were compared with each other or were compared with conventional 
systemic agents. Most comparative studies were hampered by differences at start of 
treatment (e.g., baseline PASI score) which was not corrected for. Hence, a sound 
conclusion on the differences of effectiveness between biologics in daily practice 
was not possible. Therefore, we performed an analysis in which biologics for psoriasis 
were compared while correcting for confounders.
Table 1   Effectiveness of biologics and conventional systemic agents  
from daily clinical practice. Data are based on the systematic review 
described in Chapter 5 of this thesis
Agent PASI75 at week 12-16 
daily practice
Ustekinumab 63% - 80%
Infliximab 38% - 53%
Adalimumab 27% - 68%
Etanercept 12% - 66%
Methotrexate 40% - 49%
Fumarates 47%
Cyclosporine 46%
Acitretin 27%
The reader is referred to the systematic review in Chapter 5 for the doses of the drugs.
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To compare
Research question 2: Which biologic has the highest confounder-corrected 
effectiveness in daily practice psoriasis treatment using data from the prospective 
BioCAPTURE cohort?
In Chapter 6 we described the first prospective daily practice study with the objective 
to compare the effectiveness with PASI scores between the three widely used 
outpatient biologics adalimumab, etanercept and ustekinumab for patients with 
psoriasis, corrected for confounders. We took into account (1) the biologic dose, (2) 
combination treatment with a conventional systemic agent and (3) differences in 
baseline patient characteristics between the biologics, such as differences in PASI 
score at start of treatment. The primary objective was to compare the mean PASI 
descrease of adalimumab, etanercept and ustekinumab during the first 5 years of 
treatment. Secondary objectives were to compare the mean PASI decrease between 
these biologics during the first year of treatment, and the PASI75 at one year of 
treatment. Data from the multicenter BioCAPTURE cohort were used.
Results for the primary objective showed that patients treated with ustekinumab had 
a larger confounder-corrected mean PASI decrease compared with patients treated 
with etanercept during five years of treatment, without subanalyses for biologic dose. 
Secondary objective results showed that there were no differences in the confound-
er-corrected mean PASI decrease between biologics during the first year of treatment. 
On the other hand, patients treated with ustekinumab and adalimumab had a higher 
chance of achieving PASI75 compared with etanercept at one year of treatment, after 
correction for confounders.
We encountered differences in the use of biologic dose, especially regarding higher 
than label dose, between the outpatient biologics and found an influence of biologic 
dose on effectiveness results. Etanercept was most often prescribed in higher than 
label dose, followed by adalimumab and then ustekinumab. This might indicate that 
for dermatologists it was more difficult to achieve a good control of the psoriasis with 
normal doses of etanercept, than with normal doses of ustekinumab. This is confirmed 
by the observation that patients with a low-normal adalimumab, etanercept or 
ustekinumab dose (i.e., low to normal dose compared with expected label dose) 
during their treatment episode had a larger mean PASI decrease than the patients 
with a higher than label dose on the same biologic. 
When the low-normal dosed treatment episodes were considered, no differences 
were found in confounder-corrected mean PASI decrease between biologics during 
one and 5 years of treatment. For the high-dosed treatment episodes, there were also 
no differences in confounder-corrected mean PASI decrease during one and 5 years. 
Considering PASI75, low-normal doses of  adalimumab or ustekinumab were more 
effective than low-normal doses of etanercept at one year of treatment. Because 
ustekinumab (1) being significantly more often prescribed in a low-normal dose 
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compared with etanercept and (2) the low-normal dosed treatment episodes having 
a better mean PASI decrease compared with the high-dosed treatment episodes, 
ustekinumab showed on average better results than etanercept.  
Also Strober et al. conducted a comparative daily practice study, but did not use PASI 
score  nor accounted for the prescribed biologic doses.12 Biologics were compared 
and effectiveness was evaluated using Physician Global Assessment (PGA of 0 or 1; 
respectively, “clear” or “minimal psoriasis”). This study showed that ustekinumab was 
superior to the anti-TNF agents adalimumab, etanercept and infliximab at month 6 
and month 12.12 In a meta-analysis using RCT data, ustekinumab was the most 
efficacious therapeutic alternative for moderate-to-severe psoriasis, followed by 
infliximab, adalimumab and etanercept.13 In another recent meta-anaylis on RCT 
data, both adalimumab and ustekinumab had significantly higher PASI75 responses 
than etanercept.14  
Differences in effectiveness results between biologics might be explained by the 
differences in mode of action between the biologics, with ustekinumab, by blocking 
IL-12 and IL-23, exerting its action more downstream in the cascade of cytokines than 
the anti-TNF-α agents adalimumab, etanercept and infliximab.15 In addition, IL-23 
seems to be an important cytokine in the immunopathogenesis of psoriasis, as 
evidenced by the high efficacy of newer biologics that only target this cytokine 
(anti-IL-23 biologic agents).16 The difference in effectiveness between adalimumab 
and etanercept might be explained by the mode of action of adalimumab compared 
with etanercept. Etanercept is a TNF-α receptor antagonist, while adalimumab is a 
TNF-α antibody.17,18 Another reason for differences in effectiveness might be the 
existence of non-measured confounders. Although we corrected for confounders, a 
comparison using real-world data raises more analytic difficulties than RCTs. 
However, one of the strengths of our study is high external validity as it comprises 
patients with comorbidities and comedication, and patients of higher age.  As 
described previously, our results were in line with data from recent meta-analyses 
that used RCT data.Differences in effectiveness might also be explained by different 
genetic or cytokine profiles between patients with psoriasis.19,20 The search for 
biomarkers as predictors for effectiveness gets currently much attention and could 
eventually lead to more targeted treatment.
To date, little is known on the effect of dose increase of biologics in the treatment of 
patients with psoriasis in daily clinical practice, although dose increase or interval 
reduction is used in daily practice.21,22 At the moment, we do not know for which 
patient with psoriasis a dose increase is effective and we cannot predetermine this 
yet. Thus, more research is needed in order to advise dermatologists on the added 
value of dose increase of biologics compared with switching of the biologic and the 
cost-effectiveness of switching compared with short-term as well as long-term dose 
increase.
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To predict
Research question 3: What are the predictors for high clinical effectiveness of 
biologics for psoriasis in daily clinical practice using data from BioCAPTURE?
In Chapter 7 we focused on patients with psoriasis that reached a very high response, 
defined as PASI90, PASI100 or PASI≤5, at week 24 of biologic treatment. The objectives 
of our analysis with prospective daily practice data were to assess (1) the percentage 
of patients reaching high clinical response and (2) the predictors for achieving a 
high clinical effectiveness. Until then, no studies had assessed which patients with 
psoriasis were more likely to achieve these high clinical responses with biologic 
treatment.
We showed that PASI90 or PASI100 were rarely attained in daily practice psoriasis 
treatment with biologics (adalimumab, etanercept, infliximab and ustekinumab analyzed 
as one group). In 15% of treatment episodes PASI90 was reached and in only 3% of 
treatment episodes PASI100 was reached at week 24. Psoriasis Area and Severity 
Index≤5 (59% of treatment episodes) and even PASI≤2 (24% of treatment episodes) 
were more often achieved than PASI90 at week 24. This shows the importance of 
including an absolute PASI score in the assessment of psoriasis severity.
The use of a relative PASI score can therefore lead to ‘false-negatives’, i.e. patients 
that do have a high clinical response according to the absolute PASI score, but which 
is not reflected by the relative PASI score. This can be explained by the dependence 
of the relative PASI score on the baseline PASI score. It is more easy to achieve a 
PASI90 in patients with a high baseline PASI score compared with patients with low 
PASI scores at start of treatment. We showed this in our study after analyzing 
predictors for achieving a high clinical response at week 24 of biologic treatment. 
Patients with a baseline PASI≥10 had a higher chance of achieving PASI90 at week 
24 than patients with a baseline PASI<10. Patients with a baseline PASI<10 had a 
higher chance of reaching PASI≤5 at week 24 than patients with a baseline PASI≥10. 
An additional predictor for achieving PASI≤5 at week 24 of biologic treatment was 
a lower baseline BMI in our study. Thus, patients with a lower baseline BMI had a 
higher chance of reaching an absolute PASI≤5 at week 24. Baseline BMI and baseline 
PASI score did not correlate with each other, and therefore baseline BMI was an 
independent predictor.
In our study we performed sensitivity analyses for (1) adalimumab/etanercept as one 
group (excluding infliximab and ustekinumab), (2) treatment episodes with a low to normal 
biologic dose, (3) treatment episodes without a treatment interruption, (4) treatment 
episodes without combination therapy, (5) weight instead of BMI, and (6) PASI≤3 
because all treatment episodes with a PASI90 at week 24 also achieved PASI≤3 at 
week 24. These performed sensitivity analyses showed the robustness of our results 
with PASI≥10 being a predictor for PASI90, and PASI<10 as well as a lower BMI 
(or weight) being predictors for PASI≤5 (or PASI≤3). 
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The finding that weight and weight loss of patients with psoriasis have an influence 
on the efficacy of antipsoriatic treatment, is suggested in literature, but high quality 
RCTs are missing.23-28 However, not every study that was conducted in patients with 
psoriasis found an influence of obesity on the effectiveness of biologics.29 Additional 
studies are needed in order to answer the question whether weight loss is a good 
option to improve control of psoriasis in overweight or obese patients or that we 
should work towards creating BMI-based dosing of biologics.
Noteworthy, obesity also seems to play a negative role in the response to biologic 
treatment of other immune-mediated diseases, such as rheumatoid arthritis30,31, 
ankylosing spondylitis and non-radiographic axial spondyloarthritis32, psoriatic 
arthritis33 and Crohn’s disease34.
Possible explanations that obesity can influence the effect of biologics are the 
modification of the drug distribution, as well as the increase of certain pro-inflammatory 
cytokines produced by the adipose tissue so that treatment is less efficacious with 
the same biologic dose in obese patients than in non-obese patients.35 
Conclusions for effectiveness
•  Biologics and conventional systemic agents are effective in the treatment of 
psoriasis in daily practice.
•  Ustekinumab is, compared with etanercept, significantly more effective in 
decreasing the PASI score during the first 5 years of psoriasis treatment in daily 
practice. 
•  Ustekinumab is, compared with adalimumab and etanercept, the biologic that is 
most often prescribed in low to normal dose during a treatment period of 5 years 
in our cohort.
•  It is important to include an absolute PASI score in the assessment of psoriasis 
severity, because the relative PASI score might not reflect a high clinical response 
in patients with PASI<10 at start of treatment. 
•  Patients with a baseline PASI≥10 have a higher chance of achieving PASI90 at 
week 24 than patients with a baseline PASI<10. Patients with a baseline PASI<10 
have a higher chance of reaching PASI≤5 at week 24 than patients with a baseline 
PASI≥10.  
•  Baseline BMI is an important, modifiable predictor for reaching a high clinical 
response (PASI≤5, but also PASI≤3) with biologics in daily practice psoriasis 
treatment at week 24.
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Drug survival
Drug survival of biologic treatment is the probability that a patient is still treated with 
a biologic after a period of time. Drug survival can be assessed for different reasons of 
discontinuation. Reasons for discontinuation are ineffectiveness, side-effects, pregnancy 
wish, and other reasons such as patient wish. In overall drug survival, all reasons of 
treatment discontinuation are included (i.e., discontinuation in general). Drug survival 
can also be split for discontinuation due to ineffectiveness or discontinuation due to 
side-effects.
We performed two drug survival studies in psoriasis with data from the prospective, 
multicenter BioCAPTURE cohort. 
In Chapter 8 one-year overall drug survival of adalimumab, etanercept and ustekinumab 
was described and compared after confounder-correction. Also, the one year drug 
survival of adalimumab, etanercept and ustekinumab (analyzed as one group) was 
combined with a quality of life measure (the DLQI). Combining drug survival with 
DLQI had not been done before. 
In Chapter 9 long-term (ten years) drug survival of adalimumab, etanercept and 
ustekinumab was presented. Overall drug survival, as well as drug survival split for 
discontinuation due to ineffectiveness and side-effects were assessed and compared 
after correction for confounders. This was unique in current literature. In this study 
we also analyzed the predictors for overall drug survival, and drug survival split for 
discontinuation due to ineffectiveness and side-effects. Research into predictors 
for discontinuation split for ineffectiveness and side-effects had only gained little 
attention. The few studies that addressed this issue had not been conducted with the 
same variables at start, leading to a heterogeneity in the selection of candidate 
predictors. In our study, we selected the candidate predictors from a set of baseline 
variables that was similar for every biologic. There was no drug survival study present 
in the literature in which this had been done before. 
To explore
Research question 4: What is the long-term overall drug survival of adalimumab, 
etanercept, and ustekinumab in patients with psoriasis?
In Chapter 8 and 9, we showed that overall drug survival percentages of adalimumab, 
etanercept and ustekinumab were high in daily practice psoriasis treatment. In 
Chapter 8, overall drug survival rates were 74%, 68% and 85% with, respectively, 
adalimumab, etanercept and ustekinumab after one year of treatment. The study in 
Chapter 9 is the most recent study. In this study, we showed that overall drug survival 
percentages of adalimumab, etanercept and ustekinumab were, respectively, 74.6%, 
75.8% and 84% survival after one year and 41%, 34% and 61% survival after 5 years 
of treatment. 
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Overall drug survival percentages from a study by Inzinger et al. for adalimumab, 
etanercept and infliximab were, respectively, 70.9%, 70.8% and 58% after one year, 
and 47.5%, 44.6% and 11.7% after 5 years of treatment in patients with psoriasis.2 In 
the study of Warren et al., overall drug survival percentages in patients with psoriasis 
were 89% for ustekinumab, 79% for adalimumab, 70% for etanercept and 65% for 
infliximab after one year, and, respectively, 75%, 59%, 40% and 35% after 3 years of 
treatment.36 The overall drug survival percentages after one and 5 years of treatment 
from our study are in line with the overall drug survival percentages from the studies 
of Inzinger et al. and Warren et al.
These drug survival percentages suggest that patients with psoriasis discontinue 
treatment less often with ustekinumab, compared with adalimumab, etanercept and 
infliximab, and this would make ustekinumab an interesting biologic for long-term 
treatment of psoriasis. However, in order to compare drug survival amongst biologics, 
correction for potential confounders has to be made, and this is described under 
research question 6.
Research question 5: Is drug survival accompanied with a good skin-specific 
quality of life in patients with psoriasis?
Since psoriasis is a skin disease with a high impact on the quality of life of patients, 
including a quality-of-life-indicator is important in order to evaluate treatment success 
with biologics. In Chapter 8 we combined overall drug survival with the skin-specific 
quality of life questionnaire DLQI. From the patients with psoriasis that were still being 
treated with a biologic after a year, we saw that the percentage of patients with a good 
quality of life (defined as happy patients; those with a DLQI≤5) increased over time. 
Of patients, 27% was ‘happy’ at baseline and 79% was ‘happy’ at one year of biologic 
treatment. Limitations were that (1) at different time points, different patient groups 
were presented; (2) there were patients who were still being treated with a biologic, 
but did not return a DLQI questionnaire; and (3) there were patients that did not return 
a DLQI questionnaire because they already discontinued the biologic. However, 
there were no differences between the group that returned DLQI questionnaires and 
the group in which no DLQI questionnaires were returned. Also, DLQI questionnaires 
were missing at random time points, and therefore selection bias was less likely. 
Altogether, we have shown that there was a large increase in the percentage of 
patients with psoriasis with a good quality of life amongst those patients who stayed 
on treatment with biologics during the first year and returned a DLQI questionnaire. In 
addition, we have shown that a group of patients (21%) still has an impaired quality of 
life (DLQI>5) after one year of biologic treatment. It would be of interest to analyze 
why the DLQI in these patients remains > 5 despite the continuation of biologic 
treatment. By combining DLQI with drug survival, we have shown that biologics are 
of high value in the treatment of patients with psoriasis in daily practice. 
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The concept of ‘happy’ drug survival (drug survival combined with DLQI questionnaires) 
is new in the current literature. Therefore no other studies were available to compare 
our study with. 
To compare
Research question 6: Which biologic has the highest confounder-corrected, 
long-term overall drug survival in patients with psoriasis?
Our daily practice study in Chapter 8 showed that ustekinumab had the highest 
 confounder-corrected, overall drug survival compared with etanercept and that there 
was a trend towards a better drug survival of ustekinumab compared with adalimumab 
after one year of treatment.
In Chapter 9 we showed that the long-term (> 5 years) confounder-corrected, overall 
drug survival of ustekinumab was significantly higher compared with the long-term 
overall drug survival of adalimumab and etanercept. Thus, patients with psoriasis 
had significantly less chance to discontinue ustekinumab treatment for any reason, 
compared with adalimumab or etanercept. 
Other prospective and retrospective daily practice studies showed similar results with 
ustekinumab having the highest confounder-corrected, long-term overall drug 
survival compared with the biologics adalimumab, etanercept and infliximab.36-39 
In two of these studies36,37, ustekinumab had the highest confounder-corrected, 
overall drug survival of these four biologics in patients with psoriasis who started a 
biologic for the first time. Thus, when considering overall drug survival, ustekinumab 
is well-suited for long-term treatment of psoriasis in daily practice. Of note, drug 
survival can be influenced by external factors such as the number of available 
biologics after the current biologic (i.e., the number of choices left), and the decision 
of physicians and patients to consider a biologic to be “ineffective”. The number of 
available biologics left is, however, not of influence on drug survival when the patients 
with psoriasis who received a biologic for the first time, are considered. Also in this 
group of patients, ustekinumab was superior to adalimumab, etanercept and 
infliximab.34 In our BioCAPTURE cohort, infliximab was the last choice biologic, and 
therefore our results are not likely to be influenced by the number of available biologics 
left. The number of patients treated with infliximab was to low in our cohort to include 
infliximab into the analyses.
Although results are in favour of ustekinumab, other biologics are also important in the 
treatment of patients with psoriasis. The course of psoriasis varies between individuals, 
and individual patients with psoriasis have their own profile of comorbidities and 
comedication. Effectiveness and safety are both very important in long-term treatment 
with a biologic for sustained disease control. To be able to control disease for patients 
with these different profiles, it is important that treatments with different mechanisms 
of action and safety profiles are at the patients and doctors disposal.
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Research question 7: Which biologic has the highest confounder-corrected, 
long-term drug survival split for reasons of discontinuation, i.e. ineffectiveness 
and side-effects, in patients with psoriasis?
Unique in our study in Chapter 9 compared with other drug survival studies was the 
comparison of confounder-corrected drug survival of biologics split for reasons of 
discontinuation. We showed that long-term (> 5 years) confounder-corrected drug 
survival of ustekinumab was significantly higher compared with the long-term drug 
survival of adalimumab and etanercept, split for ineffectiveness as well as for 
side-effects as reasons for discontinuation. This means that ustekinumab during 
long-term treatment of patients with psoriasis, is significantly less often discontinued 
due to ineffectiveness or side-effects compared with adalimumab or etanercept. 
The number of studies that split drug survival for reason of discontinuation is scarce. 
In psoriasis, two other prospective studies split drug survival, but did not correct for 
confounders. In these studies, patients with psoriasis discontinued treatment due to 
ineffectiveness most often with etanercept and due to side-effects most often with 
infliximab.36,38
To predict
Research question 8: What are the predictors of long-term overall drug survival 
of biologics in patients with psoriasis?
In Chapter 9 we showed that the most important predictors for a shorter overall drug 
survival were a higher baseline BMI and female sex when the biologics adalimumab, 
etanercept and ustekinumab were analyzed as one group. In other words, patients with a 
higher BMI at start of treatment as well as female patients had a significantly higher 
chance of discontinuing outpatient biologic treatment. When only adalimumab was 
considered, no significant predictors were found for a shorter overall drug survival. In 
etanercept treatment, predictors for a shorter overall drug survival were higher 
baseline BMI, female sex and the presence of specific comorbidities (i.e., comorbidities 
that would have resulted in exclusion from participation in RCTs). In ustekinumab 
treatment, the predictor for a shorter overall drug survival was higher baseline BMI. 
In prospective and retrospective drug survival studies in patients with psoriasis, a 
heterogeneity exists in the predictors for overall drug survival.2,36-43 This heterogeneity 
can be explained by the selection of different (baseline) variables for analyzing the 
predictors. It is, however, remarkable that female sex is mentioned most often in 
these drug survival studies as a predictor for discontinuation in general (i.e., overall 
drug survival) of biologics in the treatment of patients with psoriasis.2,36-38,40 Body 
Mass Index (or obesity) is also mentioned several times as a predictor for early 
 discontinuation in general of biologics.39,41,43  
Noteworthy, female sex is also frequently mentioned as reason for early discontinuation 
in general of biologic treatment in other indications with registered use for biologics. 
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Female sex is stated to predict shorter overall drug survival in studies of biologic 
treatment in patients with psoriatic arthritis44,45, rheumatoid arthritis46, and ankylosing 
spondylitis47-51. 
Research question 9: What are the predictors of long-term drug survival split 
for biologics and split for reasons of discontinuation, i.e. ineffectiveness and 
side- effects, in patients with psoriasis?
In our study in Chapter 9, we showed that a higher baseline BMI was a predictor for 
discontinuation of a biologic in patients with psoriasis due to ineffectiveness for 
adalimumab, etanercept, and ustekinumab as one group, and for etanercept and 
ustekinumab separately. For adalimumab, higher baseline BMI was not statistically 
significant. 
Female sex was a predictor for discontinuation of a biologic due to side-effects for 
adalimumab, etanercept, and ustekinumab as one group, but was also a consistent 
predictor for adalimumab, etanercept and ustekinumeb separately. 
The finding that in female patients the treatment with a biologic is more often discontinued 
due to side-effects compared with male patients, is intriguing. No specific patterns of 
side-effects that were a reason for ending biologic therapy in female patients were 
found in the studied cohort. 
Although scarce, publications on this topic have demonstrated gender differences in 
the presentation of symptoms, prognosis of diseases and treatment outcomes as 
well as communication.52 One prospective study found that, after correction for 
possible confounders, female patients compared with male patients experienced 
more adverse drug reactions to certain drugs, i.e. anti-inflammatory agents for the 
musculoskeletal system and antibacterials.53 In another prospective study regarding 
hospital in-patients it was shown that severe adverse drug reactions were seen more 
often in women than in men.54 Thus, it is possible that female patients experience 
more side-effects compared with male patients in general or to certain drugs.
In other indications, the number of studies assessing predictors for the different 
reasons of discontinuation of biologics is scarce. In patients with rheumatoid arthritis 
it was seen that female sex predicted early discontinuation of the biologic due to 
side-effects, but also due to ineffectiveness.46 The number of studies in rheumatoid 
arthritis is, however, limited.46 
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Conclusions for drug survival
•  Long-term drug survival of biologics for psoriasis treatment is high in daily 
practice.
•  Drug survival is accompanied with a good quality of life in patients with psoriasis. 
At baseline, the percentage of patients with psoriasis on biologic treatment in 
daily practice that were ‘happy’ (i.e., DLQI≤5) was 27%. After 1 year of biologic 
treatment, the percentage of ‘happy’ patients increased to 79%.
•  Ustekinumab has the highest confounder–corrected, long-term (> 5 years) overall 
drug survival in the treatment of psoriasis in daily practice, compared with 
adalimumab and etanercept. 
•  Ustekinumab, compared with adalimumab and etanercept, has the highest 
confounder- corrected, long-term drug survival split for discontinuation due to 
ineffectiveness as well for side-effects in psoriasis treatment in daily practice.
•  Patients with psoriasis with a higher BMI at start of treatment as well as female 
patients have a significantly higher probability of discontinuing outpatient 
biologic treatment (i.e., adalimumab, etanercept and ustekinumab as one group).
•  A higher baseline BMI predicts discontinuation due to ineffectiveness in patients 
with psoriasis treated with etanercept or ustekinumab in daily practice.
•  Female sex predicts discontinuation due to side-effects in patients with psoriasis 
treated with adalimumab, etanercept or ustekinumab in daily practice.
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Improvements of efficacy and effectiveness 
To explore
Research question 10: What are the guidelines that dermatologists in  
the Netherlands should adhere to when treating patients with psoriasis  
in daily practice?
Until the moment of translating and publishing the Dutch guidelines on Psoriasis 2011 
as described in Chapter 10, no Dutch guidelines on psoriasis treatment had been 
published in the international literature. A guideline was available in the Dutch Journal 
of Medicine (NTvG).55 
Until then, guidelines on the treatment of psoriasis were already available from 
England, Germany, Europe and the United States in the international literature.8,56-60 
In contrast to these guidelines, the Dutch guidelines on psoriasis contain unique 
chapters on the treatment of psoriasis of the face and flexures, childhood psoriasis 
as well as the patient’s perspective on treatment. These chapters were therefore of 
added value to the current literature. For the contents of the Dutch guidelines on 
Psoriasis 2011, the reader is referred to Chapter 10. 
Information that is mostly lacking in almost all guidelines on the treatment of psoriasis, 
is the use of conventional systemic agents in combination with biologics or with other 
conventional systemic agents. A difference between the Dutch guidelines on 
Psoriasis 2011 and the German guidelines on psoriasis is the addition of the ‘treatment 
goals’ in the German guidelines. These treatment goals advise a physician when to 
consider treatment adjustment or switching to another treatment.7 Both combination 
treatment as well as ‘treatment goals’ could improve the care of patients with 
psoriasis. In Chapter 11 and Chapter 12, these subjects were highlighted and they 
will be discussed below.
Research question 11: Since information on systemic combination therapy is 
largely lacking in current guidelines on psoriasis treatment, what is the current 
evidence from RCTs on systemic combination treatment in psoriasis?
In Chapter 11 we described our systematic review on the efficacy of systemic 
combination treatments in patients with psoriasis. The recently developed GRADE 
(Grading of Recommendations Assessment, Development and Evaluation) approach 
was used to assess the level of evidence for different outcome measures from 
selected RCTs. A systematic review on the systemic combination treatments in 
psoriasis had, until then, not been performed using the GRADE method.
Eventually, 17 RCTs were included that described one of the following combination 
treatments: (1) phototherapy in combination with traditional systemic agents except 
acitretin, (2) phototherapy in combination with biologics, (3) biologics in combination 
with traditional systemic agents, and (4) combination of traditional systemic agents. 
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Phototherapy combined with acitretin was excluded from our systemic review 
because, for this type of combination therapy, an overview of RCT evidence according 
to the GRADE approach already existed in the NICE (National Institute for Health and 
Care Excellence) guidelines on psoriasis 2012.59 The reader is referred to these NICE 
guidelines for the results on phototherapy combined with acitretin.
The evidence on the use of combination treatments in psoriasis is low. Best evidence 
currently exists for the superior efficacy of etanercept combined with methotrexate 
from start of treatment in the short-term compared with etanercept monotherapy. 
Since dermatologists have to combine treatments in patients with psoriasis in daily 
practice3, well-designed RCTs on the efficacy an safety of combination treatments 
are needed.
Research question 12: Do dermatologists already intuitively apply ‘treatment 
goals’ in patients with psoriasis treated with biologics in daily practice?
Treatment goals for psoriasis were drafted in 2011 (Figure 1). Treatment goals advise 
physicians that in patients with psoriasis in which a PASI50 has not been reached, 
treatment should be adjusted (e.g., dose increase, shortening of treatment interval, 
combination treatment with a topical or conventional systemic agent, or switching of 
treatment).7,62-64 Physicians are advised to continue treatment in patients in which a 
PASI75 is reached during treatment. Physicians should use the DLQI questionnaire 
for patients that fall into the ‘gray zone’, i.e. with a PASI50 but not a PASI75 during 
Figure 1   Treatment goals in psoriasis
Treatment goals in psoriasis. Figure adapted from Mrowietz, et al.62
PASI<50 PASI≥50 - <75 PASI≥75 
DLQI>5 DLQI≤5 
Modify 
treatment 
regimen 
Continue 
treatment 
regimen 
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treatment, in order to evaluate whether treatment should be continued or adjustments 
to treatment should be made.62 In patients with a DLQI similar to or below 5 (good 
quality of life) treatment may be continued without modification, and a DLQI above 5 
should lead to modification of treatment.62 
These treatment goals are based on consensus. Formal study on the effect of treatment 
goals in daily practice is currently lacking. Treatment goals were evaluated with data 
from RCTs of adalimumab65, although treatment goals have been made for daily 
practice.
In our study, described in Chapter 12, we used prospective data from the BioCAPTURE 
registry to evaluate whether dermatologists intuitively followed treatment goals, 
without the active implementation of treatment goals in daily practice. This had never 
been done before.
Our study showed that in 64% of the in total 395 analysed visits, dermatologists intuitively 
followed treatment goals. In 233 visits no treatment modification was necessary and 
therapy was indeed not modified in 194 (83%) of these visits. Noteworthy, of the 
40 modifications that were performed in this group, 26 (65%) modifications were a 
dose decrease. Although this is not in accordance with the advice from the treatment 
goals, these changes are not as necessarily ‘wrong’. Some modifications (7 out of 
40 modifications) included a dose increase of biologics, although according to the 
treatment goals treatment should have been continued without modification.
In 103 (64%) of the 162 visits in which treatment should have been modified according 
to treatment goals, treatment was continued without modification. In this group of 
patients with a PASI<50 or a PASI50-<75 and a DLQI>5, most room for improvement 
of psoriasis care exists. In only 59 of 162 (26%) visits, treatment was indeed modified. 
Usually this was a dose increase of the biologic (24 of 61 modifications), or a switch 
to another biologic (11 of 61 modifications). The dose of the biologic or the conventional 
systemic agents was, however, also sometimes decreased (7 of 61 modifications; in 
which 1 modification of the biologic according to label). This type of modification was 
not according to treatment goals.
With our study we have shown that dermatologists intuitively followed treatment goals 
in the majority of visits, but that in a substantial number of visits in which the 
dermatologist should have modified treatment, treatment was continued without 
modification. Optimising treatment in this latter group of patients and exposing the 
barriers amongst dermatologists and patients for modifying treatment, as well as 
research into the implementation of treatment goals in daily practice could contribute 
to a higher effectiveness of biologic treatments in this group of patients.
A drawback of the current treatment goals is the use of a relative PASI score to base 
treatment decisions on. As shown in Chapter 7 we advise to also use absolute PASI 
scores in the assessment of psoriasis severity. Treatment goals could therefore 
improve by adding absolute PASI measures. 
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A prospective study in which is evaluated whether the use of treatment goals 
contributes to an improvement of the treatment of patients with psoriasis, is needed 
before the (modified) treatment goals will be implemented in daily clinical practice. 
Especially a prospective, randomized study on the implementation of treatment 
goals as has been performed in patients with rheumatoid arthritis, could be of added 
value to the treatment of patients with psoriasis with biologics in daily practice.66 The 
study in rheumatoid arthritis patients showed that implementation of treatment goals 
in daily practice led to improved disease activity and quality of life in patients, without 
additional costs.66 A similar study in patients with psoriasis in daily practice could 
lead to a statement in future guidelines on psoriasis treatment to implement (modified) 
treatment goals in daily practice psoriasis care.   
Conclusions for improvements of efficacy  
and effectiveness
•  Combination therapy as well as use of (modified) treatment goals might improve 
the effectiveness of antipsoriatic treatments.
•  Best evidence is available from RCTs for the combination therapy etanercept 
with methotrexate on short-term (12 weeks).
•  Dermatologists intuitively followed treatment goals in the majority of visits in daily 
practice. However, in a substantial number of visits in which the dermatologist 
should have modified treatment, treatment was continued without modification. 
Optimising treatment in this group of patients with a response below PASI50 or a 
PASI50-<75 and a DLQI>5, and defining barriers amongst dermatologists and 
patients for modifying treatment, as well as research into the implementation of 
treatment goals in daily practice could contribute to a higher effectiveness of 
biologic treatments in this group of patients.
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Short summary of important findings
In this thesis, we have shown that biologics and conventional systemic agents are 
effective for the treatment of psoriasis in daily practice. Of the biologics studied, 
ustekinumab showed superior effectiveness compared to etanercept during the first 
five years of treatment. During this five year period, ustekinumab was, compared with 
adalimumab and etanercept, most often prescribed in low to normal dose. Our drug 
survival studies revealed that ustekinumab had the highest confounder corrected 
overall drug survival compared to adalimumab and etanercept as well as the lowest 
discontinuation due to ineffectiveness as well as discontinuation due to side-effects. 
Ustekinumab is therefore an interesting biologic for long-term treatment of psoriasis.
Important predictors for treatment success (i.e. high clinical effectiveness at week 24 
or long-term drug survival) of psoriasis with biologics were baseline BMI, baseline 
PASI score, and gender. Patients with a lower BMI at start of treatment had a higher 
chance of achieving PASI≤5 (and even PASI≤3) at week 24 and a higher probability 
of long-term drug survival compared to patients with higher baseline BMI. A higher 
baseline BMI predicted discontinuation due to ineffectiveness in patients with 
psoriasis treated with etanercept or ustekinumab. Male patients had a higher 
probability of long-term drug survival compared to female patients. Female gender 
predicted more frequent discontinuation due to side-effects in patients with psoriasis 
treated with adalimumab, etanercept or ustekinumab. Patients with a baseline 
PASI<10 had a higher chance of achieving PASI≤5 (and even PASI≤3) at week 24 
compared to patients with PASI≥10. Of these predictors, BMI is modifyable and might 
become of high value in improving treatment outcome in daily practice psoriasis 
treatment. 
Other strategies to improve treatment outcome with biologics in daily practice might 
include the use of combination therapy (i.e. the combination of a biologic with a 
conventional systemic agent) and the use of (modified) treatment goals to identify 
those patients in need of treatment modification.
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Future directions
Future research in the treatment of psoriasis on the main themes effectiveness, drug 
survival and targeted treatment are essential for improving psoriasis care. 
Although the PASI score is the most widely used measure in efficacy and effectiveness 
of antipsoriatic treatments, other measures are also being used, leading to a 
heterogeneity in outcomes for efficacy/effectiveness. This makes comparison of 
efficacy/effectiveness amongst studies difficult. Also, the time point at which PASI is 
assessed varies across studies, making comparisons even more of a challenge. 
Having multiple outcome measure could also potentially lead to different predictors 
for different outcomes. Hence, an international consensus is needed on the primary 
endpoint of efficacy/effectiveness and the time point of evaluation of short- and 
long-term treatment, analogues to what is being performed in eczema (HOME 
initiative).67 Support from the international psoriasis community is needed to achieve 
the use of these outcome measures worldwide.
We showed that the number of comparative studies in psoriasis treatment is scarce. 
There is a need for long-term daily practice studies that compare the biologics as well as 
studies that compare the conventional systemic agents, with correction for confounders 
and accounting for doses. Comparative randomized studies could provide insight 
into a hierarchy of antipsoriatic treatments, complemented with studies from daily 
practice. Pragmatic randomized daily practice studies could provide physicians 
long-term data on comparative effectiveness of anti-psoriatic agents.68
We also showed that obesity might have an influence on effectiveness results of 
biologic treatments for psoriasis. A well-designed randomized (daily practice) study 
is needed, in which the effect of weight loss in patients with psoriasis treated with 
biologics (adalimumab, etanercept, infliximab, ustekinumab and secukinumab) is 
assessed. Performing such a study is a challenge. For example, patients with psoriasis 
treated with biologics could be randomized into a group with diet and physical 
exercise with a personal trainer and a group without the intervention. A blinded 
assessor would assess the PASI score at baseline and at several predefined 
time-points during the study. A questionnaire on adherence with biologic treatment 
has to be implemented into the study. Treatment adherence could be a confounder, 
since a higher adherence might be expected in the intervention group. In this study, 
also pro- and anti-inflammatory cytokines that are being produced by the adipose 
tissue, such as TNF-α, IL-6, leptin, and adiponectin, should be measured in serum at 
several time points during the study. In order to circumvent the problem for the 
biologics that are being administered based on weight (infliximab, ustekinumab), the 
first study could include only those biologics that have a fixed dose (adalimumab, 
etanercept and secukinumab). Future studies could also address BMI-based dosing.
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With our BioCAPTURE cohort, we have shown that BMI is a predictor for discon tinuation 
due to ineffectiveness for etanercept and ustekinumab, and that female sex is a 
predictor for discontinuation due to side-effects. These results should be replicated 
in larger, multicenter, prospective daily practice studies.
Observational studies are needed into why female patients are more prone to 
discontinuing biologic treatment in psoriasis due to side-effects, and whether in 
general female patients discontinue medication more often than male patients and 
the reasons for this sex difference.
Targeted treatment could arise from assessing predictors such as patient character-
istics (e.g., obesity, female sex), but also from other biomarkers such as genetics. At 
the moment, BioCAPTURE is gathering information on biomarkers in order to evaluate 
the possibilities of patient-targeted treatment. 
Treatment of biologics in psoriasis could be improved by information on the effect of 
combination therapy of conventional systemic agents with biologics. Currently, best 
evidence exists only for the combination etanercept with methotrexate and only on 
short-term treatment (12 weeks). More RCTs are needed on the short- and long-term 
efficacy (and safety) of combination therapy of biologics with conventional systemic 
agents. At the moment, the randomized multicenter study OPTIMAP (OPTIMising 
Adalimumab treatment in Psoriasis with concomitant methotrexate) is being conducted 
in order to compare adalimumab monotherapy with the combination of adalimumab 
with low dose methotrexate.
Improving treatment outcome might also be done by increasing biologic dose. More 
studies are needed to evaluate whether dose increase of biologics is indeed an 
effective measure in daily practice psoriasis treatment and to identify which patients 
with psoriasis benefit from such a dose increase. Of note, dose decreases are also 
of interest in that it might lead to successful treatment with biologics but with lower 
costs. Currently, we are conducting the randomized, multicenter study CONDOR 
(CONtrolled DOse Reduction), in which we assess the controlled decrease of biologic 
dose in psoriasis treatment.  
Implementing treatment goals into daily practice might improve the prescription of 
biologics with dose adjustments and combination treatments for the group of patients 
in which PASI score is not sufficiently low enough. However, treatment goals should 
first be modified, so that decisions on treatment adjustments are not based (solely) 
on relative PASI measure as a first step of evaluation, but also on absolute PASI 
measures. Subsequently, the implementation of a modified treatment goals algorithm 
could then be evaluated in a randomized study, analogous to the randomized study 
(TICORA) in rheumatoid arthritis.66
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Nederlandse Samenvatting
In Nederland hebben ongeveer 500.000 personen de huidziekte psoriasis, waarvan 
± ⅓ matig-ernstige tot ernstige psoriasis heeft. Psoriasis gaat gepaard met een 
grote impact op de kwaliteit van leven. Het verbeteren van de zorg en het optimaliseren 
van de behandeling van patiënten met psoriasis is een continu proces waarbij weten-
schappelijk onderzoek essentieel is.
Een van de nieuwste generatie behandelingsopties van matig-ernstige tot ernstige 
psoriasis zijn de biologics. Biologics zijn medicijnen die vervaardigd zijn via levende 
organismen, en die specifiek aangrijpen op cellen van het immuunsysteem. Adalimumab, 
etanercept en infliximab grijpen aan op tumor necrose factor (TNF)-α en ustekinumab 
grijpt aan op interleukine (IL)-12 en IL-23. Infliximab en ustekinumab worden, in 
tegenstelling tot adalimumab en etanercept, gedoseerd op het gewicht van de 
patiënt.   
Het doel van dit proefschrift was het exploreren, vergelijken en voorspellen van de 
effectiviteit van biologics voor psoriasis in de dagelijkse praktijk, het exploreren van 
drug survival (een samengestelde maat voor behandelsucces, dat wil zeggen 
effectiviteit, veiligheid, en gedrag van de patiënt en van de arts), het vergelijken en 
voorspellen van lange termijn drug survival en het exploreren van gebieden met 
ruimte voor verbetering in de behandeling van psoriasis in de dagelijkse praktijk.
De studies in dit proefschrift zijn gebaseerd op data uit de literatuur en afkomstig uit 
BioCAPTURE (Continuous Assessment of Psoriasis Treatment Use REgistry with 
Biologics). BioCAPTURE is een prospectief, multicenter cohort van patiënten met 
matig tot ernstige psoriasis die behandeld worden met biologics. Data over effectiviteit, 
veiligheid, patiënt gerapporteerde uitkomstmaten en kosten-effectiviteit worden 
verzameld. BioCAPTURE is gesitueerd in het Radboudumc Nijmegen en is opgezet 
in 2005. Vanaf 2010 participeren grote regionale ziekenhuizen in BioCAPTURE, 
met op het moment negen regionale centra. BioCAPTURE bevat dus data van 
academische en niet-academische ziekenhuizen.
Data afkomstig uit dagelijkse praktijk cohorten zijn belangrijk en relevant en een 
aanvulling op data uit gerandomiseerde klinische studies (RCTs) doordat in dagelijkse 
praktijk studies (1) grotere aantallen patiënten geïncludeerd kunnen worden met 
andere patiëntkarakteristieken dan de patiënten in RCTs, (2) patiënten gedurende 
een langere tijd gevolgd kunnen worden, (3) behandelstrategieën verschillen met de 
strategieën in RCTs, (4) veiligheid van medicatie goed kan worden vastgesteld door 
de inclusie van grotere aantallen patiënten en een langere follow-up tijd dan in RCTs, 
en (5) het gedrag van artsen en patiënten geëvalueerd kan worden.
In dit hoofdstuk worden de resultaten van hoofdstuk 5 – 12 samengevat.
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Effectiviteit
Exploreren
Hoofdstuk 5 beschrijft de eerste systematische review waarin de effectiviteit van 
biologics (adalimumab, etanercept, infliximab, ustekinumab) en conventionele systemische 
medicatie (acitretine, cyclosporine, fumaarzuur, methotrexaat) voor de behandeling 
van psoriasis geaggregeerd werd op basis van data uit dagelijkse praktijk studies. 
Wij zagen dat zowel biologics als conventionele systemische medicatie effectief 
waren in de behandeling van psoriasis in de dagelijkse praktijk. Opvallend was dat 
de meeste studies geen goede beschrijving gaven van bepaalde belangrijke patiënt-
karakteristieken bij start (‘baseline’) van de behandeling, alsmede geen goede 
beschrijving gaven van (het effect van) dosisophoging en het voorschrijven van 
conventionele systemische medicatie in combinatie met biologics. Ook ontbraken 
goed uitgevoerde studies waarin de effectiviteit van systemische antipsoriatische 
medicatie onderling vergeleken werd bij de behandeling van psoriasis in de dagelijkse 
praktijk.
Vergelijken
In hoofdstuk 6 beschreven we de eerste dagelijkse praktijk studie waarin de lange 
termijn (5 jaars) effectiviteit door middel van de PASI (Psoriasis Area and Severity 
Index) score werd vergeleken tussen de meest gebruikte biologics adalimumab, 
etanercept en ustekinumab bij patiënten met psoriasis, waarbij gecorrigeerd werd 
voor mogelijke verstorende variabelen (‘confounders’). We hielden rekening met (1) 
de dosering van de biologic, (2) combinatietherapieën van een biologic met een 
conventioneel systemisch medicament, en (3) verschillen in baseline patiënten-
karakteristieken bij start met een biologic, zoals verschillen in baseline PASI scores. 
De primaire uitkomst was het vergelijken van het gemiddelde PASI verloop tussen de 
biologics gedurende de eerste 5 jaar van psoriasis behandeling. We zagen dat 
ustekinumab, vergeleken met etanercept, significant effectiever was in het verlagen 
van de PASI score gedurende de periode van 5 jaar behandeling van psoriasis in de 
dagelijkse praktijk. Ook was ustekinumab, vergeleken met adalimumab en etanercept, 
de biologic die het vaakst in een dosering werd voorgeschreven die in overeenstemming 
was met of lager was dan de verwachte label dosering gedurende deze 5 jaar in ons 
cohort. De andere biologics werden vaker in een hogere dosering dan wat verwacht 
mocht worden volgens label dosering voorgeschreven. Dit maakt ustekinumab 
aantrekkelijk voor lange termijn behandeling van patiënten met psoriasis.
Voorspellen
Met de studie in hoofdstuk 7 analyseerden we het percentage van behandelepi-
soden met een hoge respons en voorspellers voor een hoge respons op biologic 
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therapie bij psoriasis op week 24 van de behandeling. Hoge respons werd 
gedefinieerd als een PASI90 (90% reductie in de PASI score ten opzichte van de 
baseline PASI score), PASI100 of een absolute PASI≤5, met in een van de sensitiviteits-
analyses PASI≤3. Om de power te verhogen analyseerden we de biologics 
(adalimumab, etanercept, infliximab en ustekinumab) als één groep. We zagen een 
laag percentage PASI90 (15%) en PASI100 (3%) op week 24 van de biologic 
behandeling bij psoriasis. Een absolute PASI≤5 (59%) en zelfs een PASI≤2 (24%) 
werden vaker bereikt dan PASI90 op week 24. Dit toont het belang aan van het 
includeren van een absolute PASI score bij de beoordeling van de ernst van de 
psoriasis.
Als voorspeller voor PASI90 op week 24 vonden we een baseline PASI≥10, en voor 
PASI≤5 op week 24 vonden we een baseline PASI<10 en een lage baseline BMI 
(body mass index). Patiënten met psoriasis met een hogere baseline PASI (PASI≥10) 
hadden dus meer kans om een PASI90 te halen op week 24 dan patiënten met een 
lage baseline PASI score (PASI<10), en patiënten met psoriasis met een lage baseline 
PASI score hadden meer kans om een PASI≤5 en zelfs een PASI≤3 te halen op week 
24 dan patiënten met een hoge baseline PASI score. Ook patiënten met psoriasis met 
een lagere BMI bij start van de behandeling hadden meer kans op het behalen van 
een PASI≤5 en zelfs een PASI≤3 op week 24 dan patiënten met een hogere baseline 
BMI. Van deze predictoren is baseline BMI een modificeerbare voorspeller. Patiënten 
zouden kunnen afvallen voordat zij starten met een biologic. De huidige studies in de 
literatuur zijn nog van onvoldoende kwaliteit om te kunnen stellen dat gewichtsverlies 
leidt tot een betere respons op biologic therapie bij psoriasis in de dagelijkse praktijk. 
Er zijn additionele studies nodig om dit te analyseren. Daarnaast bestaat de vraag of 
we moeten gaan toewerken naar op BMI gebaseerde biologic doseringen.
Drug survival
Drug survival bij de behandeling met biologics is de kans (waarschijnlijkheid) dat een 
patiënt nog steeds behandeld wordt met een biologic na een bepaalde periode. Een 
drug survival curve kan gemaakt worden voor verschillende redenen van stop. 
Redenen voor het stoppen van de biologic kunnen zijn ineffectiviteit, bijwerkingen, 
zwangerschapswens, of andere redenen zoals de wens van de patiënt. Bij ‘overall’ 
drug survival worden alle redenen van stop meegenomen in de analyse. Drug survival 
kan ook gesplitst worden voor de belangrijkste redenen van stop: ineffectiviteit en 
bijwerkingen.
We hebben twee drug survival studies uitgevoerd voor psoriasis met data uit de 
prospectieve, multicenter BioCAPTURE.
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Exploreren
In hoofstuk 8 zagen we drug survival percentages van 74%, 68% en 85% voor 
 respectievelijk adalimumab, etanercept en ustekinumab na één jaar biologic behandeling 
bij psoriasis. In hoofdstuk 9 zagen we voor adalimumab, etanercept en ustekinumab 
 respectievelijk drug survival percentages van 74.6%, 75.8% en 84% na één jaar behandeling 
en 41%, 34% en 61% na een periode van 5 jaar behandeling. Deze lange termijn drug 
survival percentages zijn hoog in de dagelijkse praktijk en komen overeen met de 
percentages uit andere studies. De hoogste percentages worden gezien voor ustekinumab.
In hoofdstuk 8 hebben we de drug survival over een periode van één jaar gekoppeld 
aan de kwaliteit van leven van de patiënt met behulp van de DLQI (Dermatology Life 
Quality Index) vragenlijst. Dit was nog nooit eerder gedaan. We zagen een toename 
in het percentage patiënten met een goede DLQI, gedefinieerd als een DLQI≤5, met 
op baseline 27% van de patiënten met een DLQI≤5 en na één jaar behandeling 79% 
van de patiënten met een DLQI≤5. Door het combineren van drug survival met DLQI 
hebben we laten zien dat biologics van grote waarde zijn voor de behandeling van 
patiënten met psoriasis in de dagelijkse praktijk. Wat we hiermee ook getoond 
hebben, is dat er patiënten zijn (21%) die na een jaar biologic behandeling alsnog 
een beperkte kwaliteit van leven hebben (DLQI>5). Er is dus ruimte voor verbetering 
en onderzoek is nodig naar de reden van een DLQI > 5 bij deze groep patiënten 
ondanks langdurige behandeling met biologics. 
Vergelijken
In hoofdstuk 8 toonden we dat ustekinumab de hoogste confounder-gecorrigeerde, 
overall drug survival heeft vergeleken met etanercept en dat er een trend was voor 
een betere drug survival van ustekinumab ten opzichte van adalimumab in de 
behandeling van psoriasis na een periode van één jaar. In hoofdstuk 9 lieten we zien 
dat ustekinumab de hoogste confounder-gecorrigeerde, overall drug survival heeft 
vergeleken met adalimumab en etanercept na een periode van >5 jaar behandeling 
van patiënten met psoriasis. Psoriasis patiënten die behandeld werden met 
ustekinumab hadden dus op de lange termijn minder kans om te stoppen met deze 
biologic dan patiënten die behandeld werden met adalimumab of etanercept. In 
hoofdstuk 9 voerden we als eersten de confounder-gecorrigeerde analyses uit voor 
drug survival opgeplitst voor redenen van stop. We toonden dat ustekinumab de 
hoogste confounder-gecorrigeerde drug survival heeft voor de stopreden ‘ineffectiviteit’ 
én voor de stopreden ‘bijwerkingen’ vergeleken met adalimumab en etanercept na 
een periode van >5 jaar behandeling van patiënten met psoriasis. Patiënten met 
psoriasis die behandeld werden met ustekinumab hadden dus minder kans om te 
stoppen met deze biologic ten gevolge van ineffectiviteit of bijwerkingen dan patiënten 
met psoriasis die behandeld werden met adalimumab of etanercept, gekeken over 
een periode van >5 jaar behandeling.
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Hoewel deze vergelijkende studies in het voordeel zijn voor ustekinumab als biologic 
in de behandeling van psoriasis patiënten in de dagelijkse praktijk, willen we als 
kanttekening maken dat andere biologics ook belangrijk blijven in de behandeling 
van psoriasis. Elke patiënt heeft zijn/haar eigen psoriasis en zijn/haar eigen profiel 
van comorbiditeiten en comedicatie, en daarom zijn biologics met verschillende 
werkingsmechanismen en veiligheidsprofielen nodig om de individuele patiënt zo 
goed mogelijk te kunnen behandelen.
Voorspellen
Tot het uitvoeren van onze studie in hoofdstuk 9 had het voorspellen van drug 
survival nog maar weinig aandacht gekregen en hadden de onderzoekers die deze 
studies uitvoerden gebruik gemaakt van een heterogene set aan baseline variabelen 
om de drug survival te voorspellen. Dit resulteerde in een heterogene set aan 
predictoren (voorspellers) voor de verschillende biologics. In onze studie hebben we 
binnen één cohort de voorspellers vastgesteld voor overall drug survival en de drug 
survival gesplitst voor ineffectiviteit en voor bijwerkingen door gebruik te maken van 
dezelfde baseline variabelen voor elke analyse. Wij analyseerden daarbij de biologics 
adalimumab, etanercept en ustekinumab als één groep, maar ook afzonderlijk in de 
behandeling van psoriasis.
Wij toonden aan dat een hogere BMI bij de start van behandeling en het vrouwelijk 
geslacht voorspellers waren voor het eerder stoppen met een biologic behandeling 
(adalimumab, etanercept en ustekinumab als één groep geanalyseerd) voor patiënten 
met psoriasis in de dagelijkse praktijk. Bij opsplitsen van drug survival naar redenen 
van stop lieten we zien dat een hogere baseline BMI een voorspeller was voor het 
eerder stoppen met etanercept of ustekinumab met als stopreden ‘ineffectiviteit’. 
Het vrouwelijk geslacht was een consistente voorspeller voor het eerder stoppen van 
adalimumab, etanercept of ustekinumab ten gevolge van bijwerkingen.
Grotere prospectieve cohorten zijn nodig om onze predictoren te bevestigen. Verder 
zijn, zoals reeds eerder gesteld, additionele studies nodig naar de invloed van 
 gewichtsreductie op de effectiviteit van biologic behandeling. Eveneens interessant 
is de vraag waarom vrouwelijke patiënten met psoriasis meer kans hebben om de 
biologic behandeling te stoppen in verband met bijwerkingen. Observationele studies 
zijn nodig om dit te analyseren en om uit te zoeken of vrouwen in het algemeen vaker 
stoppen met medicijnen dan mannen en wat de reden is van dit geslachtsverschil.
513529-L-bw-zweegers
Processed on: 6-9-2017 PDF page: 328
328
Chapter 14
Het verbeteren van de effectiviteit
Exploreren
Met hoofdstuk 10 hebben we de Nederlandse richtlijn voor de behandeling van 
patiënten met psoriasis gepubliceerd in de internationale literatuur. In tegenstelling 
tot andere richtlijnen die al aanwezig waren in deze literatuur beslaat de Nederlandse 
richtlijn unieke hoofdstukken over de behandeling van psoriasis van het gelaat en de 
lichaamsplooien, psoriasis op de kinderleeftijd en het patiëntenperspectief op de 
behandeling.
In bijna alle huidige richtlijnen ontbreekt informatie over combinatietherapie van 
conventionele systemische medicatie met biologics of met andere conventionele 
systemische medicatie. De Duitse richtlijn heeft als toevoeging de behandeldoelen 
(‘treatment goals’) voor psoriasis. Zowel combinatietherapie als behandeldoelen 
kunnen de zorg van patiënten met psoriasis verbeteren. In hoofdstuk 11 en 
hoofdstuk 12 hebben we deze onderwerpen belicht en we zullen ze hieronder kort 
bespreken.
In hoofdstuk 11 beschreven we een systematisch review over de effectiviteit van 
systemische combinatietherapieën bij patiënten met psoriasis en gebruikten daarbij 
de GRADE (Grading of Recommendations Assessment, Development and Evaluation) 
methode om de mate van bewijs vast te stellen voor verschillende uitkomstmaten van 
de geselecteerde RCTs. Een systematisch review over systemische combinatie-
therapieën in psoriasis gebruik makend van de GRADE methode was tot dan toe nog 
niet uitgevoerd. De geselecteerde RCTs over combinatietherapieën hadden over het 
algemeen een laag niveau van bewijs. Op dit moment bestaat het beste bewijs voor 
een superieure effectiviteit van etanercept gecombineerd met methotrexaat vanaf 
start van de behandeling vergeleken met etanercept monotherapie na 12 weken 
behandeling.
In hoofdstuk 12 voerden we voor het eerst een studie uit waarbij de behandeldoelen 
voor psoriasis, zonder voorafgaande implementatie van deze behandeldoelen, 
geëvalueerd werden met prospectief verzamelde data uit BioCAPTURE betreffende 
de dagelijkse praktijk behandeling van psoriasis. We zagen dat dermatologen intuïtief 
de behandeldoelen volgden in het merendeel van de visites in de dagelijkse praktijk. 
Echter in een substantieel deel van de visites zagen we ook dat dermatologen de 
behandeling voor patiënten met psoriasis hadden moeten aanpassen volgens de 
behandeldoelen, maar dat de huidige behandeling van de patiënt gecontinueerd werd 
zonder modificaties. Met name in de groep met een PASI<50 of met een PASI50-<75 en 
een DLQI>5 is winst te behalen. Het optimaliseren van de behandeling van patiënten 
met een respons onder de PASI50 of met een PASI50-<75 en een DLQI>5, en het 
onderzoeken van barrières onder dermatologen en patiënten om de behandeling 
aan te passen, evenals onderzoek naar de implementatie van behandeldoelen in 
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de dagelijkse praktijk zou kunnen leiden tot een hogere effectiviteit van biologic 
behandelingen in deze groep patiënten.
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dat je Carmen en Marco Kooijmans bereid hebt gevonden om eveneens gegevens uit 
vragenlijsten in te laten voeren. Als moeder van de PASI score heb ik je omgedoopt 
tot “Ma PASI”. Samenwerkend aan het systematic review hebben we ontzettend veel 
gelachen en kwamen we tot de Cruijffiaanse wijsheid “klaar is klaar”. Dank voor de 
onwijs gezellige tijd en bedankt dat je mijn paranimf wilt zijn!
Selma Atalay en Lieke van Vugt, erg fijn dat jullie het BioCAPTURE team zijn komen 
versterken. Heel veel succes met jullie PhD’s!
Lia Schalkwijk, dank je dat je het BioCAPTURE team bent komen ondersteunen met 
de invoer van alle  dagelijkse praktijk data (wat voorheen ook wel bekend stond als 
“de groene formuliertjes”). De BioCAPTURE blijft maar groeien en we hebben je hulp 
daarom hard nodig. Met jouw werkervaring ben je een grote aanwinst voor ons!
Karin van Hoven-van Loo,dank je voor je expertise en het toedienen van infliximab 
infusies bij onze patiënten met psoriasis op de dagbehandeling van de Maag-Darm- 
Leverziekten. Het is altijd weer gezellig om even een praatje met je te maken en bij te 
kletsen over de vakanties!
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Dr. Marieke Seyger, dank je voor je bijdrage aan het systematic review over effectiviteit 
van biologicals en conventionele systemische medicatie voor de behandeling van 
psoriasis in de dagelijkse praktijk en onze samenwerking aan het artikel in de JAAD.
Dr. Marcia Tummers, een tijdje was je bij ons het aanspreekpunt voor de statistiek. 
Ik heb het als prettig ervaren, heel erg bedankt daarvoor.
Hans Groenewoud, voor de ingewikkelde statistiek met betrekking tot het vergelijken 
van effectiviteitsdata kon ik bij je terecht. Ik vond onze samenwerking heel fijn. 
Je stond laagdrempelig voor me klaar met je kennis en kunde. Dank je wel!
Celine Busard, Karien Pluijmen, Britt Roosenboom, fijn dat we hebben kunnen samen- 
werken aan verschillende onderzoeken. Het was voor mij erg leuk en leerzaam om 
jullie mede te hebben mogen begeleiden bij jullie wetenschappelijke stages. Celine, 
succes met jouw PhD en opleiding in het AMC Amsterdam! 
Perifere centra die deelnemen aan de BioCAPTURE registry, jullie deelname is van 
onnoemelijke meerwaarde voor het creëren van een representatieve groep van 
patiënten. Dank voor jullie interesse en enthousiasme, het meeschrijven aan de 
artikelen en onze jaarlijkse meetings waarin we het BioCAPTURE jaarverslag door- 
namen en filosofeerden over nieuwe onderzoeken.
Jane Cerqueira, ik vind het erg fijn dat je als vriendin van de familie en ‘tante Jane’ van 
Samuel deze dag naast mij kunt staan. Ik waardeer je vriendschap, je goede hart, 
behulpzaamheid en flexibiliteit om samen met de familie dingen te ondernemen. Ik 
vind het geweldig dat je mijn paranimf kunt zijn.
Tessa Kouwenhoven, Jorre Mertens, Kim Nguyen, Inge Bronckers, Maartje van Geel, 
Malou Peppelman, Denise Falcone, als collega onderzoekers hebben we een 
gezellige tijd gehad met uiteten, hardlopen, presentaties geven in het congrescentrum 
De Werelt in Lunteren en partyen (dansen en karaoke [alsnog excuses voor mijn 
zangkwaliteiten]). Tessa, Jorre, Kim, Inge en Denise, succes met (het afronden van) 
jullie PhD’s!
Alle stafleden en arts-assistenten dermatologie, dank voor de fijne tijd en de gezellige 
dagjes uit! In het bijzonder dank aan mijn huidige kamergenoten Marleen Veenstra, 
André Moyakine en Daan Smulders voor de gezellige tijd en het delen van vrijwel alle 
persoonlijke dingen met elkaar.
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Chantal Versfeld, bedankt dat ik je prachtige schilderij mocht gebruiken als omslag 
van mijn proefschrift.
Marc Beerens (Ipskamp), bedankt voor het meedenken bij alles rondom het drukken 
van dit proefschrift.
Harald Pieper (Promotie in Zicht), bedankt voor je tijd en inspanningen bij de vormgeving 
van dit proefschrift.
Alle medewerkers afdeling dermatologie, dank voor jullie interesse in mijn onderzoek! 
In het bijzonder wil ik Mascha Eilander bedanken, die over de jaren heen nauw 
betrokken is geweest bij het biological spreekuur (afnemen van PASI scores, meten 
van lengte, gewicht en buikomtrek, geven van instructies aan patiënten over de 
biological injecties) en ook nu Marisol versterkt bij het onderzoek. 
Alle medewerkers laboratorium dermatologie, dank iedereen voor de gezellige tijd, 
de interessante Lotto praatjes, het dansen en zingen tijdens Lunteren en de gezellige 
dagjes uit met de afdeling.
Stef Menting, Oda van Cranenburgh, het was leuk om samen te werken aan het anti- 
stoffen onderzoek c.q. de richtlijn psoriasis 2011.
Astrid Kuijpers, Tim Smits, Jorn Bovenschen, Mandy Prins en het hele team van het 
Maxima Medisch Centrum Dermatologie Eindhoven/Veldhoven, ik wil jullie in het 
bijzonder bedanken voor jullie enthousiasme en jullie hulp bij mijn eerste ‘babystapjes’ 
in de Dermatologie en natuurlijk ook bij het samen schrijven van artikelen. De sfeer 
op jullie afdeling is geweldig en jullie enthousiasme werkt aanstekelijk.
Alle familie en vrienden, dank voor jullie interesse! Fijn dat we een gezellige tijd kunnen 
beleven met elkaar in de weekenden. Wat is het fijn om met jullie deze mijlpaal te 
mogen delen.
Jack en Bahati Mukamurenzi, dank voor de leuke tijd en jullie gastvrijheid tijdens onze 
vakanties in Rwanda! 
Verediyana Mukamurenzi, dank je wel voor je liefde, openheid, gastvrijheid, voor het 
opvoeden van en het delen van je wijsheid met Frazima. Je ging veel te vroeg, rust in 
vrede.
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Ad, Anja en Fiona Zweegers, pap, mam en zusje, dank voor jullie geloof in mij en jullie 
steun over de jaren heen.
Frazima Zweegers-Mukamurenzi, lieve Frazima, wat ben ik ontzettend dankbaar dat 
ik jou heb mogen ontmoeten en dat je met mij dit avontuur wilde aangaan. Wat ik voor 
je voel is niet in woorden te omschrijven. Jij hebt me het verschil laten zien tussen 
verliefdheid en liefde en daarmee de wijsheid gegeven dat verliefdheid blind maakt, 
maar liefde niet. Ik ben dankbaar dat we samen mogen genieten van ons lieve 
manneke Samuel en ben benieuwd wat de toekomst ons gaat brengen!
Samuel Zweegers, ook al besef je nog totaal niet waar papa mee bezig is en kun je 
nog niet lezen wat hier staat, papa is super dankbaar dat je er bent en super trots om 
te zien dat je je zo goed ontwikkelt en vooral hoe je kunt genieten van de kleine 
dingen in het leven. Jouw schaterlach is de mooiste lach die ik heb gehoord in mijn 
leven. Laten we samen nog vele mijlpalen bereiken en daarbij lachen tegen het leven! 
En onthoud: 
“Fall down seven times, get up eight” (Denzel Washington)
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